US20210198208A1 - 4-substituted aminoisoquinoline derivatives - Google Patents

4-substituted aminoisoquinoline derivatives Download PDF

Info

Publication number
US20210198208A1
US20210198208A1 US17/187,931 US202117187931A US2021198208A1 US 20210198208 A1 US20210198208 A1 US 20210198208A1 US 202117187931 A US202117187931 A US 202117187931A US 2021198208 A1 US2021198208 A1 US 2021198208A1
Authority
US
United States
Prior art keywords
alkyl
group
heterocycloalkyl
cycloalkyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
US17/187,931
Inventor
Herman O. Sintim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Research Foundation
Original Assignee
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation filed Critical Purdue Research Foundation
Priority to US17/187,931 priority Critical patent/US20210198208A1/en
Publication of US20210198208A1 publication Critical patent/US20210198208A1/en
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • C07D209/49—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide and having in the molecule an acyl radical containing a saturated three-membered ring, e.g. chrysanthemumic acid esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
    • C07D233/08—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms
    • C07D233/10—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Definitions

  • This invention relates to 4-substituted aminoisoquinoline compounds and their derivatives and uses thereof for treatment of cancer, for example, acute myeloid leukemia.
  • Ponatinib an approved FDA drug, is a 7-alkynyl imidazo[1.5-b]pyridazine compound and it is used against CML.
  • Ponatinib has toxic side effects and about 40% of patients on ponatinib developed some form of thrombosis.
  • the FDA temporarily halted the sale of ponatinib in 2014 due to this adverse issue and it is now given as a drug of last resort for CML patients who have ABL (T315I) mutation and have not responded to any other therapy (Gainor, J. F. et al., Ponatinib: Accelerated Disapproval. Oncologist, 20(8), 847-848 (2015); Talbert. D. R. et al., Toxicol. Sci, 143 (1), 147-155 (2015).
  • 4-substituted isoquinolines are privileged kinases inhibitors. Further, the substitution pattern of these 4-substituted isoquinolines play critical roles in kinase selectivity and hence cancer selectivity. 4-Alkynyl-substituted aminoisoquinolines in particular have shown exceptional activity against various kinases and potently inhibit cancer proliferation. This important discovery has facilitated the tailoring of 4-substituted aminoisoquinoline into compounds that inhibit various cancers. Additionally, the 4-alkynyl-substituted 1- or 3-amino isoquinolines can be tuned for selectivity and toxicity and hence represent a new-generation alkyne-containing kinase inhibitors with desirable drug-like properties.
  • the present invention features a compound represented by a compound of formula (IV)
  • W is NR′, alkene, alkyne, C 1-8 alkyl, heteroalkyl containing 1-8 carbon and hetero atoms, cycloalkyl, hetereocycloalkyl, aryl, or heteroaryl, wherein cycloalkyl, hetereocycloalkyl, aryl, and heteroaryl optionally form a fused aryl or heteroaryl group with Ring A;
  • U, Y, and Z are each N or CR 6 , wherein R 6 is H or NR a R b ;
  • R 7 and R 8 are each independently H, alkyl, alkenyl, alkynyl, halo, nitro, OR c , SR c , CN, haloalkyl, O-haloalkyl, (CO)R d , NR a R b , NH(CO)R d , NH(CO)OR c , NH(CO)NR a R b , (CO)OR c , (CO)NR a R b , SO 2 NR a R b , cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
  • R 7 and R 8 together with the carbon atoms to which they are attached, form a cycloalkyl, heterocycloalkyl, aryl, or heteroaryl group, each optionally substituted with substituents independently selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, halo, nitro, OR c , SR c , CN, haloalkyl, O-haloalkyl, NR a R b , (CO)R d , (CO)OR c , (CO)NR a R b . SO 2 NR a R b , and —C(CH 3 )( ⁇ N—NHC(NH)NH 2 ;
  • Ring A is a 5- or 6-membered aryl or heteroaryl group, wherein Ring A is optionally substituted with substituents selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, halo, nitro, OR c , SR c , CN, haloalkyl, O-haloalkyl, NR m R n , (CO)R d , (CO)OR c . SO 2 NR m R n , (CO)NR m R n , C(NH)NR m R n , NH(CO)R d , NH(CO)OR c . NH(CO)NR m R n , aryl, heteroaryl;
  • R m and R n are each independently
  • alkyl —(CH 2 ) p -T, -aryl-(CH 2 ) p -T, —(CH 2 ) p -aryl-T, -heteroaryl-(CH 2 ) p -T, —(CH 2 ) p -heteroaryl-T, each optionally substituted with alkyl, halo, nitro, CN, haloalkyl, O-haloalkyl, OR c , SR c , NR a R b , (CO)R d , NH(CO)R d , NH(CO)OR c , NH(CO)NR a R b , NHC(NH)NH 2 , (CO)OR c , (CO)NR a R b , SO 2 NR a R b , arylamino, or heteroarylamino,
  • R m and R n together with the nitrogen atom they are attached, form a heterocycloalkyl group, optionally substituted with alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, halo, nitro, CN, OR c , SR c , COR d , NR a R b , NH(CO)R d , NH(CO)OR c , NH(CO)NR a R b , a guanidine group, (CO)OR c , or (CO)NR a R b ;
  • T is NR a R b , OR c , SR c , O—(CH 2 ) q —NR a R b , cycloalkyl, heterocycloalkyl, aryl, heteroaryl, a guanidine group, or an isonicotinimidamide group;
  • R′ is H, alkyl, or cycloalkyl
  • R a , R b , R c , and R d are each independently H, alkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, —(CH 2 ) q -cycloalkyl, —(CH) q -heterocycloalkyl, —(CH 2 ) q -aryl, —(CH) q -heteroaryl, —(CO)-alkyl, —(CO)-cycloalkyl, —(CO)-heterocycloalkyl, —(SO 2 )-alkyl, —(SO 2 )-cycloalkyl, or —(SO 2 )-heterocycloalkyl, or R a and R b , together with the nitrogen atom to which they are attached, form a heterocycloalkyl group, wherein cycloalkyl, heterocycloalkyl, aryl and hetero
  • p and q are each independently 0-8;
  • the present invention is directed to a pharmaceutical composition
  • a pharmaceutical composition comprising one or more compounds as described herein, or a pharmaceutically acceptable salt, N-oxide, hydrate, solvate, tautomer, or optical isomer thereof, and a pharmaceutically acceptable carrier or diluent.
  • the present invention is directed to a method of treating, inhibiting, suppressing, or reducing the severity of cancer in a subject in need thereof, wherein the method comprises administering to the subject a therapeutically effective amount of a compound as described herein, or a pharmaceutically acceptable salt.
  • a compound as described herein or a pharmaceutically acceptable salt.
  • the present invention is directed to a method of treating, inhibiting, suppressing, or reducing the severity of a disease or a disorder associated with protein kinase in a subject in need thereof, wherein the method comprises administering to the subject a therapeutically effective amount of a compound as described herein, or a pharmaceutically acceptable salt.
  • a compound as described herein or a pharmaceutically acceptable salt.
  • FIG. 1 depicts that the length of the amide head group, substitution pattern, and relative position to the alkyne moiety remarkably affects the anticancer activity against MV4-11 cell line (AML cell line).
  • FIG. 2 depicts that Compound 1703 is potent against MCF-7 cell lines.
  • FIG. 3 depicts that Compound 1703 is potent against HeLa cell lines.
  • FIG. 4 depicts 4-substituted isoquinoline/quinoline/quinazoline/purine compounds.
  • FIG. 5 depicts general structures of the compounds of the invention.
  • FIG. 6 depicts the compounds of the invention.
  • FIG. 7 depicts displacement of halogen on quinolone or isoquinoline or quinazoline for the preparation of the compounds of the invention.
  • FIGS. 8A, 8B, and 8C depict dose-response curves and Western Blot analyses.
  • FIG. 8A Dose-response curves of HSW1651 against FLT3 and important FLT3 mutants.
  • FIGS. 8B and 8C Western Blot analyses of p-FLT3/total FLT3 ( FIG. 8B ) and p-STAT5/STAT5 (FIG. 8 C) protein expression in MV4-11 after treatment with HSM1651 and DMSO vehicle (V) control. Scanned images were analyzed using image J software.
  • FIG. 9 depicts representative examples of compounds synthesized.
  • FIG. 10 depicts the percentage inhibition of proliferation in MV4-11 cell line with various analogs (100 nM).
  • Table 2 provides IC 50 values for selected compounds D7. D15. D6. A15. D28. D30 and midostaurin (compounds are described in FIG. 9 ).
  • FIG. 11 depicts D30 analogs that were synthesized to investigate the influence of the quinoline/quinazoline/isoquinoline core on anticancer activity and kinase inhibition.
  • FIG. 12 depicts HSN286 (D30) activity against FLT3-driven MV4-11 and MOLM-14 but not other cancer cell lines and normal cell line. MRC5.
  • FIG. 13 depicts docked quizartinib bound to the inactive form of wild-type FLT3 (A) and docked HSN286 bound to the inactive form of wild-type FLT3 (B).
  • the docked quizartinib matched the ligand in the crystal structure of FLT3/quizartinib. Key residues D835, Y842 and F691 which when mutated block binding of FLT3 inhibitors are shown as sticks.
  • FIG. 14 depicts FLT3 residues that are within 6 ⁇ of quizartinib in the docked structure (A) and FLT3 residues that are within 6 ⁇ of HSN286 in the docked structure (B).
  • FIG. 15 depicts overlays of FLT3 binding mode of quizartinib and the compounds of the invention.
  • FIG. 16 depicts enzymatic inhibition of FLT3. FLT3 ITD and Src Kinases, respectively, by the compounds of the invention.
  • FIGS. 17A and 17B depict Western Blot analysis after treating MV4-11 with HSN286.
  • FIG. 17A Phospho-FLT3/FLT3, PhosphoSRC/SRC and phospho-STAT3/STAT3; and
  • FIG. 17B phospho-STAT5/STAT5 and phospho-p-38/p-38.
  • Cells were treated with DMSO vehicle (V), HSN286 (9 nM and 45 nM) for 6 h, 24 h and 48 h.
  • Western Blot with anti-rabbit or anti-mouse antibody Scanned images were analyzed using image J software.
  • FIG. 18 depicts compounds of the invention with different substitution pattern.
  • FIG. 19 depicts compounds of the invention with different substitution pattern.
  • FIG. 20 depicts the percent survival at day 60 of NSG mice injected with AML cell line MV4-11 and treated with various compounds at 25 mg/Kg, 3 ⁇ /week.
  • the present invention features a compound represented by a compound of formula (IV)
  • W is NR′, alkene, alkyne, C 1-8 alkyl, heteroalkyl containing 1-8 carbon and hetero atoms, cycloalkyl, hetereocycloalkyl, aryl, or heteroaryl, wherein cycloalkyl, hetereocycloalkyl, aryl, and heteroaryl optionally form a fused aryl or heteroaryl group with Ring A;
  • U, Y, and Z are each N or CR 6 , wherein R 6 is H or NR a R b ;
  • R 7 , and R H are each independently H, alkyl, alkenyl, alkynyl, halo, nitro, OR c , SR c , CN, haloalkyl, O-haloalkyl, (CO)R d , NR a R b , NH(CO)R d , NH(CO)OR c , NH(CO)NR a R b , (CO)OR c , (CO)NR a R b , SO 2 NR a R b , cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
  • R 7 and R 8 together with the carbon atoms to which they are attached, form a cycloalkyl, heterocycloalkyl, aryl, or heteroaryl group, each optionally substituted with substituents independently selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, halo, nitro, OR c , SR c , CN, haloalkyl, O-haloalkyl.
  • substituents independently selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, halo, nitro, OR c , SR c , CN, haloalkyl, O-haloalkyl.
  • NR a R b (CO)R d , (CO)OR c , (CO)NR a R b , SO 2 NR a R b , and —C(CH 3 )( ⁇ N—NHC(
  • Ring A is a 5- or 6-membered aryl or heteroaryl group, wherein Ring A is optionally substituted with substituents selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, halo, nitro, OR c , SR c , CN, haloalkyl, O-haloalkyl NR a R b , (CO)R d , (CO)OR c , SO 2 NR m R n , (CO)NR m R n , C(NH)NR m R n , NH(CO)R d , NH(CO)OR c , NH(CO)NR m R n , aryl, heteroaryl;
  • R m and R n are each independently
  • alkyl —(CH 2 ) p -T, -aryl-(CH 2 ) p -T, —(CH 2 ) p -aryl-T, -heteroaryl-(CH 2 ) p -T, —(CH 2 ) p -heteroaryl-T, each optionally substituted with alkyl, halo, nitro.
  • CN haloalkyl, O-haloalkyl, OR c , SR c , NR a R b , (CO)R d , NH(CO)R d , NH(CO)OR c , NH(CO)NR a R b .
  • R m and R n together with the nitrogen atom they are attached, form a heterocycloalkyl group, optionally substituted with alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, halo, nitro, CN.
  • T is NR a R b , OR c , SR c , O—(CH 2 ) q —NR a R b , cycloalkyl, heterocycloalkyl, aryl, heteroaryl, a guanidine group, or an isonicotinimidamide group;
  • R′ is H, alkyl, or cycloalkyl
  • R a . R b . R c , and R d are each independently H, alkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, —(CH 2 ) q -cycloalkyl, —(CH) q -heterocycloalkyl, —(CH 2 ) q -aryl, —(CH) q -heteroaryl, —(CO)-alkyl, —(CO)-cycloalkyl, —(CO)-heterocycloalkyl, —(SO 2 )-alkyl, —(SO 2 )-cycloalkyl, or —(SO 2 )-heterocycloalkyl, or R a and R b , together with the nitrogen atom to which they are attached, form a heterocycloalkyl group, wherein cycloalkyl, heterocycloalkyl, aryl and hetero
  • p and q are each independently 0-8;
  • the compound of the invention is represented by a compound of formula (V)
  • W is NR′, —C ⁇ C—, or a heterocycloalkyl group containing a 5- or 6-membered ring, wherein R′ is H or alkyl;
  • U, Y, and Z are each N or CR 6 , wherein R 6 is H or NR a R b ;
  • V, U 1 , Y 1 , and Z 1 are each N or CR 6 ′;
  • R 1 , R 2 , and R 6 ′ are each independently H, alkyl, cycloalkyl, halo, nitro. OR c , SR c , CN, haloalkyl, O-haloalkyl, or NR a R b ;
  • R 3 , R 4 , and R 5 are each independently H, alkyl, cycloalkyl, heterocycloalkyl, halo, nitro.
  • R m and R n are each independently
  • alkyl —(CH 2 ) p T, -aryl-(CH 2 ) p T, —(CH 2 ) p -aryl-T, -heteroaryl-(CH 2 ) p -T, —(CH 2 ) p -heteroaryl-T, each optionally substituted with alkyl, cycloalkyl, halo, nitro, CN, haloalkyl, O-haloalkyl, OR c , SR c , (CO)R d , NR a R b . NH(CO)R d , NH(CO)OR c , NH(CO)NR a R b . NHC(NH)NH 2 , (CO)OR c , (CO)NR a R b , and SO 2 NR a R b .
  • R m and R n together with the nitrogen atom they are attached, form a heterocycloalkyl group, optionally substituted with alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, halo, nitro, CN.
  • T is NR a R b , OR c , SR c , O—(CH 2 ) q —NR a R b , cycloalkyl, heterocycloalkyl, aryl, heteroaryl, a guanidine group, or an isonicotinimidamide group;
  • R a , R b , R c , and R d are each independently H, alkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, —(CH 2 ) q -cycloalkyl, —(CH) q -heterocycloalkyl, —(CH 2 ) q -aryl, —(CH) q -heteroaryl, —(CO)-alkyl, —(CO)-cycloalkyl, or —(CO)-heterocycloalkyl, or R a and R b , together with the nitrogen atom to which they are attached, form a heterocycloalkyl group, wherein cycloalkyl, heterocycloalkyl, aryl and heteroaryl are each optioncally substituted with a group consisting of alkyl, halo, nitro. CN, haloalkyl, O-haloalky
  • p and q are each independently 0-5.
  • R 6 is NR a R b .
  • one of R 3 , R 4 , and R 5 is heterocycloalkyl, CN, NR m R n , (CO)R d , (CO)OR c , SO 2 NR m R n . (CO)NR m R n . C(NH)NR m R n , or NH(CO)R d .
  • one of R 3 , R 4 , and R 5 is (CO)NR m R n .
  • R m is H and R is —(CH 2 ) p -T, -aryl-(CH 2 ) p -T, —(CH 2 ) p -aryl-T, or -heteroaryl-(CH 2 ) p -T, each optionally substituted with alkyl, halo, and OR c .
  • T is NR a R b , O—(CH 2 )—NR a R b , heterocycloalkyl, aryl, or heteroaryl.
  • R m and R n together with the nitrogen atom they are attached, form a heterocycloalkyl group, optionally substituted with alkyl, cycloalkyl, heterocycloalkyl NR a R b .
  • R 1 and R 2 are each independently H, alkyl, halo, CN, OR c , SR c , or NR a R b .
  • the compound of the invention is a compound of the formula:
  • R 1 , R 2 , R 10 , R 11 , R 12 , and R 13 are each independently 1-1, alkyl, cycloalkyl, halo, nitro, OR c , SR c , CN, haloalkyl, O-haloalkyl, or NR a R b ;
  • R 3 , R 4 , and R 5 are each independently H, alkyl, cycloalkyl, heterocycloalkyl, halo, nitro, OR c , SR c . CN, haloalkyl, O-haloalkyl, NR m R n , (CO)R d . (CO)OR c , S 2 NR m R n , (CO)NR m R n , C(NH)NR m R n , NH(CO)R d , NH(CO)OR c , NH(CO)NR m R n , aryl, or heteroaryl;
  • R 1 is H or NR a R b ;
  • R m and R n are each independently
  • alkyl —(CH 2 ) p -T, -aryl-(C 2 ) p -aryl-T, -heteroaryl-(CH 2 ) p -T, (CH 2 ) p -heteroaryl-T, each optionally substituted with alkyl, cycloalkyl, halo, nitro, CN, haloalkyl, haloalkyl, OR c , SR c , (CO)R d , NR a R b , NH(CO)R d , NH(CO)OR c , NH(CO)NR a R b , NHC(NH)NH 2 , (CO)OR c , (CO)NR a R b , and SO 2 NR a R b .
  • R m and R n together with the nitrogen atom they are attached, form a heterocycloalkyl group, optionally substituted with alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, halo, nitro, CN.
  • T is NR a R b , OR c , SR c , O—(CH 2 ) q NR a R b , cycloalkyl, heterocycloalkyl, aryl, heteroaryl, a guanidine group, or an isonicotinimidamide group;
  • R a , R b , R c , and R d are each independently H, alkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, —(CH) q -cycloalkyl, —(CH) q -heterocycloalkyl, —(CH 2 ) q -aryl, —(CH) q -heteroaryl.
  • p and q are each independently 0-5;
  • R 6 is NR a R b .
  • one of R 3 , R 4 , and R 5 is heterocycloalkyl, CN.
  • one of R 3 , R 4 , and R 5 is (CO)NR m R n .
  • R m is H and R n is —(CH 2 ) p -T, -aryl-(CH 2 ) p -T, —(CH 2 ) p -aryl-T, or -heteroaryl-(CH 2 ) p -T, each optionally substituted with alkyl, halo, and OR c .
  • T is NR a R b , O—(CH 2 ) q —NR a R b , heterocycloalkyl, aryl, or heteroaryl.
  • R m and R n together with the nitrogen atom they are attached, form a heterocycloalkyl group, optionally substituted with alkyl, cycloalkyl, heterocycloalkyl, NR a R b , NH(CO)R d , NH(CO)OR c , and NH(CO)NR a R b .
  • R 1 and R 2 are each independently H, alkyl, halo, CN. OR c . SR c , or NR a R b .
  • the compound of the invention is a compound of the following formula
  • V, U 1 , Y 1 , and Z 1 are each N or CR 6 ′;
  • R 1 , R 2 , and R 6 ′ are each independently H, alkyl, cycloalkyl, halo, nitro, OR c , SR c . CN, haloalkyl, O-haloalkyl, or NR a R b ;
  • R 3 , R 4 , and R 5 are each independently H, alkyl, cycloalkyl, heterocycloalkyl, halo, nitro, OR c , SR c , CN, haloalkyl, O-haloalkyl, NR m R a , (CO)R d , (CO)OR c , SO 2 NR m R a , (CO)NR m R a , C(NH)NR m R n , NH(CO)R d , NH(CO)OR c , NH(CO)NR m R n , aryl, or heteroaryl;
  • R 6 is H or NR a R b ;
  • R 7 and R 5 are each independently H, alkyl, alkenyl, alkynyl, halo, nitro.
  • R m and R n are each independently
  • alkyl —(CH 2 ) p -T, -aryl-(CH 2 ) p -T, —(CH 2 ) p -aryl-T, -heteroaryl-(CH 2 ) p -T, —(CH 2 ) p heteroaryl-T, each optionally substituted with alkyl, cycloalkyl, halo, nitro, CN, haloalkyl, O-haloalkyl, OR c , SR c , (CO)R d , NR a R b , NH(CO)R d , NH(CO)OR c , NH(CO)NR a R b , NHC(NH)NH 2 , (CO)OR 4 .
  • T is NR a R b , OR c , SR c , O—(CH 2 ) q —NR a R b , cycloalkyl, heterocycloalkyl, aryl, heteroaryl, a guanidine group, or an isonicotinimidamide group;
  • R a , R b , R c , and R d are each independently H, alkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, —(CH 2 ) q -cycloalkyl, —(CH) q -heterocycloalkyl, —(CH 2 ) q -aryl, —(CH) q -heteroaryl, —(CO)-alkyl, —(CO)-cycloalkyl, or —(CO)-heterocycloalkyl, or R a and R b , together with the nitrogen atom to which they are attached, form a heterocycloalkyl group, wherein cycloalkyl, heterocycloalkyl, aryl and heteroaryl are each optioncally substituted with a group consisting of alkyl, halo, nitro, CN, haloalkyl, O-haloalky
  • p and q are each independently 0-5;
  • R b is NR a R b ,
  • one of R 3 , R 4 , and R 5 is heterocycloalkyl, CN, NR m R n , (CO)R d , (CO)OR c , SO 2 NR m R n . (CO)NR m R n . C(NH)NR m R n , or NH(CO)R d .
  • one of R 3 , R 4 , and R 5 is (CO)NR m R n .
  • R m is H and R n is —(CH 2 ) p -T, -aryl-(CH 2 ) p -T, —(CH 2 ) p -aryl-T, or -heteroaryl-(CH 2 ) p -T, each optionally substituted with alkyl, halo, and OR c .
  • T is NR a R b , O—(CH 2 ) q —NR a R b , heterocycloalkyl, aryl, or heteroaryl.
  • R m and R n together with the nitrogen atom they are attached, form a heterocycloalkyl group, optionally substituted with alkyl, cycloalkyl, heterocycloalkyl, NR a R b , NH(CO)R d , NH(CO)OR c , and NH(CO)NR a R b .
  • R 1 and R 2 are each independently H, alkyl, halo, CN, OR c , SR c , or NR a R b .
  • the compound is a compound of the following formula:
  • V, U 1 , Y 1 , and Z 1 are each N or CR 6 ′;
  • R 1 , R 2 , and R 6 ′ are each independently H, alkyl, cycloalkyl, halo, nitro, OR c , SR c , CN, haloalkyl, O-haloalkyl, or NR a R b ;
  • R 3 , R 4 , and R 5 are each independently H, alkyl, cycloalkyl, heterocycloalkyl, halo, nitro, OR c , SR c , CN, haloalkyl, O-haloalkyl, NR m R n , (CO)R d , (CO)OR c , SO 2 NR m R n , (CO)NR m R n , C(NH)NR m R n , NH(CO)R d , NH(CO)OR c , NH(CO)NR m R n , aryl, or heteroaryl;
  • R 6 is H or NR a R b ;
  • R 7 and R 8 are each independently H, alkyl, alkenyl, alkynyl, halo, nitro, OR c , SR c , CN, haloalkyl, O-haloalkyl, (CO)R d .
  • NR a R b NH(CO)R d , NH(CO)OR c , NH(CO)NR a R b , (CO)OR c , (CO)NR a R b , SO 2 NR a R b , cycloalkyl, heterocycloalkyl aryl, or heteroaryl;
  • R m and R n are each independently
  • alkyl —(CH 2 ) p T, -aryl-(CH 2 ) p -T, —(CH 2 ) p -aryl-T, -heteroaryl-(CH 2 ) p T, —(CH 2 ) p heteroaryl-T, each optionally substituted with alkyl, cycloalkyl, halo, nitro. CN, haloalkyl, O-haloalkyl.
  • NH(CO)OR c NH(CO)NR a R b , NHC(NH)NH 2 , (CO)OR c , (CO)NR a R b , and SO 2 NR a R b ,
  • R m and R n together with the nitrogen atom they are attached, form a heterocycloalkyl group, optionally substituted with alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, halo, nitro, CN, OR c , SR c , COR d , NR a R b , NH(CO)R d , NH(CO)OR c , NH(CO)NR a R b , a guanidine group, (CO)OR c , and (CO)NR a R b ;
  • T is NR a R b , OR c , SR c , O—(CH 2 ) q —NR a R b , cycloalkyl, heterocycloalkyl, aryl, heteroaryl, a guanidine group, or an isonicotinimidamide group;
  • R a , R b , R c , and R d are each independently H alkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, —(CH 2 ) q -cycloalkyl, —(CH) q -heterocycloalkyl, —(CH 2 ) q -aryl.
  • cycloalkyl, heterocycloalkyl, aryl and heteroaryl are each optioncally substituted with a group consisting of alkyl, halo, nitro, CN, haloalkyl, O-haloalkyl, OH, O-alkyl, SH, S-alkyl, NH 2 , NH(alkyl), and N(alkyl) 2 ; and
  • p and q are each independently 0-5;
  • R 6 is NR a R b .
  • one of R 3 , R 4 , and R 5 is heterocycloalkyl, CN, NR m R n , (CO)R d , (CO)OR c , SO 2 NR m R n , (CO)NR m R n , C(NH)NR m R n , or NH(CO)R d .
  • one of R 3 , R 4 , and R 5 is (CO)NR m R n .
  • R m is H and R is —(CH 2 ) p -T, -aryl-(CH 2 ) p -T, —(CH 2 ) p -aryl-T, or -heteroaryl-(CH 2 ) p -T, each optionally substituted with alkyl, halo, and OR c .
  • T is NR a R b , O—(CH 2 ) q —NR a R b , heterocycloalkyl, aryl, or heteroaryl.
  • R m and R n together with the nitrogen atom they are attached, form a heterocycloalkyl group, optionally substituted with alkyl, cycloalkyl, heterocycloalkyl.
  • NR a R b NH(CO)R d , NH(CO)OR c , and NH(CO)NR a R b .
  • R 1 and R 2 are each independently H, alkyl, halo, CN, OR c , SR c , or NR a R b .
  • the compound is a compound of formula (XV)
  • R′ is H or alkyl
  • R 1 , R 2 , R 10 , R 11 , R 12 , and R 13 are each independently H, alkyl, cycloalkyl, halo, nitro, OR c , SR c , CN, haloalkyl, O-haloalkyl, or NR a R b ;
  • R 3 , R 4 , and R 5 are each independently H, alkyl, cycloalkyl, heterocycloalkyl, halo, nitro. OR c , SR c , CN, haloalkyl, O-haloalkyl.
  • R m and R n are each independently
  • alkyl —(CH 2 ) p -T, -aryl-(CH 2 ) p -T, —(CH 2 ) p -aryl-T, -heteroaryl-(CH 2 ) p -T, —(CH 2 ) p -heteroaryl-T, each optionally substituted with alkyl, cycloalkyl, halo, nitro, CN, haloalkyl, O-haloalkyl, OR c , SR c , (CO)R d , NR a R b , NH(CO)R d , NH(CO)OR c , NH(CO)NR a R b , NHC(NH)NH 2 , (CO)OR c , (CO)NR a R b , and SO 2 NR a R b ,
  • R m and R n together with the nitrogen atom they are attached, form a heterocycloalkyl group, optionally substituted with alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, halo, nitro, CN.
  • T is NR a R b , OR c .
  • SR c O—(CH 2 ) q —NR a R b , cycloalkyl, heterocycloalkyl, aryl, heteroaryl, a guanidine group, or an isonicotinimidamide group:
  • R a , R b , R c , and R d are each independently H, alkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, —(CH 2 ) q -cycloalkyl, —(CH) q -heterocycloalkyl, —(CH 2 ) q -aryl, —(CH) q -heteroaryl, —(CO)-alkyl, —(CO)-cycloalkyl, or —(CO)-heterocycloalkyl, or R a and R b , together with the nitrogen atom to which they are attached, form a heterocycloalkyl group, wherein cycloalkyl, heterocycloalkyl, aryl and heteroaryl are each optioncally substituted with a group consisting of alkyl, halo, nitro, CN, haloalkyl, O-haloalky
  • p and q are each independently 0-5.
  • R′ is H.
  • one of R 3 , R 4 , and R 5 is heterocycloalkyl, CN, NR m R n , (CO)R d , (CO)OR c , SO 2 NR m R n . (CO)NR m R n . C(NH)NR m R n , or NH(CO)R d .
  • one of R 3 , R 4 , and R 5 is (C)NR m R n .
  • R m is H and R n is —(C 2 ) p -T, -aryl-(CH 2 ) p -T, —(CH 2 ) p -aryl-T, or -heteroaryl-(CH 2 ) p -T, each optionally substituted with alkyl, halo, and OR c .
  • T is NR a R b , O—(CH 2 ) q —NR a R b , heterocycloalkyl, aryl, or heteroaryl.
  • R m and R n together with the nitrogen atom they are attached, form a heterocycloalkyl group, optionally substituted with alkyl, cycloalkyl, heterocycloalkyl.
  • NR a R b NH(CO)R d , NH(CO)OR c , and NH(CO)NR a R b .
  • R 1 and R 2 are each independently H, alkyl, halo, CN, OR c , SR c , or NR a R b .
  • the present invention provides a compound represented by formula (I):
  • Ring A is a 5- or 6-membered aryl or heteroaryl group, optionally substituted
  • Y and Z are each N or CR 9 , wherein R 9 is H, alkyl, halo, nitro. OH, SH, CN, O-alkyl, haloalkyl, O-haloalkyl. S-alkyl, (CO)-alkyl, (CO)-alkenyl, NR a R b . (CO)OR c . (CO)NR a R b , or SO 2 NR a R b , wherein R a , R b , and R c are H or alkyl;
  • W is azo, alkene, alkyne, C 1-8 alkyl, heteroalkyl containing 1-8 carbon and hetero atoms, cycloalkyl, hetereocycloalkyl, aryl, or heteroaryl, wherein cycloalkyl, hetereocycloalkyl, aryl, and heteroaryl optionally form a fused aryl or heteroaryl group with Ring A;
  • R 6 , R 7 , and R 8 are each independently H, alkyl, alkenyl, alkynyl, halo, nitro, OH, SH, CN, O-alkyl, haloalkyl, O-haloalkyl.
  • Ring A is optionally substituted with substituents independently selected from:
  • alkyl alkenyl, alkynyl, halo, nitro.
  • OH, SH, CN O-alkyl, haloalkyl, O-haloalkyl, S-alkyl, (CO)-alkyl, (CO)-alkenyl, NR a R b , NH(CO)-alkyl.
  • NH(CO)OR c NH(CO)NR a R b , (CO)OR c , SO 2 NR a R b ;
  • cycloalkyl cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, each optionally substituted with substituents independently selected from alkyl, aminoalkyl, heterocycloalkyl-alkyl, heterocycloalkyl, cycloalkyl-alkyl, and cycloalkyl;
  • R m and R n together with the nitrogen atom they are attached, form a heterocycloalkyl or heteroaryl group, optionally substituted with alkyl, halo, nitro, CN, OH, SH, O-alkyl.
  • T is NR a R b , O-alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkylamino, heterocycloalkylamino, arylamino, heteroarylamino, a guanidine group, or an isonicotinimidamide group;
  • Y is N.
  • Z is CH.
  • W is azo. —CH ⁇ CH—. —C ⁇ C—, a phenyl group, or a 5- or 6-membered heteroaryl group. In other embodiments. W is azo. In certain embodiments. W is —C ⁇ C—.
  • R 6 is (CO)NR m R n . In other embodiments, wherein R 6 is C(NH)NR m R n .
  • R 6 is NH 2 .
  • the compound of formula (I) is represented by the following formulas:
  • R 1 and R 2 are each independently H, alkyl, alkenyl, alkynyl, halo, nitro. OH, SH, CN, O-alkyl, haloalkyl, O-haloalkyl, S-alkyl, (CO)-alkyl, (CO)-alkenyl, NR a R b , NH(CO)-alkyl NH(CO)OR c , NH(CO)NR a R b , (CO)OR c , (CO)NR a R b , SO 2 NR a R b , cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
  • R 3 is:
  • cycloalkyl, heterocycloalkyl, aryl, or heteroaryl each optionally substituted with substituents independently selected from alkyl, aminoalkyl, heterocycloalkyl-alkyl, heterocycloalkyl, cycloalkyl-alkyl, and cycloalkyl; and (CO)NR m R n or C(NH)NR m R n , wherein R m and R n are each independently H, alkyl, —(CH 2 ) p -T cycloalkyl, heterocycloaryl, aryl, or heteroaryl, wherein —(CH 2 ) p -T, cycloalkyl, heterocycloaryl aryl, and heteroaryl are each optionally substituted with alkyl, halo, nitro, CN, OH, SH, O-alkyl, S-alkyl, (CO)-alkyl, (CO)-alkenyl, NR a R b ,
  • R m and R n together with the nitrogen atom they are attached, form a heterocycloalkyl or heteroaryl group, optionally substituted with alkyl, halo, nitro, CN. OH, SH. O-alkyl, S-alkyl, —CO-alkyl, —CO-alkenyl. NR a R b , (CO)OR c , or (CO)NR a R b ;
  • p 0-8;
  • T is NR a R b , O-alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkylamino, heterocycloalkylamino, arylamino, heteroarylamino, a guanidine group, or an isonicotinimidamide group.
  • the compound of formula (I) is represented by the following formulas:
  • E. Y 2 , Y 3 , Y 4 , and Y 5 are each O, S N or NR 14 , wherein R 14 is H, alkyl, (CO)-alkyl, (CO)OR c , (CO)NR a R b , or SO 2 NR a R b ;
  • R 3 is:
  • cycloalkyl cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, each optionally substituted with substituents independently selected from alkyl, aminoalkyl, heterocycloalkyl-alkyl, heterocycloalkyl, cycloalkyl-alkyl, and cycloalkyl;
  • R m and R n are each independently H, alkyl, —(CH 2 ) p -T, cycloalkyl, heterocycloaryl, aryl, or heteroaryl, wherein —(CH 2 ) p -T, cycloalkyl, heterocycloaryl, aryl, and heteroaryl are each optionally substituted with alkyl, halo, nitro, CN, OH, SH, O-alkyl, S-alkyl, (CO)-alkyl (CO)-alkenyl, NR a R b , (CO)OR c , (CO)NR a R b . SO 2 NR a R b , cycloalkylamino, heterocycloalkylamino, arylamino, or heteroarylamino;
  • R m and R n together with the nitrogen atom they are attached, form a heterocycloalkyl or heteroaryl group, optionally substituted with alkyl, halo, nitro, CN, OH, SH, O-alkyl, S-alkyl, —CO-alkyl, —CO-alkenyl, NR a R b , (CO)OR c , or (CO)NR a R b ;
  • p 0-8;
  • T is NR a R b , O-alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkylamino, heterocycloalkylamino, arylamino, heteroarylamino, a guanidine group, or an isonicotinimidamide group.
  • a compound of formula (I) is represented by formula (Ia)
  • R 1 , R 2 , R 4 , and R 5 are each independently H, alkyl, alkenyl, alkynyl, halo, nitro, OH, SH, CN, O-alkyl, haloalkyl, O-haloalkyl, S-alkyl, (CO)-alkyl, (CO)-alkenyl, NR a R b , NH(CO)-alkyl, NH(CO)OR c , NH(CO)NR a R b , (CO)OR c , (CO)NR a R b , SO 2 NR a R b , cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
  • R 3 is:
  • cycloalkyl cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, each optionally substituted with substituents independently selected from alkyl, aminoalkyl, heterocycloalkyl-alkyl, heterocycloalkyl, cycloalkyl-alkyl, and cycloalkyl;
  • R m and R n are each independently H, alkyl, —(CH 2 ) p -T, cycloalkyl, heterocycloaryl, aryl, or heteroaryl, wherein —(CH 2 ) p -T, cycloalkyl, heterocycloaryl, aryl, and heteroaryl are each optionally substituted with alkyl, halo, nitro.
  • CN OH, SH, O-alkyl, S-alkyl, (CO)-alkyl, (CO)-alkenyl, NR a R b , (CO)OR c , (CO)NR a R b , SO 2 NR a R b , cycloalkylamino, heterocycloalkylamino, arylamino, or heteroarylamino;
  • R m and R n together with the nitrogen atom they are attached, form a heterocycloalkyl or heteroaryl group, optionally substituted with alkyl, halo, nitro, CN.
  • NR a R b (CO)OR c , or (CO)NR a R b ;
  • p 0-8;
  • T is NR a R b .
  • the compound of formula (Ia) is represented by a compound of formula (II)
  • R 10 , R 11 , R 12 , and R 13 are each independently H, alkyl, alkenyl, alkynyl, halo, nitro. OH, SH, CN, O-alkyl, haloalkyl, O-haloalkyl. S-alkyl, (CO)-alkyl, (CO)-alkenyl.
  • NR a R b (CO)OR c , (CO)NR a R b , SO 2 NR a R b , —C(CH 3 )( ⁇ N—NHC(NH)NH 2 , cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, wherein alkyl, alkenyl, alkynyl cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are each optionally substituted with amino, alkylamino, dialkylamino, —NH(CO)-alkyl, or —NH(CO)— alkenyl.
  • R 11 , R 12 , and R 13 are each independently H, alkyl, alkynyl, halo, OH, CN, amino, alkylamino, or di-alkylamino.
  • R 11 is alkynyl, optionally substituted with amino, alkylamino, dialkylamino, or —NH(CO)-alkenyl. In other embodiments. R 11 is halo. In certain embodiments, R 11 is chloro.
  • R 6 is NH 2 .
  • R 1 , R 2 . R 4 , and R 5 are each H.
  • R 3 is CN. In other embodiments, R 3 is heterocycloalkyl or heteroaryl, optionally substituted with alkyl, aminoalkyl, heterocycloalkyl-alkyl, heterocycloalkyl, cycloalkyl-alkyl, and cycloalkyl.
  • R 3 is (CO)NR m R n . In other embodiments. R 3 is C(NH)NR m R n . In some embodiments, R m is H and R n is heterocycloalkyl. In some embodiments, R m is H and R n is (CH 2 ) p -T, optionally substituted with alkyl, halo, or OH. In some embodiments, p is 1-4.
  • T is NR a R b or O-alkyl. In some embodiments. T is —N(alkyl) 2 . In certain embodiments. T is N(CH 3 ) 2 . In other embodiments. T is OCH 3 . In some embodiments, T is heterocycloalkylamino, a guanidine group, or an isonicotinimidamide group. In some embodiments. T is heterocycloalkyl. In certain embodiments, T is a 5- or 6-membered heterocycloalkyl group. In some embodiments. T is piperidine or pyrrolidine.
  • R m is H and R n is aryl or heteroaryl. In other embodiments. R m and R n , together with the nitrogen atom they are attached, form a heterocycloalkyl group. In some embodiments, R m and R n are independently alkyl.
  • the compound of formula (I) is represented by a compound of formula (III)
  • the compound of formula (I) is represented by a compound of formulas IV a -IV f :
  • R 1 , R 2 . R 4 , R 5 , R 10 , and R 13 are each independently H, alkyl, alkenyl, alkynyl, halo, nitro, OH, SH, CN, O-alkyl, haloalkyl, O-haloalkyl, S-alkyl, (CO)-alkyl, (CO)-alkenyl, NR a R b , NH(CO)-alkyl, NH(CO)OR c , NH(CO)NR a R b , (CO)OR c , (CO)NR a R b , SO 2 NR a R b , cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; and
  • R 11 and R 12 are each independently H, alkyl, alkenyl, alkynyl, halo, nitro, OH, SH, CN, O-alkyl, haloalkyl, O-haloalkyl, S-alkyl, (CO)-alkyl, (CO)-alkenyl, NR a R b , (CO)OR c , (CO)NR a R b , SO 2 NR a R b , —C(CH 3 )( ⁇ N—NHC(NH)NH 2 , cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, wherein alkyl, alkenyl, alkynyl cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are each optionally substituted with amino, alkylamino, dialkylamino, —NH(CO)-alkyl, or —NH(CO)— alkenyl.
  • R m is H and R n is (CH 2 ) p -T, optionally substituted with OH. In other embodiments. R m and R n are independently alkyl. In some embodiments, p is 1-4. In some embodiments, T is NR a R b or O-alkyl. In certain embodiments, T is N(CH 3 ) 2 . In other embodiments, T is OCH 3 . In some embodiments, T is heterocycloalkyl. In some embodiments. T is a 5- or 6-membered heterocycloalkyl group. In certain embodiments. T is piperidine or pyrrolidine.
  • R m and R n together with the nitrogen atom they are attached, form a 5- or 6-membered heterocycloalkyl group.
  • R 6 is NH 2 .
  • R 11 is halo. In certain embodiments. R 11 is chloro.
  • the compound of the invention is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • the compound of the invention is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • the compound of the invention is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • the compound of the invention is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • the compound of the invention is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • the compound of the invention is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • the compound of the invention is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • the compound of the invention is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • the compound is the invention is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • the compound of formula (I) of the invention is represented by a compound of formulas V a -V f
  • R 2 , R 4 , and R 5 are each independently H, alkyl, alkenyl, alkynyl, halo, nitro, OH, SH. CN, O-alkyl, haloalkyl, O-haloalkyl, S-alkyl, (CO)-alkyl, (CO)-alkenyl.
  • NR a R b NH(CO)-alkyl, NH(CO)OR c , NH(CO)NR a R b , (CO)OR c , (CO)NR a R b , SO 2 NR a R b , cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; and
  • R 11 and R 12 are each independently H, alkyl, alkenyl, alkynyl, halo, nitro, OH, SH, CN, O-alkyl, haloalkyl, O-haloalkyl, S-alkyl, (CO)-alkyl, (CO)-alkenyl, NR a R b , (CO)OR c , (CO)NR a R b , SO 2 NR a R b , —C(CH 3 )( ⁇ N—NHC(NH)NH 2 , cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, wherein alkyl, alkenyl, alkynyl cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are each optionally substituted with amino, alkylamino, dialkylamino, —NH(CO)-alkyl, or —NH(CO)— alkenyl.
  • the compound of formula (I) of the invention is represented by a compound of formulas VI a -VI c
  • R 1 . R 2 . R 4 , and R 5 are each independently H, alkyl, alkenyl, alkynyl, halo, nitro. OH, SH, CN, O-alkyl, haloalkyl, O-haloalkyl. S-alkyl, (CO)-alkyl, (CO)-alkenyl. NR a R b . NH(CO)-alkyl.
  • R′ is the same or different R 1 and R 1 are each independently H, alkyl, alkenyl, alkynyl, halo, nitro, OH, SH, CN, O-alkyl, haloalkyl, O-haloalkyl, S-alkyl, (CO)-alkyl, (CO)-alkenyl, NR a R b , (CO)OR c , (CO)NR a R b , SO 2 NR a R b , —C(CH 3 )( ⁇ N—NHC(NH)NH 2 , cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, wherein
  • R 14 is H, alkyl, (CO)-alkyl, (CO)OR c , (CO)NR a R b , or SO 2 NR a R b .
  • the compound of formula (I) of the invention is represented by a compound of formulas VII a -VII c
  • R 1 , R 2 , R 4 , R 5 , R 16 , R 17 , R 18 , and R 19 are each independently H, alkyl, alkenyl, alkynyl, halo, nitro, OH, SH, CN, O-alkyl, haloalkyl, O-haloalkyl, -alkyl(CO)-alkyl, (CO)-alkenyl, NR a R b , NH(CO)-alkyl, NH(CO)OR c , NH(CO)NR a R b , (CO)OR c , (CO)NR a R b , SO 2 NR a R b , cycloalkyl, heterocycloalkyl, aryl, or heteroaryl:
  • R 11 and R 12 are each independently H, alkyl alkenyl alkynyl, halo, nitro, OH, SH, CN, O-alkyl, haloalkyl, O-haloalkyl, S-alkyl, (CO)-alkyl, (CO)-alkenyl.
  • R 14 is H, alkyl, (CO)-alkyl, (CO)OR c , (CO)NR a R b , or SO 2 NR a R b .
  • the compound of formula (I) of the invention is represented by a compound of formulas VII a -VIII f
  • E is O, S, or NR 14 ;
  • R 1 , R 2 , R 4 , and R 5 are each independently H, alkyl, alkenyl, alkynyl, halo, nitro, OH, SH. CN, O-alkyl, haloalkyl, O-haloalkyl, S-alkyl, (CO)-alkyl, (CO)-alkenyl.
  • NR a R b NH(CO)-alkyl, NH(CO)OR c .
  • R 14 and R 15 are each independently H, alkyl, (CO)-alkyl, (CO)OR c , (CO)NR a R b , or SO 2 NR a R b .
  • the compound of formula (I) of the invention is represented by a compound of formulas IX a -IX f
  • E is O, S, or NR 14 ;
  • R 1 , R 2 , R 4 , and R 5 are each independently H, alkyl, alkenyl, alkynyl, halo, nitro. OH, SH, CN, O-alkyl, haloalkyl, O-haloalkyl, S-alkyl, (CO)-alkyl, (CO)-alkenyl, NR a R b , NH(CO)-alkyl, NH(CO)OR c , NH(CO)NR a R b , (CO)OR c , (CO)NR a R b , SO 2 NR a R b , cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; and
  • R 14 and R 15 are each independently H, alkyl, (CO)-alkyl, (CO)OR c , (CO)NR a R b , or SO 2 NR a R b .
  • the compound of formula (I) of the invention is represented by a compound of formulas Xa-Xf
  • E is O, S, or NR 4 ;
  • R 1 , R 2 , R 4 , R 5 , R 10 , and R 13 are each independently H, alkyl, alkenyl, alkynyl, halo, nitro, OH, SH, CN, O-alkyl, haloalkyl, O-haloalkyl.
  • R 11 and R 12 are each independently H, alkyl, alkenyl, alkynyl, halo, nitro, OH, SH, CN, O-alkyl, haloalkyl, O-haloalkyl, S-alkyl, (CO)-alkyl, (CO)-alkenyl, NR a R b , (CO)OR c , (CO)NR a R b , SO 2 NR a R b , —C(CH 3 )( ⁇ N—NHC(NH)NH 2 , cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, wherein alkyl, alkenyl, alkynyl cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are each optionally substituted with amino, alkylamino, dialkylamino. —NH(CO)-alkyl, or —NH(CO)— alkenyl; and
  • R 14 and R 15 are each independently H, alkyl, (CO)-alkyl, (CO)OR c , (CO)NR a R b , or SO 2 NR a R b .
  • the compound of formula (I) of the invention is represented by a compound of formulas XI a -XI f
  • E is O, S, or NR 14 ;
  • R 1 . R 2 . R 4 , and R 5 are each independently H, alkyl, alkenyl, alkynyl, halo, nitro. OH, SH, CN, O-alkyl, haloalkyl, -haloalkyl, S-alkyl, (CO)-alkyl, (CO)-alkenyl.
  • NR a R b NH(CO)-alkyl, NH(CO)OR c , NH(CO)NR a R b , (CO)OR c .
  • R 14 and R 15 are each independently H, alkyl, (CO)-alkyl, (CO)OR c , (CO)NR a R b , or SO 2 NR a R b .
  • the compound of the invention can be prepared by the methods known in the art and the methods in the reaction schemes and experiments as described herein.
  • Scheme 1 provides a general reaction scheme for the preparation of the compounds of the invention through a halogenation reaction, followed by functionalization.
  • a compound of the invention can be prepared via Sonogashira methodology as described in Scheme 2.
  • Scheme 3 describes the preparation of a compound of the invention via Suzuki coupling.
  • a compound of the invention can be prepared by functionalization of isoquinoline amine according to Scheme 4.
  • Scheme 5 provides a general synthetic strategy for synthesis of functionalized 1-amino or 2-amino or 3-amino isoquinoline, quinoline/quinazoline and isoquinolines using quinoline or isoquinoline or quinazoline amine as nucleophile.
  • Scheme 6 provides a general synthetic strategy for synthesis of 4-Substituted isoquinolines, quinolones and quinazolines.
  • Scheme 7 provides synthesis of target compounds via Sonogashira coupling.
  • FIG. 7 A general synthetic strategy for displacement of halogen on quinoline or isoquinoline or quinazoline for preparation of compounds of the invention is described in FIG. 7 .
  • the compounds of the invention are described in FIGS. 4-6 .
  • the compounds of the invention are readily prepared via Sonogashira or Suzuki coupling of iodo arenes with alkynes or alkene boronates, catalyzed by Pd(PPh 3 ) 2 Cl 2 (Sonogashira) or Pd(PPh 3 ) 4 (Suzuki) (e.g., in Table 4) as demonstrated in Scheme 8.
  • NIS N-iodosuccinimide
  • DIPEA diisopropylethylamine
  • DMF dimethylformamide
  • the nature and substitution pattern on the amide and amidine head groups remarkably affect the anticancer properties of the compounds.
  • the compounds By systematically varying the amide and amidine functionalities, the compounds have been identified that are about two orders of magnitude more potent than the compounds previously reported by Sintim et al. (PCT/US2015/041551).
  • the length of the amide head group, substitution pattern and relative position to the alkyne moiety remarkably affects the anticancer activity against MV4-11 cell line (AML cell line).
  • AML cell line MV4-11 cell line
  • the nature of the amide group in the molecules shown in FIG. 1 had a dramatic effect on the anticancer activities of the molecules tested.
  • compounds HSM1669, M731, and HSM1684 differed from each other by a simple methylene group (CH 2 ) yet the anticancer activities against AML are 260 nM (HSM1669), 36 nM (HSM731) and 71 nM (HSM1684). It appears that anticancer potency increases with an additional methylene group (HSM1669 to M731) but then decreases when another methylene group is added (M731 to HSM1684). Further, depending on the nature of the amide linker, the relative positions of the alkyne and amide moieties appear to affect anticancer potencies.
  • the relationship between M731 and HSM1688 (para vs meta substitution) is similar to that between HSD79 and HSD82 but whereas the anticancer activity of M731 is higher than that of HSM1688 (36 nM versus 250 nM; almost a fold difference), and that of HSD79 and HSD82 are similar (108 nM versus 150 nM).
  • the anticancer activities (IC 50 ) against MV4-11 are 36 nM, 450 nM, and 108 nM, pointing to the essentiality of a nitrogen group at this 4* position.
  • the IC50 values are 250 nM for HSM1688 (nitrogen at the 4* position) and 150 nM for HSD82 (carbon at the 4* position).
  • substituents of compounds of the invention are disclosed in groups or in ranges. It is specifically intended that the invention include each and every individual subcombination of the members of such groups and ranges.
  • C 1-5 alkyl is specifically intended to individually disclose methyl, ethyl. C 3 alkyl. C 4 alkyl, and C 5 alkyl.
  • the compounds of the invention are stable.
  • “stable” refers to a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and preferably capable of formulation into an efficacious therapeutic agent. It is further appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, can also be provided in combination in a single embodiment. Conversely, various features of the invention which are, for brevity, described in the context of a single embodiment, can also be provided separately or in any suitable subcombination.
  • the term “about” can allow for a degree of variability in a value or range, for example, within 10%, within 5%, or within 1% of a stated value or of a stated limit of a range.
  • alkyl is meant to refer to a saturated hydrocarbon group which is straight-chained or branched.
  • Example alkyl groups include methyl (Me), ethyl (Et), propyl (e.g., n-propyl and isopropyl), butyl (e.g., n-butyl, isobutyl, t-butyl), pentyl (e.g., n-pentyl, isopentyl, neopentyl), and the like.
  • An alkyl group can contain from 1 to about 20, from 2 to about 20, from 1 to about 10, from 1 to about 8, from 1 to about 6, from 1 to about 4, or from 1 to about 3 carbon atoms.
  • alkenyl refers to an unsaturated monovalent chain of carbon atoms including at least one double bond, which may be optionally branched. It is understood that in embodiments that include alkenyl, illustrative variations of those embodiments include lower alkenyl, such as C 2 -C 6 , C 2 -C 4 alkenyl, and the like.
  • alkynyl refers to an unsaturated monovalent chain of carbon atoms including at least one triple bond, which may be optionally branched. It is understood that in embodiments that include alkynyl, illustrative variations of those embodiments include lower alkynyl, such as C 2 -C 6 , C 2 -C 4 alkynyl, and the like.
  • cycloalkyl refers to non-aromatic carbocycles including cyclized alkyl, alkenyl, and alkynyl groups.
  • Cycloalkyl groups can include mono- or polycyclic (e.g., having 2, 3 or 4 fused rings) ring systems, including spirocycles.
  • cycloalkyl groups can have from 3 to about 20 carbon atoms, 3 to about 14 carbon atoms, 3 to about 10 carbon atoms, or 3 to 7 carbon atoms. Cycloalkyl groups can further have 0, 1, 2, or 3 double bonds and/or 0, 1, or 2 triple bonds.
  • cycloalkyl moieties that have one or more aromatic rings fused (i.e., having a bond in common with) to the cycloalkyl ring, for example, benzo derivatives of cyclopentane, cyclopentene, cyclohexane, and the like.
  • a cycloalkyl group having one or more fused aromatic rings can be attached through either the aromatic or non-aromatic portion.
  • One or more ring-forming carbon atoms of a cycloalkyl group can be oxidized, for example, having an oxo or sulfido substituent.
  • Example cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptatrienyl, norbornyl, norpinyl, norcarnyl, adamantyl, and the like.
  • aryl refers to monocyclic or polycyclic (e.g., having 2, 3 or 4 fused rings) aromatic hydrocarbons such as, for example, phenyl, naphthyl, anthracenyl, phenanthrenyl, and the like. In some embodiments, an aryl group has from 6 to about 20 carbon atoms.
  • heteroaryl refers to an aromatic heterocycle having at least one heteroatom ring member such as sulfur, oxygen, or nitrogen.
  • Heteroaryl groups include monocyclic and polycyclic (e.g., having 2, 3 or 4 fused rings) systems. Any ring-forming N atom in a heteroaryl group can also be oxidized to form an N-oxo moiety.
  • heteroaryl groups include without limitation, pyridyl, N-oxopyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, furyl, quinolyl, isoquinolyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrryl oxazolyl, benzofuryl, benzothienyl, benzthiazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, indaolyl, 1,2,4-thiadiazolyl, isothiazolyl, benzothienyl, purinyl, carbazolyl, benzimidazolyl, indolinyl, and the like.
  • the heteroaryl group has from 1 to about 20 carbon atoms, and in further embodiments from about 3 to about 20 carbon atoms. In some embodiments, the heteroaryl group contains 3 to about 14, 3 to about 7, or 5 to 6 ring-forming atoms. In some embodiments, the heteroaryl group has 1 to about 4, 1 to about 3, or 1 to 2 heteroatoms. In some embodiments, “heteroaryl” may be optionally substituted at any one or more positions capable of bearing a hydrogen atom.
  • heterocycloalkyl refers to a non-aromatic heterocycle where one or more of the ring-forming atoms are a heteroatom such as an O, N, or S atom.
  • Heterocycloalkyl groups can include mono- or polycyclic (e.g., having 2, 3 or 4 fused rings) ring systems as well as spirocycles.
  • Example heterocycloalkyl groups include morpholino, thiomorpholino, piperazinyl, tetrahydrofuranyl, tetrahydrothienyl, 2,3-dihydrobenzofuryl, 1,3-benzodioxole, benzo-1,4-dioxane, piperidinyl, pyrrolidinyl, isoxazolidinyl, isothiazolidinyl, pyrazolidinyl, oxazolidinyl, thiazolidinyl, imidazolidinyl, and the like.
  • heterocycloalkyl moieties that have one or more aromatic rings fused (i.e., having a bond in common with) to the nonaromatic heterocyclic ring, for example phthalimidyl, naphthalimidyl, and benzo derivatives of heterocycles.
  • a heterocycloalkyl group having one or more fused aromatic rings can be attached though either the aromatic or non-aromatic portion.
  • heterocycloalkyl moieties where one or more ring-forming atoms are substituted by 1 or 2 oxo or sulfido groups.
  • the heterocycloalkyl group has from 1 to about 20 carbon atoms, and in further embodiments from about 3 to about 20 carbon atoms.
  • the heterocycloalkyl group contains 3 to about 20, 3 to about 14, 3 to about 7, or 5 to 6 ring-forming atoms.
  • the heterocycloalkyl group has 1 to about 4, 1 to about 3, or 1 to 2 heteroatoms.
  • the heterocycloalkyl group contains 0 to 3 double bonds. In some embodiments, the heterocycloalkyl group contains 0 to 2 triple bonds.
  • halo or “halogen” includes fluoro, chloro, bromo, and iodo.
  • a “halogen-substitution” or “halo” substitution designates replacement of one or more hydrogen atoms with F, Cl, Br or I.
  • haloalkyl refers to an alkyl group having one or more halogen substituents.
  • Example haloalkyl groups include CF 3 , C 2 F 5 , CHF 2 , CCl 3 , CHCl 2 , C 2 Cl 5 , and the like.
  • each of alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkylene, and heterocycle may be optionally substituted with independently selected groups such as alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, carboxylic acid and derivatives thereof, including esters, amides, and nitrites, hydroxy, alkoxy, acyloxy, amino, alky and dialkylamino, acylamino, thio, and the like, and combinations thereof.
  • the term “substituted” refers to the replacement of a hydrogen moiety with a non-hydrogen moiety in a molecule or group. It can refer to “mono-substituted” or “poly-substituted.”
  • the term “mono-substituted” or “poly-substituted” means substituted with one or more than one substituent up to the valence of the substituted group. For example, a mono-substituted group can be substituted with 1 substituent, and a poly-substituted group can be substituted with 2, 3, 4, or 5 substituents. When a list of possible substituents is provided, the substituents can be independently selected from that group.
  • substituents means that the groups in question are either unsubstituted or substituted with one or more of the substituents specified. When the groups in question are substituted with more than one substituent, the substituents may be the same or different.
  • Such other functional groups illustratively include, but are not limited to, amino, hydroxyl.
  • CN halo, thiol, alkyl, haloalkyl, heteroalkyl, aryl, arylalkyl, arylheteroalkyl, heteroaryl, heteroarylalkyl, heteroarylheteroalkyl, nitro, sulfonic acids and derivatives thereof, carboxylic acids and derivatives thereof, and the like.
  • any of amino, hydroxyl, CH, thiol, alkyl, haloalkyl, heteroalkyl, aryl, arylalkyl, arylheteroalkyl, heteroaryl, heteroarylalkyl, heteroarylheteroalkyl, and/or sulfonic acid is optionally substituted.
  • the functional groups are the substituents described herein for any one of variables.
  • independently when using the terms “independently,” “independently are,” and “independently selected from” mean that the groups in question may be the same or different. Certain of the herein defined terms may occur more than once in the structure, and upon such occurrence each term shall be defined independently of the other.
  • the formulas also include any and all hydrates and/or solvates of the compound formulas. It is appreciated that certain functional groups, such as the hydroxy, amino, and like groups form complexes and/or coordination compounds with water and/or various solvents, in the various physical forms of the compounds. Accordingly, the above formulas are to be understood to include and represent those various hydrates and/or solvates.
  • the compounds described herein can be asymmetric (e.g., having one or more stereocenters). All stereoisomers, such as enantiomers and diastereomers, are intended unless otherwise indicated.
  • Compounds of the present invention that contain asymmetrically substituted carbon atoms can be isolated in optically active or racemic forms. Methods on how to prepare optically active forms from optically active starting materials are known in the art, such as by resolution of racemic mixtures or by stereoselective synthesis. Many geometric isomers of olefins. C ⁇ N double bonds, and the like can also be present in the compounds described herein, and all such stable isomers are contemplated in the present invention. Cis and trans geometric isomers of the compounds of the present invention are described and may be isolated as a mixture of isomers or as separated isomeric forms.
  • the invention relates to the D form, the L form, and D.L mixtures and also, where more than one asymmetric carbon atom is present, to the diastereomeric forms.
  • Those compounds of the invention which contain asymmetric carbon atoms, and which as a rule accrue as racemates, can be separated into the optically active isomers in a known manner, for example using an optically active acid.
  • Tautomeric forms result from the swapping of a single bond with an adjacent double bond together with the concomitant migration of a proton.
  • Tautomeric forms include prototropic tautomers which are isomeric protonation states having the same empirical formula and total charge.
  • Example prototropic tautomers include ketone-enol pairs, amide-imidic acid pairs, lactam-lactim pairs, amide-imidic acid pairs, enamine-imine pairs, and annular forms where a proton can occupy two or more positions of a heterocyclic system, for example, 1H- and 3H-imidazole, 1H-, 2H- and 4H-1,2,4-triazole, 1H- and 2H-isoindole, and 1H- and 2H-pyrazole.
  • Tautomeric forms can be in equilibrium or sterically locked into one form by appropriate substitution.
  • Compounds of the invention can also include all isotopes of atoms occurring in the intermediates or final compounds.
  • Isotopes include those atoms having the same atomic number but different mass numbers.
  • isotopes of hydrogen include tritium and deuterium.
  • the term “compound” as used herein, is meant to include all stereoisomers, geometric isomers, tautomers, and isotopes of the structures depicted.
  • the compound of the invention is substantially isolated.
  • substantially isolated is meant that the compound is at least partially or substantially separated from the environment in which it was formed or detected.
  • Partial separation can include, for example, a composition enriched in the compound of the invention.
  • Substantial separation can include compositions containing at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, or at least about 99% by weight of the compound of the invention, or salt thereof. Methods for isolating compounds and their salts are routine in the art.
  • the term “therapeutically effective amount” refers to the amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinicians, which includes alleviation of the symptoms of the disease or disorder being treated.
  • the therapeutically effective amount is that which may treat or alleviate the disease or symptoms of the disease at a reasonable benefit/risk ratio applicable to any medical treatment.
  • Body surface area may be approximately determined from patient height and weight (see, e.g., Scientific Tables, Geigy Pharmaceuticals. Ardley, N.Y, pages 537-538 (1970)).
  • a therapeutically effective amount of the compounds described herein may be defined as any amount useful for inhibiting the growth of (or killing) a population of malignant cells or cancer cells, such as may be found in a patient in need of relief from such cancer or malignancy.
  • such effective amounts range from about 5 mg/kg to about 500 mg/kg, from about 5 mg/kg to about 250 mg/kg, and/or from about 5 mg/kg to about 150 mg/kg of compound per patient body weight. It is appreciated that effective doses may also vary depending on the route of administration, optional excipient usage, and the possibility of co-usage of the compound with other conventional and non-conventional therapeutic treatments, including other anti-tumor agents, radiation therapy, and the like.
  • the phrase “pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
  • the compound of the present invention also includes “pharmaceutically acceptable salts” of the compounds described herein.
  • “pharmaceutically acceptable salts” refers to derivatives of the disclosed compounds wherein the parent compound is modified by converting an existing acid or base moiety to its salt form.
  • examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.
  • the pharmaceutically acceptable salts of the compound of the invention include the conventional non-toxic salts of the parent compound formed, for example, from non-toxic inorganic or organic acids.
  • the pharmaceutically acceptable salts of the compound of the invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods.
  • such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred.
  • the pharmaceutically acceptable salts of the compound of the invention can be obtained by converting derivatives which possess tertiary amino groups into the corresponding quaternary ammonium salts in a manner known per se using quaternizing agents.
  • suitable quaternizing agents are alkyl halides, such as methyl iodide, ethyl bromide, and n-propyl chloride, and also arylalkyl halides, such as benzyl chloride or 2-phenylethyl bromide.
  • the “subject” used here refers to an animal or a human. In some embodiment, the term “subject” refers to a human.
  • a pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt, N-oxide, hydrate, solvate, tautomer, or optical isomer thereof, and a pharmaceutically acceptable carrier or diluent.
  • the present invention features a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of the invention as described herein, or a pharmaceutically acceptable salt, N-oxide, hydrate, solvate, tautomer, or optical isomer thereof, and a pharmaceutically acceptable carrier or diluent.
  • the pharmaceutical composition includes a therapeutically effective amount of the one or more compounds for treating a cancer patient.
  • the composition may include other component and/or ingredients, including, but not limited to, other therapeutically active compounds, and/or one or more pharmaceutically acceptable carriers, diluents, excipients, and the like.
  • pharmaceutically acceptable carrier or “pharmaceutically acceptable diluent” is art-recognized and refers to a pharmaceutically-acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting any subject composition or component thereof.
  • a pharmaceutically-acceptable material such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting any subject composition or component thereof.
  • Each carrier must be “acceptable” in the sense of being compatible with the subject composition and its components and not injurious to the patient.
  • materials which may serve as pharmaceutically acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate: (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate: (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide: (15)
  • a therapeutically effective dose of a compound according to the invention is used, in addition to physiologically acceptable carriers, diluents and/or adjuvants for producing a pharmaceutical composition.
  • the dose of the active compound can vary depending on the route of administration, the age and weight of the patient, the nature and severity of the diseases to be treated, and similar factors.
  • the daily dose can be given as a single dose, which is to be administered once, or be subdivided into two or more daily doses, and is as a rule 0.001-2000 mg. Particular preference is given to administering daily doses of 0.1-500 mg, e.g. 0.1-100 mg.
  • Suitable administration forms are oral, parenteral, intravenous, transdermal, topical, inhalative, intranasal and sublingual preparations. Particular preference is given to using oral, parenteral, e.g. intravenous or intramuscular, intranasal, e.g. dry powder or sublingual preparations of the compounds according to the invention.
  • the customary galenic preparation forms such as tablets, sugar-coated tablets, capsules, dispersible powders, granulates, aqueous solutions, alcohol-containing aqueous solutions, aqueous or oily suspensions, syrups, juices or drops, are used.
  • Solid medicinal forms can comprise inert components and carrier substances, such as calcium carbonate, calcium phosphate, sodium phosphate, lactose, starch, mannitol, alginates, gelatine, guar gum, magnesium stearate, aluminium stearate, methyl cellulose, talc, highly dispersed silicic acids, silicone oil, higher molecular weight fatty acids, (such as stearic acid), gelatine, agar agar or vegetable or animal fats and oils, or solid high molecular weight polymers (such as polyethylene glycol); preparations which are suitable for oral administration can comprise additional flavorings and/or sweetening agents, if desired.
  • carrier substances such as calcium carbonate, calcium phosphate, sodium phosphate, lactose, starch, mannitol, alginates, gelatine, guar gum, magnesium stearate, aluminium stearate, methyl cellulose, talc, highly dispersed silicic acids, silicone oil, higher mole
  • Liquid medicinal forms can be sterilized and/or, where appropriate, comprise auxiliary substances, such as preservatives, stabilizers, wetting agents, penetrating agents, emulsifiers, spreading agents, solubilizers, salts, sugars or sugar alcohols for regulating the osmotic pressure or for buffering, and/or viscosity regulators.
  • auxiliary substances such as preservatives, stabilizers, wetting agents, penetrating agents, emulsifiers, spreading agents, solubilizers, salts, sugars or sugar alcohols for regulating the osmotic pressure or for buffering, and/or viscosity regulators.
  • additives are tartrate and citrate buffers, ethanol and sequestering agents (such as ethylenediaminetetraacetic acid and its nontoxic salts).
  • High molecular weight polymers such as liquid polyethylene oxides, microcrystalline celluloses, carboxymethyl celluloses, polyvinylpyrrolidones, dextrans or gelatine, are suitable for regulating the viscosity.
  • solid carrier substances are starch, lactose, mannitol, methyl cellulose, talc, highly dispersed silicic acids, high molecular weight fatty acids (such as stearic acid), gelatine, agar agar, calcium phosphate, magnesium stearate, animal and vegetable fats, and solid high molecular weight polymers, such as polyethylene glycol.
  • Oily suspensions for parenteral or topical applications can be vegetable synthetic or semisynthetic oils, such as liquid fatty acid esters having in each case from 8 to 22 C atoms in the fatty acid chains, for example palmitic acid, lauric acid, tridecanoic acid, margaric acid, stearic acid, arachidic acid, myristic acid, behenic acid, pentadecanoic acid, linoleic acid, elaidic acid, brasidic acid, erucic acid or oleic acid, which are esterified with monohydric to trihydric alcohols having from 1 to 6 C atoms, such as methanol, ethanol, propanol, butanol, pentanol or their isomers, glycol or glycerol.
  • vegetable synthetic or semisynthetic oils such as liquid fatty acid esters having in each case from 8 to 22 C atoms in the fatty acid chains, for example palmitic acid, lauric acid, tride
  • fatty acid esters are commercially available miglyols, isopropyl myristate, isopropyl palmitate, isopropyl stearate, PEG 6-capric acid, caprylic/capric acid esters of saturated fatty alcohols, polyoxyethylene glycerol trioleates, ethyl oleate, waxy fatty acid esters, such as artificial ducktail gland fat, coconut fatty acid isopropyl ester, oleyl oleate, decyl oleate, ethyl lactate, dibutyl phthalate, diisopropyl adipate, polyol fatty acid esters, inter alia.
  • Silicone oils of differing viscosity are also suitable.
  • Tt is furthermore possible to use vegetable oils, such as castor oil, almond oil, olive oil, sesame oil, cotton seed oil, groundnut oil or soybean oil.
  • Suitable solvents, gelatinizing agents and solubilizers are water or watermiscible solvents.
  • suitable substances are alcohols, such as ethanol or isopropyl alcohol, benzyl alcohol, 2-octyldodecanol, polyethylene glycols, phthalates, adipates, propylene glycol, glycerol, di- or tripropylene glycol, waxes, methyl cellosolve, cellosolve, esters, morpholines, dioxane, dimethyl sulphoxide, dimethylformamide, tetrahydrofuran, cyclohexanone, etc.
  • gelatinizing agents and film-forming agents are also perfectly possible.
  • ionic macromolecules such as sodium carboxymethyl cellulose, polyacrylic acid, polymethacrylic acid and their salts, sodium amylopectin semiglycolate, alginic acid or propylene glycol alginate as the sodium salt, gum arabic, xanthan gum, guar gum or carrageenan.
  • surfactants for example of Na lauryl sulphate, fatty alcohol ether sulphates, di-Na—N-lauryl- ⁇ -iminodipropionate, polyethoxylated castor oil or sorbitan monooleate, sorbitan monostearate, polysorbates (e.g. Tween), cetyl alcohol, lecithin, glycerol monostearate, polyoxyethylene stearate, alkylphenol polyglycol ethers, cetyltrimethylammonium chloride or mono-/dialkylpolyglycol ether orthophosphoric acid monoethanolamine salts can also be required for the formulation.
  • surfactants for example of Na lauryl sulphate, fatty alcohol ether sulphates, di-Na—N-lauryl- ⁇ -iminodipropionate, polyethoxylated castor oil or sorbitan monooleate, sorbitan monostearate, polysorbates (e.g. T
  • Stabilizers such as montmorillonites or colloidal silicic acids, for stabilizing emulsions or preventing the breakdown of active substances such as antioxidants, for example tocopherols or butylhydroxyanisole, or preservatives, such as p-hydroxybenzoic acid esters, can likewise be used for preparing the desired formulations.
  • Preparations for parenteral administration can be present in separate dose unit forms, such as ampoules or vials.
  • Use is preferably made of solutions of the active compound, preferably aqueous solution and, in particular, isotonic solutions and also suspensions.
  • These injection forms can be made available as ready-to-use preparations or only be prepared directly before use, by mixing the active compound, for example the lyophilisate, where appropriate containing other solid carrier substances, with the desired solvent or suspending agent.
  • Intranasal preparations can be present as aqueous or oily solutions or as aqueous or oily suspensions. They can also be present as lyophilisates which are prepared before use using the suitable solvent or suspending agent.
  • inhalable preparations can present as powders, solutions or suspensions.
  • inhalable preparations are in the form of powders, e.g. as a mixture of the active ingredient with a suitable formulation aid such as lactose.
  • the preparations are produced, aliquoted and sealed under the customary antimicrobial and aseptic conditions.
  • a compound of the invention may be administered as a combination therapy with further active agents.
  • therapeutically active compounds useful in the treatment of cancer for example, prostate cancer, ovarian cancer, lung cancer, or breast cancer.
  • the cancer is acute myeloid leukemia, chronic myeloid leukemia, ovarian cancer, cervical cancer, pancreatic cancer, breast cancer, brain cancer, skin cancer, lung cancer, prostate cancer. Lymphoma, Leukemia, colon cancer, head cancer, neck cancer, thyroid cancer, kidney cancer, liver cancer and stomach cancer.
  • the active ingredients may be formulated as compositions containing several active ingredients in a single dose form and/or as kits containing individual active ingredients in separate dose forms. The active ingredients used in combination therapy may be coadministered or administered separately.
  • a compound of the invention as described herein is a protein kinase inhibitor.
  • the present invention features a method of inhibiting a protein kinase, wherein the method comprises contacting the protein kinase with an effective amount of a compound of the invention.
  • such protein kinase includes, but is not limited to.
  • the protein kinase is Abl, Abl2, AFK, ALK, AMPK_group, ATM, ATR, Aurora A, Aurora B, Axl, BCKDK, BLK, BMPR1B, BMX, Brk, BRSK1, BTK, CaM-KIalpha, CaM-KIIalpha, CaMKK_group, CaM-KIV, CaM-KKalpha, CaM-KKbeta, CCDPK, CCRK, CDK1, CDK11, CDK2, CDK4, CDK5, CDK6, CDK7, CDK9, CDK_group, CDPK, Chak1, CHK1, CHK2, CK1 alpha, CK1 delta, CK1 epsilon, CK1_group, CK2 alpha, CK2_beta, CK2_group, CLK1, CSF1R, Csk, DAPK1, DAPK2, DAPK3, DAPK_group, D
  • a compound of the invention as described herein can be used for treating, inhibiting, suppressing, or reducing the severity of a disease or a disorder associated with a protein kinase, wherein the method comprises administering to the subject in need thereof a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt.
  • a compound of the invention or a pharmaceutically acceptable salt.
  • the protein kinase is one known in the art.
  • the protein kinase includes, but is not limited to, FLT3 and TrkC.
  • the protein kinase is Abl, Abl2, AFK, ALK, AMPK_group, ATM, ATR, Aurora A, Aurora B, Axl, BCKDK, BLK, BMPR1B, BMX, Brk, BRSK1, BTK, CaM-KIalpha, CaM-KIIalpha, CaMKK_group, CaM-KIV, CaM-KKalpha, CaM-KKbeta, CCDPK, CCRK, CDK1, CDK11, CDK2, CDK4, CDK5, CDK6, CDK7, CDK9, CDK_group, CDPK, Chak1, CHK1, CHK2, CK1alpha, CK1delta, CK1 epsilon, CKL_group, CK2 alpha, CK2_beta, CK2_group, CLK1, CSF1R, Csk DAPK1, DAPK2, DAPK3, DAPK_group, DCAMKL1, DMPK_
  • the disease or disorder associated with a protein kinase includes, but is not limited to, cancer, diabetes, malaria, viral infections (such as HIV), cardiovascular and hypertension, CNS and neurodegeneration (such as Alzheimer's. Parkinson, manic depression, supranuclear palsy), osteoporosis, inflammation and autoimmune (such as rheumatoid arthritis, myelofibrosis, inflammatory bowel disease, Crohn's disease, colitis, psoriasis, systemic lupus erythematosus, keratoconjunctivitis sicca), allergy (general allergic disease, allergic asthma, allergic rhinitis).
  • the disease or disorder associated with a protein kinase is cancer, diabetes, malaria, viral infections, cardiovascular and hypertension. CNS and neurodegeneration, osteoporosis, pulmonary fibrosis, retinitis pigmentosis. Wet macular degeneration, Duchenne muscular dystrophy, diabetic eye disease, inflammation and autoimmune, or allergy. In some embodiments, the disease or disorder associated with a protein kinase is cancer.
  • the invention is directed to a method of treating, inhibiting, suppressing, or reducing the severity of cancer in a subject in need thereof, wherein the method comprises administering to the subject a therapeutically effective amount of a compound as described herein, or a pharmaceutically acceptable salt, N-oxide, hydrate, solvate, tautomer, or optical isomer thereof, or a pharmaceutical composition containing one or more of the compounds as described herein.
  • the invention disclosed herein relates to a method for the treatment of a cancer patient wherein abnormal kinase activities are implicated by administrating a therapeutically effective amount of a compound disclosed herein to the patient in need of relief from said cancer.
  • a compound disclosed herein may be used alone or in combination with other compounds useful for treating cancer, including those compounds that may be therapeutically effective by the same or different modes of action.
  • the compounds described herein may be used in combination with other compounds that are administered to treat other symptoms of cancer, such as nausea, vomiting, pain, etc.
  • the cancer is selected from the group consisting of acute myeloid leukemia, chronic myeloid leukemia, ovarian cancer, cervical cancer, pancreatic cancer, breast cancer, brain cancer, skin cancer lung cancer, prostate cancer. Lymphoma. Leukemia, colon cancer, head cancer, neck cancer, thyroid cancer, kidney cancer, liver cancer and stomach cancer. In some embodiments, the cancer is acute myeloid leukemia.
  • a compound of the invention as described herein can be used for treating, inhibiting, suppressing, or reducing the severity of cancer in a subject, wherein the method comprises administering to the subject in need thereof a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt.
  • a compound of the invention or a pharmaceutically acceptable salt.
  • the cancer that can be treated, inhibited, suppressed, or reduced the severity of by a compound of the invention as described anywhere herein includes, but is not limited to, ovarian cancer, pancreatic cancer, breast cancer, brain cancer, skin cancer, lung cancer, prostate cancer, Lymphoma, Leukemia, colon cancer, head cancer, neck cancer, and stomach cancer.
  • the cancer that can be treated, inhibited, suppressed, or reduced the severity of by a compound of the invention as described anywhere herein includes, but is not limited to, acute myeloid leukemia, chronic myeloid leukemia, ovarian cancer, cervical cancer, pancreatic cancer, breast cancer, brain cancer, skin cancer, lung cancer, prostate cancer. Lymphoma.
  • the cancer is breast cancer. In other embodiments, the cancer is ovarian cancer. In some embodiments, the cancer is prostate cancer. In some embodiments, the cancer is acute myeloid leukemia.
  • a compound of the invention as described herein is a protein kinase inhibitor.
  • the compound of the invention can be used for treating, inhibiting, suppressing, or reducing the severity of a disease or a disorder associated with protein kinase, wherein the method comprises administering to the subject in need thereof a therapeutically effective amount of a compound of invention, or a pharmaceutically acceptable salt, N-oxide, hydrate, solvate, tautomer, or optical isomer thereof.
  • the protein kinase is one known in the art.
  • the protein kinase includes, but is not limited to. FLT3 and TrkC.
  • the protein kinase is Abl, Abl2, AFK, ALK, AMPK_group, ATM, ATR, Aurora A, Aurora B, Axl, BCKDK, BLK, BMPR1B, BMX, Brk, BRSK1, BTK, CaM-KIalpha, CaM-KIIalpha, CaMKK_group, CaM-KIV, CaM-KKalpha, CaM-KKbeta, CCDPK, CCRK, CDK1, CDK11, CDK2, CDK4, CDK5, CDK6, CDK7, CDK9, CDK_group, CDPK, Chak1, CHK1, CHK2, CK1 alpha, CK1 delta, CK1 epsilon, CK1_group, CK2 alpha, CK2_beta, CK2_group, CLK1, CSF1R, Csk, DAPK1, DAPK2, DAPK3, DAPK_group, DCAMKL1, DMPK_
  • the disease or disorder associated with protein kinase includes those known in the art.
  • the disease or disorder associated with protein kinase is cancer, diabetes, malaria, viral infections (such as HIV), cardiovascular and hypertension.
  • CNS and neurodegeneration such as Alzheimer's, Parkinson, manic depression, supranuclear palsy), osteoporosis, inflammation and autoimmune (such as rheumatoid arthritis, myelofibrosis, inflammatory bowel disease, Crohn's disease, colitis, psoriasis, systemic lupus erythematosus, keratoconjunctivitis sicca), allergy (general allergic disease, allergic asthma, allergic rhinitis).
  • each possibility represents a separate embodiment of the present invention.
  • the compound of the invention can be used for treating bacterial infections.
  • the disease or disorder associated with protein kinase is cancer, diabetes, malaria, viral infections, cardiovascular and hypertension, CNS and neurodegeneration, osteoporosis, pulmonary fibrosis, retinitis pigmentosis, Wet macular degeneration, Duchenne muscular dystrophy, diabetic eye disease, inflammation and autoimmune, or allergy.
  • the compound of the invention can be used for treating cancer, for example, acute myeloid leukemia, chronic myeloid leukemia, ovarian cancer, cervical cancer, pancreatic cancer, breast cancer, brain cancer, skin cancer, lung cancer, prostate cancer, Lymphoma, Leukemia, colon cancer, head cancer, neck cancer, thyroid cancer, kidney cancer, liver cancer and stomach cancer.
  • the cancer is breast cancer.
  • the cancer is ovarian cancer.
  • the cancer is prostate cancer.
  • the cancer is acute myeloid leukemia.
  • a compound of the invention can be used for treating, inhibiting, suppressing, or reducing the severity of acute myeloid leukemia in a subject, wherein the method comprises administering to said subject a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt, N-oxide, hydrate, solvate, tautomer, or optical isomer thereof.
  • the compounds of the invention exhibits low nanomolar IC50 values in the tests for their anticancer properties, which are desired for clinical translation.
  • the compound of the invention is a kinase (especially FLT3, c-Kit, and TrK) inhibitor.
  • the compound of the invention inhibits kinases, such as FLT3, TrkC, and c-Kit at the protein level.
  • a compound of the invention shows potent anticancer activities (low nanomolar IC50 values) against acute myeloid leukemia.
  • a compound of the invention is also active against other cancer cell lines, such as pancreatic, breast, and ovarian cancers.
  • the cancer is acute myeloid leukemia, chronic myeloid leukemia, ovarian cancer, cervical cancer, pancreatic cancer, breast cancer, brain cancer, skin cancer, lung cancer, prostate cancer, Lymphoma Leukemia, colon cancer, head cancer, neck cancer, thyroid cancer, kidney cancer, liver cancer and stomach cancer.
  • the cancer is breast cancer. In other embodiments, the cancer is ovarian cancer. In some embodiments, the cancer is prostate cancer. In some embodiments, the cancer is acute myeloid leukemia.
  • a compound of the invention In addition to targeting FLT-3, a compound of the invention also inhibits other protein kinase TrkC as well as c-MyC and Ras oncogenic proteins. Due to the multi-targeting of oncogenic drivers, the compound of the invention has superior performance against AML with mutant FLT-3 than what is known in the art. Moreover, due to its multi targeting nature, a compound of the invention is also effective against other cancer cell lines, for example, ovarian cancer, pancreatic cancer, breast cancer, brain cancer, skin cancer, lung cancer, prostate cancer, Lymphoma. Leukemia, colon cancer, head cancer, neck cancer, and stomach cancer. In some embodiments, the cancer is breast cancer.
  • the cancer that can be treated, inhibited, suppressed, or reduced the severity of by a compound of the invention as described anywhere herein includes, but is not limited to, acute myeloid leukemia, chronic myeloid leukemia, ovarian cancer, cervical cancer, pancreatic cancer, breast cancer, brain cancer, skin cancer, lung cancer, prostate cancer. Lymphoma. Leukemia, colon cancer, head cancer, neck cancer, thyroid cancer, kidney cancer, liver cancer and stomach cancer. In other embodiments, the cancer is ovarian cancer. In some embodiments, the cancer is prostate cancer. In some embodiments, the cancer is acute myeloid leukemia.
  • the compound of the invention inhibits the proliferation of several cancer cell lines at nano molar concentrations. Further, the compound of the invention inhibits protein kinase FLT-3 phosphorylation and also inhibits the proliferation of FLT-3 driven cancers, such as MV4-11 (an acute myeloid leukemia) with low (e.g., single digit nanomolar) IC50 values.
  • FLT-3 driven cancers such as MV4-11 (an acute myeloid leukemia) with low (e.g., single digit nanomolar) IC50 values.
  • a compound of the invention as a potent kinase inhibitor can be used to treat cancers, malaria, arthritis, diseases related to the immune system and other diseased states that kinases play key roles in disease establishment or progression.
  • ESI-MS experiments were performed using an Agilent MSD/TOF mass spectrometer at the Bindley Bioscience Center Metabolomics Facility (Purdue University). The instrument was calibrated to a resolution of 10000 with a 10% valley between peaks using the appropriate polypropylene glycol standards.
  • Analytical thin layer chromatography was carried out on silica gel 60 F254 plastic-backed TLC plates. Compounds were visualized with both short and long wavelength UV light and iodine/silica gel staining unless otherwise specified. Flash column chromatography was performed using Teledyne Isco's Combi-Flash Rf+ with RediSep R f silica gel disposable flash columns, 40-60 microns (Catalog #692203304). For purities estimated by HPLC, the major peak accounted for ⁇ 95% of the combined total peak area when monitored by a UV detector at 254 nm unless otherwise specified. All yields refer to isolated compounds.
  • HotSpot assay platform was used to measure kinase/inhibitor interactions exactly as previously described.
  • Kinase and substrate were mixed in a buffer containing 20 mM HEPES pH 7.5, 10 mM MgCl 2 , 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na 3 VO 4 , 2 mM DTT and 1% DMSO.
  • Single-dose of compounds 500 nM were then added to each reaction mixture. After 20-minute incubation.
  • ATP Sigma
  • [ ⁇ - 33 P] ATP Perkin Elmer
  • the docking package CANDOCK 1 was used to identify docking poses of HSW630-1 in the binding site of FLT3 kinases.
  • the structure of FLT3 was obtained from the protein databank (PDB #4XUF). The entire protein was considered flexible. No binding site was provided to CANDOCK and the location of this site was determined by the program automatically.
  • CANDOCK used default parameters with interactive flexibility with a maximum iteration of 10 and only the top 2% of the top seed values were used to generate full ligands.
  • Molm-14 cells were the kind gift of Dr. Mark Levis from Johns Hopkins University. THP-1. MV4-11, K-562 and MRC-5A cells were purchased from ATCC (ATCC, Manassas, Va.). All cell lines were grown in 37° C. with 5% CO atmosphere with RPMI 1640 (Life technologies, Carlsbad. Calif.) supplemented with heat-inactivated 10% (V/V) fetal bovine serum. Cell lines were grown and maintained according to ATCC recommendations.
  • 96-well plates were seeded the afternoon before treatment. Plates were then treated with compound diluted in dimethyl sulfoxide (DMSO) as well as a DMSO control the following day for 72 hours. After this time the plates were then treated with 10 ⁇ L of CellTiter-Blue Cell Viability Assay (Promega, Madison, Wis.) for 4 hours. Then the plates were read on a plate reader (Bio-Tek, Winooski, Vt.). Data was analyzed on Excel as a percent of the DMSO vehicle.
  • DMSO dimethyl sulfoxide
  • Midostaurin hydrate (control compound) was purchased from Sigma-Aldrich (St. Louis, Mo.). >98% HPLC purity and used without further purification.
  • Cell lines were seeded into 96-well plates the afternoon prior to treatment. Approximately 18 hours later, compounds were diluted in dimethyl sulfoxide (DMSO) and added to cells. Plates were incubated for 72 hours and cells viability determined with CellTiter-Blue Cell Viability Assay (Promega, Madison, Wis.). Plates were read after 4 additional hours of incubation at 37° C. using plate reader (Bio-Tek, Winooski. Vt.). Data was analyzed and graphed using GraphPad Prism Software (Graphpad, La Jolla, Calif.).
  • HSW630-1 Effect of HSW630-1 on protein expression was tested in the MV4-11 leukemia cell line.
  • Total protein extracts were prepared using RIPA buffer (SIGMA) supplemented with Complete MiniTM protease inhibitor and PHOStopTM phosphatase inhibitors (Roche). Equal amounts of proteins (up to 25 ⁇ g) were separated on 4-12% NuPAGE gels in 1 ⁇ MOPS or 1 ⁇ MES buffer (Invitrogen) and transferred onto PVDF membranes (Millipore).
  • the membrane was blocked with 5% dry milk in 1 ⁇ TBS/0.1% Tween 20 (TBST) for at least 1 h at room temperature and incubated with human specific primary antibodies: FLT3, Phospho-FLT3, c-Myc (Cell Signaling Technologies), KRAS (Santa Cruz), or mouse anti- ⁇ -actin (SIGMA) overnight at 4° C.
  • TBST 1 ⁇ TBS/0.1% Tween 20
  • human specific primary antibodies FLT3, Phospho-FLT3, c-Myc (Cell Signaling Technologies), KRAS (Santa Cruz), or mouse anti- ⁇ -actin (SIGMA) overnight at 4° C.
  • the membrane was washed 3 times in TBST and incubated with a horseradish peroxidase-conjugated secondary anti-rabbit or anti-mouse antibody (Cell Signaling Technologies) for 1 h at room temperature. Blots were again washed and the signal was detected with SuperSignal West Femto Chemilumin
  • Example 1D 6-(3-(diethylamino)prop-1-yn-1-yl)isoquinolin-3-amine
  • Example 1G tert-butyl (3-(3-aminosoquinolin-6-yl)prop-2-yn-1-yl)carbamate
  • 6-chloroisoquinolin-3-amine was dissolved in 150 ml anhydrous MeOH at 0° and stirred for 5 minutes before 675 mg NIS was added in portions slowly in 10 minutes. Stop the reaction by remove all solvents when TLC showed the reaction was completed (usually within 15 minutes).
  • 420 mg 6-chloro-4-iodoisoquinolin-3-amine was obtained either by flash column or Combi-flash using 100% hexane-100% ethyl acetate.
  • Example 5J tert-butyl 4-(3-(4-ethynylbenzamido)propyl)piperazine-1-carboxylate
  • Example 13 4-((3-amino-6-chloroisoquinolin-4-yl)ethynyl)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)benzamide
  • Example 16 4-((3-amino-6-chloroisoquinolin-4-yl)ethynyl)-N-(3-(pyrrolidin-1-yl)propyl)benzamide
  • Example 17 4-((3-amino-6-chloroisoquinolin-4-yl)ethynyl)-N-(3-(4-methylpiperazin-1-yl)propyl)benzamide
  • Example 18 4-((3-amino-6-chloroisoquinolin-4-yl)ethynyl)-N-(3-(piperidin-1-yl)propyl)benzamide
  • Example 25 tert-butyl ((1r,4r)-4-(4-((3-amino-6-chloroisoquinolin-4-yl)ethynyl)benzamido)cyclohexyl)carbamate
  • Example 28 tert-butyl ((r,4r)-4-(4-((3-amino-6-chloroisoquinolin-4-yl)ethynyl)benzamido)cyclohexyl)carbamate
  • 2,4-dibromoquinoline (550 mg), N 2 ,N-diethylethane-1,2-diamine (240 mg), Cs 2 CO 3 (650 mg) and DMSO (4 mL) were placed in a round bottle and the mixture was heated to 150° C. for 12 h. The mixture was cooled to room temperature and purified using flash chromatography.
  • Example 48 4-((4-(4,4-dimethyl-4,5-dihydro-1H-imidazol-2-yl)phenyl)ethynyl)-6,7-dimethoxyquinazolin-2-amine (HSN335)
  • Example 62 4-((4-(4,4-dimethyl-4,5-dihydro-1H-imidazol-2-yl)-3-fluorophenyl)ethynyl)quinolin-2-amine (HSM1856)
  • Example 70 4-((6-chloro-3-(cyclopropanecarboxamido)isoquinolin-4-yl)ethynyl)-N-(2-(piperidin-1-yl)ethyl)benzamide (HSN329)
  • Example 72 3-((8-amino-1,7-naphthyridin-5-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide (HSN356)
  • Example 80 3-((3-amino-1-methylisoquinolin-4-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide (HSN375)
  • Example 82 3-((3-amino-6-chloroisoquinolin-4-yl)ethynyl)-4-methyl-N-(4-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide (HSN380)
  • Example 83 5-((3-amino-6-chloroisoquinolin-4-yl)ethynyl)-6-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)nicotinamide (HSN387)
  • Example 84 3-((3-amino-6-chloroisoquinolin-4-yl)ethynyl)-N-(3,5-dichloro-4-(2-(dimethylamino)ethoxy)phenyl)-4-methylbenzamide (HSN391)
  • Example 90 4-((3-amino-6-chloroisoquinolin-4-yl)ethynyl)-5-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)picolinamide (HSN404)
  • Example 100 3-((8-amino-1,7-naphthyridin-5-yl)ethynyl)-N-(3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)-4-methylbenzamide (HSN445)
  • Example 101 3-((2-amino-6,7-dimethoxyquinazolin-4-yl)ethynyl)-N-(3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)-4-methylbenzamide (HSN446)
  • Example 102 3-((2-amino-6,7-dimethoxyquinazolin-4-yl)ethynyl)-N-(4-(2-(dimethylamino)ethoxy)phenyl)-4-methylbenzamide (HSN447)
  • Example 103 5-((8-amino-1,7-naphthyridin-5-yl)ethynyl)-6-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)nicotinamide (HSN459)
  • Example 104 5-((1-aminoisoquinolin-4-yl)ethynyl)-6-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)nicotinamide (HSN461)
  • Example 105 2-((8-amino-1,7-naphthyridin-5-yl)ethynyl)-5-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)thiazole-4-carboxamide (HSN482)
  • Example 106 4-((1-aminoisoquinolin-4-yl)ethynyl)-3-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide (HSN485)
  • Example 107 4-((3-amino-6-chloroisoquinolin-4-yl)ethynyl)-3-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide (HSN486)
  • Example 108 4-((1-aminoisoquinolin-4-yl)ethynyl)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide (HSN489)
  • Example 109 4-((3-amino-6-chloroisoquinolin-4-yl)ethynyl)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide (HSN490)
  • Example 110 3-((8-amino-1,7-naphthyridin-5-yl)ethynyl)-4-methyl-N-(4-(morpholinomethyl)-3-(trifluoromethyl)phenyl)benzamide (HSN514)
  • Example 111 3-((8-amino-1,7-naphthyridin-5-yl)ethynyl)-N-(4-((4-ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-4-methylbenzamide (HSN515)
  • Example 112 5-((1-aminoisoquinolin-4-yl)ethynyl)-1-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-1H-pyrazole-3-carboxamide (HSN516)
  • 6-chloroisoquinolin-3-amine (3.2 mmol) was iodinated by N-Iodosuccinimide (675 mg) and purified by flash column (part 1), 4-ethynylbenzaldehyde (1 eq) was dissolved in tert-butyl alcohol and the corresponding diamine (1 eq) was added and stirred for 1 hour at room temperature, 1.1 eq of iodine and 3 eq of potassium carbonate were added and the mixture was reflux overnight. Crude product was subject to column purification (part 2).
  • Example 120 4-((4-(4,5-dihydro-1H-imidazol-2-yl)phenyl)ethynyl)-1H-pyrrolo[2,3-c]pyridin-5-amine
  • Example 127 Activity Studies against AML Cell Line, MV4-11
  • Cells were added to 96 well plates at 2000 cells per well for adherent lines and 4000 cells per well for suspension lines and kept in an incubator overnight. The following day the plates were treated with compounds to give rise to the final concentrations of; 100 ⁇ M, 10 ⁇ M, 5 ⁇ M 1 ⁇ M, 500 nM, 100 nM, 10 nM, 10 ⁇ M. The plates were then stored in the incubator for 72 hours. On the third day the cells were assayed with 20 ⁇ L of CellTiter—Blue Cell Viability Assay per well and were incubated for 4 hours. After 4 hours' fluorescence intensity was taken on a plate reader: Excitation: 560/10 Emission: 590/10. IC 50 analysis was performed on GraphPad Prism 7.
  • HotSpot assay platform was used to measure kinase/inhibitor interactions exactly as previously described.
  • Kinase and substrate were mixed in a buffer containing 20 mM HEPES pH 7.5, 10 mM MgCl 2 , 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na 3 VO 4 , 2 mM DTT and 1% DMSO.
  • Single-dose of compounds 500 nM were then added to each reaction mixture. After 20-minute incubation.
  • ATP Sigma
  • [ ⁇ - 33 P] ATP Perkin Elmer
  • IC 50 proliferation assay Cell lines and primary cells we seeded into 96-well plates the afternoon prior to treatment. Approximately 18 hours later, compounds were semi-serially diluted in dimethyl sulfoxide (DMSO) and then growth medium, and added to cells. Plates were incubated for 72 hours prior to addition of Alamar Blue (Life Technologies, Carlsbad. Calif.). Plates were read after 4 additional hours of incubation at 37° C. using a Bio-Tek Synergy HT plate reader (Bio-Tek, Winooski. Vt.). Data was analyzed and graphed using GraphPad Prism Software (Graphpad, La Jolla, Calif.). Experimental results are summarized in Table 3.
  • IC50 proliferation inhibition against leukemia cell lines MV4-11 and K562.
  • HSM1856 also inhibited MiaPaca-2 and HLY-1 with IC50 of 0.4 and 0.08 ⁇ M respectively.
  • MiaPaca-2 Pancreatic cell line
  • HLY-1 Lymphoma cell line
  • MV4-11 AML cell line
  • K562 CML cell line.

Abstract

This invention relates to 4-substituted isoquinoline compounds and their derivatives and uses thereof for treatment of cancer, for example, acute myeloid leukemia.

Description

    CROSS REFERENCE TO RELATED APPLICATIONS
  • This application claims the benefit of U.S. Provisional Application Ser. No. 62/461,295, filed on Feb. 21, 2017 and U.S. Provisional Application Ser. No. 62/375,154, filed on Aug. 15, 2016, both of which are incorporated herein by reference in their entirety.
    • TECHNICAL FIELD
  • This invention relates to 4-substituted aminoisoquinoline compounds and their derivatives and uses thereof for treatment of cancer, for example, acute myeloid leukemia.
    • BACKGROUND
  • In human cells there are over 500 kinases regulating important processes, such as cell cycle regulation, proliferation, apoptosis and migration. Inhibitors of protein kinases have the potential to treat many diseases that are controlled by disregulation of protein kinases. Thus far over twenty kinase inhibitors have been approved by the FDA to treat various diseases.
  • Ponatinib, an approved FDA drug, is a 7-alkynyl imidazo[1.5-b]pyridazine compound and it is used against CML. Ponatinib, however, has toxic side effects and about 40% of patients on ponatinib developed some form of thrombosis. The FDA temporarily halted the sale of ponatinib in 2014 due to this adverse issue and it is now given as a drug of last resort for CML patients who have ABL (T315I) mutation and have not responded to any other therapy (Gainor, J. F. et al., Ponatinib: Accelerated Disapproval. Oncologist, 20(8), 847-848 (2015); Talbert. D. R. et al., Toxicol. Sci, 143 (1), 147-155 (2015).
  • In the efforts to develop kinase inhibitors against several disease-related kinases, it is discovered that 4-substituted isoquinolines are privileged kinases inhibitors. Further, the substitution pattern of these 4-substituted isoquinolines play critical roles in kinase selectivity and hence cancer selectivity. 4-Alkynyl-substituted aminoisoquinolines in particular have shown exceptional activity against various kinases and potently inhibit cancer proliferation. This important discovery has facilitated the tailoring of 4-substituted aminoisoquinoline into compounds that inhibit various cancers. Additionally, the 4-alkynyl-substituted 1- or 3-amino isoquinolines can be tuned for selectivity and toxicity and hence represent a new-generation alkyne-containing kinase inhibitors with desirable drug-like properties.
    • SUMMARY OF THE INVENTION
  • In one aspect, the present invention features a compound represented by a compound of formula (IV)
  • Figure US20210198208A1-20210701-C00001
  • wherein
  • W is NR′, alkene, alkyne, C1-8 alkyl, heteroalkyl containing 1-8 carbon and hetero atoms, cycloalkyl, hetereocycloalkyl, aryl, or heteroaryl, wherein cycloalkyl, hetereocycloalkyl, aryl, and heteroaryl optionally form a fused aryl or heteroaryl group with Ring A;
  • U, Y, and Z are each N or CR6, wherein R6 is H or NRaRb;
  • R7 and R8 are each independently H, alkyl, alkenyl, alkynyl, halo, nitro, ORc, SRc, CN, haloalkyl, O-haloalkyl, (CO)Rd, NRaRb, NH(CO)Rd, NH(CO)ORc, NH(CO)NRaRb, (CO)ORc, (CO)NRaRb, SO2NRaRb, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
  • or R7 and R8, together with the carbon atoms to which they are attached, form a cycloalkyl, heterocycloalkyl, aryl, or heteroaryl group, each optionally substituted with substituents independently selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, halo, nitro, ORc, SRc, CN, haloalkyl, O-haloalkyl, NRaRb, (CO)Rd, (CO)ORc, (CO)NRaRb. SO2NRaRb, and —C(CH3)(═N—NHC(NH)NH2;
  • Ring A is a 5- or 6-membered aryl or heteroaryl group, wherein Ring A is optionally substituted with substituents selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, halo, nitro, ORc, SRc, CN, haloalkyl, O-haloalkyl, NRmRn, (CO)Rd, (CO)ORc. SO2NRmRn, (CO)NRmRn, C(NH)NRmRn, NH(CO)Rd, NH(CO)ORc. NH(CO)NRmRn, aryl, heteroaryl;
  • Rm and Rn are each independently
  • H, OH.
  • alkyl, —(CH2)p-T, -aryl-(CH2)p-T, —(CH2)p-aryl-T, -heteroaryl-(CH2)p-T, —(CH2)p-heteroaryl-T, each optionally substituted with alkyl, halo, nitro, CN, haloalkyl, O-haloalkyl, ORc, SRc, NRaRb, (CO)Rd, NH(CO)Rd, NH(CO)ORc, NH(CO)NRaRb, NHC(NH)NH2, (CO)ORc, (CO)NRaRb, SO2NRaRb, arylamino, or heteroarylamino,
  • or Rm and Rn, together with the nitrogen atom they are attached, form a heterocycloalkyl group, optionally substituted with alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, halo, nitro, CN, ORc, SRc, CORd, NRaRb, NH(CO)Rd, NH(CO)ORc, NH(CO)NRaRb, a guanidine group, (CO)ORc, or (CO)NRaRb;
  • T is NRaRb, ORc, SRc, O—(CH2)q—NRaRb, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, a guanidine group, or an isonicotinimidamide group;
  • R′ is H, alkyl, or cycloalkyl;
  • Ra, Rb, Rc, and Rd are each independently H, alkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, —(CH2)q-cycloalkyl, —(CH)q-heterocycloalkyl, —(CH2)q-aryl, —(CH)q-heteroaryl, —(CO)-alkyl, —(CO)-cycloalkyl, —(CO)-heterocycloalkyl, —(SO2)-alkyl, —(SO2)-cycloalkyl, or —(SO2)-heterocycloalkyl, or Ra and Rb, together with the nitrogen atom to which they are attached, form a heterocycloalkyl group, wherein cycloalkyl, heterocycloalkyl, aryl and heteroaryl are each optionally substituted with a group consisting of alkyl, halo, nitro, CN, haloalkyl, O-haloalkyl, OH, O-alkyl. SH, S-alkyl, NH2, NH(alkyl), and N(alkyl)2; and
  • p and q are each independently 0-8;
  • or a pharmaceutically acceptable salt. N-oxide, hydrate, solvate, tautomer, or optical isomer thereof.
  • In another aspect, the present invention is directed to a pharmaceutical composition comprising one or more compounds as described herein, or a pharmaceutically acceptable salt, N-oxide, hydrate, solvate, tautomer, or optical isomer thereof, and a pharmaceutically acceptable carrier or diluent.
  • In yet another aspect, the present invention is directed to a method of treating, inhibiting, suppressing, or reducing the severity of cancer in a subject in need thereof, wherein the method comprises administering to the subject a therapeutically effective amount of a compound as described herein, or a pharmaceutically acceptable salt. N-oxide, hydrate, solvate, tautomer, or optical isomer thereof, or a pharmaceutical composition containing one or more compounds as described herein.
  • In yet another aspect, the present invention is directed to a method of treating, inhibiting, suppressing, or reducing the severity of a disease or a disorder associated with protein kinase in a subject in need thereof, wherein the method comprises administering to the subject a therapeutically effective amount of a compound as described herein, or a pharmaceutically acceptable salt. N-oxide, hydrate, solvate, tautomer, or optical isomer thereof, or a pharmaceutical composition containing one or more compounds as described herein.
  • The details of one or more embodiments of the invention are set forth in the accompanying the description below. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 depicts that the length of the amide head group, substitution pattern, and relative position to the alkyne moiety remarkably affects the anticancer activity against MV4-11 cell line (AML cell line).
  • FIG. 2 depicts that Compound 1703 is potent against MCF-7 cell lines.
  • FIG. 3 depicts that Compound 1703 is potent against HeLa cell lines.
  • FIG. 4 depicts 4-substituted isoquinoline/quinoline/quinazoline/purine compounds.
  • FIG. 5 depicts general structures of the compounds of the invention.
  • FIG. 6 depicts the compounds of the invention.
  • FIG. 7 depicts displacement of halogen on quinolone or isoquinoline or quinazoline for the preparation of the compounds of the invention.
  • FIGS. 8A, 8B, and 8C depict dose-response curves and Western Blot analyses. FIG. 8A: Dose-response curves of HSW1651 against FLT3 and important FLT3 mutants. FIGS. 8B and 8C: Western Blot analyses of p-FLT3/total FLT3 (FIG. 8B) and p-STAT5/STAT5 (FIG. 8C) protein expression in MV4-11 after treatment with HSM1651 and DMSO vehicle (V) control. Scanned images were analyzed using image J software.
  • FIG. 9 depicts representative examples of compounds synthesized.
  • FIG. 10 depicts the percentage inhibition of proliferation in MV4-11 cell line with various analogs (100 nM). Table 2 provides IC50 values for selected compounds D7. D15. D6. A15. D28. D30 and midostaurin (compounds are described in FIG. 9).
  • FIG. 11 depicts D30 analogs that were synthesized to investigate the influence of the quinoline/quinazoline/isoquinoline core on anticancer activity and kinase inhibition.
  • FIG. 12 depicts HSN286 (D30) activity against FLT3-driven MV4-11 and MOLM-14 but not other cancer cell lines and normal cell line. MRC5.
  • FIG. 13 depicts docked quizartinib bound to the inactive form of wild-type FLT3 (A) and docked HSN286 bound to the inactive form of wild-type FLT3 (B). PDB #4xuf. Docking was done with Autodock Vina. The docked quizartinib matched the ligand in the crystal structure of FLT3/quizartinib. Key residues D835, Y842 and F691 which when mutated block binding of FLT3 inhibitors are shown as sticks.
  • FIG. 14 depicts FLT3 residues that are within 6 Å of quizartinib in the docked structure (A) and FLT3 residues that are within 6 Å of HSN286 in the docked structure (B).
  • FIG. 15 depicts overlays of FLT3 binding mode of quizartinib and the compounds of the invention.
  • FIG. 16 depicts enzymatic inhibition of FLT3. FLT3 ITD and Src Kinases, respectively, by the compounds of the invention.
  • FIGS. 17A and 17B depict Western Blot analysis after treating MV4-11 with HSN286. FIG. 17A: Phospho-FLT3/FLT3, PhosphoSRC/SRC and phospho-STAT3/STAT3; and FIG. 17B: phospho-STAT5/STAT5 and phospho-p-38/p-38. Cells were treated with DMSO vehicle (V), HSN286 (9 nM and 45 nM) for 6 h, 24 h and 48 h. Western Blot with anti-rabbit or anti-mouse antibody. Scanned images were analyzed using image J software.
  • FIG. 18 depicts compounds of the invention with different substitution pattern.
  • FIG. 19 depicts compounds of the invention with different substitution pattern.
  • FIG. 20 depicts the percent survival at day 60 of NSG mice injected with AML cell line MV4-11 and treated with various compounds at 25 mg/Kg, 3×/week.
    •  DETAILED DESCRIPTION
  • In one aspect, the present invention features a compound represented by a compound of formula (IV)
  • Figure US20210198208A1-20210701-C00002
  • wherein
  • W is NR′, alkene, alkyne, C1-8 alkyl, heteroalkyl containing 1-8 carbon and hetero atoms, cycloalkyl, hetereocycloalkyl, aryl, or heteroaryl, wherein cycloalkyl, hetereocycloalkyl, aryl, and heteroaryl optionally form a fused aryl or heteroaryl group with Ring A;
  • U, Y, and Z are each N or CR6, wherein R6 is H or NRaRb;
  • R7, and RH are each independently H, alkyl, alkenyl, alkynyl, halo, nitro, ORc, SRc, CN, haloalkyl, O-haloalkyl, (CO)Rd, NRaRb, NH(CO)Rd, NH(CO)ORc, NH(CO)NRaRb, (CO)ORc, (CO)NRaRb, SO2NRaRb, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
  • or R7 and R8, together with the carbon atoms to which they are attached, form a cycloalkyl, heterocycloalkyl, aryl, or heteroaryl group, each optionally substituted with substituents independently selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, halo, nitro, ORc, SRc, CN, haloalkyl, O-haloalkyl. NRaRb, (CO)Rd, (CO)ORc, (CO)NRaRb, SO2NRaRb, and —C(CH3)(═N—NHC(NH)NH2;
  • Ring A is a 5- or 6-membered aryl or heteroaryl group, wherein Ring A is optionally substituted with substituents selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, halo, nitro, ORc, SRc, CN, haloalkyl, O-haloalkyl NRaRb, (CO)Rd, (CO)ORc, SO2NRmRn, (CO)NRmRn, C(NH)NRmRn, NH(CO)Rd, NH(CO)ORc, NH(CO)NRmRn, aryl, heteroaryl;
  • Rm and Rn are each independently
  • H, OH,
  • alkyl, —(CH2)p-T, -aryl-(CH2)p-T, —(CH2)p-aryl-T, -heteroaryl-(CH2)p-T, —(CH2)p-heteroaryl-T, each optionally substituted with alkyl, halo, nitro. CN, haloalkyl, O-haloalkyl, ORc, SRc, NRaRb, (CO)Rd, NH(CO)Rd, NH(CO)ORc, NH(CO)NRaRb. NHC(NH)NH2, (CO)ORc, (CO)NRaRb, SO2NRaRb, arylamino, or heteroarylamino,
  • or Rm and Rn, together with the nitrogen atom they are attached, form a heterocycloalkyl group, optionally substituted with alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, halo, nitro, CN. ORc, SRc, CORd, NRaRb, NH(CO)Rd, NH(CO)ORc, NH(CO)NRaRb, a guanidine group, (CO)ORc, or (CO)NRaRb);
  • T is NRaRb, ORc, SRc, O—(CH2)q—NRaRb, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, a guanidine group, or an isonicotinimidamide group;
  • R′ is H, alkyl, or cycloalkyl;
  • Ra. Rb. Rc, and Rd are each independently H, alkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, —(CH2)q-cycloalkyl, —(CH)q-heterocycloalkyl, —(CH2)q-aryl, —(CH)q-heteroaryl, —(CO)-alkyl, —(CO)-cycloalkyl, —(CO)-heterocycloalkyl, —(SO2)-alkyl, —(SO2)-cycloalkyl, or —(SO2)-heterocycloalkyl, or Ra and Rb, together with the nitrogen atom to which they are attached, form a heterocycloalkyl group, wherein cycloalkyl, heterocycloalkyl, aryl and heteroaryl are each optioncally substituted with a group consisting of alkyl, halo, nitro, CN, haloalkyl, O-haloalkyl, OH, O-alkyl, SH, S-alkyl, NH2, NH(alkyl), and N(alkyl)2; and
  • p and q are each independently 0-8;
  • or a pharmaceutically acceptable salt. N-oxide, hydrate, solvate, tautomer, or optical isomer thereof.
  • In some embodiments, the compound of the invention is represented by a compound of formula (V)
  • Figure US20210198208A1-20210701-C00003
  • wherein
  • W is NR′, —C≡C—, or a heterocycloalkyl group containing a 5- or 6-membered ring, wherein R′ is H or alkyl;
  • U, Y, and Z are each N or CR6, wherein R6 is H or NRaRb;
  • V, U1, Y1, and Z1 are each N or CR6′;
  • R1, R2, and R6′ are each independently H, alkyl, cycloalkyl, halo, nitro. ORc, SRc, CN, haloalkyl, O-haloalkyl, or NRaRb;
  • R3, R4, and R5 are each independently H, alkyl, cycloalkyl, heterocycloalkyl, halo, nitro. ORc, SRc. CN, haloalkyl, O-haloalkyl, NRmRn, (CO)Rd. (CO)ORc, S2NRmRn, (CO)NRmRn, C(NH)NRmRn, NH(CO)Rd, NH(CO)ORc, NH(CO)NRmRn, aryl, or heteroaryl;
  • Rm and Rn are each independently
  • H, OH.
  • alkyl, —(CH2)pT, -aryl-(CH2)pT, —(CH2)p-aryl-T, -heteroaryl-(CH2)p-T, —(CH2)p-heteroaryl-T, each optionally substituted with alkyl, cycloalkyl, halo, nitro, CN, haloalkyl, O-haloalkyl, ORc, SRc, (CO)Rd, NRaRb. NH(CO)Rd, NH(CO)ORc, NH(CO)NRaRb. NHC(NH)NH2, (CO)ORc, (CO)NRaRb, and SO2NRaRb.
  • or Rm and Rn, together with the nitrogen atom they are attached, form a heterocycloalkyl group, optionally substituted with alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, halo, nitro, CN. ORc, SRc. CORd. NRaRb. NH(CO)Rd, NH(CO)ORc. NH(CO)NRaRb, a guanidine group, (CO)ORc, and (CO)NRaRb;
  • T is NRaRb, ORc, SRc, O—(CH2)q—NRaRb, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, a guanidine group, or an isonicotinimidamide group;
  • Ra, Rb, Rc, and Rd are each independently H, alkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, —(CH2)q-cycloalkyl, —(CH)q-heterocycloalkyl, —(CH2)q-aryl, —(CH)q-heteroaryl, —(CO)-alkyl, —(CO)-cycloalkyl, or —(CO)-heterocycloalkyl, or Ra and Rb, together with the nitrogen atom to which they are attached, form a heterocycloalkyl group, wherein cycloalkyl, heterocycloalkyl, aryl and heteroaryl are each optioncally substituted with a group consisting of alkyl, halo, nitro. CN, haloalkyl, O-haloalkyl, OH, O-alkyl. SH, S-alkyl. NH2, NH(alkyl), and N(alkyl)2; and
  • p and q are each independently 0-5.
  • or a pharmaceutically acceptable salt. N-oxide, hydrate, solvate, tautomer, or optical isomer thereof.
  • In some embodiments. R6 is NRaRb.
  • In some embodiments, one of R3, R4, and R5 is heterocycloalkyl, CN, NRmRn, (CO)Rd, (CO)ORc, SO2NRmRn. (CO)NRmRn. C(NH)NRmRn, or NH(CO)Rd.
  • In some embodiments, one of R3, R4, and R5 is (CO)NRmRn.
  • In some embodiments. Rm is H and R is —(CH2)p-T, -aryl-(CH2)p-T, —(CH2)p-aryl-T, or -heteroaryl-(CH2)p-T, each optionally substituted with alkyl, halo, and ORc.
  • In some embodiments, T is NRaRb, O—(CH2)—NRaRb, heterocycloalkyl, aryl, or heteroaryl.
  • In some embodiments. Rm and Rn, together with the nitrogen atom they are attached, form a heterocycloalkyl group, optionally substituted with alkyl, cycloalkyl, heterocycloalkyl NRaRb. NH(CO)Rd. NH(CO)ORc, and NH(CO)NRaRb.
  • In some embodiments, R1 and R2 are each independently H, alkyl, halo, CN, ORc, SRc, or NRaRb.
  • In some embodiments, the compound of the invention is a compound of the formula:
  • Figure US20210198208A1-20210701-C00004
    Figure US20210198208A1-20210701-C00005
    Figure US20210198208A1-20210701-C00006
    Figure US20210198208A1-20210701-C00007
    Figure US20210198208A1-20210701-C00008
  • wherein
  • R1, R2, R10, R11, R12, and R13 are each independently 1-1, alkyl, cycloalkyl, halo, nitro, ORc, SRc, CN, haloalkyl, O-haloalkyl, or NRaRb;
  • R3, R4, and R5 are each independently H, alkyl, cycloalkyl, heterocycloalkyl, halo, nitro, ORc, SRc. CN, haloalkyl, O-haloalkyl, NRmRn, (CO)Rd. (CO)ORc, S2NRmRn, (CO)NRmRn, C(NH)NRmRn, NH(CO)Rd, NH(CO)ORc, NH(CO)NRmRn, aryl, or heteroaryl;
  • R1 is H or NRaRb;
  • Rm and Rn are each independently
  • H, OH,
  • alkyl, —(CH2)p-T, -aryl-(C2)p-aryl-T, -heteroaryl-(CH2)p-T, (CH2)p-heteroaryl-T, each optionally substituted with alkyl, cycloalkyl, halo, nitro, CN, haloalkyl, haloalkyl, ORc, SRc, (CO)Rd, NRaRb, NH(CO)Rd, NH(CO)ORc, NH(CO)NRaRb, NHC(NH)NH2, (CO)ORc, (CO)NRaRb, and SO2NRaRb.
  • or Rm and Rn, together with the nitrogen atom they are attached, form a heterocycloalkyl group, optionally substituted with alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, halo, nitro, CN. ORc, SRc, CORd, NRaRb, NH(CO)Rd, NH(CO)ORc, NH(CO)NRaRb, a guanidine group, (CO)ORc, and (CO)NRaRb;
  • T is NRaRb, ORc, SRc, O—(CH2)qNRaRb, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, a guanidine group, or an isonicotinimidamide group;
  • Ra, Rb, Rc, and Rd are each independently H, alkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, —(CH)q-cycloalkyl, —(CH)q-heterocycloalkyl, —(CH2)q-aryl, —(CH)q-heteroaryl. —(CO)-alkyl, —(CO)-cycloalkyl, or —(CO)-heterocycloalkyl, or Ra and Rb, together with the nitrogen atom to which they are attached, form a heterocycloalkyl group, wherein cycloalkyl, heterocycloalkyl, aryl and heteroaryl are each optioncally substituted with a group consisting of alkyl, halo, nitro. CN, haloalkyl, O-haloalkyl, OH. O-alkyl, SH, S-alkyl, NH2, NH(alkyl), and N(alkyl)2; and
  • p and q are each independently 0-5;
  • or a pharmaceutically acceptable salt, N-oxide, hydrate, solvate, tautomer, or optical isomer thereof.
  • In some embodiments. R6 is NRaRb.
  • In some embodiments, one of R3, R4, and R5, is heterocycloalkyl, CN. NRmRn, (CO)Rd, (CO)ORc, SO2NRmRn, (CO)NRmRn, C(NH)NRmRn, or NH(CO)Rd.
  • In some embodiments, one of R3, R4, and R5 is (CO)NRmRn.
  • In some embodiments, Rm is H and Rn is —(CH2)p-T, -aryl-(CH2)p-T, —(CH2)p-aryl-T, or -heteroaryl-(CH2)p-T, each optionally substituted with alkyl, halo, and ORc.
  • In some embodiments, T is NRaRb, O—(CH2)q—NRaRb, heterocycloalkyl, aryl, or heteroaryl.
  • In some embodiments, Rm and Rn, together with the nitrogen atom they are attached, form a heterocycloalkyl group, optionally substituted with alkyl, cycloalkyl, heterocycloalkyl, NRaRb, NH(CO)Rd, NH(CO)ORc, and NH(CO)NRaRb.
  • In some embodiments. R1 and R2 are each independently H, alkyl, halo, CN. ORc. SRc, or NRaRb.
  • In some embodiments, the compound of the invention is a compound of the following formula
  • Figure US20210198208A1-20210701-C00009
    Figure US20210198208A1-20210701-C00010
    Figure US20210198208A1-20210701-C00011
  • wherein
  • V, U1, Y1, and Z1 are each N or CR6′;
  • R1, R2, and R6′ are each independently H, alkyl, cycloalkyl, halo, nitro, ORc, SRc. CN, haloalkyl, O-haloalkyl, or NRaRb;
  • R3, R4, and R5, are each independently H, alkyl, cycloalkyl, heterocycloalkyl, halo, nitro, ORc, SRc, CN, haloalkyl, O-haloalkyl, NRmRa, (CO)Rd, (CO)ORc, SO2NRmRa, (CO)NRmRa, C(NH)NRmRn, NH(CO)Rd, NH(CO)ORc, NH(CO)NRmRn, aryl, or heteroaryl;
  • R6 is H or NRaRb;
  • R7 and R5 are each independently H, alkyl, alkenyl, alkynyl, halo, nitro. ORc, SRc, CN, haloalkyl, O-haloalkyl, (CO)Rd, NRaRb, NH(CO)Rd, NH(CO)ORc, NH(CO)NRaRb, (CO)ORc, (CO)NRaRb, SO2NRaRb, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
  • Rm and Rn are each independently
  • H, OH.
  • alkyl, —(CH2)p-T, -aryl-(CH2)p-T, —(CH2)p-aryl-T, -heteroaryl-(CH2)p-T, —(CH2)p heteroaryl-T, each optionally substituted with alkyl, cycloalkyl, halo, nitro, CN, haloalkyl, O-haloalkyl, ORc, SRc, (CO)Rd, NRaRb, NH(CO)Rd, NH(CO)ORc, NH(CO)NRaRb, NHC(NH)NH2, (CO)OR4. (CO)NRaRb, and SO2NRaRb, or Rm and Rn, together with the nitrogen atom they are attached, form a heterocycloalkyl group, optionally substituted with alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, halo, nitro, CN, ORc, SRc, CORd, NRaRb, NH(CO)Rd, NH(CO)ORc, NH(CO)NRaRb, a guanidine group, (CO)ORc, and (CO)NRaRb;
  • T is NRaRb, ORc, SRc, O—(CH2)q—NRaRb, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, a guanidine group, or an isonicotinimidamide group;
  • Ra, Rb, Rc, and Rd are each independently H, alkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, —(CH2)q-cycloalkyl, —(CH)q-heterocycloalkyl, —(CH2)q-aryl, —(CH)q-heteroaryl, —(CO)-alkyl, —(CO)-cycloalkyl, or —(CO)-heterocycloalkyl, or Ra and Rb, together with the nitrogen atom to which they are attached, form a heterocycloalkyl group, wherein cycloalkyl, heterocycloalkyl, aryl and heteroaryl are each optioncally substituted with a group consisting of alkyl, halo, nitro, CN, haloalkyl, O-haloalkyl, OH, O-alkyl, SH, S-alkyl, NH2, NH(alkyl), and N(alkyl)2; and
  • p and q are each independently 0-5;
  • or a pharmaceutically acceptable salt. N-oxide, hydrate, solvate, tautomer, or optical isomer thereof.
  • In some embodiments, Rb is NRaRb,
  • In some embodiments, one of R3, R4, and R5 is heterocycloalkyl, CN, NRmRn, (CO)Rd, (CO)ORc, SO2NRmRn. (CO)NRmRn. C(NH)NRmRn, or NH(CO)Rd.
  • In some embodiments, one of R3, R4, and R5 is (CO)NRmRn.
  • In some embodiments. Rm is H and Rn is —(CH2)p-T, -aryl-(CH2)p-T, —(CH2)p-aryl-T, or -heteroaryl-(CH2)p-T, each optionally substituted with alkyl, halo, and ORc.
  • In some embodiments. T is NRaRb, O—(CH2)q—NRaRb, heterocycloalkyl, aryl, or heteroaryl.
  • In some embodiments. Rm and Rn, together with the nitrogen atom they are attached, form a heterocycloalkyl group, optionally substituted with alkyl, cycloalkyl, heterocycloalkyl, NRaRb, NH(CO)Rd, NH(CO)ORc, and NH(CO)NRaRb.
  • In some embodiments, R1 and R2 are each independently H, alkyl, halo, CN, ORc, SRc, or NRaRb.
  • In some embodiments, the compound is a compound of the following formula:
  • Figure US20210198208A1-20210701-C00012
    Figure US20210198208A1-20210701-C00013
    Figure US20210198208A1-20210701-C00014
    Figure US20210198208A1-20210701-C00015
  • wherein
  • V, U1, Y1, and Z1 are each N or CR6′;
  • R1, R2, and R6′ are each independently H, alkyl, cycloalkyl, halo, nitro, ORc, SRc, CN, haloalkyl, O-haloalkyl, or NRaRb;
  • R3, R4, and R5 are each independently H, alkyl, cycloalkyl, heterocycloalkyl, halo, nitro, ORc, SRc, CN, haloalkyl, O-haloalkyl, NRmRn, (CO)Rd, (CO)ORc, SO2NRmRn, (CO)NRmRn, C(NH)NRmRn, NH(CO)Rd, NH(CO)ORc, NH(CO)NRmRn, aryl, or heteroaryl;
  • R6 is H or NRaRb;
  • R7 and R8 are each independently H, alkyl, alkenyl, alkynyl, halo, nitro, ORc, SRc, CN, haloalkyl, O-haloalkyl, (CO)Rd. NRaRb, NH(CO)Rd, NH(CO)ORc, NH(CO)NRaRb, (CO)ORc, (CO)NRaRb, SO2NRaRb, cycloalkyl, heterocycloalkyl aryl, or heteroaryl;
  • Rm and Rn are each independently
  • H, OH,
  • alkyl, —(CH2)pT, -aryl-(CH2)p-T, —(CH2)p-aryl-T, -heteroaryl-(CH2)pT, —(CH2)p heteroaryl-T, each optionally substituted with alkyl, cycloalkyl, halo, nitro. CN, haloalkyl, O-haloalkyl. ORc, SRc, (CO)Rd, NRaRb, NH(CO)Rd. NH(CO)ORc, NH(CO)NRaRb, NHC(NH)NH2, (CO)ORc, (CO)NRaRb, and SO2NRaRb,
  • or Rm and Rn, together with the nitrogen atom they are attached, form a heterocycloalkyl group, optionally substituted with alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, halo, nitro, CN, ORc, SRc, CORd, NRaRb, NH(CO)Rd, NH(CO)ORc, NH(CO)NRaRb, a guanidine group, (CO)ORc, and (CO)NRaRb;
  • T is NRaRb, ORc, SRc, O—(CH2)q—NRaRb, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, a guanidine group, or an isonicotinimidamide group;
  • Ra, Rb, Rc, and Rd are each independently H alkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, —(CH2)q-cycloalkyl, —(CH)q-heterocycloalkyl, —(CH2)q-aryl. —(CH)q-heteroaryl, —(CO)-alkyl, —(CO)-cycloalkyl, or —(CO)-heterocycloalkyl, or Ra and Rb, together with the nitrogen atom to which they are attached, form a heterocycloalkyl group, wherein cycloalkyl, heterocycloalkyl, aryl and heteroaryl are each optioncally substituted with a group consisting of alkyl, halo, nitro, CN, haloalkyl, O-haloalkyl, OH, O-alkyl, SH, S-alkyl, NH2, NH(alkyl), and N(alkyl)2; and
  • p and q are each independently 0-5;
  • or a pharmaceutically acceptable salt, N-oxide, hydrate, solvate, tautomer, or optical isomer thereof.
  • In some embodiments. R6 is NRaRb.
  • In some embodiments, one of R3, R4, and R5 is heterocycloalkyl, CN, NRmRn, (CO)Rd, (CO)ORc, SO2NRmRn, (CO)NRmRn, C(NH)NRmRn, or NH(CO)Rd.
  • In some embodiments, one of R3, R4, and R5 is (CO)NRmRn.
  • In some embodiments, Rm is H and R is —(CH2)p-T, -aryl-(CH2)p-T, —(CH2)p-aryl-T, or -heteroaryl-(CH2)p-T, each optionally substituted with alkyl, halo, and ORc.
  • In some embodiments. T is NRaRb, O—(CH2)q—NRaRb, heterocycloalkyl, aryl, or heteroaryl.
  • In some embodiments, Rm and Rn, together with the nitrogen atom they are attached, form a heterocycloalkyl group, optionally substituted with alkyl, cycloalkyl, heterocycloalkyl. NRaRb. NH(CO)Rd, NH(CO)ORc, and NH(CO)NRaRb.
  • In some embodiments, R1 and R2 are each independently H, alkyl, halo, CN, ORc, SRc, or NRaRb.
  • In some embodiments, the compound is a compound of formula (XV)
  • Figure US20210198208A1-20210701-C00016
  • wherein
  • R′ is H or alkyl;
  • R1, R2, R10, R11, R12, and R13 are each independently H, alkyl, cycloalkyl, halo, nitro, ORc, SRc, CN, haloalkyl, O-haloalkyl, or NRaRb;
  • R3, R4, and R5 are each independently H, alkyl, cycloalkyl, heterocycloalkyl, halo, nitro. ORc, SRc, CN, haloalkyl, O-haloalkyl. NRmRn, (CO)Rd, (CO)ORc, SO2NRmRn, (CO)NRmRn. C(NH)NRaRb, NH(CO)Rd, NH(CO)ORc, NH(CO)NRaRb, aryl, or heteroaryl;
  • Rm and Rn are each independently
  • H, OH,
  • alkyl, —(CH2)p-T, -aryl-(CH2)p-T, —(CH2)p-aryl-T, -heteroaryl-(CH2)p-T, —(CH2)p-heteroaryl-T, each optionally substituted with alkyl, cycloalkyl, halo, nitro, CN, haloalkyl, O-haloalkyl, ORc, SRc, (CO)Rd, NRaRb, NH(CO)Rd, NH(CO)ORc, NH(CO)NRaRb, NHC(NH)NH2, (CO)ORc, (CO)NRaRb, and SO2NRaRb,
  • or Rm and Rn, together with the nitrogen atom they are attached, form a heterocycloalkyl group, optionally substituted with alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, halo, nitro, CN. ORc, SRc, CORd, NRaRb, NH(CO)Rd, NH(CO)ORc, NH(CO)NRaRb, a guanidine group, (CO)ORc, and (CO)NRaRb;
  • T is NRaRb, ORc. SRc, O—(CH2)q—NRaRb, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, a guanidine group, or an isonicotinimidamide group:
  • Ra, Rb, Rc, and Rd are each independently H, alkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, —(CH2)q-cycloalkyl, —(CH)q-heterocycloalkyl, —(CH2)q-aryl, —(CH)q-heteroaryl, —(CO)-alkyl, —(CO)-cycloalkyl, or —(CO)-heterocycloalkyl, or Ra and Rb, together with the nitrogen atom to which they are attached, form a heterocycloalkyl group, wherein cycloalkyl, heterocycloalkyl, aryl and heteroaryl are each optioncally substituted with a group consisting of alkyl, halo, nitro, CN, haloalkyl, O-haloalkyl, OH, O-alkyl. SH, S-alkyl, NH2. NH(alkyl), and N(alkyl)2; and
  • p and q are each independently 0-5.
  • or a pharmaceutically acceptable salt, N-oxide, hydrate, solvate
  • In some embodiments, R′ is H.
  • In some embodiments, one of R3, R4, and R5 is heterocycloalkyl, CN, NRmRn, (CO)Rd, (CO)ORc, SO2NRmRn. (CO)NRmRn. C(NH)NRmRn, or NH(CO)Rd.
  • In some embodiments, one of R3, R4, and R5 is (C)NRmRn.
  • In some embodiments. Rm is H and Rn is —(C2)p-T, -aryl-(CH2)p-T, —(CH2)p-aryl-T, or -heteroaryl-(CH2)p-T, each optionally substituted with alkyl, halo, and ORc.
  • In some embodiments, T is NRaRb, O—(CH2)q—NRaRb, heterocycloalkyl, aryl, or heteroaryl.
  • In some embodiments. Rm and Rn, together with the nitrogen atom they are attached, form a heterocycloalkyl group, optionally substituted with alkyl, cycloalkyl, heterocycloalkyl. NRaRb. NH(CO)Rd, NH(CO)ORc, and NH(CO)NRaRb.
  • In some embodiments, R1 and R2 are each independently H, alkyl, halo, CN, ORc, SRc, or NRaRb.
  • The present invention provides a compound represented by formula (I):
  • Figure US20210198208A1-20210701-C00017
  • wherein
  • Ring A is a 5- or 6-membered aryl or heteroaryl group, optionally substituted;
  • Y and Z are each N or CR9, wherein R9 is H, alkyl, halo, nitro. OH, SH, CN, O-alkyl, haloalkyl, O-haloalkyl. S-alkyl, (CO)-alkyl, (CO)-alkenyl, NRaRb. (CO)ORc. (CO)NRaRb, or SO2NRaRb, wherein Ra, Rb, and Rc are H or alkyl;
  • W is azo, alkene, alkyne, C1-8 alkyl, heteroalkyl containing 1-8 carbon and hetero atoms, cycloalkyl, hetereocycloalkyl, aryl, or heteroaryl, wherein cycloalkyl, hetereocycloalkyl, aryl, and heteroaryl optionally form a fused aryl or heteroaryl group with Ring A;
  • R6, R7, and R8 are each independently H, alkyl, alkenyl, alkynyl, halo, nitro, OH, SH, CN, O-alkyl, haloalkyl, O-haloalkyl. S-alkyl, (CO)-alkyl, (CO)-alkenyl, NRaRb, NH(CO)-alkyl, NH(CO)ORc, NH(CO)NRaRb, (CO)ORc. (CO)NRaRb, SO2NRaRb, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
      • or R7 and R8, together with the carbon atoms to which they are attached, form a cycloalkyl, heterocycloalkyl, aryl, or heteroaryl group, each optionally substituted with substituents independently selected from alkyl, alkenyl, alkynyl, halo, nitro. OH, SH, CN, O-alkyl, haloalkyl, O-haloalkyl, S-alkyl, (CO)-alkyl, (CO)-alkenyl, NRaRb (CO)ORc, (CO)NRaRb, SO2NRaRb, —C(CH3)(═N—NHC(NH)NH2, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, wherein alkyl, alkenyl, alkynyl cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are each optionally substituted with amino, alkylamino, alkylamino. —NH(CO)-alkyl, or —NH(CO)-alkenyl;
  • wherein Ring A is optionally substituted with substituents independently selected from:
  • alkyl, alkenyl, alkynyl, halo, nitro. OH, SH, CN, O-alkyl, haloalkyl, O-haloalkyl, S-alkyl, (CO)-alkyl, (CO)-alkenyl, NRaRb, NH(CO)-alkyl. NH(CO)ORc, NH(CO)NRaRb, (CO)ORc, SO2NRaRb;
  • cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, each optionally substituted with substituents independently selected from alkyl, aminoalkyl, heterocycloalkyl-alkyl, heterocycloalkyl, cycloalkyl-alkyl, and cycloalkyl; and
  • (CO)NRmRn or CNH)NRmRn, wherein Rm and Rn are each independently H, alkyl, —(CH2)p-T, cycloalkyl, heterocycloaryl, aryl, or heteroaryl, wherein —(CH2)p-T, cycloalkyl, heterocycloaryl, aryl, and heteroaryl are each optionally substituted with alkyl, halo, nitro. CN, OH, SH, O-alkyl, S-alkyl, (CO)-alkyl, (CO)-alkenyl. NRaRb. (CO)ORc. (CO)NRaRb. SO2NRaRb, cycloalkylamino, heterocycloalkylamino, arylamino, or heteroarylamino:
  • or Rm and Rn, together with the nitrogen atom they are attached, form a heterocycloalkyl or heteroaryl group, optionally substituted with alkyl, halo, nitro, CN, OH, SH, O-alkyl. S-alkyl, —CO-alkyl, —CO-alkenyl, NRaRb, (CO)ORc, or (CO)NRaRb;
  • wherein p is 0-8; and
  • wherein T is NRaRb, O-alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkylamino, heterocycloalkylamino, arylamino, heteroarylamino, a guanidine group, or an isonicotinimidamide group;
  • or a pharmaceutically acceptable salt, N-oxide, hydrate, solvate, tautomer, or optical isomer thereof.
  • In some embodiment, Y is N.
  • In some embodiment, Z is CH.
  • In some embodiment. W is azo. —CH═CH—. —C≡C—, a phenyl group, or a 5- or 6-membered heteroaryl group. In other embodiments. W is azo. In certain embodiments. W is —C≡C—.
  • In some embodiment. R6 is (CO)NRmRn. In other embodiments, wherein R6 is C(NH)NRmRn.
  • In some embodiments, R6 is NH2.
  • In some embodiments, the compound of formula (I) is represented by the following formulas:
  • Figure US20210198208A1-20210701-C00018
  • wherein
  • R1 and R2 are each independently H, alkyl, alkenyl, alkynyl, halo, nitro. OH, SH, CN, O-alkyl, haloalkyl, O-haloalkyl, S-alkyl, (CO)-alkyl, (CO)-alkenyl, NRaRb, NH(CO)-alkyl NH(CO)ORc, NH(CO)NRaRb, (CO)ORc, (CO)NRaRb, SO2NRaRb, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
  • R3 is:
  • H or CN;
  • cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, each optionally substituted with substituents independently selected from alkyl, aminoalkyl, heterocycloalkyl-alkyl, heterocycloalkyl, cycloalkyl-alkyl, and cycloalkyl; and (CO)NRmRn or C(NH)NRmRn, wherein Rm and Rn are each independently H, alkyl, —(CH2)p-T cycloalkyl, heterocycloaryl, aryl, or heteroaryl, wherein —(CH2)p-T, cycloalkyl, heterocycloaryl aryl, and heteroaryl are each optionally substituted with alkyl, halo, nitro, CN, OH, SH, O-alkyl, S-alkyl, (CO)-alkyl, (CO)-alkenyl, NRaRb, (CO)ORc, (CO)NRaRb SO2NRaRb, cycloalkylamino, heterocycloalkylamino, arylamino, or heteroarylamino;
  • or Rm and Rn, together with the nitrogen atom they are attached, form a heterocycloalkyl or heteroaryl group, optionally substituted with alkyl, halo, nitro, CN. OH, SH. O-alkyl, S-alkyl, —CO-alkyl, —CO-alkenyl. NRaRb, (CO)ORc, or (CO)NRaRb;
  • p is 0-8; and
  • T is NRaRb, O-alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkylamino, heterocycloalkylamino, arylamino, heteroarylamino, a guanidine group, or an isonicotinimidamide group.
  • In some embodiments, the compound of formula (I) is represented by the following formulas:
  • Figure US20210198208A1-20210701-C00019
  • wherein
  • E. Y2, Y3, Y4, and Y5 are each O, S N or NR14, wherein R14 is H, alkyl, (CO)-alkyl, (CO)ORc, (CO)NRaRb, or SO2NRaRb;
  • R3 is:
  • H or CN;
  • cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, each optionally substituted with substituents independently selected from alkyl, aminoalkyl, heterocycloalkyl-alkyl, heterocycloalkyl, cycloalkyl-alkyl, and cycloalkyl; and
  • (CO)NRmRn or C(NH)NRmRn, wherein Rm and Rn are each independently H, alkyl, —(CH2)p-T, cycloalkyl, heterocycloaryl, aryl, or heteroaryl, wherein —(CH2)p-T, cycloalkyl, heterocycloaryl, aryl, and heteroaryl are each optionally substituted with alkyl, halo, nitro, CN, OH, SH, O-alkyl, S-alkyl, (CO)-alkyl (CO)-alkenyl, NRaRb, (CO)ORc, (CO)NRaRb. SO2NRaRb, cycloalkylamino, heterocycloalkylamino, arylamino, or heteroarylamino;
  • or Rm and Rn, together with the nitrogen atom they are attached, form a heterocycloalkyl or heteroaryl group, optionally substituted with alkyl, halo, nitro, CN, OH, SH, O-alkyl, S-alkyl, —CO-alkyl, —CO-alkenyl, NRaRb, (CO)ORc, or (CO)NRaRb;
  • p is 0-8; and
  • T is NRaRb, O-alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkylamino, heterocycloalkylamino, arylamino, heteroarylamino, a guanidine group, or an isonicotinimidamide group.
  • In some embodiments, a compound of formula (I) is represented by formula (Ia)
  • Figure US20210198208A1-20210701-C00020
  • wherein
  • R1, R2, R4, and R5 are each independently H, alkyl, alkenyl, alkynyl, halo, nitro, OH, SH, CN, O-alkyl, haloalkyl, O-haloalkyl, S-alkyl, (CO)-alkyl, (CO)-alkenyl, NRaRb, NH(CO)-alkyl, NH(CO)ORc, NH(CO)NRaRb, (CO)ORc, (CO)NRaRb, SO2NRaRb, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
  • R3 is:
  • H or CN;
  • cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, each optionally substituted with substituents independently selected from alkyl, aminoalkyl, heterocycloalkyl-alkyl, heterocycloalkyl, cycloalkyl-alkyl, and cycloalkyl; and
  • (CO)NRmRa or C(NH)NRaRb, wherein Rm and Rn are each independently H, alkyl, —(CH2)p-T, cycloalkyl, heterocycloaryl, aryl, or heteroaryl, wherein —(CH2)p-T, cycloalkyl, heterocycloaryl, aryl, and heteroaryl are each optionally substituted with alkyl, halo, nitro. CN, OH, SH, O-alkyl, S-alkyl, (CO)-alkyl, (CO)-alkenyl, NRaRb, (CO)ORc, (CO)NRaRb, SO2NRaRb, cycloalkylamino, heterocycloalkylamino, arylamino, or heteroarylamino;
  • or Rm and Rn, together with the nitrogen atom they are attached, form a heterocycloalkyl or heteroaryl group, optionally substituted with alkyl, halo, nitro, CN. OH, SH, O-alkyl, S-alkyl, —CO-alkyl, —CO-alkenyl. NRaRb, (CO)ORc, or (CO)NRaRb;
  • p is 0-8; and
  • T is NRaRb. O-alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkylamino, heterocycloalkylamino, arylamino, heteroarylamino, a guanidine group, or an isonicotinimidamide group.
  • In some embodiments, the compound of formula (Ia) is represented by a compound of formula (II)
  • Figure US20210198208A1-20210701-C00021
  • wherein
  • R10, R11, R12, and R13 are each independently H, alkyl, alkenyl, alkynyl, halo, nitro. OH, SH, CN, O-alkyl, haloalkyl, O-haloalkyl. S-alkyl, (CO)-alkyl, (CO)-alkenyl. NRaRb, (CO)ORc, (CO)NRaRb, SO2NRaRb, —C(CH3)(═N—NHC(NH)NH2, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, wherein alkyl, alkenyl, alkynyl cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are each optionally substituted with amino, alkylamino, dialkylamino, —NH(CO)-alkyl, or —NH(CO)— alkenyl.
  • In some embodiments. R6. R10. R11, R12, and R13 are each independently H, alkyl, alkynyl, halo, OH, CN, amino, alkylamino, or di-alkylamino.
  • In some embodiments. R11 is alkynyl, optionally substituted with amino, alkylamino, dialkylamino, or —NH(CO)-alkenyl. In other embodiments. R11 is halo. In certain embodiments, R11 is chloro.
  • In some embodiments. R6 is NH2.
  • In some embodiments, R1, R2. R4, and R5 are each H.
  • In some embodiments, R3 is CN. In other embodiments, R3 is heterocycloalkyl or heteroaryl, optionally substituted with alkyl, aminoalkyl, heterocycloalkyl-alkyl, heterocycloalkyl, cycloalkyl-alkyl, and cycloalkyl.
  • In some embodiments. R3 is (CO)NRmRn. In other embodiments. R3 is C(NH)NRmRn. In some embodiments, Rm is H and Rn is heterocycloalkyl. In some embodiments, Rm is H and Rn is (CH2)p-T, optionally substituted with alkyl, halo, or OH. In some embodiments, p is 1-4.
  • In some embodiments, T is NRaRb or O-alkyl. In some embodiments. T is —N(alkyl)2. In certain embodiments. T is N(CH3)2. In other embodiments. T is OCH3. In some embodiments, T is heterocycloalkylamino, a guanidine group, or an isonicotinimidamide group. In some embodiments. T is heterocycloalkyl. In certain embodiments, T is a 5- or 6-membered heterocycloalkyl group. In some embodiments. T is piperidine or pyrrolidine.
  • In some embodiments. Rm is H and Rn is aryl or heteroaryl. In other embodiments. Rm and Rn, together with the nitrogen atom they are attached, form a heterocycloalkyl group. In some embodiments, Rm and Rn are independently alkyl.
  • In some embodiments, the compound of formula (I) is represented by a compound of formula (III)
  • Figure US20210198208A1-20210701-C00022
  • In some embodiments, the compound of formula (I) is represented by a compound of formulas IVa-IVf:
  • Figure US20210198208A1-20210701-C00023
    Figure US20210198208A1-20210701-C00024
  • wherein
  • R1, R2. R4, R5, R10, and R13 are each independently H, alkyl, alkenyl, alkynyl, halo, nitro, OH, SH, CN, O-alkyl, haloalkyl, O-haloalkyl, S-alkyl, (CO)-alkyl, (CO)-alkenyl, NRaRb, NH(CO)-alkyl, NH(CO)ORc, NH(CO)NRaRb, (CO)ORc, (CO)NRaRb, SO2NRaRb, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; and
  • R11 and R12 are each independently H, alkyl, alkenyl, alkynyl, halo, nitro, OH, SH, CN, O-alkyl, haloalkyl, O-haloalkyl, S-alkyl, (CO)-alkyl, (CO)-alkenyl, NRaRb, (CO)ORc, (CO)NRaRb, SO2NRaRb, —C(CH3)(═N—NHC(NH)NH2, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, wherein alkyl, alkenyl, alkynyl cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are each optionally substituted with amino, alkylamino, dialkylamino, —NH(CO)-alkyl, or —NH(CO)— alkenyl.
  • In some embodiments. Rm is H and Rn is (CH2)p-T, optionally substituted with OH. In other embodiments. Rm and Rn are independently alkyl. In some embodiments, p is 1-4. In some embodiments, T is NRaRb or O-alkyl. In certain embodiments, T is N(CH3)2. In other embodiments, T is OCH3. In some embodiments, T is heterocycloalkyl. In some embodiments. T is a 5- or 6-membered heterocycloalkyl group. In certain embodiments. T is piperidine or pyrrolidine.
  • In some embodiments, Rm and Rn, together with the nitrogen atom they are attached, form a 5- or 6-membered heterocycloalkyl group.
  • In some embodiments, R6 is NH2.
  • In some embodiments, R11 is halo. In certain embodiments. R11 is chloro.
  • In some embodiments, the compound of the invention is
  • Figure US20210198208A1-20210701-C00025
    Figure US20210198208A1-20210701-C00026
    Figure US20210198208A1-20210701-C00027
    Figure US20210198208A1-20210701-C00028
    Figure US20210198208A1-20210701-C00029
    Figure US20210198208A1-20210701-C00030
    Figure US20210198208A1-20210701-C00031
    Figure US20210198208A1-20210701-C00032
    Figure US20210198208A1-20210701-C00033
    Figure US20210198208A1-20210701-C00034
    Figure US20210198208A1-20210701-C00035
    Figure US20210198208A1-20210701-C00036
    Figure US20210198208A1-20210701-C00037
    Figure US20210198208A1-20210701-C00038
    Figure US20210198208A1-20210701-C00039
    Figure US20210198208A1-20210701-C00040
    Figure US20210198208A1-20210701-C00041
    Figure US20210198208A1-20210701-C00042
    Figure US20210198208A1-20210701-C00043
    Figure US20210198208A1-20210701-C00044
    Figure US20210198208A1-20210701-C00045
    Figure US20210198208A1-20210701-C00046
    Figure US20210198208A1-20210701-C00047
    Figure US20210198208A1-20210701-C00048
    Figure US20210198208A1-20210701-C00049
    Figure US20210198208A1-20210701-C00050
    Figure US20210198208A1-20210701-C00051
    Figure US20210198208A1-20210701-C00052
    Figure US20210198208A1-20210701-C00053
    Figure US20210198208A1-20210701-C00054
    Figure US20210198208A1-20210701-C00055
    Figure US20210198208A1-20210701-C00056
    Figure US20210198208A1-20210701-C00057
    Figure US20210198208A1-20210701-C00058
  • In some embodiments, the compound of the invention is
  • Figure US20210198208A1-20210701-C00059
    Figure US20210198208A1-20210701-C00060
    Figure US20210198208A1-20210701-C00061
    Figure US20210198208A1-20210701-C00062
    Figure US20210198208A1-20210701-C00063
    Figure US20210198208A1-20210701-C00064
    Figure US20210198208A1-20210701-C00065
    Figure US20210198208A1-20210701-C00066
    Figure US20210198208A1-20210701-C00067
    Figure US20210198208A1-20210701-C00068
    Figure US20210198208A1-20210701-C00069
    Figure US20210198208A1-20210701-C00070
    Figure US20210198208A1-20210701-C00071
    Figure US20210198208A1-20210701-C00072
    Figure US20210198208A1-20210701-C00073
  • In some embodiments, the compound of the invention is
  • Figure US20210198208A1-20210701-C00074
    Figure US20210198208A1-20210701-C00075
    Figure US20210198208A1-20210701-C00076
    Figure US20210198208A1-20210701-C00077
    Figure US20210198208A1-20210701-C00078
    Figure US20210198208A1-20210701-C00079
    Figure US20210198208A1-20210701-C00080
  • In some embodiments, the compound of the invention is
  • Figure US20210198208A1-20210701-C00081
    Figure US20210198208A1-20210701-C00082
    Figure US20210198208A1-20210701-C00083
    Figure US20210198208A1-20210701-C00084
    Figure US20210198208A1-20210701-C00085
    Figure US20210198208A1-20210701-C00086
    Figure US20210198208A1-20210701-C00087
    Figure US20210198208A1-20210701-C00088
  • In some embodiments, the compound of the invention is
  • Figure US20210198208A1-20210701-C00089
    Figure US20210198208A1-20210701-C00090
    Figure US20210198208A1-20210701-C00091
    Figure US20210198208A1-20210701-C00092
    Figure US20210198208A1-20210701-C00093
    Figure US20210198208A1-20210701-C00094
    Figure US20210198208A1-20210701-C00095
    Figure US20210198208A1-20210701-C00096
    Figure US20210198208A1-20210701-C00097
    Figure US20210198208A1-20210701-C00098
    Figure US20210198208A1-20210701-C00099
    Figure US20210198208A1-20210701-C00100
    Figure US20210198208A1-20210701-C00101
    Figure US20210198208A1-20210701-C00102
    Figure US20210198208A1-20210701-C00103
    Figure US20210198208A1-20210701-C00104
    Figure US20210198208A1-20210701-C00105
    Figure US20210198208A1-20210701-C00106
    Figure US20210198208A1-20210701-C00107
  • In some embodiments, the compound of the invention is
  • Figure US20210198208A1-20210701-C00108
    Figure US20210198208A1-20210701-C00109
  • In some embodiments, the compound of the invention is
  • Figure US20210198208A1-20210701-C00110
    Figure US20210198208A1-20210701-C00111
    Figure US20210198208A1-20210701-C00112
  • In some embodiments, the compound of the invention is
  • Figure US20210198208A1-20210701-C00113
    Figure US20210198208A1-20210701-C00114
    Figure US20210198208A1-20210701-C00115
    Figure US20210198208A1-20210701-C00116
    Figure US20210198208A1-20210701-C00117
    Figure US20210198208A1-20210701-C00118
    Figure US20210198208A1-20210701-C00119
    Figure US20210198208A1-20210701-C00120
    Figure US20210198208A1-20210701-C00121
    Figure US20210198208A1-20210701-C00122
    Figure US20210198208A1-20210701-C00123
    Figure US20210198208A1-20210701-C00124
    Figure US20210198208A1-20210701-C00125
    Figure US20210198208A1-20210701-C00126
    Figure US20210198208A1-20210701-C00127
    Figure US20210198208A1-20210701-C00128
    Figure US20210198208A1-20210701-C00129
    Figure US20210198208A1-20210701-C00130
    Figure US20210198208A1-20210701-C00131
    Figure US20210198208A1-20210701-C00132
    Figure US20210198208A1-20210701-C00133
    Figure US20210198208A1-20210701-C00134
    Figure US20210198208A1-20210701-C00135
    Figure US20210198208A1-20210701-C00136
    Figure US20210198208A1-20210701-C00137
    Figure US20210198208A1-20210701-C00138
    Figure US20210198208A1-20210701-C00139
    Figure US20210198208A1-20210701-C00140
    Figure US20210198208A1-20210701-C00141
  • In some embodiments, the compound is the invention is
  • Figure US20210198208A1-20210701-C00142
    Figure US20210198208A1-20210701-C00143
    Figure US20210198208A1-20210701-C00144
    Figure US20210198208A1-20210701-C00145
    Figure US20210198208A1-20210701-C00146
    Figure US20210198208A1-20210701-C00147
    Figure US20210198208A1-20210701-C00148
    Figure US20210198208A1-20210701-C00149
    Figure US20210198208A1-20210701-C00150
    Figure US20210198208A1-20210701-C00151
    Figure US20210198208A1-20210701-C00152
    Figure US20210198208A1-20210701-C00153
    Figure US20210198208A1-20210701-C00154
    Figure US20210198208A1-20210701-C00155
    Figure US20210198208A1-20210701-C00156
    Figure US20210198208A1-20210701-C00157
    Figure US20210198208A1-20210701-C00158
    Figure US20210198208A1-20210701-C00159
    Figure US20210198208A1-20210701-C00160
    Figure US20210198208A1-20210701-C00161
    Figure US20210198208A1-20210701-C00162
    Figure US20210198208A1-20210701-C00163
    Figure US20210198208A1-20210701-C00164
    Figure US20210198208A1-20210701-C00165
    Figure US20210198208A1-20210701-C00166
    Figure US20210198208A1-20210701-C00167
    Figure US20210198208A1-20210701-C00168
    Figure US20210198208A1-20210701-C00169
    Figure US20210198208A1-20210701-C00170
    Figure US20210198208A1-20210701-C00171
    Figure US20210198208A1-20210701-C00172
    Figure US20210198208A1-20210701-C00173
    Figure US20210198208A1-20210701-C00174
    Figure US20210198208A1-20210701-C00175
    Figure US20210198208A1-20210701-C00176
    Figure US20210198208A1-20210701-C00177
    Figure US20210198208A1-20210701-C00178
    Figure US20210198208A1-20210701-C00179
  • or a pharmaceutically acceptable salt, N-oxide, hydrate, solvate, tautomer, or optical isomer thereof.
  • In some embodiments, the compound of formula (I) of the invention is represented by a compound of formulas Va-Vf
  • Figure US20210198208A1-20210701-C00180
    Figure US20210198208A1-20210701-C00181
  • wherein
  • R1. R2, R4, and R5 are each independently H, alkyl, alkenyl, alkynyl, halo, nitro, OH, SH. CN, O-alkyl, haloalkyl, O-haloalkyl, S-alkyl, (CO)-alkyl, (CO)-alkenyl. NRaRb NH(CO)-alkyl, NH(CO)ORc, NH(CO)NRaRb, (CO)ORc, (CO)NRaRb, SO2NRaRb, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; and
  • R11 and R12 are each independently H, alkyl, alkenyl, alkynyl, halo, nitro, OH, SH, CN, O-alkyl, haloalkyl, O-haloalkyl, S-alkyl, (CO)-alkyl, (CO)-alkenyl, NRaRb, (CO)ORc, (CO)NRaRb, SO2NRaRb, —C(CH3)(═N—NHC(NH)NH2, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, wherein alkyl, alkenyl, alkynyl cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are each optionally substituted with amino, alkylamino, dialkylamino, —NH(CO)-alkyl, or —NH(CO)— alkenyl.
  • In some embodiments, the compound of formula (I) of the invention is represented by a compound of formulas VIa-VIc
  • Figure US20210198208A1-20210701-C00182
  • wherein
  • R′. R1. R2. R4, and R5 are each independently H, alkyl, alkenyl, alkynyl, halo, nitro. OH, SH, CN, O-alkyl, haloalkyl, O-haloalkyl. S-alkyl, (CO)-alkyl, (CO)-alkenyl. NRaRb. NH(CO)-alkyl. NH(CO)ORc, NH(CO)NRaRb, (CO)ORc, (CO)NRaRb, SO2NRaRb, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, wherein each R′ is the same or different R1 and R1 are each independently H, alkyl, alkenyl, alkynyl, halo, nitro, OH, SH, CN, O-alkyl, haloalkyl, O-haloalkyl, S-alkyl, (CO)-alkyl, (CO)-alkenyl, NRaRb, (CO)ORc, (CO)NRaRb, SO2NRaRb, —C(CH3)(═N—NHC(NH)NH2, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, wherein alkyl, alkenyl, alkynyl cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are each optionally substituted with amino, alkylamino, dialkylamino. —NH(CO)-alkyl, or —NH(CO)— alkenyl; and
  • R14 is H, alkyl, (CO)-alkyl, (CO)ORc, (CO)NRaRb, or SO2NRaRb.
  • In some embodiments, the compound of formula (I) of the invention is represented by a compound of formulas VIIa-VIIc
  • Figure US20210198208A1-20210701-C00183
  • wherein
  • R1, R2, R4, R5, R16, R17, R18, and R19 are each independently H, alkyl, alkenyl, alkynyl, halo, nitro, OH, SH, CN, O-alkyl, haloalkyl, O-haloalkyl, -alkyl(CO)-alkyl, (CO)-alkenyl, NRaRb, NH(CO)-alkyl, NH(CO)ORc, NH(CO)NRaRb, (CO)ORc, (CO)NRaRb, SO2NRaRb, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl:
  • R11 and R12 are each independently H, alkyl alkenyl alkynyl, halo, nitro, OH, SH, CN, O-alkyl, haloalkyl, O-haloalkyl, S-alkyl, (CO)-alkyl, (CO)-alkenyl. NRaRb, (CO)ORc, (CO)NRaRb, SO2NRaRb, —C(CH3)(═N—NHC(NH)NH2, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, wherein alkyl, alkenyl, alkynyl cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are each optionally substituted with amino, alkylamino, dialkylamino, —NH(CO)-alkyl, or —NH(CO)— alkenyl; and
  • R14 is H, alkyl, (CO)-alkyl, (CO)ORc, (CO)NRaRb, or SO2NRaRb.
  • In some embodiments, the compound of formula (I) of the invention is represented by a compound of formulas VIIa-VIIIf
  • Figure US20210198208A1-20210701-C00184
    Figure US20210198208A1-20210701-C00185
  • wherein
  • E is O, S, or NR14;
  • R1, R2, R4, and R5 are each independently H, alkyl, alkenyl, alkynyl, halo, nitro, OH, SH. CN, O-alkyl, haloalkyl, O-haloalkyl, S-alkyl, (CO)-alkyl, (CO)-alkenyl. NRaRb, NH(CO)-alkyl, NH(CO)ORc. NH(CO)NRaRb, (CO)ORc, (CO)NRaRb. SO2NRaRb, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; and
  • R14 and R15 are each independently H, alkyl, (CO)-alkyl, (CO)ORc, (CO)NRaRb, or SO2NRaRb.
  • In some embodiments, the compound of formula (I) of the invention is represented by a compound of formulas IXa-IXf
  • Figure US20210198208A1-20210701-C00186
  • wherein
  • E is O, S, or NR14;
  • R1, R2, R4, and R5 are each independently H, alkyl, alkenyl, alkynyl, halo, nitro. OH, SH, CN, O-alkyl, haloalkyl, O-haloalkyl, S-alkyl, (CO)-alkyl, (CO)-alkenyl, NRaRb, NH(CO)-alkyl, NH(CO)ORc, NH(CO)NRaRb, (CO)ORc, (CO)NRaRb, SO2NRaRb, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; and
  • R14 and R15 are each independently H, alkyl, (CO)-alkyl, (CO)ORc, (CO)NRaRb, or SO2NRaRb.
  • In some embodiments, the compound of formula (I) of the invention is represented by a compound of formulas Xa-Xf
  • Figure US20210198208A1-20210701-C00187
  • wherein
  • E is O, S, or NR4;
  • R1, R2, R4, R5, R10, and R13 are each independently H, alkyl, alkenyl, alkynyl, halo, nitro, OH, SH, CN, O-alkyl, haloalkyl, O-haloalkyl. S-alkyl, (CO)-alkyl, (CO)-alkenyl, NRaRb, NH(CO)-alkyl, NH(CO)ORc, NH(CO)NRaRb, (CO)ORc, (CO)NRaRb, SO2NRaRb, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
  • R11 and R12 are each independently H, alkyl, alkenyl, alkynyl, halo, nitro, OH, SH, CN, O-alkyl, haloalkyl, O-haloalkyl, S-alkyl, (CO)-alkyl, (CO)-alkenyl, NRaRb, (CO)ORc, (CO)NRaRb, SO2NRaRb, —C(CH3)(═N—NHC(NH)NH2, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, wherein alkyl, alkenyl, alkynyl cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are each optionally substituted with amino, alkylamino, dialkylamino. —NH(CO)-alkyl, or —NH(CO)— alkenyl; and
  • R14 and R15 are each independently H, alkyl, (CO)-alkyl, (CO)ORc, (CO)NRaRb, or SO2NRaRb.
  • In some embodiments, the compound of formula (I) of the invention is represented by a compound of formulas XIa-XIf
  • Figure US20210198208A1-20210701-C00188
  • wherein
  • E is O, S, or NR14;
  • R1. R2. R4, and R5 are each independently H, alkyl, alkenyl, alkynyl, halo, nitro. OH, SH, CN, O-alkyl, haloalkyl, -haloalkyl, S-alkyl, (CO)-alkyl, (CO)-alkenyl. NRaRb. NH(CO)-alkyl, NH(CO)ORc, NH(CO)NRaRb, (CO)ORc. (CO)NRaRb, SO2NRaRb, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; and
  • R14 and R15 are each independently H, alkyl, (CO)-alkyl, (CO)ORc, (CO)NRaRb, or SO2NRaRb.
  • The compound of the invention can be prepared by the methods known in the art and the methods in the reaction schemes and experiments as described herein.
  • Scheme 1 provides a general reaction scheme for the preparation of the compounds of the invention through a halogenation reaction, followed by functionalization.
  • Figure US20210198208A1-20210701-C00189
  • For alkynes-containing compounds, a compound of the invention can be prepared via Sonogashira methodology as described in Scheme 2.
  • Figure US20210198208A1-20210701-C00190
    Figure US20210198208A1-20210701-C00191
  • Scheme 3 describes the preparation of a compound of the invention via Suzuki coupling.
  • Figure US20210198208A1-20210701-C00192
  • A compound of the invention can be prepared by functionalization of isoquinoline amine according to Scheme 4.
  • Figure US20210198208A1-20210701-C00193
  • Scheme 5 provides a general synthetic strategy for synthesis of functionalized 1-amino or 2-amino or 3-amino isoquinoline, quinoline/quinazoline and isoquinolines using quinoline or isoquinoline or quinazoline amine as nucleophile.
  • Figure US20210198208A1-20210701-C00194
  • Scheme 6 provides a general synthetic strategy for synthesis of 4-Substituted isoquinolines, quinolones and quinazolines.
  • Figure US20210198208A1-20210701-C00195
  • Scheme 7 provides synthesis of target compounds via Sonogashira coupling.
  • Figure US20210198208A1-20210701-C00196
  • A general synthetic strategy for displacement of halogen on quinoline or isoquinoline or quinazoline for preparation of compounds of the invention is described in FIG. 7.
  • In some embodiments, the compounds of the invention are described in FIGS. 4-6.
  • In some embodiments, the compounds of the invention are readily prepared via Sonogashira or Suzuki coupling of iodo arenes with alkynes or alkene boronates, catalyzed by Pd(PPh3)2Cl2 (Sonogashira) or Pd(PPh3)4 (Suzuki) (e.g., in Table 4) as demonstrated in Scheme 8.
  • Figure US20210198208A1-20210701-C00197
  • NIS (N-iodosuccinimide); DIPEA (diisopropylethylamine); DMF (dimethylformamide)
  • In the compounds of the invention, the nature and substitution pattern on the amide and amidine head groups remarkably affect the anticancer properties of the compounds. By systematically varying the amide and amidine functionalities, the compounds have been identified that are about two orders of magnitude more potent than the compounds previously reported by Sintim et al. (PCT/US2015/041551).
  • As described in FIG. 1, in the compounds of the invention, the length of the amide head group, substitution pattern and relative position to the alkyne moiety remarkably affects the anticancer activity against MV4-11 cell line (AML cell line). For example, the nature of the amide group in the molecules shown in FIG. 1 had a dramatic effect on the anticancer activities of the molecules tested.
  • For example, compounds HSM1669, M731, and HSM1684 differed from each other by a simple methylene group (CH2) yet the anticancer activities against AML are 260 nM (HSM1669), 36 nM (HSM731) and 71 nM (HSM1684). It appears that anticancer potency increases with an additional methylene group (HSM1669 to M731) but then decreases when another methylene group is added (M731 to HSM1684). Further, depending on the nature of the amide linker, the relative positions of the alkyne and amide moieties appear to affect anticancer potencies. For example, the relationship between M731 and HSM1688 (para vs meta substitution) is similar to that between HSD79 and HSD82 but whereas the anticancer activity of M731 is higher than that of HSM1688 (36 nM versus 250 nM; almost a fold difference), and that of HSD79 and HSD82 are similar (108 nM versus 150 nM). This indicates that the effect of substitution pattern of the benzamide part on anticancer activity (para vs. meta vs. ortho) is context dependent.
  • For the para analogs M731, HSM1692 and HSD79 (analogs differing at the 4* position) the anticancer activities (IC50) against MV4-11 are 36 nM, 450 nM, and 108 nM, pointing to the essentiality of a nitrogen group at this 4* position. However, for the meta analogs HSM1688 and HSD82, the IC50 values are 250 nM for HSM1688 (nitrogen at the 4* position) and 150 nM for HSD82 (carbon at the 4* position). Thus, putting a hydroxyl group at the 2-position of M731 (to give HSM1702) remarkably affected the anticancer property (compare IC50 of 36 nM for M731 vs. 3 nM for HSM1702; an order of magnitude difference).
  • As used herein, all compounds starting with MXC are the same as HSM, N—I═HSN, and DGBI=HSD.
  • At various places in the present specification, substituents of compounds of the invention are disclosed in groups or in ranges. It is specifically intended that the invention include each and every individual subcombination of the members of such groups and ranges. For example, the term “C1-5 alkyl” is specifically intended to individually disclose methyl, ethyl. C3 alkyl. C4 alkyl, and C5 alkyl.
  • It is further intended that the compounds of the invention are stable. As used herein “stable” refers to a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and preferably capable of formulation into an efficacious therapeutic agent. It is further appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, can also be provided in combination in a single embodiment. Conversely, various features of the invention which are, for brevity, described in the context of a single embodiment, can also be provided separately or in any suitable subcombination.
  • Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art.
  • In some embodiments, the term “about” can allow for a degree of variability in a value or range, for example, within 10%, within 5%, or within 1% of a stated value or of a stated limit of a range.
  • In some embodiments, the term “alkyl” is meant to refer to a saturated hydrocarbon group which is straight-chained or branched. Example alkyl groups include methyl (Me), ethyl (Et), propyl (e.g., n-propyl and isopropyl), butyl (e.g., n-butyl, isobutyl, t-butyl), pentyl (e.g., n-pentyl, isopentyl, neopentyl), and the like. An alkyl group can contain from 1 to about 20, from 2 to about 20, from 1 to about 10, from 1 to about 8, from 1 to about 6, from 1 to about 4, or from 1 to about 3 carbon atoms.
  • As used herein, in some embodiments, the term “alkenyl” refers to an unsaturated monovalent chain of carbon atoms including at least one double bond, which may be optionally branched. It is understood that in embodiments that include alkenyl, illustrative variations of those embodiments include lower alkenyl, such as C2-C6, C2-C4 alkenyl, and the like.
  • As used herein, in some embodiments, the term “alkynyl” refers to an unsaturated monovalent chain of carbon atoms including at least one triple bond, which may be optionally branched. It is understood that in embodiments that include alkynyl, illustrative variations of those embodiments include lower alkynyl, such as C2-C6, C2-C4 alkynyl, and the like.
  • In some embodiments. “cycloalkyl” refers to non-aromatic carbocycles including cyclized alkyl, alkenyl, and alkynyl groups. Cycloalkyl groups can include mono- or polycyclic (e.g., having 2, 3 or 4 fused rings) ring systems, including spirocycles. In some embodiments, cycloalkyl groups can have from 3 to about 20 carbon atoms, 3 to about 14 carbon atoms, 3 to about 10 carbon atoms, or 3 to 7 carbon atoms. Cycloalkyl groups can further have 0, 1, 2, or 3 double bonds and/or 0, 1, or 2 triple bonds. Also included in the definition of cycloalkyl are moieties that have one or more aromatic rings fused (i.e., having a bond in common with) to the cycloalkyl ring, for example, benzo derivatives of cyclopentane, cyclopentene, cyclohexane, and the like. A cycloalkyl group having one or more fused aromatic rings can be attached through either the aromatic or non-aromatic portion. One or more ring-forming carbon atoms of a cycloalkyl group can be oxidized, for example, having an oxo or sulfido substituent. Example cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptatrienyl, norbornyl, norpinyl, norcarnyl, adamantyl, and the like.
  • In some embodiments, “aryl” refers to monocyclic or polycyclic (e.g., having 2, 3 or 4 fused rings) aromatic hydrocarbons such as, for example, phenyl, naphthyl, anthracenyl, phenanthrenyl, and the like. In some embodiments, an aryl group has from 6 to about 20 carbon atoms.
  • In some embodiments, “heteroaryl” refers to an aromatic heterocycle having at least one heteroatom ring member such as sulfur, oxygen, or nitrogen. Heteroaryl groups include monocyclic and polycyclic (e.g., having 2, 3 or 4 fused rings) systems. Any ring-forming N atom in a heteroaryl group can also be oxidized to form an N-oxo moiety. Examples of heteroaryl groups include without limitation, pyridyl, N-oxopyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, furyl, quinolyl, isoquinolyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrryl oxazolyl, benzofuryl, benzothienyl, benzthiazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, indaolyl, 1,2,4-thiadiazolyl, isothiazolyl, benzothienyl, purinyl, carbazolyl, benzimidazolyl, indolinyl, and the like. In some embodiments, the heteroaryl group has from 1 to about 20 carbon atoms, and in further embodiments from about 3 to about 20 carbon atoms. In some embodiments, the heteroaryl group contains 3 to about 14, 3 to about 7, or 5 to 6 ring-forming atoms. In some embodiments, the heteroaryl group has 1 to about 4, 1 to about 3, or 1 to 2 heteroatoms. In some embodiments, “heteroaryl” may be optionally substituted at any one or more positions capable of bearing a hydrogen atom.
  • In some embodiments. “heterocycloalkyl” refers to a non-aromatic heterocycle where one or more of the ring-forming atoms are a heteroatom such as an O, N, or S atom. Heterocycloalkyl groups can include mono- or polycyclic (e.g., having 2, 3 or 4 fused rings) ring systems as well as spirocycles. Example heterocycloalkyl groups include morpholino, thiomorpholino, piperazinyl, tetrahydrofuranyl, tetrahydrothienyl, 2,3-dihydrobenzofuryl, 1,3-benzodioxole, benzo-1,4-dioxane, piperidinyl, pyrrolidinyl, isoxazolidinyl, isothiazolidinyl, pyrazolidinyl, oxazolidinyl, thiazolidinyl, imidazolidinyl, and the like. Also included in the definition of heterocycloalkyl are moieties that have one or more aromatic rings fused (i.e., having a bond in common with) to the nonaromatic heterocyclic ring, for example phthalimidyl, naphthalimidyl, and benzo derivatives of heterocycles. A heterocycloalkyl group having one or more fused aromatic rings can be attached though either the aromatic or non-aromatic portion.
  • Also included in the definition of heterocycloalkyl are moieties where one or more ring-forming atoms are substituted by 1 or 2 oxo or sulfido groups. In some embodiments, the heterocycloalkyl group has from 1 to about 20 carbon atoms, and in further embodiments from about 3 to about 20 carbon atoms. In some embodiments, the heterocycloalkyl group contains 3 to about 20, 3 to about 14, 3 to about 7, or 5 to 6 ring-forming atoms. In some embodiments, the heterocycloalkyl group has 1 to about 4, 1 to about 3, or 1 to 2 heteroatoms. In some embodiments, the heterocycloalkyl group contains 0 to 3 double bonds. In some embodiments, the heterocycloalkyl group contains 0 to 2 triple bonds.
  • In some embodiments, “halo” or “halogen” includes fluoro, chloro, bromo, and iodo. A “halogen-substitution” or “halo” substitution designates replacement of one or more hydrogen atoms with F, Cl, Br or I.
  • In some embodiments, “haloalkyl” refers to an alkyl group having one or more halogen substituents. Example haloalkyl groups include CF3, C2F5, CHF2, CCl3, CHCl2, C2Cl5, and the like.
  • It is understood that each of alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkylene, and heterocycle may be optionally substituted with independently selected groups such as alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, carboxylic acid and derivatives thereof, including esters, amides, and nitrites, hydroxy, alkoxy, acyloxy, amino, alky and dialkylamino, acylamino, thio, and the like, and combinations thereof.
  • In some embodiments, the term “substituted” refers to the replacement of a hydrogen moiety with a non-hydrogen moiety in a molecule or group. It can refer to “mono-substituted” or “poly-substituted.” The term “mono-substituted” or “poly-substituted” means substituted with one or more than one substituent up to the valence of the substituted group. For example, a mono-substituted group can be substituted with 1 substituent, and a poly-substituted group can be substituted with 2, 3, 4, or 5 substituents. When a list of possible substituents is provided, the substituents can be independently selected from that group.
  • The term “optionally substituted.” or “optional substituents,” as used herein, means that the groups in question are either unsubstituted or substituted with one or more of the substituents specified. When the groups in question are substituted with more than one substituent, the substituents may be the same or different. Such other functional groups illustratively include, but are not limited to, amino, hydroxyl. CN, halo, thiol, alkyl, haloalkyl, heteroalkyl, aryl, arylalkyl, arylheteroalkyl, heteroaryl, heteroarylalkyl, heteroarylheteroalkyl, nitro, sulfonic acids and derivatives thereof, carboxylic acids and derivatives thereof, and the like. Illustratively, any of amino, hydroxyl, CH, thiol, alkyl, haloalkyl, heteroalkyl, aryl, arylalkyl, arylheteroalkyl, heteroaryl, heteroarylalkyl, heteroarylheteroalkyl, and/or sulfonic acid is optionally substituted. In some embodiments, the functional groups are the substituents described herein for any one of variables. Furthermore, when using the terms “independently,” “independently are,” and “independently selected from” mean that the groups in question may be the same or different. Certain of the herein defined terms may occur more than once in the structure, and upon such occurrence each term shall be defined independently of the other.
  • In each of the foregoing and each of the following embodiments, it is to be understood that the formulas also include any and all hydrates and/or solvates of the compound formulas. It is appreciated that certain functional groups, such as the hydroxy, amino, and like groups form complexes and/or coordination compounds with water and/or various solvents, in the various physical forms of the compounds. Accordingly, the above formulas are to be understood to include and represent those various hydrates and/or solvates.
  • The compounds described herein can be asymmetric (e.g., having one or more stereocenters). All stereoisomers, such as enantiomers and diastereomers, are intended unless otherwise indicated. Compounds of the present invention that contain asymmetrically substituted carbon atoms can be isolated in optically active or racemic forms. Methods on how to prepare optically active forms from optically active starting materials are known in the art, such as by resolution of racemic mixtures or by stereoselective synthesis. Many geometric isomers of olefins. C═N double bonds, and the like can also be present in the compounds described herein, and all such stable isomers are contemplated in the present invention. Cis and trans geometric isomers of the compounds of the present invention are described and may be isolated as a mixture of isomers or as separated isomeric forms.
  • In the case of the compounds which contain an asymmetric carbon atom, the invention relates to the D form, the L form, and D.L mixtures and also, where more than one asymmetric carbon atom is present, to the diastereomeric forms. Those compounds of the invention which contain asymmetric carbon atoms, and which as a rule accrue as racemates, can be separated into the optically active isomers in a known manner, for example using an optically active acid. However, it is also possible to use an optically active starting substance from the outset, with a corresponding optically active or diastereomeric compound then being obtained as the end product.
  • Compounds of the invention also include tautomeric forms. Tautomeric forms result from the swapping of a single bond with an adjacent double bond together with the concomitant migration of a proton. Tautomeric forms include prototropic tautomers which are isomeric protonation states having the same empirical formula and total charge. Example prototropic tautomers include ketone-enol pairs, amide-imidic acid pairs, lactam-lactim pairs, amide-imidic acid pairs, enamine-imine pairs, and annular forms where a proton can occupy two or more positions of a heterocyclic system, for example, 1H- and 3H-imidazole, 1H-, 2H- and 4H-1,2,4-triazole, 1H- and 2H-isoindole, and 1H- and 2H-pyrazole. Tautomeric forms can be in equilibrium or sterically locked into one form by appropriate substitution.
  • Compounds of the invention can also include all isotopes of atoms occurring in the intermediates or final compounds. Isotopes include those atoms having the same atomic number but different mass numbers. For example, isotopes of hydrogen include tritium and deuterium.
  • In some embodiments, the term “compound” as used herein, is meant to include all stereoisomers, geometric isomers, tautomers, and isotopes of the structures depicted.
  • In some embodiments, the compound of the invention is substantially isolated. By “substantially isolated” is meant that the compound is at least partially or substantially separated from the environment in which it was formed or detected. Partial separation can include, for example, a composition enriched in the compound of the invention. Substantial separation can include compositions containing at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, or at least about 99% by weight of the compound of the invention, or salt thereof. Methods for isolating compounds and their salts are routine in the art.
  • In some embodiments, as used herein, the term “therapeutically effective amount” refers to the amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinicians, which includes alleviation of the symptoms of the disease or disorder being treated. In one aspect, the therapeutically effective amount is that which may treat or alleviate the disease or symptoms of the disease at a reasonable benefit/risk ratio applicable to any medical treatment.
  • In addition, it is appreciated that there is an interrelationship of dosages determined for humans and those dosages determined for animals, including test animals (illustratively based on milligrams per meter squared of body surface) as described by Freireich, E. J., et al., Cancer Chemother. Rep. 1966, 50 (4), 219, the disclosure of which is incorporated herein by reference. Body surface area may be approximately determined from patient height and weight (see, e.g., Scientific Tables, Geigy Pharmaceuticals. Ardley, N.Y, pages 537-538 (1970)). A therapeutically effective amount of the compounds described herein may be defined as any amount useful for inhibiting the growth of (or killing) a population of malignant cells or cancer cells, such as may be found in a patient in need of relief from such cancer or malignancy.
  • Typically, such effective amounts range from about 5 mg/kg to about 500 mg/kg, from about 5 mg/kg to about 250 mg/kg, and/or from about 5 mg/kg to about 150 mg/kg of compound per patient body weight. It is appreciated that effective doses may also vary depending on the route of administration, optional excipient usage, and the possibility of co-usage of the compound with other conventional and non-conventional therapeutic treatments, including other anti-tumor agents, radiation therapy, and the like.
  • In some embodiments, the phrase “pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
  • The compound of the present invention also includes “pharmaceutically acceptable salts” of the compounds described herein. As used herein, “pharmaceutically acceptable salts” refers to derivatives of the disclosed compounds wherein the parent compound is modified by converting an existing acid or base moiety to its salt form. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts of the compound of the invention include the conventional non-toxic salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. The pharmaceutically acceptable salts of the compound of the invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred.
  • The pharmaceutically acceptable salts of the compound of the invention can be obtained by converting derivatives which possess tertiary amino groups into the corresponding quaternary ammonium salts in a manner known per se using quaternizing agents. Examples of suitable quaternizing agents are alkyl halides, such as methyl iodide, ethyl bromide, and n-propyl chloride, and also arylalkyl halides, such as benzyl chloride or 2-phenylethyl bromide.
  • The “subject” used here refers to an animal or a human. In some embodiment, the term “subject” refers to a human. A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt, N-oxide, hydrate, solvate, tautomer, or optical isomer thereof, and a pharmaceutically acceptable carrier or diluent.
  • In another aspect, the present invention features a pharmaceutical composition comprising a compound of the invention as described herein, or a pharmaceutically acceptable salt, N-oxide, hydrate, solvate, tautomer, or optical isomer thereof, and a pharmaceutically acceptable carrier or diluent.
  • In some embodiment, the pharmaceutical composition includes a therapeutically effective amount of the one or more compounds for treating a cancer patient. It is to be understood that the composition may include other component and/or ingredients, including, but not limited to, other therapeutically active compounds, and/or one or more pharmaceutically acceptable carriers, diluents, excipients, and the like.
  • The term “pharmaceutically acceptable carrier” or “pharmaceutically acceptable diluent” is art-recognized and refers to a pharmaceutically-acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting any subject composition or component thereof. Each carrier must be “acceptable” in the sense of being compatible with the subject composition and its components and not injurious to the patient. Some examples of materials which may serve as pharmaceutically acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate: (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate: (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide: (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethyl alcohol; (20) phosphate buffer solutions; and (21) other non-toxic compatible substances employed in pharmaceutical formulations.
  • A therapeutically effective dose of a compound according to the invention is used, in addition to physiologically acceptable carriers, diluents and/or adjuvants for producing a pharmaceutical composition. The dose of the active compound can vary depending on the route of administration, the age and weight of the patient, the nature and severity of the diseases to be treated, and similar factors. The daily dose can be given as a single dose, which is to be administered once, or be subdivided into two or more daily doses, and is as a rule 0.001-2000 mg. Particular preference is given to administering daily doses of 0.1-500 mg, e.g. 0.1-100 mg.
  • Suitable administration forms are oral, parenteral, intravenous, transdermal, topical, inhalative, intranasal and sublingual preparations. Particular preference is given to using oral, parenteral, e.g. intravenous or intramuscular, intranasal, e.g. dry powder or sublingual preparations of the compounds according to the invention. The customary galenic preparation forms, such as tablets, sugar-coated tablets, capsules, dispersible powders, granulates, aqueous solutions, alcohol-containing aqueous solutions, aqueous or oily suspensions, syrups, juices or drops, are used.
  • Solid medicinal forms can comprise inert components and carrier substances, such as calcium carbonate, calcium phosphate, sodium phosphate, lactose, starch, mannitol, alginates, gelatine, guar gum, magnesium stearate, aluminium stearate, methyl cellulose, talc, highly dispersed silicic acids, silicone oil, higher molecular weight fatty acids, (such as stearic acid), gelatine, agar agar or vegetable or animal fats and oils, or solid high molecular weight polymers (such as polyethylene glycol); preparations which are suitable for oral administration can comprise additional flavorings and/or sweetening agents, if desired.
  • Liquid medicinal forms can be sterilized and/or, where appropriate, comprise auxiliary substances, such as preservatives, stabilizers, wetting agents, penetrating agents, emulsifiers, spreading agents, solubilizers, salts, sugars or sugar alcohols for regulating the osmotic pressure or for buffering, and/or viscosity regulators. Examples of such additives are tartrate and citrate buffers, ethanol and sequestering agents (such as ethylenediaminetetraacetic acid and its nontoxic salts). High molecular weight polymers, such as liquid polyethylene oxides, microcrystalline celluloses, carboxymethyl celluloses, polyvinylpyrrolidones, dextrans or gelatine, are suitable for regulating the viscosity. Examples of solid carrier substances are starch, lactose, mannitol, methyl cellulose, talc, highly dispersed silicic acids, high molecular weight fatty acids (such as stearic acid), gelatine, agar agar, calcium phosphate, magnesium stearate, animal and vegetable fats, and solid high molecular weight polymers, such as polyethylene glycol.
  • Oily suspensions for parenteral or topical applications can be vegetable synthetic or semisynthetic oils, such as liquid fatty acid esters having in each case from 8 to 22 C atoms in the fatty acid chains, for example palmitic acid, lauric acid, tridecanoic acid, margaric acid, stearic acid, arachidic acid, myristic acid, behenic acid, pentadecanoic acid, linoleic acid, elaidic acid, brasidic acid, erucic acid or oleic acid, which are esterified with monohydric to trihydric alcohols having from 1 to 6 C atoms, such as methanol, ethanol, propanol, butanol, pentanol or their isomers, glycol or glycerol. Examples of such fatty acid esters are commercially available miglyols, isopropyl myristate, isopropyl palmitate, isopropyl stearate, PEG 6-capric acid, caprylic/capric acid esters of saturated fatty alcohols, polyoxyethylene glycerol trioleates, ethyl oleate, waxy fatty acid esters, such as artificial ducktail gland fat, coconut fatty acid isopropyl ester, oleyl oleate, decyl oleate, ethyl lactate, dibutyl phthalate, diisopropyl adipate, polyol fatty acid esters, inter alia. Silicone oils of differing viscosity, or fatty alcohols, such as isotridecyl alcohol, 2-octyldodecanol, cetylstearyl alcohol or oleyl alcohol, or fatty acids, such as oleic acid, are also suitable. Tt is furthermore possible to use vegetable oils, such as castor oil, almond oil, olive oil, sesame oil, cotton seed oil, groundnut oil or soybean oil.
  • Suitable solvents, gelatinizing agents and solubilizers are water or watermiscible solvents. Examples of suitable substances are alcohols, such as ethanol or isopropyl alcohol, benzyl alcohol, 2-octyldodecanol, polyethylene glycols, phthalates, adipates, propylene glycol, glycerol, di- or tripropylene glycol, waxes, methyl cellosolve, cellosolve, esters, morpholines, dioxane, dimethyl sulphoxide, dimethylformamide, tetrahydrofuran, cyclohexanone, etc.
  • Mixtures of gelatinizing agents and film-forming agents are also perfectly possible. In this case, use is made, in particular, of ionic macromolecules such as sodium carboxymethyl cellulose, polyacrylic acid, polymethacrylic acid and their salts, sodium amylopectin semiglycolate, alginic acid or propylene glycol alginate as the sodium salt, gum arabic, xanthan gum, guar gum or carrageenan. The following can be used as additional formulation aids: glycerol, paraffin of differing viscosity, triethanolamine, collagen, allantoin and novantisolic acid. Use of surfactants, emulsifiers or wetting agents, for example of Na lauryl sulphate, fatty alcohol ether sulphates, di-Na—N-lauryl-β-iminodipropionate, polyethoxylated castor oil or sorbitan monooleate, sorbitan monostearate, polysorbates (e.g. Tween), cetyl alcohol, lecithin, glycerol monostearate, polyoxyethylene stearate, alkylphenol polyglycol ethers, cetyltrimethylammonium chloride or mono-/dialkylpolyglycol ether orthophosphoric acid monoethanolamine salts can also be required for the formulation. Stabilizers, such as montmorillonites or colloidal silicic acids, for stabilizing emulsions or preventing the breakdown of active substances such as antioxidants, for example tocopherols or butylhydroxyanisole, or preservatives, such as p-hydroxybenzoic acid esters, can likewise be used for preparing the desired formulations.
  • Preparations for parenteral administration can be present in separate dose unit forms, such as ampoules or vials. Use is preferably made of solutions of the active compound, preferably aqueous solution and, in particular, isotonic solutions and also suspensions. These injection forms can be made available as ready-to-use preparations or only be prepared directly before use, by mixing the active compound, for example the lyophilisate, where appropriate containing other solid carrier substances, with the desired solvent or suspending agent.
  • Intranasal preparations can be present as aqueous or oily solutions or as aqueous or oily suspensions. They can also be present as lyophilisates which are prepared before use using the suitable solvent or suspending agent.
  • Inhalable preparations can present as powders, solutions or suspensions. Preferably, inhalable preparations are in the form of powders, e.g. as a mixture of the active ingredient with a suitable formulation aid such as lactose.
  • The preparations are produced, aliquoted and sealed under the customary antimicrobial and aseptic conditions.
  • As indicated above, a compound of the invention may be administered as a combination therapy with further active agents. e.g. therapeutically active compounds useful in the treatment of cancer, for example, prostate cancer, ovarian cancer, lung cancer, or breast cancer. In some embodiments, the cancer is acute myeloid leukemia, chronic myeloid leukemia, ovarian cancer, cervical cancer, pancreatic cancer, breast cancer, brain cancer, skin cancer, lung cancer, prostate cancer. Lymphoma, Leukemia, colon cancer, head cancer, neck cancer, thyroid cancer, kidney cancer, liver cancer and stomach cancer. For a combination therapy, the active ingredients may be formulated as compositions containing several active ingredients in a single dose form and/or as kits containing individual active ingredients in separate dose forms. The active ingredients used in combination therapy may be coadministered or administered separately.
  • It is another aspect of the invention that a compound of the invention as described herein is a protein kinase inhibitor. Thus, the present invention features a method of inhibiting a protein kinase, wherein the method comprises contacting the protein kinase with an effective amount of a compound of the invention. In some embodiments, such protein kinase includes, but is not limited to. FLT3 and TrkC, In some embodiments, the protein kinase is Abl, Abl2, AFK, ALK, AMPK_group, ATM, ATR, Aurora A, Aurora B, Axl, BCKDK, BLK, BMPR1B, BMX, Brk, BRSK1, BTK, CaM-KIalpha, CaM-KIIalpha, CaMKK_group, CaM-KIV, CaM-KKalpha, CaM-KKbeta, CCDPK, CCRK, CDK1, CDK11, CDK2, CDK4, CDK5, CDK6, CDK7, CDK9, CDK_group, CDPK, Chak1, CHK1, CHK2, CK1 alpha, CK1 delta, CK1 epsilon, CK1_group, CK2 alpha, CK2_beta, CK2_group, CLK1, CSF1R, Csk, DAPK1, DAPK2, DAPK3, DAPK_group, DCAMKL1, DMPK_group, DNA-PK, DYRK1A, DYRK1B, DYRK2, DYRK3, eEF2K, Eg3 kinase, EGFR, EIF2AK2, EphA2, EphA3, EphA4, EphA8, EphB1, EphB2, EphB3, EphB5, ErbB2, FAK, Fer, Fes, FGFR1, FGFR3, FGFR4, FGFR_group, Fgr, FLT1, FLT3, FLT4, Fyn, GRK-1, GRK-2, GRK-3, GRK-4, GRK-5, GRK-6, GRK_group, GSK-3alpha, GSK-3beta, GSK-3_group, HCK, HIPK2, HIPK3, HRI, ICK, IGF1R, IKK-alpha, IKK-beta, IKK-epsilon ILK, InsR, IPL1, IRAK1, IRAK4, ITK, JAK1, JAK2, JAK3, JAK_group, JNK_group, KDR, KIS, Kit, KSR1, Lck, LIMK1, LIMK2, LKB1, LOK, Lyn, MAP2K1, MAP2K2, MAP2K3, MAP2K4, MAP2K6, MAP2K7, MAPK2_group, MAP3K1, MAP3K11, MAP3K14, MAP3K5, MAP3K7, MAP3K8, MAPK3_group, MAP4K1, MAP4K2, MAP4K4, MAPK1, MAPK10, MAPK11, MAPK12, MAPK13, MAPK14, MAPK3, MAPK4, MAPK6, MAPK7, MAPK8, MAPK9, MAPK_group, MAPKAPK2, MARK_group, Mer, Met, MHCK, MLCK_group, Mnk1, Mnk2, MOS, MRCKa, MST1, MST3, mTOR, NDR1, NDR2, NEK1, NEK2, NEK6, NEK9, NEK_group, NLK, NuaK1, p37 kinase, p38_group, p70S6K, p70S6Kb, P70S6K_group, PAK1, PAK2, PAK3, PAK5, PAK6, PAK_group, PASK, P-CIP2, PCIAIRE1, PDGFR alpha, PDGFR beta, PDGFR_group, PDHK1, PDHK2, PDHK3, PDHK4, PDK-1, PDK-2, PDK_group, PHK_group, PIK3CA, PIK3CB, PIK3CD, PIK3CG, Pim-1, PKA alpha, Pka_group, PKB beta, PKB_group, PKC alpha, PKC beta, PKC delta, PKC epsilon, PKC eta, PKC gamma, PKC iota, PKC theta, PKC zeta, PKC_group, PKD1, PKD2, PKD3, PKG1/cGK-I, PKG2/cGK-11, PKG2/cGK_group, PKN1, PLK1, PLK2, PLK3, PRP4, PYK2, RAF1, Ret, ROCK, ROCK2, Ron, RPL10, RSK-1, RSK-2, RSK-3, RSK-5, SDK1, SGK_group, SIK, Sky, Src, Src_group, S7LK3, Syk, TBK1, Tec, TESK1, TESK2, TGFbR1, TGFbR2, Tie1, Tie2, Titin kinase, TNK2, TRKA, TRKB, tropomyosin kinase, TSSK3, TXK, Tyk2, TYK2, VRK1, Wee1, Wnk1, WNK1, Yes, ZAP70. In some embodiments, each possibility represents a separate embodiment of the present invention.
  • It is a further aspect of the invention that a compound of the invention as described herein can be used for treating, inhibiting, suppressing, or reducing the severity of a disease or a disorder associated with a protein kinase, wherein the method comprises administering to the subject in need thereof a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt. N-oxide, hydrate, solvate, tautomer, or optical isomer thereof. In some embodiments, the protein kinase is one known in the art. In some embodiments, the protein kinase includes, but is not limited to, FLT3 and TrkC. In some embodiments, the protein kinase is Abl, Abl2, AFK, ALK, AMPK_group, ATM, ATR, Aurora A, Aurora B, Axl, BCKDK, BLK, BMPR1B, BMX, Brk, BRSK1, BTK, CaM-KIalpha, CaM-KIIalpha, CaMKK_group, CaM-KIV, CaM-KKalpha, CaM-KKbeta, CCDPK, CCRK, CDK1, CDK11, CDK2, CDK4, CDK5, CDK6, CDK7, CDK9, CDK_group, CDPK, Chak1, CHK1, CHK2, CK1alpha, CK1delta, CK1 epsilon, CKL_group, CK2 alpha, CK2_beta, CK2_group, CLK1, CSF1R, Csk DAPK1, DAPK2, DAPK3, DAPK_group, DCAMKL1, DMPK_group, DNA-PK, DYRK1A, DYRK1B, DYRK2, DYRK3, eEF2K, Eg3 kinase, EGFR, EIF2AK2, EphA2, EphA3, EphA4, EphA8, EphB1, EphB2, EphB3, EphB5, ErbB2, FAK, Fer, Fes, FGFR1, FGFR3, FGFR4, FGFR_group, Fgr, FLT1, FLT3, FLT4, Fyn, GRK-1, GRK-2, GRK-3, GRK-4, GRK-5, GRK-6, GRK_group, GSK-3alpha, GSK-3beta, GSK-3_group, HCK, HIPK2, HIPK3, HRI, ICK, IGF1R, IKK-alpha, IKK-beta, IKK-epsilon ILK, InsR, IPL1, IRAK, IRAK4, ITK, JAK1, JAK2, JAK3, JAK_group, JNK_group, KDR, KIS, Kit, KSR1, Lck, LIMK1, LIMK2, LKB1, LOK, Lyn, MAP2K, MAP2K2, MAP2K3, MAP2K4, MAP2K6, MAP2K7, MAPK2_group, MAP3K1, MAP3K1, MAP3K14, MAPK5, MAP3K7, MAP3K8, MAPK3_group, MAP4K1, MAP4K2, MAP4K4, MAPK1, MAPK10, MAPK11, MAPK12, MAPK13, MAPK14, MAPK3, MAPK4, MAPK6, MAPK7, MAPK8, MAPK9, MAPK_group, MAPKAPK2, MARK_group, Mer, Met, MHCK, MLCK_group, Mnk1, Mnk2, MOS, MRCKa, MST1, MST3, mTOR, NDR1, NDR2, NEK1, NEK2, NEK6, NEK9, NEK_group, NLK, NuaK1, p37 kinase, p38_group, p70S6K, p70S6Kb, P70S6K_group, PAK1, PAK2, PAK3, PAK, PAK6, PAK_group, PASK, P-CIP2, PCTAIRE1, PDGFR alpha, PDGFR beta, PDGFR_group, PDHK1, PDHK2, PDHK3, PDHK4, PDK-1, PDK-2, PDK_group, PHK_group, PIK3CA, PIK3CB, PIK3CD, PIK3CG, Pim-1, PKA alpha, Pka_group, PKB beta, PKB_group, PKC alpha, PKC beta, PKC delta, PKC epsilon, PKC eta, PKC gamma, PKC iota, PKC theta, PKC zeta, PKC_group, PKD1, PKD2, PKD3, PKG1/cGK-1, PKG2/cGK-II, PKG2/cGK_group, PKN1, PLK1, PLK2, PLK3, PRP4, PYK2, RAF1, Ret, ROCK, ROCK2, Ron, RPL10, RSK-1, RSK-2, RSK-3, RSK-5, SDK1, SGK_group, SIK, Sky, Sc, Src_group, STLK3, Syk, TBK1, Tec, TESK1, TESK2, TGFbR1, TGFbR2, Tie1, Tie2, Titin kinase, TNK2, TRKA, TRKB, tropomyosin kinase, TSSK3, TXK, Tyk2, TYK2, VRK1, Wee1, Wnk1, WNK1, Yes, ZAP70. In some embodiments, each possibility represents a separate embodiment of the present invention.
  • In some embodiments, the disease or disorder associated with a protein kinase includes, but is not limited to, cancer, diabetes, malaria, viral infections (such as HIV), cardiovascular and hypertension, CNS and neurodegeneration (such as Alzheimer's. Parkinson, manic depression, supranuclear palsy), osteoporosis, inflammation and autoimmune (such as rheumatoid arthritis, myelofibrosis, inflammatory bowel disease, Crohn's disease, colitis, psoriasis, systemic lupus erythematosus, keratoconjunctivitis sicca), allergy (general allergic disease, allergic asthma, allergic rhinitis). In some embodiments, the disease or disorder associated with a protein kinase is cancer, diabetes, malaria, viral infections, cardiovascular and hypertension. CNS and neurodegeneration, osteoporosis, pulmonary fibrosis, retinitis pigmentosis. Wet macular degeneration, Duchenne muscular dystrophy, diabetic eye disease, inflammation and autoimmune, or allergy. In some embodiments, the disease or disorder associated with a protein kinase is cancer.
  • In another aspect, the invention is directed to a method of treating, inhibiting, suppressing, or reducing the severity of cancer in a subject in need thereof, wherein the method comprises administering to the subject a therapeutically effective amount of a compound as described herein, or a pharmaceutically acceptable salt, N-oxide, hydrate, solvate, tautomer, or optical isomer thereof, or a pharmaceutical composition containing one or more of the compounds as described herein.
  • In some embodiments, the invention disclosed herein relates to a method for the treatment of a cancer patient wherein abnormal kinase activities are implicated by administrating a therapeutically effective amount of a compound disclosed herein to the patient in need of relief from said cancer. It is appreciated herein that the compounds described herein may be used alone or in combination with other compounds useful for treating cancer, including those compounds that may be therapeutically effective by the same or different modes of action. It is appreciated herein that the compounds described herein may be used in combination with other compounds that are administered to treat other symptoms of cancer, such as nausea, vomiting, pain, etc.
  • In some embodiments, the cancer is selected from the group consisting of acute myeloid leukemia, chronic myeloid leukemia, ovarian cancer, cervical cancer, pancreatic cancer, breast cancer, brain cancer, skin cancer lung cancer, prostate cancer. Lymphoma. Leukemia, colon cancer, head cancer, neck cancer, thyroid cancer, kidney cancer, liver cancer and stomach cancer. In some embodiments, the cancer is acute myeloid leukemia.
  • It is another aspect of the invention that a compound of the invention as described herein can be used for treating, inhibiting, suppressing, or reducing the severity of cancer in a subject, wherein the method comprises administering to the subject in need thereof a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt. N-oxide, hydrate, solvate, tautomer, or optical isomer thereof, or a pharmaceutical composition containing one or more of the compounds as described herein. In some embodiments, the cancer that can be treated, inhibited, suppressed, or reduced the severity of by a compound of the invention as described anywhere herein includes, but is not limited to, ovarian cancer, pancreatic cancer, breast cancer, brain cancer, skin cancer, lung cancer, prostate cancer, Lymphoma, Leukemia, colon cancer, head cancer, neck cancer, and stomach cancer. In some embodiments, the cancer that can be treated, inhibited, suppressed, or reduced the severity of by a compound of the invention as described anywhere herein includes, but is not limited to, acute myeloid leukemia, chronic myeloid leukemia, ovarian cancer, cervical cancer, pancreatic cancer, breast cancer, brain cancer, skin cancer, lung cancer, prostate cancer. Lymphoma. Leukemia, colon cancer, head cancer, neck cancer, thyroid cancer, kidney cancer, liver cancer and stomach cancer. In some embodiments, the cancer is breast cancer. In other embodiments, the cancer is ovarian cancer. In some embodiments, the cancer is prostate cancer. In some embodiments, the cancer is acute myeloid leukemia.
  • It is yet another aspect of the invention that a compound of the invention as described herein is a protein kinase inhibitor. The compound of the invention can be used for treating, inhibiting, suppressing, or reducing the severity of a disease or a disorder associated with protein kinase, wherein the method comprises administering to the subject in need thereof a therapeutically effective amount of a compound of invention, or a pharmaceutically acceptable salt, N-oxide, hydrate, solvate, tautomer, or optical isomer thereof. In some embodiments, the protein kinase is one known in the art. In some embodiments, the protein kinase includes, but is not limited to. FLT3 and TrkC.
  • In some embodiments, the protein kinase is Abl, Abl2, AFK, ALK, AMPK_group, ATM, ATR, Aurora A, Aurora B, Axl, BCKDK, BLK, BMPR1B, BMX, Brk, BRSK1, BTK, CaM-KIalpha, CaM-KIIalpha, CaMKK_group, CaM-KIV, CaM-KKalpha, CaM-KKbeta, CCDPK, CCRK, CDK1, CDK11, CDK2, CDK4, CDK5, CDK6, CDK7, CDK9, CDK_group, CDPK, Chak1, CHK1, CHK2, CK1 alpha, CK1 delta, CK1 epsilon, CK1_group, CK2 alpha, CK2_beta, CK2_group, CLK1, CSF1R, Csk, DAPK1, DAPK2, DAPK3, DAPK_group, DCAMKL1, DMPK_group, DNA-PK, DYRK1A, DYRK1B, DYRK2, DYRK3, eEF2K, Eg3 kinase, EGFR, EIF2AK2, EphA2, EphA3, EphA4, EphA8, EphB1, EphB2, EphB3, EphB5, ErbB2, FAK, Fer, Fes, FGFR1, FGFR3, FGFR4, FGFR_group, Fgr, FLT1, FLT3, FLT4, Fyn, GRK-1, GRK-2, GRK-3, GRK-4, GRK-5, GRK-6, GRK_group, GSK-3alpha, GSK-3beta, GSK-3_group, HCK, HIPK2, HIPK3, HRI, ICK, IGF1R, IKK-alpha, IKK-beta, IKK-epsilon ILK, InsR, IPL1, IRAK1, IRAK4, ITK, JAK1, JAK2, JAK3, JAK_group, JNK_group, KDR, KIS, Kit, KSR1, Lck, LIMK1, LIMK2, LKB1, LOK, Lyn, MAP2K1, MAP2K2, MAP2K3, MAP2K4, MAP2K6, MAP2K7, MAPK2_group, MAP3K), MAP3K1, MAP3K14, MAP3K5, MAP3K7, MAP3K8, MAPK3_group, MAP4K1, MAP4K2, MAP4K4, MAPK1, MAPK10, MAPK1, MAPK12, MAPK13, MAPK4, MAPK3, MAPK4, MAPK6, MAPK7, MAPK8, MAPK9, MAPK_group, MAPKAPK2, MARK_group, Mer, Met, MHCK, MLCK_group, Mnk1, Mnk2, MOS, MRCKa, MST1, MST3, mTOR, NDR1, NDR2, NEK1, NEK2, NEK6, NEK9, NEK_group, NLK, NuaK1, p37 kinase, p38_group, p70S6K, p70S6Kb, P70S6K_group, PAK, PAK2, PAK3, PAK5, PAK6, PAK_group, PASK, P-CIP2, PCTAIRE1, PDGFR alpha, PDGFR beta, PDGFR_group, PDHK1, PDHK2, PDHK3, PDHK4, PDK-1, PDK-2, PDK_group, PHK_group, PIK3CA, PIK3CB, PIK3CD, PIK3CG, Pin-1, PKA alpha, Pka_group, PKB beta, PKB_group, PKC alpha, PKC beta, PKC delta, PKC epsilon, PKC eta, PKC gamma, PKC iota, PKC theta, PKC zeta, PKC_group, PKD1, PKD2, PKD3, PKG1/cGK-1, PKG2/cGK-11, PKG2/cGK_group, PKN1, PLK1, PLK2, PLK3, PRP4, PYK2, RAF), Ret, ROCK, ROCK2, Ron, RPL10, RSK-1, RSK-2, RSK-3, RSK-5, SDK1, SGK_group, SIK, Sky, Src, Src_group, STLK3, Syk, TBK1, Tec, TESK1, TESK2, TGFbR1, TGFbR2, Tie), Tie2, Titin kinase, TNK2, TRKA, TRKB, tropomyosin kinase, TSSK3, TXK, Tyk2, TYK2, VRK1, Wee1, Wnk1, WNK1, Yes, ZAP70. In some embodiments, each possibility represents a separate embodiment of the present invention.
  • In some embodiments, the disease or disorder associated with protein kinase includes those known in the art. In certain embodiments, the disease or disorder associated with protein kinase is cancer, diabetes, malaria, viral infections (such as HIV), cardiovascular and hypertension. CNS and neurodegeneration (such as Alzheimer's, Parkinson, manic depression, supranuclear palsy), osteoporosis, inflammation and autoimmune (such as rheumatoid arthritis, myelofibrosis, inflammatory bowel disease, Crohn's disease, colitis, psoriasis, systemic lupus erythematosus, keratoconjunctivitis sicca), allergy (general allergic disease, allergic asthma, allergic rhinitis). In some embodiments, each possibility represents a separate embodiment of the present invention. In other embodiments, the compound of the invention can be used for treating bacterial infections. In some embodiments, the disease or disorder associated with protein kinase is cancer, diabetes, malaria, viral infections, cardiovascular and hypertension, CNS and neurodegeneration, osteoporosis, pulmonary fibrosis, retinitis pigmentosis, Wet macular degeneration, Duchenne muscular dystrophy, diabetic eye disease, inflammation and autoimmune, or allergy. In some embodiments, the compound of the invention can be used for treating cancer, for example, acute myeloid leukemia, chronic myeloid leukemia, ovarian cancer, cervical cancer, pancreatic cancer, breast cancer, brain cancer, skin cancer, lung cancer, prostate cancer, Lymphoma, Leukemia, colon cancer, head cancer, neck cancer, thyroid cancer, kidney cancer, liver cancer and stomach cancer. In some embodiments, the cancer is breast cancer. In other embodiments, the cancer is ovarian cancer. In some embodiments, the cancer is prostate cancer. In some embodiments, the cancer is acute myeloid leukemia.
  • It is another aspect of the invention that a compound of the invention can be used for treating, inhibiting, suppressing, or reducing the severity of acute myeloid leukemia in a subject, wherein the method comprises administering to said subject a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt, N-oxide, hydrate, solvate, tautomer, or optical isomer thereof.
  • It is a further aspect of the invention the compounds of the invention exhibits low nanomolar IC50 values in the tests for their anticancer properties, which are desired for clinical translation. The compound of the invention is a kinase (especially FLT3, c-Kit, and TrK) inhibitor. For example, the compound of the invention inhibits kinases, such as FLT3, TrkC, and c-Kit at the protein level. In some embodiments, a compound of the invention shows potent anticancer activities (low nanomolar IC50 values) against acute myeloid leukemia. In some embodiments, a compound of the invention is also active against other cancer cell lines, such as pancreatic, breast, and ovarian cancers. In some embodiments, the cancer is acute myeloid leukemia, chronic myeloid leukemia, ovarian cancer, cervical cancer, pancreatic cancer, breast cancer, brain cancer, skin cancer, lung cancer, prostate cancer, Lymphoma Leukemia, colon cancer, head cancer, neck cancer, thyroid cancer, kidney cancer, liver cancer and stomach cancer.
  • In some embodiments, the cancer is breast cancer. In other embodiments, the cancer is ovarian cancer. In some embodiments, the cancer is prostate cancer. In some embodiments, the cancer is acute myeloid leukemia.
  • In addition to targeting FLT-3, a compound of the invention also inhibits other protein kinase TrkC as well as c-MyC and Ras oncogenic proteins. Due to the multi-targeting of oncogenic drivers, the compound of the invention has superior performance against AML with mutant FLT-3 than what is known in the art. Moreover, due to its multi targeting nature, a compound of the invention is also effective against other cancer cell lines, for example, ovarian cancer, pancreatic cancer, breast cancer, brain cancer, skin cancer, lung cancer, prostate cancer, Lymphoma. Leukemia, colon cancer, head cancer, neck cancer, and stomach cancer. In some embodiments, the cancer is breast cancer. In some embodiments, the cancer that can be treated, inhibited, suppressed, or reduced the severity of by a compound of the invention as described anywhere herein includes, but is not limited to, acute myeloid leukemia, chronic myeloid leukemia, ovarian cancer, cervical cancer, pancreatic cancer, breast cancer, brain cancer, skin cancer, lung cancer, prostate cancer. Lymphoma. Leukemia, colon cancer, head cancer, neck cancer, thyroid cancer, kidney cancer, liver cancer and stomach cancer. In other embodiments, the cancer is ovarian cancer. In some embodiments, the cancer is prostate cancer. In some embodiments, the cancer is acute myeloid leukemia.
  • The compound of the invention inhibits the proliferation of several cancer cell lines at nano molar concentrations. Further, the compound of the invention inhibits protein kinase FLT-3 phosphorylation and also inhibits the proliferation of FLT-3 driven cancers, such as MV4-11 (an acute myeloid leukemia) with low (e.g., single digit nanomolar) IC50 values. A compound of the invention as a potent kinase inhibitor can be used to treat cancers, malaria, arthritis, diseases related to the immune system and other diseased states that kinases play key roles in disease establishment or progression.
  • Tt will be appreciated by persons skilled in the art that the present invention is not limited by what has been particularly shown and described herein above. Rather the scope of the present invention includes both combinations and subcombinations of the various features described hereinabove as well as variations and modifications which would occur to persons skilled in the art upon reading the specification and which are not in the prior art.
  • The details of one or more embodiments of the invention are set forth in the accompanying the description below. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims.
    • EXAMPLES
  • Materials and Methods
  • Solvents and reagents were purchased from commercial vendors and were used without further purification. 1H NMR spectra were recorded at 500 MHz, using a Bruker Avance 500 spectrometers with a CryoProbe.
  • ESI-MS experiments were performed using an Agilent MSD/TOF mass spectrometer at the Bindley Bioscience Center Metabolomics Facility (Purdue University). The instrument was calibrated to a resolution of 10000 with a 10% valley between peaks using the appropriate polypropylene glycol standards.
  • Analytical thin layer chromatography was carried out on silica gel 60 F254 plastic-backed TLC plates. Compounds were visualized with both short and long wavelength UV light and iodine/silica gel staining unless otherwise specified. Flash column chromatography was performed using Teledyne Isco's Combi-Flash Rf+ with RediSep Rf silica gel disposable flash columns, 40-60 microns (Catalog #692203304). For purities estimated by HPLC, the major peak accounted for ≥95% of the combined total peak area when monitored by a UV detector at 254 nm unless otherwise specified. All yields refer to isolated compounds.
  • Quizartinib (>99.5% purity) and crenolanib (>99.5% purity) were purchased from Chemietek.com. Unless otherwise noted, all materials were obtained from commercial suppliers and used as obtained. Solvents were purchased from Sigma and used directly without purification. NMR spectra were recorded on a Bruker 400, 500 or 600 MHz spectrometer at ambient temperature. Chemical shifts are reported in parts per million (δ) and are calibrated using residual undeuterated solvent as an internal reference. Data for 1H NMR spectra are reported as follows: chemical shift (δ ppm) (multiplicity, coupling constant (Hz), integration). Multiplicities are reported as follows: s=singlet, d=doublet, t=triplet, q=quartet, in =multiplet, br=broad, or combinations thereof.
  • In Vitro Kinase Assays
  • The Reaction Biology Corporation (www.reactionbiology.com, Malvern. Pa.) HotSpot assay platform was used to measure kinase/inhibitor interactions exactly as previously described. Kinase and substrate were mixed in a buffer containing 20 mM HEPES pH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT and 1% DMSO. Single-dose of compounds (500 nM) were then added to each reaction mixture. After 20-minute incubation. ATP (Sigma) and [γ-33P] ATP (Perkin Elmer) were added at a final total concentration of 100 μM for addition 2 hours at room temperature, followed by spotting onto P81 ion exchange cellulose chromatography paper (Whatman, Inc.). Filter paper was washed in 0.75% phosphoric acid to remove unincorporated ATP. Percent remaining kinase activity of a vehicle (DMSO) containing kinase reaction was calculated for each kinase/inhibitor pair using Prism 5 (GraphPad).
  • Docking Method for FLT3
  • The docking package CANDOCK1 was used to identify docking poses of HSW630-1 in the binding site of FLT3 kinases. The structure of FLT3 was obtained from the protein databank (PDB #4XUF). The entire protein was considered flexible. No binding site was provided to CANDOCK and the location of this site was determined by the program automatically. CANDOCK used default parameters with interactive flexibility with a maximum iteration of 10 and only the top 2% of the top seed values were used to generate full ligands.
  • Cell Lines and Culturing
  • Molm-14 cells were the kind gift of Dr. Mark Levis from Johns Hopkins University. THP-1. MV4-11, K-562 and MRC-5A cells were purchased from ATCC (ATCC, Manassas, Va.). All cell lines were grown in 37° C. with 5% CO atmosphere with RPMI 1640 (Life technologies, Carlsbad. Calif.) supplemented with heat-inactivated 10% (V/V) fetal bovine serum. Cell lines were grown and maintained according to ATCC recommendations.
  • IC50 Proliferation Assay
  • Cell lines were seeded into 96-well plates the afternoon prior to treatment. Approximately 18 hours later, compounds were semi-serially diluted in dimethyl sulfoxide (DMSO) and then growth medium, and added to cells. Plates were incubated for 72 hours prior to addition of Alamar Blue (Life Technologies. Carlsbad, Calif.). Plates were read after 4 additional hours of incubation at 37° C. using a Bio-Tek Synergy HT plate reader (Bio-Tek, Winooski. Vt.). Data was analyzed and graphed using GraphPad Prism Software (Graphpad, La Jolla, Calif.).
  • Proliferation Inhibition at 100 nM or 1 mM Inhibitor Concentration
  • To determine inhibition at 100 nM or 1 mM, 96-well plates were seeded the afternoon before treatment. Plates were then treated with compound diluted in dimethyl sulfoxide (DMSO) as well as a DMSO control the following day for 72 hours. After this time the plates were then treated with 10 μL of CellTiter-Blue Cell Viability Assay (Promega, Madison, Wis.) for 4 hours. Then the plates were read on a plate reader (Bio-Tek, Winooski, Vt.). Data was analyzed on Excel as a percent of the DMSO vehicle.
  • IC50 Determination (Proliferation Assay)
  • Midostaurin hydrate (control compound) was purchased from Sigma-Aldrich (St. Louis, Mo.). >98% HPLC purity and used without further purification. Cell lines were seeded into 96-well plates the afternoon prior to treatment. Approximately 18 hours later, compounds were diluted in dimethyl sulfoxide (DMSO) and added to cells. Plates were incubated for 72 hours and cells viability determined with CellTiter-Blue Cell Viability Assay (Promega, Madison, Wis.). Plates were read after 4 additional hours of incubation at 37° C. using plate reader (Bio-Tek, Winooski. Vt.). Data was analyzed and graphed using GraphPad Prism Software (Graphpad, La Jolla, Calif.).
  • Western Blotting
  • Effect of HSW630-1 on protein expression was tested in the MV4-11 leukemia cell line. Total protein extracts were prepared using RIPA buffer (SIGMA) supplemented with Complete Mini™ protease inhibitor and PHOStop™ phosphatase inhibitors (Roche). Equal amounts of proteins (up to 25 μg) were separated on 4-12% NuPAGE gels in 1×MOPS or 1×MES buffer (Invitrogen) and transferred onto PVDF membranes (Millipore). The membrane was blocked with 5% dry milk in 1×TBS/0.1% Tween 20 (TBST) for at least 1 h at room temperature and incubated with human specific primary antibodies: FLT3, Phospho-FLT3, c-Myc (Cell Signaling Technologies), KRAS (Santa Cruz), or mouse anti-β-actin (SIGMA) overnight at 4° C. The membrane was washed 3 times in TBST and incubated with a horseradish peroxidase-conjugated secondary anti-rabbit or anti-mouse antibody (Cell Signaling Technologies) for 1 h at room temperature. Blots were again washed and the signal was detected with SuperSignal West Femto Chemiluminescent Substrate (Pierce) and exposed to HyBlot CL® autoradiography film (Denville).
    • Example 1
  • Figure US20210198208A1-20210701-C00198
  • In a 50 ml round bottom flask, 50 mg 6-bromo-isoquinolin-3-amine, 10 mol % Bis(triphenylphosphine)palladium(II) dichloride, 10 mol % triphenylphosphine were added, purged with nitrogen three times before 5 ml anhydrous DMF was added. Stirred at 45° C. stirred for another 5 minutes before the corresponding alkyne was added via syringe in 1 ml anhydrous DMF in 2 minutes, 2 ml DIPEA was added and stirred overnight. After TCL showed the reaction was completed, equal volume of distilled water was added, and extracted with DCM three times (50 ml*3), washed with brine and dried with anhydrous sodium sulfate, removed solvents. Pure product was obtained by Combi-flash using 100% DCM to 35% MeOH.
    • Example 1A: 6-(3,3-dimethylbut-1-yn-1-yl)isoquinolin-3-amine
  • Figure US20210198208A1-20210701-C00199
  • 1H NMR (500 MHz, DMSO) δ 8.78 (d, J=19.0 Hz, 1H), 7.80-7.64 (m, 1H), 7.53 (s, 1H), 7.09 (ddd, J=97.0, 8.5, 1.5 Hz, 1H), 6.55 (d, J=3.7 Hz, 1H), 6.05 (d, J=62.4 Hz, 2H), 1.28 (s, 9H). LR-MS(ESI) m/z calcd for C15H16N2 ([M+H]+) 225.1 found 225.3.
    • Example 1B: 6-(hexa-1,5-diyn-1-yl)isoquinolin-3-amine
  • Figure US20210198208A1-20210701-C00200
  • LR-MS(ESI) m/z calcd for C15H12N2 ([M+H]+) 221.1 found 221.1.
    • Example 1C: 6-(cyclopropylethynyl)isoquinolin-3-amine
  • Figure US20210198208A1-20210701-C00201
  • LR-MS(ESI) m/z calcd for C15H12N2 ([M+H]+) 209.1 found 209.1.
    • Example 1D: 6-(3-(diethylamino)prop-1-yn-1-yl)isoquinolin-3-amine
  • Figure US20210198208A1-20210701-C00202
  • 1H NMR (500 MHz, CDCl3) δ 7.72-7.63 (m, 2H), 7.54 (dd, J=7.6, 1.2 Hz, 1H), 7.46 (td, J=7.6, 2.8 Hz, 1H), 7.26 (s, 1H), 3.50 (s, 2H), 2.56 (d, J=7.2 Hz, 4H), 1.07 (t. J=7.2 Hz, 6H). LR-MS(ESI) m/z calcd for C16H19N3 ([M+H]+) 254.2 found 254.2.
    • Example 1E: 6-(hex-1-yn-1-yl)isoquinolin-3-amine
  • Figure US20210198208A1-20210701-C00203
  • LR-MS(ESI) n/z calcd for C15H16N2 ([M+H]+) 225.1 found 225.6.
    • Example 1F: 6-ethynylisoquinolin-3-amine
  • Figure US20210198208A1-20210701-C00204
  • LR-MS(ESI) m/z calcd for C11H16N2 ([M+H]+) 169.1 found 169.5.
    • Example 1G: tert-butyl (3-(3-aminosoquinolin-6-yl)prop-2-yn-1-yl)carbamate
  • Figure US20210198208A1-20210701-C00205
  • 1H NMR (500 MHz, MeOD) δ 8.72 (s, 1H), 7.97 (s, 1H), 7.81-7.45 (m, 3H), 7.15 (dd, J=8.5, 1.1 Hz, 1H), 6.71 (s, 1H), 4.08 (s, 2H), 1.47 (s, 9H); 13C NMR (126 MHz, DMSO) δ 157.45, 155.76, 151.79, 138.47, 128.62, 127.88, 124.22, 124.08, 121.69, 97.05, 89.51, 82.19, 78.78, 30.65, 28.66. LR-MS(ESI) m/z calcd for C17H19N3O2 ([M+H]+) 298.1 found 298.4.
    • Example 1H: 6-(3-aminoprop-1-yn-1-yl)isoquinolin-3-amine
  • Figure US20210198208A1-20210701-C00206
  • LR-MS(ESI) m/z calcd for C12H11N3 ([M+H]+) 198.0 found 198.6.
    • Example 1I: 6-(3-aminosoquinolin-6-yl)hex-5-ynenitrile
  • Figure US20210198208A1-20210701-C00207
  • LR-MS(ESI) n/z calcd for C15H13N3 ([M+H]+) 236.1 found 236.6.
    • Example 2
  • Figure US20210198208A1-20210701-C00208
  • To a 50 ml round bottom flask, 1 eq 6-chloro-isoquinolin-3-amine was dissolved in concentrated sulfuric acid at room temperature, after stirred the mixture for 5 minutes, sodium nitrate was added all at once, and the mixture was stirred overnight. After TLC showed the reaction was completed, 100 ml cooled water was added, and extracted with DCM three times (50 ml*3), washed with brine and dried with anhydrous sodium sulfate, removed solvents. The crude product was directly treated with 100 ml aqueous sodium hydroxide and 5 eq of sodium dithionite was added and the mixture was stirred overnight. After TLC showed the reaction was completed, equal volume of distilled water was added, and extracted with DCM three times (50 ml*3), washed with brine and dried with anhydrous sodium sulfate, removed solvents. Pure product was obtained by Combi-flash using 100% DCM to 35% MeOH.
    • Example 2A: 6-chloro-4-nitroisoquinolin-3-amine
  • Figure US20210198208A1-20210701-C00209
  • LR-MS(ESI) m/z calcd for C9H6ClN3O2 ([M+H]+) 224.1 found 224.4.
    • Example 2B: 6-chloroisoquinoline-3,4-diamine
  • Figure US20210198208A1-20210701-C00210
  • LR-MS(ESI) m/z calcd for C9H8ClN3 ([M+H]+) 194.0 found 194.2.
    • Example 3: pyrido[3,4-b]pyrazin-7-amine
  • Figure US20210198208A1-20210701-C00211
  • To a 50 ml round bottom flask, 1 eq pyridine-2,4,5-triamine was dissolved in anhydrous ethanol at room temperature, after stirred the mixture for 5 minutes, oxalaldehyde was added all at once, and the mixture was stirred overnight. After TLC showed the reaction was completed, 100 ml cooled water was added, and extracted with DCM three times (50 ml*3), washed with brine and dried with anhydrous sodium sulfate, removed solvents. Pure product was obtained by Combi-flash using 100% DCM to 35% MeOH.
  • Figure US20210198208A1-20210701-C00212
  • LR-MS(ESI) m/z calcd for C7H6N4 ([M+H]+) 147.0 found 147.1.
    • Example 4: 3-aminoisoquinoline-6-carbonitrile
  • Figure US20210198208A1-20210701-C00213
  • In a 50 ml round bottom flask, 50 mg 6-bromo-isoquinolin-3-amine, 10 mol % tetrakis(triphenylphosphine)palladium(0). 1 mol % zinc, 1.5 eq zinc cyanide were added, purged with nitrogen three times before 5 ml anhydrous DMF was added. Stirred at 80° C. overnight. After TCL shows the reaction is completed, equal volume of distilled water was added, and extracted with DCM three times (50 ml*3), washed with brine and dried with anhydrous sodium sulfate, removed solvents. Pure product was obtained by Combi-flash using 100% DCM to 35% MeOH.
  • Figure US20210198208A1-20210701-C00214
  • 1H NMR (500 MHz, DMSO) δ 8.95 (s, 1H), 8.18 (s, 1H), 7.67-7.50 (m, 2H), 7.35 (dd, J=8.4, 1.3. Hz, 1H), 6.69 (s, 1H) 6.32 (s, 2H); LR-MS(ESI) m/z calcd for C10H7N3 ([M+H]+) 170.1 found 170.6.
    • Example 5
  • Figure US20210198208A1-20210701-C00215
  • In a 250 ml round bottom flask, 579 mg 1 eq 6-chloroisoquinolin-3-amine was dissolved in 150 ml anhydrous MeOH at 0° and stirred for 5 minutes before 675 mg NIS was added in portions slowly in 10 minutes. Stop the reaction by remove all solvents when TLC showed the reaction was completed (usually within 15 minutes). 420 mg 6-chloro-4-iodoisoquinolin-3-amine was obtained either by flash column or Combi-flash using 100% hexane-100% ethyl acetate.
  • In a 100 ml round bottom flask, 290 mg 1 eq 4-ethynylbenzoic acid was dissolved in 50 ml anhydrous DCM at 0° C. 800 mg of HBTU was added and stirred for another 10 minutes before 1.1 eq of the corresponding amine was added. After 30 seconds, 1 eq. of DIPEA was added and the mixture was stirred overnight. After TLC showed the reaction was completed, stop the reaction by adding equal volume of distilled water. Extracted with DCM three times (50 ml*3), washed with brine and dried with anhydrous sodium sulfate, removed solvents. Pure benzamide was obtained by Combi-flash using 100% DCM to 20% MeOH.
  • In a 50 ml round bottom flask, 50 mg 6-chloro-4-iodoisoquinolin-3-amine, 10 mol % Bis(triphenylphosphine)palladium(II) dichloride, 10 mol % triphenylphosphine were added, purged with nitrogen three times before 5 ml anhydrous DMF was added. Stirred at 45° C. for another 5 minutes before the corresponding benzamide was added via syringe in 1 ml anhydrous DMF in 2 minutes. 2 ml DIPEA was added and stirred overnight. After TCL shows the reaction is completed, equal volume of distilled water was added, and extracted with DCM three times (50 ml*3), washed with brine and dried with anhydrous sodium sulfate, removed solvents. Pure product was obtained by Combi-flash using 100% DCM to 35% MeOH.
    • Example 5A: 4-ethynyl-N-(3-morpholinopropyl)benzamide
  • Figure US20210198208A1-20210701-C00216
  • LR-MS(ESI) m/z calcd for C16H20N2O2 ([M+H]+) 273.2, found, 273.8.
    • Example 5B: N-(3-(dimethylamino)propyl)-3-ethynylbenzamide
  • Figure US20210198208A1-20210701-C00217
  • LR-MS(ESI) m/z calcd for C14H18N2O ([M+H]+) 231.1, found 231.6.
    • Example 5C: 4-ethynyl-N-(3-(4-methylpiperazin-1-yl)propyl)benzamide
  • Figure US20210198208A1-20210701-C00218
  • LR-MS(ESI) m/z calcd for C17H23N30 ([M+H]+) 286.1, found 286.4.
    • Example 5D: 4-ethynyl-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)benzamide
  • Figure US20210198208A1-20210701-C00219
  • LR-MS(ESI) m/z calcd for C17H23N3O ([M+H]+) 334.2. found 334.4.
    • Example 5E: N-(2-(dimethylamino)ethyl)-4-ethynylbenzamide
  • Figure US20210198208A1-20210701-C00220
  • LR-MS(ESI) m/z calcd for C13H16N2O ([M+H]+) 217.1, found 217.2.
    • Example 5F: 4-ethynyl-N-(3-(pyrrolidin-1-yl)propyl)benzamide
  • Figure US20210198208A1-20210701-C00221
  • LR-MS(ESI) m/z calcd for C16H20N2O ([M+H]+) 257.1. found 257.3.
    • Example 5G: 4-ethynyl-N-(3-(piperidin-1-yl)propyl)benzamide
  • Figure US20210198208A1-20210701-C00222
  • LR-MS(ESI) m/z calcd for C17H22N2O ([M+H]+) 271.2. found 271.6.
    • Example 5H: N-(5-(dimethylamino)pentyl)-4-ethynylbenzamide
  • Figure US20210198208A1-20210701-C00223
  • LR-MS(ESI) m/z calcd for C16H22N2O ([M+H]+) 259.2, found 259.6.
    • Example 51:4-ethynyl-N-(3-methoxypropyl)benzamide
  • Figure US20210198208A1-20210701-C00224
  • 1H NMR (500 MHz, CDCl3) δ 7.73 (d, J=8.5 Hz, 2H), 7.54 (d, J=8.5 Hz, 2H), 3.62-3.51 (m, 4H), 3.39 (s, 3H), 1.90 (dd. J=6.5, 5.5 Hz, 2H); 13C NMR (126 MHz, CDCl3) δ 166.40, 134.78, 132.22, 126.82, 125.06, 82.61, 79.31, 72.19, 58.99, 39.01, 28.58. LR-MS(ESI) m/z calcd for C13H15NO2 ([M+H]+) 218.1, found 218.3.
    • Example 5J: tert-butyl 4-(3-(4-ethynylbenzamido)propyl)piperazine-1-carboxylate
  • Figure US20210198208A1-20210701-C00225
  • LR-MS(ESI) m/calcd for C21H29N3O3 ([M+H]+) 217.1, found 271.3.
    • Example 5K: N-(3-(dimethylamino)-2-hydroxypropyl)-4-ethynylbenzamide
  • Figure US20210198208A1-20210701-C00226
  • LR-MS(ESI) n/z calcd for C14H18N2O2 ([M+H]+) 217.1, found 217.5.
    • Example 5L: 4-ethynyl-N-(2-hydroxy-3-(piperidin-1-yl)propyl)benzamide
  • Figure US20210198208A1-20210701-C00227
  • LR-MS(ESI) m/z calcd for C17H22N2O2 ([M+H]+) 287.2, found 287.4.
    • Example 5M: 2-ethynyl-N-(3-(piperidin-1-yl)propyl)benzamide
  • Figure US20210198208A1-20210701-C00228
  • LR-MS(ESI) m/z calcd for C17H22N2O ([M+H]+) 271.1. found 270.2.
    • Example 5N: 4-ethynyl-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide
  • Figure US20210198208A1-20210701-C00229
  • LR-MS(ESI) m/z calcd for C25H19N5O ([M+H]+) 406.2, found 406.4.
    • Example 5O: 4-ethynyl-N-(2-(piperidn-1-yl)ethyl)benzamide
  • Figure US20210198208A1-20210701-C00230
  • 1H NMR (500 MHz, Chloroform-d) δ 7.74 (d, J=8.2 Hz, 2H), 7.53 (d, J=8.2 Hz, 2H), 7.13 (s, 1H), 3.52 (q, J=5.7 Hz, 2H), 3.18 (s, 1H), 2.56 (t. J=6.0 Hz, 2H), 2.45 (s, 4H), 1.59 (p, J=5.6 Hz, 4H), 1.46 (t, J=6.0 Hz, 2H); 13C NMR (126 MHz, CDCl3) δ 166.53, 134.67, 132.24, 126.97, 125.14, 82.87, 79.34, 56.94, 54.24, 36.38, 25.89, 24.22.
    • Example 5P: N-(4-aminophenethyl)-4-ethynylbenzamide
  • Figure US20210198208A1-20210701-C00231
  • 1H NMR (500 MHz, Chloroform-d) δ 7.64 (d, J=8.4 Hz, 2H), 7.51 (d, J=8.5 Hz, 2H), 7.01 (d, J=8.3 Hz, 2H), 6.66 (d, J=8.3 Hz, 2H), 6.11 (s, 1H), 3.65 (q, J=6.6 Hz, 2H), 3.18 (s, 1H), 2.81 (t, J=6.8 Hz, 2H); 13C NMR (126 MHz, CDCl3) δ 166.57, 145.01, 134.71, 132.29, 129.66, 128.54, 126.80, 125.22, 115.50, 82.78, 79.40, 41.37, 34.72.
    • Example 5Q: tert-butyl (1-(4-ethynylbenzyl)piperidin-4-yl)carbamate
  • Figure US20210198208A1-20210701-C00232
  • 1H NMR (500 MHz, Chloroform-d) δ 7.51 (d, J=8.1 Hz, 2H), 7.33 (d, J=8.3 Hz, 2H), 4.57-4.59 (2H), 3.69 (s, 2H), 3.14 (s, 1H), 3.08 (s, 1H), 2.95 (s, 1H), 1.99 (d, J=47.4 Hz, 2H), 1.44-1.25 (11H); 13C NMR (126 MHz, CDCl3) δ 169.60, 155.05, 136.10, 132.26, 126.91, 123.63, 82.81, 79.67, 78.71, 47.88, 33.11, 32.15, 28.39.
    • Example 5R: tert-butyl (1-(3-ethynylbenzoyl)piperidin-4-yl)carbamate
  • Figure US20210198208A1-20210701-C00233
  • 1H NMR (500 MHz, Chloroform-d) δ 7.52 (dd, J=6.0, 2.3 Hz, 1H), 7.49 (s, 1H), 7.40-7.32 (m, 2H), 4.59-4.49 (NH & NH—CH, 2H), 3.69 (s, 2H), 3.11 (s, C≡C—H & N—CHaHb, 2H), 2.96 (s, N—CHaHb 1H), 2.05-1.94 (2H), 1.45-1.28 (—(CH3)3 & CH2, 11H); 13C NMR (126 MHz, CDCl3) δ 169.33, 155.04, 136.23, 133.24, 130.38, 128.67, 127.16, 122.62, 82.71, 79.67, 78.23, 47.89, 38.63, 32.15, 28.39.
    • Example 5S: [1,4′-bipiperidin]-1′-yl(4-ethynylphenyl)methanone
  • Figure US20210198208A1-20210701-C00234
  • 1H NMR (500 MHz, Chloroform-d) δ 7.50 (d, J=7.8 Hz, 2H), 7.34 (d, J=8.1 Hz, 2H), 4.72 (s, 1H), 3.73 (s, 1H), 3.13 (s, 1H), 2.98 (s, 1H), 2.74 (s, 1H), 2.53 (s, 5H), 1.93 (s, 1H), 1.77 (s, 1H), 1.63-1.40 (m, 7H); 13C NMR (126 MHz, CDCl3) δ 169.41, 136.33, 132.23, 126.90, 123.49, 82.85, 78.62, 62.54, 50.29, 26.18, 24.55.
    • Example 5T: N-(4-(2-(dimethylamino)ethoxy)benzyl)-4-ethynylbenzamide
  • Figure US20210198208A1-20210701-C00235
  • 1H NMR (500 MHz, Chloroform-d) δ 7.73 (d, J=8.4 Hz, 2H), 7.51 (d, J=8.3 Hz, 2H), 7.24 (d, J=8.5 Hz, 2H), 6.87 (d, J=8.5 Hz, 2H), 6.53 (t, J=5.7 Hz, 1H), 4.54 (d, J=5.5 Hz, 2H), 4.06 (t, J=5.7 Hz, 2H), 3.18 (s, 1H), 2.76 (t, J=5.6 Hz, 2H), 2.36 (s, 6H); 13C NMR (126 MHz, CDCl3) δ 166.46, 158.31, 134.42, 132.27, 130.28, 129.31, 126.98, 125.34, 114.85, 82.76, 79.52, 65.83, 58.17, 45.76, 43.69.
    • Example 5U: 3-ethynyl-N-(2-(piperidin-1-yl)ethyl)benzamide
  • Figure US20210198208A1-20210701-C00236
  • 1H NMR (500 MHz, Chloroform-d) δ 8.85 (s, 1H), 8.10 (s, 1H), 8.03 (dd, J=7.8, 1.5 Hz, 1H), 7.55 (dd. J=7.5, 1.4 Hz, 1H), 7.36 (t. J=7.8 Hz, 1H), 3.85 (q, J=5.5 Hz, 2H), 3.19 (t. J=5 Hz, 2H), 3.08 (bs, 5H), 1.97 (s, 4H), 1.61 (s, 2H); 13C NMR (126 MHz, CDCl3) δ 166.99, 135.09, 133.60, 131.58, 128.62, 127.79, 122.51, 82.82, 78.10, 57.71, 54.32, 34.83, 22.86, 22.08.
    • Example 5V: N-(2-(1H-imidazol-4-yl)ethyl)-4-ethynylbenzamide
  • Figure US20210198208A1-20210701-C00237
  • 1H NMR (500 MHz, DMSO-d6) δ 8.66 (t. J=5.6 Hz, 1H), 7.82 (d, J=8.3 Hz, 2H), 7.60-7.49 (m, 3H), 6.82 (s, 1H), 4.36 (s, 1H), 3.50-3.43 (m, 2H), 2.74 (t. J=7.5 Hz, 2H); 13C NMR (126 MHz, DMSO) δ 165.73, 135.16, 135.12, 132.11, 127.89, 124.76, 117.11, 83.38, 83.27, 27.29.
    • Example 5W: tert-butyl-4-(4-ethynylbenzamido)cyclohexyl)carbamate
  • Figure US20210198208A1-20210701-C00238
  • 1H NMR (500 MHz, DMSO-d6) δ 8.31 (d, J=7.9 Hz, 1H), 7.82 (d, J=7.9 Hz, 2H), 7.53 (d, J=7.9 Hz, 2H), 6.75 (d, J=8.0 Hz, 1H), 4.36 (s, 1H), 3.74-3.61 (m 0.1H), 3.18 (m, 1H), 1.81-1.73 (m, 4H), 1.36 (m, 11H), 1.26-1.14 (m, 2H); 13C NMR (126 MHz, DMSO) δ 165.07, 155.33, 135.19, 132.00, 128.02, 124.69, 83.40, 83.23, 77.87, 49.04, 48.30, 31.91, 31.44, 28.74.
    • Example 5X: Bis-Boc-4-ethynyl-N-(4-guanidinocyclohexyl)benzamide
  • Figure US20210198208A1-20210701-C00239
  • 1H NMR (500 MHz, Chloroform-d) δ 11.53 (s, 1H), 8.27 (d, J=8.3 Hz, 1H), 7.71 (d, J=8.0 Hz, 2H), 7.54 (d, J=8.3 Hz, 2H), 5.90 (d, J=7.9 Hz, 1H), 3.99 (d, J=45.1 Hz, 1H), 3.19 (s, 1H), 2.15-2.10 (m, 4H), 1.50 (d, J=4.7 Hz, 18H), 1.38 (q, J=5.2, 4.6 Hz, 4H); 13C NMR (126 MHz, CDCl3) δ 165.99, 163.78, 155.58, 153.30, 134.70, 132.29, 126.86, 125.29, 83.15, 82.77, 79.45, 79.25, 48.23, 48.14, 31.54, 31.50, 28.32, 28.12.
    • Example 6
  • Figure US20210198208A1-20210701-C00240
  • To a 50 ml round bottom. 1 eq 4-ethynylbenzaldehyde was dissolved in tBuOH and 1 eq of the corresponding diamine was added all at once, stirred for 1 hour at room temperature. 1.1 eq of iodine and 3 eq of potassium carbonate were added and the mixture was reflux overnight. After TCL shows the reaction is completed, equal volume of distilled water was added, and extracted with DCM three limes (50 ml*3), washed with brine and dried with anhydrous sodium sulfate, removed solvents. Pure product was obtained by Combi-flash using 100% DCM to 35% MeOH.
    • Example 7: 4-cyclopropyl-2-(4-ethynylphenyl)-4,5-dihydro-1H-imidazole
  • Figure US20210198208A1-20210701-C00241
  • LR-MS(ESI) m/z calcd for C14H14N2 ([M+H]+) 211.1 found 211.3.
    • Example 8: 2-(4-ethynylphenyl)-4,5-dihydro-1H-imidazole
  • Figure US20210198208A1-20210701-C00242
  • LR-MS(ESI) m/z calcd for C11H10N2 ([M+H]+) 171.1 found 171.3.
    • Example 9: 1-(2-(2-(4-ethynylphenyl)-4,5-dihydro-1H-imidazol-1-yl)ethyl)piperidine
  • Figure US20210198208A1-20210701-C00243
  • LR-MS(ESI) m/z calcd for C18H23N3 ([M+H]+) 282.2 found 282.4.
    • Example 10: 4-(2-(2-(4-ethynylphenyl)-4,5-dihydro-1H-imidazol-1-yl)ethyl)morpholine
  • Figure US20210198208A1-20210701-C00244
  • LR-MS(ESI) m/z calcd for C17H21N30 ([M+H]+) 211.1 found 211.3.
    • Example 11: 2-(4-ethynylphenyl)-4,4-dimethyl-4,5-dihydro-1H-imidazole
  • Figure US20210198208A1-20210701-C00245
  • LR-MS(ESI) m/z calcd for C15H14N2 ([M+H]+) 199.1 found 199.2.
    • Example 12: 4-((3-amino-6-chloroisoquinolin-4-yl)ethynyl)-N-(3-morpholinopropyl)benzamide
  • Figure US20210198208A1-20210701-C00246
  • 1H NMR (500 MHz, MeOD) δ 8.79 (s, 1H), 7.93-7.82 (m, 4H), 7.76 (d, J=8.4 Hz, 2H), 7.25 (dd, J=8.6, 1.9 Hz, 1H), 3.72 (t, J=4.6 Hz, 4H), 3.47 (t, J=6.9 Hz, 2H), 2.58-2.49 (m, 6H), 1.93-1.81 (m, 2H); 13C NMR (125 MHz, MeOD) δ 167.91, 157.55, 151.88, 138.75, 138.03, 133.81, 131.01, 130.33, 127.09, 126.33, 123.67, 121.30, 120.77, 99.21, 90.21, 84.49, 66.25, 56.38, 53.35, 38.16, 25.52; LR-MS(ESI) m/z calcd for C25H26ClN4O2 ([M+H]+) 449.2, found 449.3.
    • Example 13: 4-((3-amino-6-chloroisoquinolin-4-yl)ethynyl)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)benzamide
  • Figure US20210198208A1-20210701-C00247
  • 1H NMR (500 MHz, DMSO) δ 10.34 (s, 1H), 8.91 (s, 1H), 8.03 (d, J=8.3 Hz, 2H), 7.96-7.85 (m, 3H), 7.74 (d, J=8.4 Hz, 2H), 7.32-7.20 (m, 3H), 6.88 (s, 2H), 3.43 (s, 2H), 2.63-2.31 (m, 8H), 2.24 (s, 3H); 13C NMR (125 MHz, DMSO) δ 165.16, 158.79, 153.44, 138.78, 138.45, 137.47, 134.50, 131.64, 129.62, 128.32, 126.51, 123.54, 121.35, 120.76, 120.63, 99.58, 88.35, 86.33, 61.88, 54.71, 52.25, 45.47; LR-MS(ESI) m/z calcd for C30H29ClN5O ([M+H]+) 510.2, found 510.5.
    • Example 14: 6-chloro-4-((4-(4,5-dihydro-1H-imidazol-2-yl)phenyl)ethynyl)isoquinolin-3-amine
  • Figure US20210198208A1-20210701-C00248
  • 1H NMR (500 MHz, DMSO) δ 8.92 (s, 1H), 7.96 (d, J=8.6 Hz, 1H), 7.93-7.81 (m, 5H), 7.28 (dd, J=8.6, 1.8 Hz, 1H), 6.85 (s, 2H), 3.68 (s, 4H); 13C NMR (125 MHz, DMSO) δ 163.73, 158.70, 153.30, 138.73, 137.42, 131.64, 131.56, 129.45, 127.78, 125.60, 123.52, 121.33, 120.61, 99.69, 88.45, 85.91, 49.51; LR-MS(ESI) m/z calcd for C20H15ClN4 ([M+H]+) 347.1. found 347.4.
    • Example 15: 3-((3-amino-6-chloroisoquinolin-4-yl)ethynyl)-N-(3-(dimethylamino)propyl)benzamide
  • Figure US20210198208A1-20210701-C00249
  • 1H NMR (500 MHz, DMSO) δ 8.90 (s, 1H), 8.64 (1. J=5.4 Hz, 1H), 8.16 (s, 1H), 7.92 (dd, J=18.9, 8.2 Hz, 2H), 7.86 (d, J=1.3 Hz, 1H), 7.82 (d, J=7.9 Hz, 1H), 7.52 (t, J=7.7 Hz, 1H), 7.26 (dd, J=8.6, 1.9 Hz, 1H), 6.82 (s, 2H), 3.30 (dd, J=12.8, 6.7 Hz, 2H), 2.35 (t, J=7.1 Hz, 2H), 2.19 (s, 6H), 1.73-1.60 (m, 2H); 13C NMR (125 MHz, DMSO) δ 165.99, 158.69, 153.15, 138.77, 137.37, 135.51, 134.23, 131.58, 130.35, 129.09, 127.53, 123.49, 123.45, 121.30, 120.63, 99.47, 88.53, 84.37, 57.13, 45.32, 38.16, 27.21: LR-MS(ESI) m/z calcd for C23H24ClN4O ([M+H]+) 407.2, found 407.2.
    • Example 16: 4-((3-amino-6-chloroisoquinolin-4-yl)ethynyl)-N-(3-(pyrrolidin-1-yl)propyl)benzamide
  • Figure US20210198208A1-20210701-C00250
  • 1H NMR (500 MHz, MeOD) δ 8.80 (s, 1H), 7.97-7.84 (m, 4H), 7.77 (dd, J=5.8, 4.1 Hz, 2H), 7.26 (dd, J=8.7, 2.0 Hz, 1H), 3.50 (t, J=6.8 Hz, 2H), 3.33 (dt, J=3.3, 1.6 Hz, 4H), 2.86-2.80 (m, 2H), 1.94 (d, J=3.6 Hz, 6H) 13C NMR (125 MHz, MeOD) δ 168.08, 157.58, 151.92, 138.76, 138.05, 133.59, 131.02, 130.36, 127.13, 126.43, 123.68, 121.30, 120.79, 99.19, 90.18, 84.55, 53.68, 53.37, 37.58, 27.33, 22.74; LR-MS(ESI) m/z calcd for C25H26ClN4O ([M+H]+) 433.2. found 433.4.
    • Example 17: 4-((3-amino-6-chloroisoquinolin-4-yl)ethynyl)-N-(3-(4-methylpiperazin-1-yl)propyl)benzamide
  • Figure US20210198208A1-20210701-C00251
  • 1H NMR (500 MHz, MeOD) δ 8.76 (s, 1H), 7.90-7.87 (m, 1H), 7.87-7.84 (m, 2H), 7.82 (d, J=8.6 Hz, 1H), 7.75-7.71 (m, 2H), 7.22 (dd, J=8.6, 2.0 Hz, 1H), 3.44 (t, J=6.9 Hz, 2H), 2.77-2.37 (m 10H), 2.28 (s, 3H), 1.83 (dd. J=14.5, 7.2 Hz, 2H); 13C NMR (125 MHz, MeOD) δ 167.90, 157.57, 151.90, 138.77, 138.05, 133.85, 131.03, 130.36, 127.13, 126.34, 123.68, 121.32, 120.79, 99.23, 90.21, 84.51, 55.88, 54.24, 52.27, 44.56, 38.25, 25.80; LR-MS(ESI) m/z calcd for C26H28ClN5O ([M+H]+) 462.2. found 462.2.
    • Example 18: 4-((3-amino-6-chloroisoquinolin-4-yl)ethynyl)-N-(3-(piperidin-1-yl)propyl)benzamide
  • Figure US20210198208A1-20210701-C00252
  • 1H NMR (500 MHz, MeOD) 8.81 (s, 1H), 7.95 (s, 1H), 7.93 (d, J=1.9 Hz, 2H), 7.87 (d, J=8.8 Hz, 1H), 7.78 (d, J=8.5 Hz, 2H), 7.27 (dd. J=8.6, 2.0 Hz, 1H), 3.54 (t. J=6.6 Hz, 2H), 3.33 (dt, J=3.3, 1.6 Hz, 6H), 3.22-3.17 (m, 2H), 1.91 (s, 6H); 13C NMR (125 MHz, MeOD) δ 168.53, 157.63, 152.01, 137.98, 133.10, 131.06, 130.41, 127.33, 125.30, 123.70, 121.29, 117.28, 110.55, 99.15, 90.11, 86.23, 84.74, 54.45, 52.95, 36.48, 24.18, 22.99, 21.36; LR-MS(ESI) m/z calcd for C26H28ClN4O ([M+H]+) 447.2. found 447.3.
    • Example 19: 4-((3-amino-6-chloroisoquinolin-4-yl)ethynyl)-N-(5-(dimethylamino)pentyl)benzamide
  • Figure US20210198208A1-20210701-C00253
  • 1H NMR (500 MHz, MeOD) δ 7.92 (s, 1H), 7.90 (s, 1H), 7.86 (d, J=8.7 Hz, 1H), 7.76 (d, J=8.3 Hz, 1H), 7.43 (s, 2H), 7.26 (dd, J=8.6, 1.9 Hz, 1H), 3.45 (t. J=6.9 Hz, 2H), 3.21-3.12 (m, 2H), 2.91 (s, 6H), 1.82 (dt, J=12.0, 8.0 Hz, 2H), 1.77-1.68 (m, 2H), 1.49 (dt, J=15.0, 7.7 Hz, 2H); 13C NMR (125 MHz, MeOD) δ 167.99, 157.58, 151.86, 138.75, 138.05, 133.79, 131.02, 130.40, 127.16, 126.31, 125.93, 124.96, 123.70, 121.29, 99.25, 84.50, 57.52, 44.62, 42.04, 39.07, 28.53, 23.85, 23.35; LR-MS(ESI) m/z calcd for C25H28ClN4O ([M+H]+) 435.2. found 435.3.
    • Example 20: 4-((3-amino-6-chloroisoquinolin-4-yl)ethynyl)-N-(3-(dimethylamino)-2-hydroxypropyl)benzamide
  • Figure US20210198208A1-20210701-C00254
  • 1H NMR (500 MHz, MeOD) δ 8.79 (s, 1H), 7.92 (s, 2H), 7.90 (s, 1H), 7.85 (d, J=8.7 Hz, 1H), 7.76 (d, J=8.4 Hz, 2H), 7.25 (dd. J=8.6, 1.9 Hz, 1H), 4.05-3.94 (m, 1H), 3.55 (dd, J=13.6, 4.8 Hz, 1H), 3.42-3.35 (m, 1H), 2.47-2.43 (m, 2H), 2.33 (s, 6H); 13C NMR (125 MHz, MeOD) δ 168.24, 157.56, 151.88, 138.76, 138.05, 133.69, 131.00, 130.34, 127.18, 126.38, 123.67, 121.30, 120.78, 99.22, 90.21, 84.49, 67.43, 63.23, 44.75, 44.70; LR-MS(ESI) m/z calcd for C23H24ClN4O2 ([M+H]+) 423.2, found 423.3.
    • Example 21: 4-((3-amino-6-chloroisoquinolin-4-yl)ethynyl)benzonitrile
  • Figure US20210198208A1-20210701-C00255
  • 1H NMR (500 MHz, MeOD) δ 8.84 (s, 1H), 7.94 (d, J=1.6 Hz, 1H), 7.89 (d, J=8.7 Hz, 1H), 7.85 (d, J=8.4 Hz, 2H), 7.80 (d, J=8.4 Hz, 2H), 7.28 (dd. J=8.6, 1.9 Hz, 1H); LR-MS(ESI) m/z calcd for C18H11ClN3 ([M+H]+) 304.1, found 304.1.
    • Example 22: 2-((3-amino-6-chloroisoquinolin-4-yl)ethynyl)-N-(3-(piperidin-1-yl)propyl)benzamide
  • Figure US20210198208A1-20210701-C00256
  • 1H NMR (500 MHz, DMSO) δ 8.90 (d, J=0.4 Hz, 1H), 8.61 (s, 1H), 7.98 (d, J=2.0 Hz, 1H), 7.93 (d, J=8.6 Hz, 1H), 7.88 (dd. J=7.7, 0.9 Hz, 1H), 7.58-7.50 (I, 2H), 7.46 (td. J=7.5, 1.3 Hz, 1H), 7.26 (dd. J=8.6, 2.0 Hz, 1H), 6.92 (s, 2H), 2.51 (dt, J=3.6, 1.8 Hz, 3H), 2.30-2.21 (m, 2H), 2.16 (s, 4H), 1.71-1.59 (m, 2H), 1.42-1.30 (m, 4H), 1.27 (d, J=4.7 Hz, 2H); 13C NMR (126 MHz, DMSO) δ 168.30, 159.29, 153.12, 138.80, 138.68, 137.32, 132.81, 131.37, 130.23, 128.44, 127.80, 123.43, 121.69, 121.39, 120.54, 98.53, 88.83, 87.85, 56.93, 54.41, 39.65, 39.48, 38.55, 26.68, 26.00, 24.55.
    • Example 23: 4-((3-amino-6-chloroisoquinolin-4-yl)ethynyl)-N-(3-(1,3-dioxoisoindolin-2-yl)propyl)benzamide
  • Figure US20210198208A1-20210701-C00257
  • 1H NMR (500 MHz, DMSO) δ 8.92 (d, J=0.8 Hz, 1H), 7.96 (d, J=8.6 Hz, 1H), 7.92-7.77 (m, 8H), 7.71 (d, J=8.4 Hz, 1H), 7.29 (dd, J=8.6, 2.0 Hz, 1H), 6.85 (s, 2H), 3.65 (d, J=7.2 Hz, 2H), 3.30 (s, 2H), 1.89 (q. J=7.1 Hz, 2H); LR-MS(ESI) m/z calcd for C29H22ClN4O3 ([M+H]+) 509.1. found 509.4.
    • Example 24: 4-((3-amino-6-chloroisoquinolin-4-yl)ethynyl)-N-(3-aminopropyl)benzamide
  • Figure US20210198208A1-20210701-C00258
  • 1H NMR (500 MHz, MeOD) δ 8.71 (s, 1H), 7.93 (d, J=1.9 Hz, 1H), 7.88-7.79 (M, 2H), 7.73 (d, J=8.6 Hz, 1H), 7.69-7.61 (m, 2H), 7.21 (dd, J=8.6, 2.0 Hz, 1H), 3.45 (t, J=6.7 Hz, 2H), 3.34-3.29 (m, 2H), 1.79-1.72 (m, 2H); 13C NMR (125 MHz, MeOD) δ 168.26, 157.20, 151.91, 139.19, 138.80, 134.19, 131.71, 130.49, 127.61, 126.43, 124.90, 122.52, 121.36, 100.08, 91.97, 85.03, 37.61, 33.97, 29.93, 25.19; LR-MS(ESI) m/z calcd for C21H19ClN4ONa 378.12, found 401.30.
    • Example 25: tert-butyl ((1r,4r)-4-(4-((3-amino-6-chloroisoquinolin-4-yl)ethynyl)benzamido)cyclohexyl)carbamate
  • Figure US20210198208A1-20210701-C00259
  • 1H NMR (500 MHz, Methanol-d4) δ 8.77 (s, 1H), 7.91-7.86 (m, 3H), 7.83 (d, J=8.6 Hz, 1H), 7.73 (d, J=8.3 Hz, 2H), 7.33 (d, J=8.8 Hz, 2H), 7.23 (dd. J=8.6, 2.0 Hz, 1H), 6.97 (d, J=8.7 Hz, 1H), 4.53 (s, 2H), 4.29-4.16 (m, 2H), 3.23 (t. J=5.3 Hz, 2H), 2.70 (s, 6H); 13C NMR (126 MHz, MeOD) δ 167.81, 157.59, 157.41, 151.93, 138.77, 138.06, 133.75, 131.87, 131.04, 130.38, 128.70, 127.21, 126.40, 123.69, 121.31, 120.80, 114.31, 99.24, 90.21, 84.52, 63.25, 56.96, 43.32, 42.63.
    • Example 26: tert-butyl (1-(4-((3-amino-6-chloroisoquinolin-4-yl)ethynyl)benzoyl)piperidin-4-yl)carbamate
  • Figure US20210198208A1-20210701-C00260
  • 1H NMR (500 MHz, DMSO-d6) δ 8.90 (s, 1H), 7.94 (d, J=8.6 Hz, 1H), 7.85 (d, J=2.0 Hz, 1H), 7.81 (d, J=8.3 Hz, 2H), 7.40 (dd. J=8.4, 3.0 Hz, 2H), 7.26 (dd, J=8.7, 1.9 Hz, 1H), 6.88 (d, J=8.0 Hz, 1H), 6.82 (s, 2H), 4.29 (s, 1H), 3.09 (s, 1H), 1.75 (d, J=41.7 Hz, 3H), 1.37 (d, J=2.5 Hz, 11H); 13C NMR (126 MHz, DMSO) δ 168.85, 158.68, 155.29, 153.24, 138.78, 137.40, 136.17, 133.07, 131.82, 127.42, 124.44, 123.50, 121.32, 120.62, 99.47, 88.47, 85.12, 78.13, 55.38, 47.59, 40.50, 40.43, 40.33, 40.16, 40.00, 39.83, 39.66, 39.50, 28.72.
    • Example 27: 4-((3-amino-6-chloroisoquinolin-4-yl)ethynyl)-N-methyl-N-(3-(pyrrolidin-1-yl)propyl)benzamide
  • Figure US20210198208A1-20210701-C00261
  • 1H NMR (500 MHz, Methanol-d6) δ 8.78 (s, 1H), 7.90 (s, 1H), 7.85 (d, J=8.6 Hz, 1H), 7.78-7.74 (m, 2H), 7.50 (d, J=7.7 Hz, 1H), 7.46 (d, J=7.8 Hz, 1H), 7.24 (dd, J=8.6, 2.1 Hz, 1H), 3.61 (t, J=7.1 Hz, 1H), 3.31 (t. J=1.9 Hz, 3H), 3.10 (s, 1H), 2.87-2.71 (m, 3H), 2.42 (s, 2H), 2.27 (t, J=7.7 Hz, 1H), 2.06-1.96 (m, 1H), 1.85-1.67 (m, 3H), 1.65-1.50 (m, 3H), 1.45 (s, 1H), 1.27 (s, 1H); 13C NMR (126 MHz, MeOD) δ 171.93, 157.57, 151.87, 138.80, 138.04, 135.93, 135.54, 131.28, 131.14, 130.39, 127.00, 126.68, 124.89, 123.68, 121.31, 120.81, 99.13, 90.22, 83.82, 55.35, 53.78, 53.65, 48.12, 47.94, 47.77, 47.60, 47.44, 47.27, 47.09, 45.25, 36.78, 31.99, 29.36, 24.83, 24.30, 23.39, 22.82, 22.67.
    • Example 28: tert-butyl ((r,4r)-4-(4-((3-amino-6-chloroisoquinolin-4-yl)ethynyl)benzamido)cyclohexyl)carbamate
  • Figure US20210198208A1-20210701-C00262
  • 1H NMR (500 MHz, DMSO-d6) δ 8.90 (s, 1H), 8.29 (d, J=7.9 Hz, 1H), 7.94 (d, J=8.6 Hz, 1H), 7.91-7.85 (m, 3H), 7.83 (d, J=8.1 Hz, 2H), 7.26 (d, J=8.6 Hz, 1H), 6.84 (s, 2H), 6.74 (d, J=8.0 Hz, 1H), 3.71 (dt, J=7.7, 3.8 Hz, 1H), 1.83 (d, J=13.4 Hz, 1H), 1.37 (s, 11H), 1.25 (dd. J=23.9, 12.4 Hz, 2H). 13C NMR (126 MHz, DMSO) δ 165.22, 158.74, 155.35, 153.34, 138.76, 137.43, 134.36, 131.51, 127.88, 125.95, 123.53, 121.34, 120.63, 99.62, 88.41, 85.90, 77.87, 49.10, 48.33, 40.50, 40.33, 40.16, 40.00, 39.83, 39.66, 39.50, 31.96, 31.51, 28.75.
    • Example 29: 4-((3-amino-6-chloroisoquinolin-4-yl)ethynyl)-N-(4-aminophenethyl)benzamide
  • Figure US20210198208A1-20210701-C00263
  • 1H NMR (500 MHz, DMSO-d6) δ 8.90 (s, 1H), 8.59 (t, J=5.6 Hz, 1H), 7.94 (d, J=8.6 Hz, 1H), 7.90-7.80 (m, 5H), 7.26 (dd, J=8.7, 2.1 Hz, 1H), 6.93-6.78 (m, 4H), 6.49 (d, J=8.2 Hz, 2H), 4.84 (s, 2H), 3.43-3.36 (m, 2H), 2.69-2.63 (m, 2H); 13C NMR (126 MHz, DMSO) δ 165.82, 158.74, 153.34, 147.29, 138.77, 137.44, 134.38, 132.91, 131.61, 129.49, 127.75, 126.79, 125.97, 123.53, 121.35, 120.63, 114.48, 99.60, 88.43, 85.90, 41.99, 34.92.
    • Example 30: [1,4′-bipiperidin]-1′-yl(4-((3-amino-6-chloroisoquinolin-4-yl)ethynyl)phenyl)methanone
  • Figure US20210198208A1-20210701-C00264
  • 1H NMR (500 MHz, Methanol-d4) δ 8.79 (s, 1H), 7.91 (d, J=12.6 Hz, 1H), 7.88-7.81 (m, 1H), 7.78-7.72 (m, 2H), 7.48 (d, J=8.3 Hz, 2H), 7.25 (d, J=8.3 Hz, 1H), 4.74 (s, 1H), 3.85 (s, 1H), 3.17 (s, 1H), 2.82 (d, J=33.4 Hz, 6H), 2.07 (s, 1H), 1.93 (s, 1H), 1.72-1.53 (m, 8H); 13C NMR (126 MHz, MeOD) δ 170.27, 157.59, 151.86, 138.83, 138.07, 135.31, 131.20, 130.31, 126.91, 124.93, 123.74, 121.37, 120.93, 99.16, 90.41, 83.88, 62.58, 49.95, 48.11, 47.94, 47.77, 47.60, 47.43, 47.26, 47.09, 24.78, 23.31.
    • Example 31: (4-((3-amino-6-chloroisoquinolin-4-yl)ethynyl)phenyl)(4-aminopiperidin-1-yl)methanone
  • Figure US20210198208A1-20210701-C00265
  • 1H NMR (500 MHz, DMSO-d6) δ 8.90 (s, 1H), 8.53 (s, 1H), 8.15 (s, 3H), 7.94 (d, J=8.6 Hz, 1H), 7.83 (d, J=8.5 Hz, 2H), 7.42 (d, J=8.3 Hz, 2H), 7.26 (m, 1H), 6.84 (s, 2H), 4.46 (s, 1H), 3.31 (s, 1H), 2.87 (s, 1H), 2.48 (d, J=2.7 Hz, 2H), 1.99 (s, 1H), 1.91-1.87 (m, 1H), 1.47 (s, 2H); 13C NMR (126 MHz, DMSO) δ 169.10, 158.67, 153.30, 138.78, 137.43, 135.77, 131.85, 131.62, 127.45, 124.63, 123.52, 121.29, 120.60, 99.44, 88.41, 85.23, 47.82, 40.40, 40.33, 40.23, 40.07, 39.90, 39.73, 39.57, 39.40
    • Example 32: 4-((3-amino-6-chloroisoquinolin-4-yl)ethynyl)-N-(2-(piperidin-1-yl)ethyl)benzamide
  • Figure US20210198208A1-20210701-C00266
  • 1H NMR (500 MHz, DMSO-d6) δ 8.90 (s, 1H), 8.48 (s, 1H), 7.93 (d, J=8.6 Hz, 1H), 7.90 (d, J=8.2 Hz, 2H), 7.87 (d, J=2.0 Hz, H), 7.83 (d, J=8.1 Hz, 2H), 7.26 (dd. J=8.6, 2.1 Hz, 1H), 6.71 (s, 2H), 3.45 (s, 2H), 3.2 (s, 2H), 2.59 (s, 4H), 1.56 (s, 4H), 1.41 (s, 2H); 13C NMR (126 MHz, DMSO) δ 166.08, 158.73, 153.28, 138.80, 137.45, 134.28, 131.59, 131.53, 127.82, 126.09, 123.57, 121.38, 120.73, 99.62, 88.62, 85.96, 57.62, 54.17, 25.44, 23.93.
    • Example 33: N-(2-(1H-imidazol-4-yl)ethyl)-4-((3-amino-6-chloroisoquinolin-4-yl)ethynyl)benzamide
  • Figure US20210198208A1-20210701-C00267
  • 1H NMR (500 MHz, DMSO-d6) δ 8.90 (s, 1H), 8.69 (t, J=5.6 Hz, 1H), 7.94 (d, J=8.6 Hz, 1H), 7.91-7.82 (m, 5H), 7.68 (s, 1H), 7.26 (dd, J=8.6, 2.1 Hz, 1H), 6.88 (d, J=9.5 Hz, 3H), 3.54-3.43 (m, 2H), 2.78 (t, J=7.5 Hz, 2H); 13C NMR (126 MHz, DMSO) δ 165.89, 158.75, 153.37, 138.76, 137.44, 135.09, 134.77, 134.22, 131.62, 127.76, 126.05, 123.53, 121.34, 120.60, 117.03, 99.59, 88.35, 85.96, 27.18.
    • Example 34: 4-((3-amino-6-chloroisoquinolin-4-yl)ethynyl)-N-((1r,4r)-4-aminocyclohexyl)benzamide
  • Figure US20210198208A1-20210701-C00268
  • 1H NMR (500 MHz, DMSO-d6) δ 8.90 (s, 1H), 8.38 (d, J=7.7 Hz, 1H), 8.02-7.92 (m, 4H), 7.91-7.81 (in, 5H), 7.27 (dd, J=8.7, 1.8 Hz, 1H), 6.84 (s, 2H), 3.72 (s, 1H), 2.99 (s, 1H), 1.94 (d, J=34.4 Hz, 4H), 1.42 (q, J=9.1, 8.4 Hz, 4H); 13C NMR (126 MHz, DMSO) δ 165.37, 153.37, 138.76, 137.43, 134.24, 131.52, 127.91, 126.03, 123.53, 121.32, 120.63, 118.96, 116.57, 99.60, 88.38, 85.96, 49.13, 47.87, 30.33, 29.72.
    • Example 35: 4-((3-amino-6-chloroisoquinolin-4-yl)ethynyl)-N-(4-(2-(dimethylamino)ethoxy)benzyl)benzamide
  • Figure US20210198208A1-20210701-C00269
  • 1H NMR (500 MHz, Methanol-d4) δ 8.77 (s, 1H), 7.91-7.86 (m, 3H), 7.83 (d, J=8.6 Hz, 1H), 7.73 (d, J=8.3 Hz, 2H), 7.33 (d, J=8.8 Hz, 2H), 7.23 (dd, J=8.6, 2.0 Hz, 1H), 6.97 (d, J=8.7 Hz, 1H), 4.53 (s, 2H), 4.29-4.16 (m, 2H), 3.23 (t, J=5.3 Hz, 2H), 2.70 (s, 6H); 13C NMR (126 MHz, MeOD) δ 167.81, 157.59, 157.41, 151.93, 138.77, 138.06, 133.75, 131.87, 131.04, 130.38, 128.70, 127.21, 126.40, 123.69, 121.31, 120.80, 114.31, 99.24, 90.21, 84.52, 63.25, 56.96, 43.32, 42.63.
    • Example 36: N-(2-(1H-imidazol-4-yl)ethyl)-3-((3-amino-6-chloroisoquinolin-4-yl)ethynyl)benzamide
  • Figure US20210198208A1-20210701-C00270
  • 1H NMR (500 MHz, DMSO-d6) δ 8.90 (s, 1H), 8.69 (t. J=5.6 Hz, 1H), 8.17 (d, J=1.8 Hz, 1H), 7.95-7.81 (m, 4H), 7.53 (dd, J=16.1, 8.2 Hz, 2H), 7.26 (dd, J=8.6, 2.1 Hz, 1H), 6.82 (d, J=12.8 Hz, 3H), 3.50 (td, J=7.6, 5.6 Hz, 2H), 2.78 (t, J=7.5 Hz, 2H); 13C NMR (126 MHz, DMSO) δ 166.01, 158.68, 153.15, 138.77, 137.40, 135.50, 135.15, 134.26, 131.58, 130.39, 129.10, 127.53, 123.51, 123.45, 121.31, 120.63, 99.47, 88.54, 84.38, 40.47, 40.30, 40.14, 40.05, 39.97, 39.80, 39.64, 39.47, 27.35.
    • Example 37: 3-((3-amino-6-chloroisoquinolin-4-yl)ethynyl)-N-(3-(dimethylamino)-2-hydroxypropyl)benzamide
  • Figure US20210198208A1-20210701-C00271
  • 1H NMR (500 MHz, DMSO-d6) δ 8.90 (s, 1H), 8.64 (t. J=5.7 Hz, 1H), 8.22 (d, J=1.8 Hz, 1H), 7.98-7.81 (m, 4H), 7.52 (t, J=7.8 Hz, 1H), 7.26 (dd, J=8.6, 2.1 Hz, 1H), 6.81 (s, 2H), 5.09 (s, 1H), 3.89-3.83 (m, 1H), 3.42 (dt, J=13.4, 5.5 Hz, 1H), 3.23-3.16 (M, 111), 2.54 (dd, J=12.4, 5.0 Hz, 1H), 2.45 (dd, J=12.6, 7.6 Hz, 1H), 2.34 (s, 61); 13C NMR (126 MHz, DMSO) δ 166.28, 158.70, 153.17, 138.76, 137.38, 135.32, 134.31, 131.60, 130.51, 129.08, 127.68, 123.51, 123.42, 121.30, 120.63, 99.47, 88.53, 84.38, 66.77, 63.21, 45.55, 45.00.
    • Example 38: BisBoc-1-(1-(4-((3-amino-6-chloroisoquinolin-4-yl)ethynyl)benzoyl)piperidin-4-yl)guanidine
  • Figure US20210198208A1-20210701-C00272
  • 1H NMR (500 MHz, Methanol-d4) δ 8.73 (s, 1H), 7.85 (d, J=2.0 Hz, 1H), 7.78 (d, J=8.6 Hz, 1H), 7.71 (d, J=8.3 Hz, 2H), 7.45 (d, J=8.1 Hz, 2H), 7.19 (dd, J=8.6, 2.1 Hz, 1H), 4.50 (s, 1H), 4.18 (q, J=4.1 Hz, 1H), 3.70 (s, 1H), 3.24 (s, 1H), 3.08 (s, 1H), 2.08 (s, 1H), 1.96 (s, 1H), 1.49 (d, J=25.7 Hz, 20H); 13C NMR (126 MHz, MeOD) δ 170.34, 163.15, 157.51, 155.43, 152.89, 151.81, 138.72, 137.98, 135.23, 131.22, 130.31, 126.90, 124.85, 123.66, 121.34, 120.74, 99.19, 90.27, 83.89, 83.30, 79.08, 48.13, 47.96, 47.80, 47.63, 47.45, 47.37, 47.28, 47.11, 31.72, 30.94, 27.20, 26.86.
    • Example 39: General Isoquinoline Synthesis
  • The majority of isoquinolines used are commercially available but can also be synthesized following the scheme below.
  • Figure US20210198208A1-20210701-C00273
  • General Procedure for Synthesizing Isoquinolines:
  • Diethoxyacetonitrile (15.5 mmol, 1 eq) was added to sodium methoxide solution, 25% w/t in methanol and stirred for 24 hours at rt. Corresponding amine (0.9 eq) was added and stirred for additional 24 hours at rt. The reaction mixture was then concentrated under vacuum. The flask was then placed on ice, followed by addition of concentrated sulfuric acid to reach final concentration as 1 M. The reaction was allowed to stir for additional 48 hours and then neutralized by 4 M potassium hydroxide solution to pH˜7. The resulting precipitate was collected and extracted with CH2Cl2 for three times. The combined organic layers were washed with brine, dried over Na2SO4 and concentrated under reduced pressure. Crude product was subject to purification by silica gel column chromatography.
    • Example 39A: 6-(trifluoromethyl)isoquinolin-3-amine
  • Figure US20210198208A1-20210701-C00274
  • Following the described general procedure, brown solid was obtained. 1H NMR (400 MHz, MeOD) δ 8.84 (s, 1H), 7.92 (d, J=8.8 Hz, 1H), 7.83 (s, 1H), 7.31-7.29 (m, 1H) 6.84 (s, 1H). 13C NMR (100 MHz, MeOD) δ 158.36, 152.70, 139.69, 133.63, 133.32, 133.00, 132.68, 130.74, 126.98, 124.99, 124.28, 123.63, 123.58, 118.73, 118.70, 100.92. LRMS (ESI+) [M+H] calcd for C10H8F3N2 213.1. found 213.4.
    • Example 39B: 6-(tert-butyl)isoquinolin-3-amine
  • Figure US20210198208A1-20210701-C00275
  • Following the described general procedure, brown solid (370 mg, 13% yield) was obtained. 1H NMR (500 MHz, MeOD) δ 8.67 (s, 1H), 7.72 (d, J=8.8 Hz. H), 7.46 (s, 1H), 7.36-7.34 (m, 1H), 6.80 (s, 1H), 1.37 (s 9H). 13C NMR (126 MHz, MeOD) δ 157.62, 155.86, 151.94, 141.81, 130.20, 129.78, 129.36, 124.15, 121.35, 102.05, 124.28, 36.86, 32.10. LRMS (ESI) [M+H] calcd for C13H17N2 201.1, found 201.2.
    • Example 39C: 6-bromoisoquinolin-3-amine
  • Figure US20210198208A1-20210701-C00276
  • Following the described general procedure, brown solid was obtained. 1H NMR (500 MHz, D6-DMSO) δ 8.79 (s, 1H), 7.78 (s, 1H), 7.71 (d, J=8.6 Hz, 1H), 7.20 (d, J=8.4 HL, 1H), 6.54 (s, 1H), 6.10 (s, 2H). 13C NMR (126 MHz, DMSO) δ 157.62, 152.25, 140.12, 130.54, 126.41, 124.95, 124.69, 121.13, 96.35.
    • Example 39D: 6-chloroisoquinolin-3-amine
  • Figure US20210198208A1-20210701-C00277
  • Following the described general procedure, brown solid was obtained. 1H NMR (500 MHz, D6-DMSO) δ 8.80 (s, 1H), 7.79 (d, J=8.6 Hz, 1H), 7.60 (s, 1H), 7.08 (d, J=8.4 Hz, 1H), 6.55 (s, 1H), 6.10 (s, 2H). 13C NMR (126 MHz, DMSO) δ 157.68, 152.13, 139.71, 135.50, 130.58, 123.11, 122.47, 121.02, 96.56.
    • Example 40: General Procedure for Amide Coupling
  • Figure US20210198208A1-20210701-C00278
  • To a solution of ethynyl benzoic acid (200 mg, 1.37 mmol, 1 equiv) in CH2Cl2 (10 mL) at 0° C. was added HBTU (623 mg, 1.64 mmol, 1.2 equiv), amine (1, 64 mmol, 1.2 equiv) and DIPEA (0.67 mL, 4.11 mmol, 3 equiv). The reaction was moved to room temperature and stirred for 12 h. Subsequently, reaction mixture was diluted with CH2C2 (40 mL) and washed with water (2×40 mL). The combined organic layer were dried over anhydrous sodium sulphate, filtered and concentrated in vacuo to obtain crude compound. The compound was purified by flash column chromatography.
    • Example 41: General Procedure for Sonogashira Coupling
  • A solution of iodo, bromo or chloro compound (100 mg, 0.33 mmol, 1 equiv). Pd catalyst (5 mol %). CuI (5 mol %) and Triphenylphosphine (10 mg, 0.04 mmol, 0.1 equiv) in Triethylamine (1 mL, 7.2 mmol, 22 equiv) was dc-oxygenated using steam of Argon gas. A de-oxygenated solution of alkyne (0.49 mmol, 1.5 equiv) in DMF (3 mL) was added slowly over a period of 15 min to the solution and the reaction temperature was increased to 70° C. and allowed to stir 12 h. The reaction was quenched by addition of NH4Cl (5 mL) at room temperature. The crude compound was extracted using EtOAc (3×40 mL). Combined organic layers were dried over anhydrous sodium sulphate, filtered and concentrated in vacuo. The pure product was obtained by flash column chromatography.
    • Example 42: N1-(4-bromoquinolin-2-yl)-N2,N2-diethylethane-1,2-diamine
  • Figure US20210198208A1-20210701-C00279
  • 2,4-dibromoquinoline (550 mg), N2,N-diethylethane-1,2-diamine (240 mg), Cs2CO3 (650 mg) and DMSO (4 mL) were placed in a round bottle and the mixture was heated to 150° C. for 12 h. The mixture was cooled to room temperature and purified using flash chromatography. 1H NMR (500 MHz, CDCl3) δ 7.92 (d, J=8.3 Hz, 1H), 7.79 (d, J=8.3 Hz, 1H), 7.72-7.65 (m, 1H), 7.49 (td, J=7.8, 3.7 Hz, 1H), 6.55 (s, 1H), 6.46 (s, 1H), 3.29 (d, J=4.7 Hz, 2H), 2.87 (t. J=6.0 Hz, 2H), 2.67 (m, 6H), 1.14 (s, 6H). 13C NMR (126 MHz, CDCl3) δ 151.10, 148.16, 143.39, 129.85, 128.80, 125.00, 119.99, 118.15, 101.86, 50.29, 46.41, 40.90, 11.96.
    • Example 43: Compound HSN225
  • Figure US20210198208A1-20210701-C00280
  • 1H NMR (500 MHz, DMSO-d6) δ 8.52 (t, J=5.7 Hz, 1H), 8.27 (d, J=8.3 Hz, 1H),8.15 (s, 1H), 8.10 (d, J=7.8 Hz, 1H), 7.89 (d, J=8.4 Hz, 2H), 7.78 (t, J=7.6 Hz, 1H), 7.67 (d, J=8.4 Hz, 2H), 7.57 (t. J=7.0 Hz, 1), 7.38 (s, 2H), 4.73 (s, 1H), 3.76 (s, 1H), 3.42 (dt, J=13.2, 5.3 Hz, 1H), 3.15 (t, J=6.1 Hz, 1H), 2.27 (dd, J=12.4, 5.9 Hz, 1H), 2.23-2.20 (m, 1H), 2.17 (s, 6H); 13C NMR (126 MHz, DMSO) δ 166.08, 158.20, 147.78, 136.41, 134.02, 131.56, 131.16, 128.03, 126.78, 126.29, 124.93, 116.72, 102.89, 93.24, 89.28, 67.52, 64.33, 46.35, 45.28; HRMS (ESI+): calcd. for C23H25N4O2 (MH+) 389.1978. found 389.2018.
    • Example 44: 4-((4-(4,5-dihydro-H-imidazol-2-yl)phenyl)ethynyl)isoquinolin-1-amine (HSM1795)
  • Figure US20210198208A1-20210701-C00281
  • 1H NMR (500 MHz, DMSO) δ 8.27 (d, J=8.3 Hz, 1H), 8.17-8.06 (M, 2H), 7.85 (d, J=7.9 Hz, 2H), 7.77 (t, J=7.5 Hz, 1H), 7.63 (d, J=7.9 Hz, 2H), 7.57 (d, J=7.5 Hz, 1H), 7.37 (s, 2H), 6.97 (s, 1H), 3.34 (s, 4H); 13C NMR (126 MHz, DMSO) δ 163.54, 158.16, 147.64, 136.44, 131.55, 131.16, 130.38, 127.82, 126.78, 125.34, 124.94, 116.75, 103.03, 93.42, 88.87, 55.48, 44.89; HR-MS(ESI) m/z calcd for C20H17N4 ([M+H]+) 313.1453. found 313.1455.
    • Example 45: 4-((4-(4,5-dihydro-1H-imidazol-2-yl)phenyl)ethynyl)quinolin-2-amine (HSM1803)
  • Figure US20210198208A1-20210701-C00282
  • 1H NMR (500 MHz, DMSO) 8.03 (dd. J=8.1.0.8 Hz, 1H), 7.91 (d, J=8.4 Hz, 2H), 7.76 (d, J=8.4 Hz, 2H), 7.57-7.44 (m, 2H), 7.26 (ddd, J=8.1, 6.7, 1.4 Hz, 1H), 7.00 (s, 1H), 6.59 (s, 2H), 3.62 (s, 4H); 13C NMR (126 MHz, DMSO) δ 163.40, 158.16, 148.49, 132.19, 131.72, 130.37, 129.10, 127.95, 126.24, 125.64, 123.57, 122.52, 122.00, 115.50, 96.07, 86.97; HR-MS(ESI) m/z calcd for C20H17N4 ([M+H]+) 313.1453. found 313.1487.
    • Example 46: 4-((2-amino-6,7-dimethoxyquinazolin-4-yl)ethynyl)benzonitrile (HSN364)
  • Figure US20210198208A1-20210701-C00283
  • 1H NMR (500 MHz, DMSO-d6) δ 7.96 (q, J=8.5 Hz, 4H), 7.28 (s, 1H), 6.87 (s, 1H), 6.61 (s, 2H), 3.90 (d, J=1.1 Hz, 6H): 13C NMR (126 MHz, DMSO) δ 160.53, 156.96, 150.97, 148.83, 147.55, 133.48, 133.27, 125.91, 118.74, 115.15, 112.82, 104.86, 103.86, 93.27, 89.06, 56.41, 56.07.
    • Example 47: 4-((4-(4,4-dimethyl-4,5-dihydro-1H-imidazol-2-yl)phenyl)ethynyl)-1-methylisoquinolin-3-amine (HSN370)
  • Figure US20210198208A1-20210701-C00284
  • 1H NMR (500 MHz, Methanol-d4) δ 8.01 (d, J=7.9 Hz, 2H), 7.82 (d, J=8.0 Hz, 2H), 7.71 (d, J=7.9 Hz, 2H), 7.63 (t. J=7.9 Hz, 1H), 7.33-7.28 (m, 1H), 3.58 (s, 2H), 2.81 (s, 3H), 1.38 (s, 6H): 13C NMR (126 MHz, MeOD) δ 159.31, 155.78, 138.09, 132.19, 131.08, 130.90, 127.89, 127.26, 126.88, 126.16, 123.20, 122.87, 121.33, 98.53, 89.81, 85.93, 62.63, 60.86, 27.24, 20.69.
    • Example 48: 4-((4-(4,4-dimethyl-4,5-dihydro-1H-imidazol-2-yl)phenyl)ethynyl)-6,7-dimethoxyquinazolin-2-amine (HSN335)
  • Figure US20210198208A1-20210701-C00285
  • 1H NMR (500 MHz, DMSO-d6) δ 8.03 (d, J=9.9 Hz, 3H), 7.97 (d, J=8.3 Hz, 1H), 7.93 (s, 1H), 7.30 (s, 1H), 6.88 (s, 1H), 6.61 (s, 2H), 3.91 (d, J=5.2 Hz, 6H), 3.77 (s, 2H), 1.46 (s, 3H), 1.44 (s, 3H); 13C NMR (126 MHz, DMSO) δ 162.00, 160.54, 156.99, 150.99, 148.86, 147.57, 133.71, 133.39, 129.33, 126.80, 126.12, 115.15, 104.90, 93.45, 89.08, 62.12, 57.30, 56.45, 56.15, 27.94.
    • Example 49: 3-((2-amino-6,7-dimethoxyquinazolin-4-yl)ethynyl)-4-methylbenzonitrile (HSN368)
  • Figure US20210198208A1-20210701-C00286
  • 1H NMR (500 MHz, DMSO-d6) δ 8.19 (d, J=1.6 Hz, 1H), 7.87 (d, J=1.8 Hz, 1H), 7.62 (d, J=8.0 Hz, 1H), 7.30 (s, 1H), 6.88 (s, 1H), 6.62 (s, 2H), 3.89 (d, J=8.4 Hz, 6H), 2.66 (s, 3H); 13C NMR (126 MHz, DMSO) 160.55, 156.88, 150.90, 149.12, 147.52, 146.97, 136.34, 133.89, 131.60, 122.56, 118.50, 115.11, 110.06, 104.88, 103.93, 91.52, 91.36, 56.05, 46.02, 21.44.
    • Example 50: Compound HSG33
  • Figure US20210198208A1-20210701-C00287
  • 1H NMR (500 MHz, Methanol-d4) δ 8.90 (d, J=4.5 Hz, 1H), 8.43 (dd, J=8.5, 1.4 Hz, 1H), 8.11 (dt, J=8.5, 0.9 Hz, 1H), 8.03-7.93 (m, 4H), 7.88 (ddd, J=8.4, 6.9, 1.4 Hz, 1H), 7.80-7.76 (m, 2H), 3.90 (s, 2H), 1.58 (s, 6H); 13C NMR (126 MHz, Methanol-d4) δ 164.44, 150.83, 148.75, 133.95, 131.87, 129.97, 129.69, 129.25, 128.76, 126.90, 125.44, 124.58, 97.95, 89.29, 63.32, 58.53, 27.92.
    • Example 51: Compound HSG39
  • Figure US20210198208A1-20210701-C00288
  • 1H NMR (500 MHz, Methanol-d4) δ 9.02 (dd. J=4.4.1.7 Hz, 1H), 8.66 (dd. J=8.4, 1.7 Hz, 1H), 8.32 (s, 1H), 7.82 (q. J=8.2 Hz, 4H), 7.61 (dd. J=8.4, 4.4 Hz, 1H), 5.12 (s, 1H), 3.71 (s, 2H), 1.46 (s, 6H); 13C NMR (126 MHz, Methanol-d4) δ 164.13, 161.49, 159.71, 155.45, 152.66, 151.48, 134.89, 132.41, 130.64, 128.36, 127.87, 122.96, 114.17, 107.49, 94.02, 88.07, 49.85, 28.75; HRMS (M+H): Calc. 342.1640. Observed 342.1715.
    • Example 52: Compound HSG42
  • Figure US20210198208A1-20210701-C00289
  • 1H NMR (500 MHz, Methanol-d4) δ 9.24-8.97 (m, 1H), 7.91 (dt, J=8.5, 0.9 Hz, 1H), 7.86-7.76 (m, 2H), 7.77-7.66 (m, 2H), 7.52 (dd, J=8.5, 7.4 Hz, 1H), 7.29 (dd, J=7.4, 0.9 Hz, 1H), 3.52 (s, 2H), 1.35 (s, 6H); 13C NMR (126 MHz, MeOD) δ 163.98, 158.77, 149.57, 140.95, 134.17, 132.71, 132.40, 130.81, 128.54, 127.13, 124.58, 123.58, 120.72, 100.91, 92.85, 85.89, 64.15, 62.96, 28.73.
    • Example 53: Compound HSG43
  • Figure US20210198208A1-20210701-C00290
  • 1H NMR (500 MHz, Methanol-d4) δ 7.92 (d, J=8.9 Hz, 1H), 7.85 (d, J=1.9 Hz, 1H), 7.82-7.77 (m, 2H), 7.63 (dd. J=8.6, 1.9 Hz, 1H), 7.61-7.56 (m, 2H), 7.51 (d, J=8.7 Hz, 1H), 6.86 (d, J=8.9 Hz, 1H), 3.51 (s, 2H) 1.34 (s, 6H); 13C NMR (126 MHz, MeOD) δ 164.02, 161.48, 160.37, 148.44, 139.04, 133.44, 132.41, 132.35, 131.00, 128.47, 127.32, 125.80, 124.28, 117.56, 114.36, 92.45, 89.03, 28.75; HRMS (M+H): Calc. 341.1688, Observed 341.1769.
    • Example 54: Compound HSG47
  • Figure US20210198208A1-20210701-C00291
  • 1H NMR (500 MHz, Methanol-d4) δ 8.77-8.53 (m, 1H), 7.86-7.78 (m, 2H), 7.74 (dt, J=1.7, 0.9 Hz, 1H), 7.72-7.64 (m, 3H), 7.12 (dd, J=8.3, 1.6 Hz, 1H), 3.52 (s, 2H), 2.51 (d, J=1.0 Hz, 3H), 1.35 (s, 6H); 13C NMR (126 MHz, MeOD) δ 163.57, 157.57, 152.04, 143.52, 139.34, 132.07, 130.30, 129.16, 128.21, 126.93, 126.67, 122.82, 122.27, 100.25, 92.73, 86.20, 78.93, 78.86, 78.67, 78.41, 63.84, 62.72, 30.43, 28.72, 22.56; HRMS (M+H): Calc. 355.1844. Observed 355.1916.
    • Example 55: Compound HSG74
  • Figure US20210198208A1-20210701-C00292
  • 1H NMR (500 MHz, Methanol-d4) δ 8.36-8.24 (m, 1H), 8.06-7.98 (m, 1H), 7.84 (s, 1H), 7.78-7.73 (m, 2H), 7.65-7.59 (i, 4H), 3.45 (s, 2H), 1.28 (s, 6H); 13C NMR (126 MHz, MeOD) δ 163.89, 142.29, 132.54, 131.14, 131.06, 130.87, 130.11, 129.52, 128.56, 127.66, 127.45, 126.74, 126.16, 122.66, 92.31, 90.05, 64.17, 63.00.
    • Example 56: Compound HSG001
  • Figure US20210198208A1-20210701-C00293
  • 1H NMR (500 MHz, Methanol-d4) δ 8.23-8.14 (In, 2H), 8.08 (s, 1H), 7.87-7.78 (m, 3H), 7.70-7.64 (m, 2H), 7.60 (ddd, J=8.3, 6.9, 1.2 Hz, 1H), 5.49 (s, 21), 3.57 (s, 2H), 1.38 (s, 6H); 13C NMR (126 MHz, MeOD) δ 164.54, 159.39, 147.42, 137.83, 134.32, 132.91, 132.66, 131.63, 129.47, 128.04, 125.99, 125.24, 122.89, 118.25, 111.11, 105.33, 93.32, 91.86, 63.17, 58.59, 27.93.
    • Example 57: Compound HSG82
  • Figure US20210198208A1-20210701-C00294
  • 1H NMR (500 MHz, DMSO-d6) δ 9.79 (s, 1H), 8.05 (dd, J=8.1, 1.4 Hz, 1H), 7.99 (d, J=1.8 Hz, 1H), 7.81 (dt, J=7.9, 1.4 Hz, 1H), 7.72 (dt, J=7.7, 1.3 Hz, 1H), 7.60-7.46 (m, 3H), 7.29 (ddd, J=8.1, 6.7, 1.4 Hz, 1H), 7.01 (s, 1H), 6.60 (s, 2H), 5.97 (s, 2H); 13C NMR (126 MHz, DMSO) δ 157.63, 149.91, 147.89, 133.96, 132.08, 129.91, 128.82, 128.77, 128.57, 126.52, 125.69, 125.12, 122.07, 121.55, 121.32, 114.96, 95.87, 85.10, 54.92.
    • Example 58: Compound HSG83
  • Figure US20210198208A1-20210701-C00295
  • 1H NMR (500 MHz, DMSO-d6) δ 8.12 (s, 1H), 8.05 (dd. J=8.1, 1.4 Hz, 1H), 8.03-7.92 (m, 2H), 7.87-7.75 (m, 2H), 7.56-7.50 (m, 3H), 7.28 (ddd, J=8.1, 6.7, 1.4 Hz, 1H), 7.02 (s, 1H), 6.60 (s, 2H); 13C NMR (126 MHz, DMSO) δ 166.98, 157.65, 147.98, 134.78, 131.73, 129.92, 128.52, 127.92, 125.75, 125.16, 124.13, 122.08, 121.49, 115.12, 109.23, 95.34, 86.75.
    • Example 59:3-((2-aminoquinolin-4-yl)ethynyl)-N-(4-(2-(dimethylamino)ethoxy)benzyl)-4-methylbenzamide (HSN316)
  • Figure US20210198208A1-20210701-C00296
  • 1H NMR (500 MHz, DMSO-d6) δ 9.07 (t, J=6.0 Hz, 1H), 8.17 (d, J=1.9 Hz, 1H), 8.03 (dd. J=8.1, 1.4 Hz, 1H), 7.88 (dd. J=8.0, 2.0 Hz, 1H), 7.59-7.46 (m, 3H), 7.28 (ddd, J=8.1, 6.6, 1.5 Hz, 1H), 7.23 (d, J=8.6 Hz, 2H), 7.02 (s, 1H), 6.88 (d, J=8.7 Hz, 2H), 6.57 (s, 2H), 4.40 (d, J=5.9 Hz, 2H), 3.99 (t. J=5.8 Hz, 2H), 2.59 (s, 5H), 2.18 (s, 6H); 13C NMR (126 MHz, DMSO) δ 165.40, 158.17, 157.90, 148.52, 143.70, 132.80, 131.97, 131.21, 130.43, 130.34, 129.23, 129.14, 128.96, 126.28, 125.47, 122.53, 121.92, 121.84, 115.57, 114.74, 94.59, 89.81, 66.22, 58.13, 45.98, 42.62, 20.93.
    • Example 60: Compound HSN303
  • Figure US20210198208A1-20210701-C00297
  • 1H NMR (500 MHz, DMSO-d6) δ 9.25 (s, 1H), 9.16 (s, 1H), 8.11 (d, J=2.4 Hz, 1H), 8.02 (d, J=8.1 Hz, 1H), 7.69-7.56 (m, 6H), 7.54-7.50 (m, 2H), 7.25 (t, J=7.3 Hz, 1H), 6.96 (s, 1H), 6.53 (s, 2H); 13C NMR (126 MHz, DMSO) δ 158.16, 152.64, 148.49, 141.06, 139.56, 133.74, 133.20, 132.51, 130.23, 129.63, 127.31, 127.07, 126.22, 125.66, 123.74, 123.06, 122.38, 122.18, 118.90, 117.44, 115.11, 97.07, 84.72; HRMS (ESI+): calcd. for C25H17ClF3N4O (MH+) 481.1043. found 481.1034.
    • Example 61: Compound HSN285
  • Figure US20210198208A1-20210701-C00298
  • 1H NMR (500 MHz, DMSO-d6) δ 10.56 (s, 1H), 8.29 (d, J=1.9 Hz, 1H), 8.21 (d, J=2.2 HL, 1H), 8.06 (dd. J=8.0, 1.3 Hz, 2H), 7.97 (dd. J=8.0, 2.0 Hz, 1H), 7.70 (d, J=8.5 HL, 1H), 7.61-7.48 (m, 3H), 7.29 (ddd, J=8.1, 6.6, 1.6 Hz, 1H), 7.05 (s, 1H), 6.59 (s, 2H), 3.55 (s, 2H), 3.15 (s, 2H), 2.63 (s, 3H), 2.37 (s, 6H), 2.14 (s, 3H); 13C NMR (126 MHz, DMSO) δ 165.06, 158.17, 148.54, 144.50, 138.60, 132.83, 132.59, 131.69, 131.59, 130.59, 130.36, 129.40, 129.19, 127.74, 126.30, 125.50, 124.00, 122.55, 121.99, 121.92, 117.76, 115.63, 94.42, 90.11, 57.92, 55.19, 53.15, 49.06, 46.17, 21.04; HRMS (ESI+): calcd. for C32H31F3N5O (MH+) 558.2481. found 558.2479.
    • Example 62: 4-((4-(4,4-dimethyl-4,5-dihydro-1H-imidazol-2-yl)-3-fluorophenyl)ethynyl)quinolin-2-amine (HSM1856)
  • Figure US20210198208A1-20210701-C00299
  • 1H NMR (500 MHz, DMSO) δ 8.08 (d, J=8.0 Hz, 1H), 7.89 (d, J=7.8 Hz, 1H), 7.75 (s, 1H), 7.58-7.47 (m, 2H), 7.29 (dd, J=10.9, 4.0 Hz, 1H), 7.05 (s, 1H), 6.66 (s, 2H), 3.61 (s, 2H), 1.38 (s, 6H); 13C NMR (126 MHz, DMSO) δ 160.58, 157.18, 147.84, 140.91, 131.91, 131.34, 130.86, 128.05, 127.64, 125.57, 124.22, 122.68, 122.44, 105.95, 94.97, 87.12, 29.08.
    • Example 63: 4-(5-(2-aminoquinolin-4-yl)-1,3,4-oxadiazol-2-yl)-N-hydroxybenzimidamide (HSM1860)
  • Figure US20210198208A1-20210701-C00300
  • 1H NMR (500 MHz, DMSO) δ 9.92 (d, J=9.2 Hz, 1H), 8.80 (dd, J=17.4, 8.5 Hz, 1H), 8.23-8.05 (m, 2H), 8.00-7.92 (m, 2H), 7.63-7.55 (m, 2H), 7.39-7.26 (m, 1H), 6.86-6.73 (m, 2H), 6.10-5.90 (m, 2H); 13C NMR (126 MHz, DMSO) δ 164.26, 163.24, 158.07, 150.41, 149.43, 137.22, 130.31, 128.79, 127.17, 126.73, 126.57, 126.02, 123.66, 123.12, 118.17, 113.60.
    • Example 64:3-((2-amino-6,7-dimethoxyquinazolin-4-yl)amino)benzonitrile (HSN295)
  • Figure US20210198208A1-20210701-C00301
  • 1H NMR (500 MHz, DMSO-d6) δ 10.79 (s, 1H), 8.36 (s, 1H), 8.14 (s, 2H), 7.90 (s, 2H), 7.75-7.53 (m, 2H), 7.00 (s, 1H), 3.92 (s, 6H); HRMS (ESI+): calcd. for C7H6N5O2 (MH+) 322.1304, found 322.1314.
    • Example 65: 3-((2-amino-6,7-dimethoxyquinazolin-4-yl)amino)-N-hydroxybenzimidamide (HSN301)
  • Figure US20210198208A1-20210701-C00302
  • 1H NMR (500 MHz, DMSO-d6) δ 9.79 (s, 1H), 9.62 (s, 1H), 8.02-7.88 (m, 2H), 7.82 (s, 1H), 7.43 (dt, J=7.8, 1.5 Hz, 1H), 7.40-7.35 (m, 1H), 6.81 (d, J=28.2 Hz, 3H), 5.79 (s, 2H), 3.87 (s, 6H); 13C NMR (126 MHz, DMSO) 158.43, 157.29, 155.27, 151.25, 146.28, 139.16, 134.27, 128.75, 124.18, 121.69, 120.61, 104.28, 103.53, 102.56, 56.70, 56.20; HRMS (ESI+): calcd. for C17H19N6O3 (MH+) 355.1519. found 355.1515.
    • Example 66: N-(4-((2-amino-6,7-dimethoxyquinazolin-4-yl)amino)phenyl)-3-(piperidin-1-yl)propanamide (HSN304)
  • Figure US20210198208A1-20210701-C00303
  • 1H NMR (500 MHz, DMSO-d6) δ 10.57 (s, 1H), 10.53 (s, 1H), 8.09 (s, 1H), 7.69 (q, J=8.7 Hz, 6H), 6.96 (s, 11H), 3.90 (s, 6H), 3.32 (t. J=5.1 Hz, 611), 3.22 (s, 21), 2.94 (t. J=7.4 Hz, 2H), 1.89-1.67 (m, 4H); 13C NMR (126 MHz, DMSO) δ 168.38, 158.76, 155.79, 154.43, 147.14, 136.86, 133.30, 125.16, 119.70, 105.48, 103.00, 99.20, 74.35, 60.46, 58.49, 57.06, 56.53, 52.63, 31.05, 22.92, 21.87; HRMS (ESI+): calcd. for C24H3N6O3 (MH+) 451.2458, found 451.2452.
    • Example 67: 4-((2-amino-6,7-dimethoxyquinazolin-4-yl)(methyl)amino)-N-hydroxybenzimidamide (HSN318)
  • Figure US20210198208A1-20210701-C00304
  • 1H NMR (500 MHz, DMSO-d6) δ 9.60 (s, 1H), 7.65 (d, J=8.6 Hz, 2H), 7.13 (d, J=8.6 Hz, 2H), 6.69 (s, 1H), 6.20 (s, 1H), 6.13 (s, 2H), 5.78 (s, 2H), 3.77 (s, 3H), 3.45 (s, 3H), 3.13 (s, 3H); 13C NMR (126 MHz, DMSO) δ 162.04, 159.86, 154.14, 151.52, 150.71, 149.48, 144.06, 130.25, 127.08, 124.86, 106.11, 105.37, 105.15, 55.84, 54.91, 41.42.
    • Example 68:3-((2-amino-6,7-dimethoxyquinazolin-4-yl)ethynyl)-N-(4-(2-(dimethylamino)ethoxy)benzyl)-4-methylbenzamide (HSN317)
  • Figure US20210198208A1-20210701-C00305
  • 1H NMR (500 MHz, DMSO-d6) δ 9.08 (t. J=5.9 Hz, 1H), 8.20 (d, J=1.9 Hz, 1H), 7.91 (dd, J=8.0, 1.9 Hz, 1H), 7.50 (d, J=8.1 Hz, 1H), 7.32 (s, 1H), 7.23 (d, J=8.6 Hz, 2H), 6.94-6.82 (m, 3H), 6.57 (s, 2H), 4.39 (d, J=5.8 Hz, 2H), 4.00 (t, J=5.8 Hz, 2H), 3.90 (s, 3H), 3.87 (s, 3H), 2.64 (s, 3H), 2.58 (t, J=5.8 Hz, 2H), 2.18 (s, 6H); 13C NMR (126 MHz, DMSO) δ 165.27, 160.60, 157.92, 156.78, 150.80, 149.56, 147.42, 144.21, 132.93, 131.91, 131.79, 130.59, 129.58, 129.14, 121.11, 115.01, 114.74, 104.91, 103.96, 93.55, 90.21, 66.24, 58.14, 56.39, 55.91, 46.00, 42.63, 20.97.
    • Example 69: Compound HSN325
  • Figure US20210198208A1-20210701-C00306
  • 1H NMR (500 MHz, DMSO-d6) δ 10.58 (s, 1H), 8.33 (d, J=1.9 Hz, 1H), 8.20 (d, J=2.2 Hz, 1H), 8.06 (d, J=8.6 Hz, 1H), 8.00 (dd, J=8.0, 2.0 Hz, 1H), 7.70 (d, J=8.5 Hz, 1H), 7.58 (d, J=8.1 Hz, 1H), 7.34 (s, 1H), 6.88 (s, 1H), 6.59 (s, 2H), 3.90 (d, J=7.0 Hz, 6H), 3.56 (s, 2H), 2.68 (s, 3H), 2.42 (s, 8H), 2.22 (s, 3H); 13C NMR (126 MHz, DMSO) δ 164.87, 160.60, 156.81, 150.83, 149.49, 147.45, 145.04, 138.64, 132.83, 132.46, 132.10, 131.75, 130.75, 130.05, 123.94, 121.26, 117.71, 115.03, 104.91, 103.95, 93.31, 90.47, 57.80, 56.40, 55.94, 54.94, 52.74, 45.72, 21.08.
    • Example 70: 4-((6-chloro-3-(cyclopropanecarboxamido)isoquinolin-4-yl)ethynyl)-N-(2-(piperidin-1-yl)ethyl)benzamide (HSN329)
  • Figure US20210198208A1-20210701-C00307
  • 1H NMR (500 MHz, Chloroform-d) δ 8.80 (s, 1H), 7.99 (d, J=1.9 Hz, 1H), 7.77 (m, 3H), 7.71 (d, J=8.4 Hz, 1H), 7.66 (d, J=8.4 Hz, 2H), 7.25 (d, J=2.0 Hz, 1H), 4.05 (t, J=6.2 Hz, 2H), 2.60 (s, 2H), 2.46-2.33 (bs, 4H), 1.43-1.33 (m, 6H), 1.24-1.22 (m, 1H), 1.06 (m, 2H), 0.67 (n, 2H); 13C NMR (126 MHz, CDCl3) δ 177.24, 173.16, 157.02, 152.12, 138.68, 138.29, 136.20, 131.63, 131.29, 130.06, 129.42, 126.83, 124.68, 122.36, 121.32, 99.58, 85.80, 57.62, 54.47, 29.71, 25.70, 24.19, 18.50, 11.76, 9.43.
    • Example 71: 1-(3-((2-aminoquinolin-4-yl)ethynyl)phenyl)-3-(4-chloro-3-(trifluoromethyl)phenyl)urea (HSN333)
  • Figure US20210198208A1-20210701-C00308
  • 1H NMR (500 MHz, DMSO-d6) δ 9.25 (s, 1H), 9.03 (s, 1H), 8.11 (d, J=2.6 Hz, 1H), 8.01 (d, J=8.1 Hz, 1H), 7.87 (s, 1H), 7.65 (dd, J=8.7, 2.5 Hz, 0.1H), 7.61 (d, J=8.8 Hz, 1H), 7.53 (d, J=5.5 Hz, 2H), 7.49 (d, J=8.0 Hz, 1H), 7.40 (t, J=7.8 Hz, 1H), 7.34 (d, J=7.5 Hz, 1H), 7.27 (t. J=7.2 Hz, 1H), 7.03 (s, 1H), 6.58 (s, 2H); 13C NMR (126 MHz, DMSO) δ 158.13, 152.89, 148.48, 140.17, 139.66, 132.48, 130.31, 129.96, 129.21, 127.30, 127.06, 126.30, 126.18, 125.52, 124.36, 123.72, 122.98, 122.49, 122.26, 122.19, 121.82, 120.46, 117.40, 96.54, 85.25.
    • Example 72: 3-((8-amino-1,7-naphthyridin-5-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide (HSN356)
  • Figure US20210198208A1-20210701-C00309
  • 1H NMR (500 MHz, DMSO-d6) δ 10.57 (s, 1H), 8.88 (dd, J=4.3, 1.6 Hz, 1H), 8.46 (dd. J=8.3, 1.6 Hz, 1H), 8.28-8.19 (m, 3H), 8.08 (d, J=8.5 Hz, 1H), 7.89 (dd. J=8.0, 2.0 Hz, 1H), 7.85 (dd. J=8.4, 4.2 Hz, 1H), 7.69 (d, J=8.5 Hz, 1H), 7.53 (s, 2H), 7.50 (d, J=8.1 Hz, 1H), 3.57 (s, 2H), 2.60 (s, 3H), 2.48 (bs, merged with DMSO, 8H), 2.29 (s, 3H); 13C NMR (126 MHz, DMSO) δ 165.32, 158.56, 149.70, 148.18, 143.41, 138.78, 133.14, 132.64, 132.52, 132.21, 131.73, 131.36, 130.82, 130.33, 128.05, 127.99, 127.75, 127.06, 124.00, 123.42, 117.76, 102.11, 91.74, 90.52, 57.69, 54.64, 52.27, 45.89, 21.19.
    • Example 73: 3-((8-amino-1,7-naphthyridin-5-yl)ethynyl)-N-(4-(2-(dimethylamino)ethoxy)benzyl)-4-methylbenzamide (HSN357)
  • Figure US20210198208A1-20210701-C00310
  • 1H NMR (500 MHz, DMSO-d6) δ 9.02 (t. J=6.0 Hz, 1H), 8.87 (dd, J=4.2, 1.6 Hz, 1H), 8.42 (dd. J=8.4.1.6 Hz, 1H), 8.21 (s, 1H), 8.09 (d, J=1.8 Hz, 1H), 7.84 (dd, J=8.4, 4.2 Hz, 1H), 7.78 (dd, J=8.0, 1.9 Hz, 1H), 7.51 (s, 2H), 7.42 (d, J=8.0 Hz, 1H), 7.23 (d, J=8.6 Hz, 2H), 6.88 (d, J=8.7 Hz, 2H), 4.39 (d, J=5.9 Hz, 2H), 4.00 (t. J=5.8 Hz, 2H), 2.61 (t. J=5.8 Hz, 2H), 2.56 (s, 3H), 2.20 (s, 6H); 13C NMR (126 MHz, DMSO) δ 165.64, 158.51, 157.85, 149.68, 148.09, 142.60, 133.08, 132.67, 132.52, 132.08, 131.34, 130.43, 130.16, 129.13, 127.58, 127.04, 123.25, 114.73, 102.18, 91.86, 90.14, 66.09, 58.05, 45.89, 42.58, 21.08.
    • Example 74: 3-((1-aminoisoquinolin-4-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide (HSN334)
  • Figure US20210198208A1-20210701-C00311
  • 1H NMR (500 MHz, DMSO-d6) δ 10.52 (s, 1H), 8.29 (d, J=8.3 Hz, 1H), 8.21 (d, J=2.2 Hz, 1H), 8.19 (s, 2H), 8.11 (d, J=8.7 Hz, 1H), 8.06 (d, J=8.5 Hz, 1H), 7.86 (dd. J=7.9, 1.9 Hz, 1H), 7.80 (t, J=7.5 Hz, 1H), 7.69 (d, J=8.5 Hz, 1H), 7.57 (t, J=7.6 Hz, 1H), 7.50 (d, J=8.0 Hz, 1H), 7.38 (s, 2H), 3.55 (s, 2H), 3.15 (d, J=3.7 Hz, 1H), 2.61 (s, 3H), 2.37 (s, 7H), 2.14 (s, 3H); 13C NMR (126 MHz, DMSO) δ 165.34, 158.17, 147.70, 143.30, 138.67, 136.38, 132.66, 132.52, 131.68, 131.60, 130.62, 130.33, 127.87, 126.77, 125.00, 124.78, 123.99, 123.69, 117.74, 116.76, 103.16, 91.94, 91.71, 57.93, 55.20, 53.18, 46.20, 21.20.
    • Example 75: Compound HSN286
  • Figure US20210198208A1-20210701-C00312
  • 1H NMR (500 MHz, DMSO-d6) δ 10.54 (s, 1H), 8.92 (d, J=0.8 Hz, 1H), 8.38 (d, J=2.0 Hz, 1H), 8.21 (d, J=2.2 Hz, 1H), 8.05 (dd, J=8.5, 2.2 Hz, 1H), 7.96 (d, J=8.6 Hz, 1H), 7.88 (dd, J=8.0, 2.0 Hz, 2H), 7.70 (d, J=8.6 Hz, 1H), 7.51 (d, J=8.1 Hz, 1H), 7.28 (dd, J=8.6, 2.0 Hz, 1H), 6.78 (s, 2H), 3.55 (s, 2H), 3.15 (d, J=3.8 Hz, 1H), 2.63 (s, 3H), 2.37 (s, 7H), 2.16 (s, 3H); 13C NMR (126 MHz, DMSO) δ 165.55, 158.55, 153.20, 143.27, 138.74, 138.69. 137.39, 132.82, 132.47, 131.70, 131.64, 131.49, 130.20, 128.05, 127.74, 125.90, 123.93, 123.48, 121.34, 120.68, 117.69, 98.17, 88.78, 88.59, 57.89, 55.14, 53.07, 46.08, 21.28; HRMS (ESI+): calcd. for C32H30F3N5O (MH+) 592.2091. found 592.2091.
    • Example 76: 3-((3-aminoisoquinolin-4-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide (HSN352)
  • Figure US20210198208A1-20210701-C00313
  • 1H NMR (500 MHz, DMSO-d6) δ 10.54 (s, 1H), 8.90 (s, 1H), 8.36 (d, J=1.9 Hz, 1H), 8.21 (s, 1H), 8.06 (d, J=8.5 Hz, 1H), 7.95 (d, J=8.4 Hz, 1H), 7.91 (d, J=8.1 Hz, 1H), 7.87 (dd, J=7.9, 2.0 Hz, 1H), 7.69 (t, J=7.7 Hz, 2H), 7.51 (d, J=8.0 Hz, 1H), 7.28 (d, J=7.8 Hz, 1H), 6.55 (s, 2H), 3.56 (s, 2H), 3.37 (s, 1H), 2.64 (s, 3H), 2.38 (bs, 7H), 2.17 (s, 3H); 13C NMR (126 MHz, DMSO) δ 165.57, 158.02, 153.10, 143.26, 138.70, 137.86, 132.79, 132.46, 132.20, 131.72, 131.37, 130.19, 129.16, 127.93, 127.75, 123.95, 123.66, 123.15, 122.71, 122.45, 97.88, 89.69, 89.38, 57.88, 55.11, 53.02, 46.02, 21.37.
    • Example 77: 3-((3-amino-8-chloroisoquinolin-4-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide (HSN353)
  • Figure US20210198208A1-20210701-C00314
  • 1H NMR (500 MHz, DMSO-d6) δ 10.53 (s, 1H), 9.10 (s, 1H), 8.37 (d, J=2.0 Hz, 1H), 8.20 (d, J=2.2 Hz, 1H), 8.05 (dd, J=8.5, 2.2 Hz, 1H), 7.94 (d, J=8.5 Hz, 1H), 7.88 (dd. J=8.0, 2.0 Hz, 1H), 7.70 (d, J=8.5 Hz, 1H), 7.63 (dd, J=8.5, 7.4 Hz, 1H), 7.51 (d, J=8.0 Hz, 1H), 7.38 (dd, J=7.4.0.9 Hz, 1H), 6.82 (s, 2H), 3.56 (s, 2H), 2.63 (s, 3H), 2.39 (s, 8H), 2.18 (s, 3H); 13C NMR (126 MHz, DMSO) δ 165.53, 158.44, 148.96, 143.46, 139.61, 138.69, 132.79. 132.62, 132.44, 132.38, 131.72, 131.57, 130.20, 128.14, 125.89, 123.94, 123.45, 123.38, 122.60, 118.91, 117.70, 117.65, 98.37, 90.06, 88.65, 57.86, 55.07, 52.96, 45.96, 21.37.
    • Example 78: Compound HSN247
  • Figure US20210198208A1-20210701-C00315
  • 1H NMR (500 MHz, Methanol-d4) δ 8.73 (s, 1H), 8.05 (d, J=2.0 Hz, 1H), 7.88 (d, J=1.9 Hz, 1H), 7.79 (d, J=8.7 Hz, 1H), 7.71 (dd. J=7.9, 2.0 Hz, 1H), 7.37 (d, J=8.0 Hz, 1H), 7.20 (dd. J=8.7, 2.0 Hz, 1H), 3.54 (t, J=7.0 Hz, 2H), 2.86-2.78 (m, 2H), 2.74 (q. J=7.2 Hz, 4H), 2.60 (s, 3H), 1.13 (t, J=7.2 Hz, 6H); 13C NMR (126 MHz, MeOD) δ 167.88, 157.31, 151.62, 142.91, 138.56, 137.95, 131.86, 130.31, 130.09, 129.53, 126.86, 123.66, 123.18, 121.37, 120.81, 98.11, 90.75, 87.08, 51.21, 46.89, 36.67, 19.97, 9.87; HRMS (ESI+): calc. for C25H28ClN4O (MH+) 435.1952. found 435.1952.
    • Example 79: Compound HSN248
  • Figure US20210198208A1-20210701-C00316
  • 1H NMR (500 MHz, Methanol-d4) δ 8.67 (s, 1H), 8.00 (d, J=2.0 Hz, 1H), 7.81 (d, J=2.0 Hz, H), 7.72 (d, J=8.6 Hz, 1H), 7.67 (dd, J=7.9, 2.0 Hz, 1H), 7.30 (d, J=8.0 Hz, 1H), 7.14 (dd, J=8.6, 1.9 Hz, 1H), 3.54 (t. J=6.9 Hz, 2H), 2.62 (t, J=6.9 Hz, 2H), 2.55 (bs, 7H), 1.63 (p, J=5.6 Hz, 4H), 1.48 (s, 2H): 13C NMR (126 MHz, MeOD) δ 167.67, 157.22, 151.52, 142.74, 138.47, 137.87, 131.86, 130.23, 130.03, 129.45, 126.84, 123.62, 123.11, 121.39, 120.76, 98.20, 90.85, 87.12, 57.54, 54.11, 36.37, 25.05, 23.61, 20.02; HRMS (ESI+): calcd. for C26H28ClN4O (MH+) 447.1952. found 447.1946.
    • Example 80: 3-((3-amino-1-methylisoquinolin-4-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide (HSN375)
  • Figure US20210198208A1-20210701-C00317
  • 1H NMR (500 MHz, DMSO-d6) δ 10.53 (s, 1H), 8.34 (d, J=1.9 Hz, 1H), 8.21 (d, J=2.2 Hz, 1H), 8.06 (d, J=7.9 Hz, 1H), 8.02 (d, J=8.3 Hz, 1H), 7.97 (d, J=8.4 Hz, 1H), 7.85 (dd, J=7.9, 2.0 Hz, 1H), 7.70 (d, J=8.5H, 111), 7.66 (t, J=7.6 Hz, 111), 7.50 (d, J=8, 1 Hz, 1H), 7.28 (ddd, J=8.2, 6.8, 1.2 Hz, 1H), 6.44 (s, 2H), 3.58 (s, 2H), 2.77 (s, 3H), 2.63 (s, 3H), 2.57-2.37 (bs, 8H, merged with solvent), 2.29 (s, 3H); 13C NMR (126 MHz, DMSO) δ 165.60, 159.76, 156.89, 143.08, 138.78, 138.07, 132.75, 132.23, 131.77, 131.73, 131.19, 130.17, 127.73, 127.17, 123.95, 123.85, 123.29, 122.93, 121.10, 117.68, 97.47, 89.85, 88.16, 57.72, 54.77, 52.44, 49.07, 22.52, 21.39.
    • Example 81: 3-((3-amino-6-methylisoquinolin-4-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide (HSN379)
  • Figure US20210198208A1-20210701-C00318
  • 1H NMR (500 MHz, DMSO-d6) δ 10.54 (s, 1H), 8.81 (d, J=0.7 Hz, 1H), 8.35 (d, J=2.0 Hz, 1H), 8.21 (d, J=2.2 Hz, 1H), 8.05 (dd, J=8.5, 2.2 Hz, 1H), 7.87 (dd, J=8.0, 2.0 Hz, 1H), 7.80 (d, J=8.3 Hz, 1H), 7.74-7.72 (m, 1H), 7.70 (d, J=8.6 Hz, 1H), 7.51 (d, J=8.1 Hz, 1H), 7.13 (dd, J=8.3, 1.5 Hz, 1H), 6.48 (s, 2H), 3.56 (s, 2H), 2.65 (s, 3H), 2.47 (s, 3H), 2.37 (bs, 8H), 2.15 (s, 3H); 13C NMR (126 MHz, DMSO) δ 165.58, 158.09, 152.60, 143.24, 142.22, 138.70, 138.16, 132.79, 132.50, 131.72, 131.33, 130.21, 129.01, 127.88, 125.91, 125.34, 123.94, 123.74, 121.73, 120.96, 117.69, 97.80, 89.57, 89.32, 57.92, 55.20, 53.16, 46.19, 22.50, 21.33.
    • Example 82: 3-((3-amino-6-chloroisoquinolin-4-yl)ethynyl)-4-methyl-N-(4-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide (HSN380)
  • Figure US20210198208A1-20210701-C00319
  • 1H NMR (500 MHz, DMSO-d6) δ 10.73 (s, 1H), 8.93 (s, 1H), 8.40 (d, J=2.0 Hz, 1H), 8.30 (s, 1H), 8.15 (s, 1H), 7.96 (d, J=8.6 Hz, 1H), 7.89 (q, J=1.3, 0.7 Hz, 2H), 7.73 (s, 1H), 7.54 (d, J=8.1 Hz, 1H), 7.49 (s, 1H), 7.28 (dd, J=8.6, 2.0 Hz, 1H), 6.93 (d, J=22.1 Hz, 1H), 6.79 (s, 2H), 2.65 (s, 3H), 2.17 (s, 3H); 13C NMR (126 MHz, DMSO) δ 165.82, 162.76, 158.57, 153.26, 151.29, 143.66, 141.74, 138.75, 138.43, 137.41, 132.46, 131.66, 131.50, 131.20, 130.34, 128.07, 125.19, 123.59, 123.51, 121.32, 120.68, 115.35, 114.71, 112.14, 108.27, 103.70, 98.06, 88.71, 21.31, 14.07.
    • Example 83: 5-((3-amino-6-chloroisoquinolin-4-yl)ethynyl)-6-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)nicotinamide (HSN387)
  • Figure US20210198208A1-20210701-C00320
  • 1H NMR (500 MHz, DMSO-d6) δ 10.71 (s, 1H), 8.95 (d, J=2.3 Hz, 1H), 8.94 (s, 1H), 8.71 (d, J=2.3 Hz, 1H), 8.19 (d, J=2.2 Hz, 1H), 8.04 (dd, J=8.5, 2.2 Hz, 1H), 7.96 (d, J=8.6 Hz, 1H), 7.87 (d, J=2.0 Hz, 1H), 7.72 (d, J=8.5 Hz, 1H), 7.29 (dd. J=8.6, 2.0 Hz, 1H), 6.92 (s, 2H), 3.56 (s, 2H), 2.84 (s, 3H), 2.38 (s, 8H), 2.17 (s, 3H); 13C NMR (126 MHz, DMSO) δ 164.32, 162.10, 158.88, 153.71, 147.25, 138.80, 138.65, 138.39, 137.55, 132.83, 131.81, 131.70, 128.17, 127.81, 125.85, 123.97, 123.55, 121.28, 120.62, 119.14, 117.69, 96.27, 90.91, 88.11, 57.88, 55.13, 53.06, 46.07, 24.37.
    • Example 84: 3-((3-amino-6-chloroisoquinolin-4-yl)ethynyl)-N-(3,5-dichloro-4-(2-(dimethylamino)ethoxy)phenyl)-4-methylbenzamide (HSN391)
  • Figure US20210198208A1-20210701-C00321
  • 1H NMR (500 MHz, DMSO-d6) δ 10.47 (s, 1H), 8.92 (s, 1H), 8.34 (d, J=1.9 Hz, 1H), 7.96 (d, J=8.7 Hz, 1H), 7.94 (s, 2H), 7.88 (d, J=1.9 Hz, 1H), 7.84 (dd, J=8.0, 2.0 Hz, 1H), 7.52 (d, J=8.1 Hz, 1H), 7.28 (dd, J=8.6, 2.0 Hz, 1H), 6.79 (s, 2H), 4.02 (t. J=5.9 Hz, 2H), 2.68 (t, J=5.9 Hz, 2H), 2.63 (s, 3H), 2.23 (s, 6H); 13C NMR (126 MHz, DMSO) δ 165.52, 158.57, 153.24, 147.01, 146.90, 143.45, 138.75, 137.40, 136.77, 132.60, 131.66, 131.46, 130.27, 128.63, 128.50, 128.02, 123.52, 121.33, 120.70, 113.72, 98.09, 88.73, 72.09, 58.71, 45.95, 21.29.
    • Example 85: 3-((3-amino-6-chloroisoquinolin-4-yl)ethynyl)-N-(6-(2-(dimethylamino)ethoxy)pyridin-3-yl)-4-methylbenzamide (HSN392)
  • Figure US20210198208A1-20210701-C00322
  • 1H NMR (500 MHz, DMSO-d6) δ 10.32 (s, 1H), 8.92 (s, 1H), 8.50 (d, J=2.7 Hz, 1H), 8.36 (d, J=1.8 Hz, 1H), 8.03 (dd, J=8.9, 2.7 Hz, 1H), 7.96 (d, J=8.6 Hz, 1H), 7.89 (s, 1H), 7.86 (d, J=7.9 Hz, 1H), 7.50 (d, J=8.0 Hz, 1H), 7.28 (dd. J=8.6, 2.0 Hz, 1H), 6.82 (d, J=8.9 Hz, 1H), 6.79 (s, 2H), 4.30 (t, J=5.9 Hz, 2H), 2.63 (s, 3H), 2.59 (t, J=5.9 Hz, 2H), 2.19 (s, 6H); 13C NMR (126 MHz, DMSO) δ 165.24, 159.98, 158.55, 153.20, 143.06, 139.32, 138.75, 137.39, 133.09, 132.85, 131.66, 131.42, 130.36, 130.18, 127.96, 123.50, 121.34, 120.68, 110.71, 98.21, 88.80, 88.55, 63.90, 58.13, 45.98, 21.27.
    • Example 86: 3-((3-amino-6,7-dichloroisoquinoline-4-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide (HSN393)
  • Figure US20210198208A1-20210701-C00323
  • 1H NMR (500 MHz, DMSO-d6) δ 10.53 (s, 1H), 8.91 (s, 1H), 8.38 (d, J=1.9 Hz, 11), 8.27 (s, 1H), 8.20 (d, J=2.2 z, 111), 8.05 (d, J=7.1 Hz, 2H), 7.88 (dd, J=7.9, 2.0 Hz, 1H), 7.70 (d, J=8.5 Hz, 1H), 7.51 (d, J=8.1 Hz, 1H), 6.91 (s, 2H), 3.55 (s, 2H), 2.63 (s, 3H), 2.37 (s, 8H), 2.15 (s, 3H); 13C NMR (126 MHz, DMSO) 165.55, 158.60, 152.47, 143.36, 138.68, 137.06, 135.39, 132.84, 132.50, 131.72, 131.59, 130.67, 130.21, 128.14, 127.75, 124.96, 124.01, 123.94, 123.34, 121.29, 117.68, 98.38, 88.45, 88.16, 57.91, 55.17, 53.11, 46.13, 21.27.
    • Example 87: 3-((3-amino-6-fluoroisoquinoline-4-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide (HSN394)
  • Figure US20210198208A1-20210701-C00324
  • 1H NMR (500 MHz, Methanol-d4) δ 8.93 (s, 1H), 8.37 (d, J=1.9 Hz, 1H), 8.25 (d, J=2.2 Hz, 1H), 8.10-8.02 (m, 2H), 7.95 (dd. J=8.0, 2.0 Hz, 1H), 7.81 (d, J=8.4 Hz, 1H), 7.66 (dd, J=10.6, 2.4 Hz, 1H), 7.57 (d, J=8.0 Hz, 1H), 7.19 (td, J=8.8, 2.5 Hz, 1H), 3.69 (s, 2H), 2.74 (s, 3H), 2.56 (s, 8H), 2.35 (s, 3H); 13C NMR (126 MHz, MeOD) 165.94, 163.90, 157.90, 152.39, 143.40, 139.79, 138.30, 132.68, 132.55, 132.45, 132.37, 131.40, 130.88, 129.95, 127.77, 123.71, 123.45, 117.68, 113.24, 113.04, 109.71, 106.14, 105.96, 98.05, 88.03, 57.65, 54.78, 52.42, 44.91, 20.48.
    • Example 87: 3-((2-amino-6,7-dimethoxyquinazolin-4-yl)ethynyl)-N-(3,5-dichloro-4-(2-(dimethylamino)ethoxy)phenyl)-4-methylbenzamide (HSN400)
  • Figure US20210198208A1-20210701-C00325
  • 1H NMR (500 MHz, DMSO-d6) δ 10.49 (s, 1H), 8.29 (s, 1H), 7.97 (dd. J=8.1, 1.9 Hz, 1H), 7.94 (s, 2H), 7.58 (d, J=8.1 Hz, 1H), 7.33 (s, 1H), 6.88 (s, 1H), 6.58 (s, 2H), 4.03 (t. J=5.9 Hz, 2H), 3.90 (d, J=7.5 Hz, 6H), 2.70 (t. J=5.9 Hz, 2H), 2.67 (s, 3H), 2.24 (s, 6H); 13C NMR (126 MHz, DMSO) δ 164.81, 160.60, 156.82, 150.85, 149.47, 147.46, 147.06, 145.21, 136.68, 132.59, 132.09, 130.80, 130.00, 128.50, 121.33, 120.74, 115.04, 104.91, 103.95, 93.22, 90.54, 71.98, 58.65, 56.41, 55.95, 45.88, 21.10.
    • Example 88: 3-((2-amino-6,7-dimethoxyquinazolin-4-yl)ethynyl)-N-(6-(2-(dimethylamino)ethoxy)pyridin-3-yl)-4-methylbenzamide (HSN401)
  • Figure US20210198208A1-20210701-C00326
  • 1H NMR (500 MHz, DMSO-df) δ 10.37 (s, 1H), 8.50 (d, J=2.7 Hz, 1H), 8.31 (d, J=2.0 Hz, 1H), 8.04 (dd. J=8.9, 2.7 Hz, 1H), 7.99 (dd. J=8.0, 2.0 Hz, 1H), 7.57 (d, J=8.1 Hz, 1H), 7.34 (s, 1H), 6.88 (s, 1H), 6.83 (d, J=8.9 Hz, 1H), 6.59 (s, 2H), 4.31 (t, J=5.9 Hz, 2H), 3.90 (s, 3H), 3.89 (s, 3H), 2.68 (s, 3H), 2.60 (s, 2H), 2.20 (s, 6H); 13C NMR (126 MHz, DMSO) δ 164.54, 160.61, 160.02, 156.82, 150.84, 149.52, 147.46, 144.83, 139.33, 133.08, 132.86, 132.03, 130.73, 130.29, 129.97, 121.24, 115.04, 110.71, 104.92, 103.96, 93.38, 90.46, 63.86, 58.09, 56.41, 55.96, 45.94, 21.08.
    • Example 89: 3-((2-amino-9-methyl-9H-purin-6-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide (HSN403)
  • Figure US20210198208A1-20210701-C00327
  • 1H NMR (500 MHz, Methanol-d4) δ 8.20 (s, 1H), 8.12 (s, 2H), 7.94 (d, J=7.6 Hz, 1H), 7.88 (d, J=9.2 Hz, 1H), 7.73 (d, J=8.4 Hz, 1H), 7.41 (d, J=8.1 Hz, 1H), 3.71 (s, 3H), 3.64 (s, 2H), 2.73-2.43 (11H), 2.34 (s, 3H); 13C NMR (126 MHz, MeOD) δ 165.96, 160.53, 145.12, 140.63, 137.87, 132.48, 132.25, 131.53, 131.14, 129.77, 128.84, 128.53, 127.15, 125.42, 123.53, 121.30, 117.67, 117.62, 94.14, 87.90, 57.44, 54.52, 52.07, 44.38, 28.40, 19.54.
    • Example 90: 4-((3-amino-6-chloroisoquinolin-4-yl)ethynyl)-5-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)picolinamide (HSN404)
  • Figure US20210198208A1-20210701-C00328
  • 1H NMR (500 MHz, DMSO-d6) δ 10.94 (s, 1H), 8.96 (s, 1H), 8.69 (s, 1H), 8.57 (s, 1H), 8.38 (d, J=2.2 Hz, 1H), 8.16 (d, J=7.9 Hz, 1H), 7.97 (d, J=8.6 Hz, 1H), 7.87 (s, 1H), 7.69 (d, J=8.5 Hz, 11), 7.29 (dd, J=8.6, 2.0 Hz, 1), 7.11 (s, 21), 3.55 (s, 21), 2.65 (s, 311), 2.38 (s, 8H), 2.16 (s, 3H); 13C NMR (126 MHz, DMSO) δ 163.27, 159.25, 154.54, 149.38, 148.11, 139.01, 138.02, 137.74, 137.12, 132.94, 132.73, 131.78, 131.60, 124.35, 124.17, 123.57, 121.26, 120.59, 117.99, 96.18, 94.13, 87.32, 57.90, 55.17, 53.11, 46.12, 18.19.
    • Example 91: 3-((6,7-dimethoxyquinazolin-4-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide (HSN405)
  • Figure US20210198208A1-20210701-C00329
  • 1H NMR (500 MHz, DMSO-d6) δ 10.56 (s, 1H), 9.09 (s, 1H), 8.38 (s, 1 f), 8.20 (s, 1H), 8.03 (dd, J=16.2, 8.2 Hz, 2H), 7.70 (d, J=8.5 Hz, 1H), 7.59 (d, J=8.0 Hz, 1H), 7.56 (s, 1H), 7.40 (s, 1H), 4.02 (s, 3H), 4.00 (s, 3H), 3.55 (s, 2H), 2.71 (s, 3H), 2.39 (bs, 8H), 2.15 (s, 3H); 13C NMR (126 MHz, DMSO) δ 164.82, 156.92, 153.87, 151.69, 148.28, 147.81, 145.23, 138.58, 132.86, 132.61, 132.23, 131.73, 130.80, 130.29, 123.96, 121.18, 121.07, 117.70, 107.19, 103.15, 95.41, 90.31, 57.90, 56.40, 55.16, 53.10, 46.12, 21.12.
    • Example 92:3-((2-amino-9H-purin-6-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide (HSN408)
  • Figure US20210198208A1-20210701-C00330
  • 1H NMR (500 MHz, DMSO-d6) δ 10.58 (s, 1H), 8.25 (s, 1H), 8.21 (d, J=2.2 Hz, 1H), 8.11 (s, 1H), 8.06 (d, J=8.5 Hz, 1H), 7.98 (dd, J=8.0, 1.9 Hz, 1H), 7.70 (d, J=8.5 Hz, 1H), 7.55 (d, J=8.1 Hz, 1H), 6.52 (s, 2H), 3.56 (s, 2H), 2.60 (s, 3H), 2.38 (s, 8H), 2.17 (s, 3H). 13C NMR (126 MHz, DMSO) δ 164.93, 160.92, 155.15, 145.09, 142.20, 140.44, 138.62, 132.73, 132.55, 131.71, 131.57, 130.64, 129.74, 128.07, 127.74, 125.89, 124.01, 121.53, 117.74, 92.44, 90.21, 57.88, 55.12, 53.03, 46.04, 20.84.
    • Example 93: 3-((2-amino-6,7-dimethoxyquinazolin-4-yl)ethynyl)-N-(3-chloro-4-(2-(dimethylamino)ethoxy)phenyl)-4-methylbenzamide (HSN409)
  • Figure US20210198208A1-20210701-C00331
  • 1H NMR (500 MHz, DMSO-d6) δ 10.32 (s, 1H), 8.29 (d, J=2.0 Hz, 1H), 7.98 (dd, J=8.0, 1.9 Hz, 1H), 7.94 (d, J=2.5 Hz, 1H), 7.66 (dd, J=9.0, 2.6 Hz, 1H), 7.56 (d, J=8.1 Hz, 1H), 7.34 (s, 1H), 7.17 (d, J=9.0 Hz, 1H), 6.88 (s, 1H), 6.59 (s, 2H), 4.12 (t, J=5.7 Hz, 2H), 3.90 (s, 3H), 3.89 (s, 3H), 2.67 (s, 5H), 2.25 (s, 6H); 13C NMR (126 MHz, DMSO) δ 164.36, 160.60, 156.81, 150.83, 150.60, 149.52, 147.45, 144.77, 133.25, 133.06, 132.02, 130.69, 129.94, 122.36, 121.30, 121.22, 120.59, 115.04, 114.40, 104.91, 103.96, 93.40, 90.44, 67.84, 57.93, 56.40, 55.95, 46.10, 21.07.
    • Example 93: 3-((3-amino-6-chloroisoquinolin-4-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)benzamide (HSN415)
  • Figure US20210198208A1-20210701-C00332
  • 1H NMR (500 MHz, DMSO-d6) δ 10.26 (s, 1H), 8.92 (s, 1H), 8.35 (s, 1H), 7.96 (d, J=8.6 Hz, 1H), 7.89 (d, J=2.0 Hz, 1H), 7.85 (dd, J=8.0, 2.0 Hz, 1H), 7.72 (d, J=8.4 Hz, 2H), 7.49 (d, J=8.0 Hz, 1H), 7.28 (dd. J=8.6, 2.0 Hz, 1H), 7.26 (d, J=8.2 Hz, 2H), 6.78 (s, 2H), 3.43 (s, 2H), 2.63 (s, 3H), 2.42 (bs, 8H), 2.23 (s, 3H). 13C NMR (126 MHz, DMSO) δ 165.21, 158.53, 153.18, 142.89, 138.75, 138.46, 137.38, 133.34, 131.66, 131.44, 130.12, 129.62, 128.01, 123.50, 123.37, 121.34, 120.68, 120.63, 98.27, 88.83, 88.49, 61.93, 54.85, 52.42, 45.44, 21.25.
    • Example 94: 6-((3-amino-6-chloroisoquinolin-4-yl)ethynyl)-5-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)picolinamide (HSN416)
  • Figure US20210198208A1-20210701-C00333
  • 1H NMR (500 MHz, DMSO-d6) δ 10.85 (s, 1H), 8.98 (s, 1H), 8.35 (d, J=2.2 Hz, 1H), 8.17 (d, J=8.5 Hz, 1H), 8.06-8.00 (m, 2H), 7.99 (d, J=8.6 Hz, 1H), 7.94 (s, 1H), 7.72 (d, J=8.6 Hz, 1H), 7.31 (dd. J=8.6.2.0 Hz, 1H), 6.88 (s, 2H), 3.57 (s, 2H), 2.66 (s, 3H), 2.38 (s, 8H), 2.16 (s, 3H); 13C NMR (126 MHz, DMSO) δ 163.02, 159.17, 154.17, 148.08, 141.92, 139.53, 139.39, 138.90, 137.89, 137.71, 132.82, 131.75, 131.67, 124.16, 123.76, 121.94, 121.42, 120.71, 117.96, 97.81, 88.52, 87.59, 57.90, 55.13, 53.07, 46.07, 19.94.
    • Example 95: 3-((6-amino-1H-pyrazolo[3,4-d]pyrimidin-4-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide (HSN422)
  • Figure US20210198208A1-20210701-C00334
  • 1H NMR (500 MHz, DMSO-d6) δ 10.55 (s, 1H), 8.31 (d, J=2.0 Hz, 1H), 8.20 (d, J=2.2 Hz, 1H), 8.07 (d, J=1.2 Hz, 1H), 8.05 (dd. J=8.5, 2.3 Hz, 1H), 7.99 (dd, J=8.0, 2.0 Hz, 1H), 7.70 (d, J=8.6 Hz, 1H), 7.57 (d, J=8.1 Hz, 1H), 6.91 (s, 2H), 3.55 (s, 2H), 2.61 (s, 3H), 2.38 (s, 8H), 2.15 (s, 3H); 13C NMR (126 MHz, DMSO) δ 164.93, 162.69, 157.33, 145.26, 138.57, 133.48, 132.88, 132.64, 132.14, 131.73, 130.69, 130.15, 125.89, 124.00, 120.96, 109.69, 108.67, 92.11, 90.25, 57.92, 55.19, 53.15, 46.17, 20.90.
    • Example 96: 3-((6-amino-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide (HSN423)
  • Figure US20210198208A1-20210701-C00335
  • 1H NMR (500 MHz, DMSO-d6) 10.57 (s, 1H), 8.32 (d, J=2.0 Hz, 1H), 8.21 (d, J=2.2 Hz, 1H), 8.09 (s, 1H), 8.05 (dd, J=8.5, 2.2 Hz, 1H), 8.00 (dd, J=8.0, 2.0 Hz, 1H), 7.70 (d, J=8.5 Hz, 1H), 7.57 (d, J=8.1 Hz, 1H), 7.06 (s, 2H), 3.80 (s, 3H), 3.56 (s, 2H), 2.60 (s, 3H), 2.40 (s, 8H), 2.20 (s, 3H); 13C NMR (126 MHz, DMSO) δ 164.92, 162.68, 155.49, 145.39, 145.30, 138.61, 132.87, 132.58, 132.23, 131.74, 130.69, 130.21, 127.76, 125.88, 124.00, 120.86, 117.74, 109.03, 92.39, 90.05, 57.83, 55.00, 52.83, 45.83, 33.58, 20.90.
  • Figure US20210198208A1-20210701-C00336
    • Example 97:3-((2-amino-6,7-dimethoxyquinazolin-4-yl)ethynyl)-4-methyl-N-(2-(piperidin-1-yl)ethyl)benzamide (HSN432)
  • 1H NMR (500 MHz, Chloroform-d) δ 8.79 (s, 1H), 7.98 (d, J=1.9 Hz, 1H), 7.82 (dd. J=8.9, 5.6 Hz, 1H), 7.65 (dd. J=7.9, 2.0 Hz, 1H), 7.61 (dd. J=10.4, 2.5 Hz, 1H), 7.37 (d, J=8.0 Hz, 1H), 7.07 (td, J=8.6, 2.4 Hz, 1H), 6.52 (s, 1H), 5.25 (bs, 2H), 3.61 (q, J=5.9 Hz, 2H), 3.18-3.03 (m, 8H), 2.81 (t. J=6.1 Hz, 2H), 2.64 (s, 3H); 13C NMR (126 MHz, CDC) δ 166.75, 156.68, 151.74, 143.25, 132.13, 131.61, 131.53, 130.30, 130.06, 126.71, 123.56, 120.38, 14.22, 114.01, 107.15, 106.96, 98.35, 87.81, 55.53, 50.81, 37.01, 29.71, 21.30.
    • Example 98: 3-((2-amino-6,7-dimethoxyquinazolin-4-yl)ethynyl)-4-methyl-N-(2-(piperidin-1-yl)ethyl)benzamide (HSN433)
  • 1H NMR (500 MHz, DMSO-d6) δ 8.50 (t, J=5.6 Hz, 1H), 8.15 (d, J=1.9 Hz, 1H), 7.86 (dd, J=8.0, 1.9 Hz, 1H), 7.49 (d, J=8.1 Hz, 1H), 7.32 (s, 1H), 6.87 (s, 1H), 6.58 (s, 2H), 3.90 (s, 3H), 3.88 (s, 3H), 3.36 (q. J=6.6 Hz, 2H), 2.63 (s, 3H), 2.42 (t. J=7.1 Hz, 2H). 2.36 (bs, 4H), 1.47 (p, J=5.6 Hz, 4H), 1.36 (bs, 2H): 13C NMR (126 MHz, DMSO) δ 165.27, 160.60, 156.79, 150.80, 149.57, 147.43, 144.10, 133.07, 131.65, 130.54, 129.48, 121.07, 115.01, 104.91, 103.96, 93.56, 90.21, 58.14, 56.40, 55.93, 54.57, 37.52, 26.07, 24.52, 20.97.
    • Example 99: 3-((6,7-dimethoxyquinazolin-4-yl)ethynyl)-4-methyl-N-(2-(piperidin-1-yl)ethyl)benzamide (HSN434)
  • Figure US20210198208A1-20210701-C00337
  • 1H NMR (500 MHz, Chloroform-d) δ 9.14 (s, 1H), 8.16 (d, J=1.9 Hz, 1H), 7.81 (dd, J=8.0, 1.9 Hz, 1H), 7.57 (s, 1H), 7.38 (d, J=8.0 Hz, 1H), 7.33 (s, 1H), 7.25 (s, 1H), 4.08 (s, 3H), 4.08 (s, 3H), 3.59 (q, J=5.4 Hz, 2H), 2.70 (s, 3H), 2.65 (t. J=5.9 Hz, 2H), 2.54 (s, 4H), 1.67-1.63 (m, 4H), 1.48 (bs, 2H); 13C NMR (126 MHz, CDCl3) δ 166.27, 156.49, 153.78, 151.27, 148.58, 148.39, 144.26, 132.64, 131.68, 130.08, 128.56, 121.63, 121.53, 106.82, 103.20, 95.62, 89.89, 57.22, 56.58, 56.37, 54.35, 36.31, 25.54, 24.04, 21.09.
    • Example 100: 3-((8-amino-1,7-naphthyridin-5-yl)ethynyl)-N-(3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)-4-methylbenzamide (HSN445)
  • Figure US20210198208A1-20210701-C00338
  • 1H NMR (500 MHz, DMSO-d6) δ 10.29 (s, 1H), 8.88 (dd, J=4.2, 1.6 Hz, 1H), 8.46 (dd. J=8.4, 1.6 Hz, 1H), 8.24 (s, 1H), 8.16 (d, J=2.0 Hz, 1H), 7.88-7.82 (m, 2H), 7.69 (dd, J=15.1, 2.4 Hz, 1H), 7.52 (s, 2H), 7.50-7.45 (m, 2H), 7.06-6.99 (m, 1H), 2.98 (s, 4H), 2.59 (s, 3H), 2.48 (s, 4H, merged with DMSO peak), 2.23 (s, 3H): 13C NMR (126 MHz, DMSO) δ 164.82, 158.56, 153.76, 149.71, 148.18, 143.13, 136.19, 134.41, 133.14, 132.97, 132.53, 131.37, 130.69, 130.28, 127.94, 127.07, 123.37, 119.55, 116.79, 109.07, 102.13, 91.80, 90.46, 55.12, 50.58, 46.15, 21.17.
    • Example 101: 3-((2-amino-6,7-dimethoxyquinazolin-4-yl)ethynyl)-N-(3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)-4-methylbenzamide (HSN446)
  • Figure US20210198208A1-20210701-C00339
  • 1H NMR (500 MHz, DMSO-d6) δ 10.34 (s, 1H), 8.29 (d, J=2.0 Hz, 1H), 7.98 (dd, J=8.0, 2.0 Hz, 1H), 7.70 (dd. J=15.1, 2.4 Hz, 1H), 7.57 (d, J=8.1 Hz, 1H), 7.46 (dd. J=8.7, 1.5 Hz, 1H), 7.34 (s, 1H), 7.07-6.98 (m, 1H), 6.88 (s, 1H), 6.59 (s, 2H), 3.91 (s, 3H), 3.89 (s, 3H), 2.97 (s, 4H), 2.67 (s, 3H), 2.46 (s, 4H), 2.21 (s, 3H); 13C NMR (126 MHz, DMSO) δ 164.36, 160.61, 156.81, 153.74, 150.83, 149.52, 147.46, 144.75, 136.25, 133.13, 132.01, 130.70, 129.97, 121.20, 119.57, 116.74, 115.04, 109.03, 108.82, 104.92, 103.97, 93.41, 90.43, 56.41, 55.96, 55.18, 50.66, 46.26, 21.07.
    • Example 102: 3-((2-amino-6,7-dimethoxyquinazolin-4-yl)ethynyl)-N-(4-(2-(dimethylamino)ethoxy)phenyl)-4-methylbenzamide (HSN447)
  • Figure US20210198208A1-20210701-C00340
  • 1H NMR (500 MHz, DMSO-d6) δ 10.21 (s, 1H), 8.29 (d, J=1.9 Hz, 1H), 7.98 (dd, J=8.0, 2.0 Hz, 1H), 7.67 (d, J=9.1 Hz, 2H), 7.56 (d, J=8.1 Hz, 1H), 7.35 (s, 1H), 6.93 (d, J=9.1 Hz, 2H), 6.88 (s, 1H), 6.59 (s, 2H), 4.02 (t, J=5.9 Hz, 2H), 3.91 (s, 3H), 3.89 (s, 3H), 2.67 (s, 3H), 2.60 (t, J=5.8 Hz, 2H), 2.20 (s, 6H): 13C NMR (126 MHz, DMSO) δ 164.16, 160.61, 156.81, 155.32, 150.83, 149.56, 147.45, 144.50, 133.44, 132.55, 132.00, 130.64, 129.92, 122.38, 121.15, 115.04, 114.84, 104.92, 103.98, 93.52, 90.37, 66.42, 58.22, 56.41, 55.96, 46.06, 21.04.
    • Example 103: 5-((8-amino-1,7-naphthyridin-5-yl)ethynyl)-6-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)nicotinamide (HSN459)
  • Figure US20210198208A1-20210701-C00341
  • 1H NMR (500 MHz, DMSO-d6) δ 10.68 (s, 1H), 8.94 (d, J=2.3 Hz, 1H), 8.88 (dd, J=4.2, 1.6 Hz, 1H), 8.51 (d, J=2.2 Hz, 1H), 8.47 (dd, J=8.3, 1.6 Hz, 1H), 8.27 (s, 1H), 8.20 (d, J=2.2 Hz, 1H), 8.04 (dd. J=8.5, 2.2 Hz, 1H), 7.72 (d, J=8.5 Hz, 1H), 7.60 (s, 2H), 3.56 (s, 2H), 2.81 (s, 3H), 2.39 (s, 8H), 2.19 (s, 3H); 13C NMR (126 MHz, DMSO) δ 164.07, 162.31, 158.81, 149.79, 148.63, 147.41, 138.39, 137.88, 133.13, 132.79, 132.48, 131.80, 131.35, 127.97, 127.14, 124.00, 118.93, 117.74, 101.58, 92.83, 90.00, 57.84, 55.05, 52.93, 45.94, 24.30.
    • Example 104: 5-((1-aminoisoquinolin-4-yl)ethynyl)-6-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)nicotinamide (HSN461)
  • Figure US20210198208A1-20210701-C00342
  • 1H NMR (500 MHz, DMSO-d6) δ 10.66 (s, 1H), 8.93 (d, J=2.3 Hz, 1H), 8.48 (d, J=2.3 Hz, 1H), 8.29 (d, J=8.1 Hz, 1H), 8.22 (s, 1H), 8.20 (d, J=2.2 Hz, 1H), 8.11 (d, J=8.1 Hz, 1H), 8.04 (dd, J=8.4, 2.2 Hz, 1H), 7.81 (ddd, J=8.1, 6.9, 1.2 Hz, 1H), 7.72 (d, J=8.5 Hz, 1H), 7.58 (ddd, J=8.3, 6.9, 1.3 Hz, 1H), 7.45 (s, 2H), 3.56 (s, 2H), 2.81 (s, 3H), 2.37 (s, 8H), 2.14 (s, 3H); 13C NMR (126 MHz, DMSO) δ 164.08, 162.21, 158.42, 148.15, 147.27, 138.36, 137.64, 136.33, 132.87, 131.78, 131.71, 127.95, 126.86, 125.03, 124.74, 124.00, 119.15, 117.74, 116.71, 102.62, 94.26, 89.98, 57.91, 55.20, 53.18, 46.21, 24.30.
    • Example 105: 2-((8-amino-1,7-naphthyridin-5-yl)ethynyl)-5-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)thiazole-4-carboxamide (HSN482)
  • Figure US20210198208A1-20210701-C00343
  • 1H NMR (500 MHz, Methanol-d4) δ 8.85 (dd. J=4.3, 1.6 Hz, 1H), 8.41 (dd. J=8.3, 1.6 Hz, 1H), 8.19 (d, J=2.2 Hz, 11), 8.16 (s, 1H), 7.89 (dd. J=8.5, 2.2 Hz, 1H), 7.77 (dd. J=8.4, 4.2 Hz, 1H), 7.72 (d, J=8.5 Hz, 1H), 3.64 (s, 2H), 2.85 (s, 3H), 2.54 (s, 8H), 2.32 (s, 3H); 13C NMR (126 MHz, MeOD) δ 160.63, 158.73, 149.46, 147.71, 143.98, 143.00, 137.35, 132.56, 132.43, 131.13, 128.57, 126.49, 123.10, 117.26, 101.20, 90.03, 85.49, 57.45, 54.54, 52.12, 44.43, 11.54.
    • Example 106: 4-((1-aminoisoquinolin-4-yl)ethynyl)-3-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide (HSN485)
  • Figure US20210198208A1-20210701-C00344
  • 1H NMR (500 MHz, Methanol-d4) δ 8.18 (t, J=8.7 Hz, 2H), 8.11 (d, J=21.9 Hz, 2H), 7.93 (d, J=8.5 Hz, 1H), 7.88 (s, 1H), 7.80 (t, J=8.4 Hz, 2H), 7.75 (d, J=8.5 Hz, 1H), 7.65 (d, J=8.0 Hz, 1H), 7.59 (t, J=7.8 Hz, 1H), 3.64 (s, 2H), 2.66 (s, 3H), 2.51 (s, 8H), 2.29 (s, 3H); 13C NMR (126 MHz, MeOD) δ 166.84, 157.63, 145.29, 139.48, 137.88, 136.44, 133.42, 132.59, 131.24, 131.15, 131.10, 128.31, 127.22, 126.52, 124.78, 124.69, 123.78, 123.57, 117.71, 116.91, 104.82, 92.18, 91.36, 57.51, 54.59, 52.29, 44.58, 19.87.
    • Example 107: 4-((3-amino-6-chloroisoquinolin-4-yl)ethynyl)-3-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide (HSN486)
  • Figure US20210198208A1-20210701-C00345
  • 1H NMR (500 MHz, Methanol-d4) δ 8.79 (s, 1H), 8.14 (s, 1H), 7.95 (m, 2H), 7.90 (s, 1H), 7.85 (d, J=8.7 Hz, 1H), 7.81 (dd. J=8.0, 1.8 Hz, 1H), 7.76 (m, 2H), 7.25 (dd, J=8.7, 2.0 Hz, 1H), 3.67 (s, 2H), 2.69 (s, 3H), 2.61 (bs, 8H), 2.40 (s, 3H); 13C NMR (126 MHz, MeOD) δ 166.72, 157.47, 151.95, 139.46, 138.68, 138.09, 137.94, 133.86, 132.42, 131.49, 131.19, 130.41, 128.39, 126.61, 124.88, 123.71, 123.59, 121.38, 120.85, 117.78, 98.24, 90.49, 88.94, 57.39, 54.44, 51.86, 44.17, 20.04.
    • Example 108: 4-((1-aminoisoquinolin-4-yl)ethynyl)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide (HSN489)
  • Figure US20210198208A1-20210701-C00346
  • 1H NMR (500 MHz, Methanol-d4) δ 8.18 (t. J=9.3 Hz, 2H), 8.13 (d, J=2.3 Hz, 1H), 8.08 (s, 1H), 7.98 (d, J=8.6 Hz, 2H), 7.94 (dd, J=8.4, 2.3 Hz, 1H), 7.81 (ddd, J=8.2, 6.9, 1.2 Hz, 1H), 7.76 (d, J=8.5 Hz, 1H), 7.71 (d, J=8.6 Hz, 2H), 7.60 (ddd, J=8.3, 7.0, 1.3 Hz, 1H), 3.65 (s, 2H), 2.52 (s, 8H), 2.30 (s, 3H); 13C NMR (126 MHz, MeOD) δ 166.67, 157.66, 145.36, 137.86, 136.51, 133.47, 132.65, 131.18, 131.12, 130.88, 128.83, 127.54, 126.53, 124.72, 123.75, 123.61, 117.76, 116.90, 104.56, 92.42, 88.07, 57.50, 54.58, 52.27, 44.56.
    • Example 109: 4-((3-amino-6-chloroisoquinolin-4-yl)ethynyl)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide (HSN490)
  • Figure US20210198208A1-20210701-C00347
  • 1H NMR (500 MHz, DMSO-d6) δ 10.56 (s, 1H), 8.92 (s, 1H), 8.21 (s, 1H), 8.06 (s, 1H), 8.04 (d, J=8.3 Hz, 2H), 7.99-7.91 (L, 3H), 7.89 (s, 1H), 7.70 (d, J=8.5 Hz, 1H), 7.28 (dd, J=8.6, 2.0 Hz, 1H), 6.89 (s, 2H), 3.56 (s, 2H), 2.38 (s, 8H), 2.17 (s, 3H); 13C NMR (126 MHz, DMSO) δ 165.49, 158.82, 153.50, 138.78, 138.64, 137.48, 133.93, 132.55, 131.71, 131.61, 128.35, 126.85, 124.05, 123.56, 121.34, 120.62, 117.77, 99.50, 88.25, 86.55, 57.88, 55.11, 53.02, 46.03.
    • Example 110: 3-((8-amino-1,7-naphthyridin-5-yl)ethynyl)-4-methyl-N-(4-(morpholinomethyl)-3-(trifluoromethyl)phenyl)benzamide (HSN514)
  • Figure US20210198208A1-20210701-C00348
  • 1H NMR (500 MHz, DMSO-d6) δ 10.53 (s, 1H), 8.88 (d, J=4.3 Hz, 1H), 8.45 (d, J=8.4 Hz, 1H), 8.24 (s, 1H), 8.21 (d, J=8.8 Hz, 2H), 8.09-8.04 (m, 1H), 7.87 (d, J=9.2 Hz, 1H), 7.86-7.82 (m, 1H), 7.72 (d, J=8.5 Hz, 1H), 7.53 (s, 2H), 7.51 (d, J=8.0 Hz, 1H), 3.62-3.52 (m, 6H), 2.60 (s, 3H), 2.37 (s, 4H); 13C NMR (126 MHz, DMSO) 165.33, 158.56, 149.71, 148.19, 143.43, 138.75, 133.12, 132.67, 132.52, 132.00, 131.83, 131.35, 130.78, 130.34, 128.04, 127.84, 127.06, 125.88, 123.94, 123.42, 117.74, 102.10, 91.74, 90.53, 66.69, 58.33, 53.76, 21.19.
    • Example 111: 3-((8-amino-1,7-naphthyridin-5-yl)ethynyl)-N-(4-((4-ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-4-methylbenzamide (HSN515)
  • Figure US20210198208A1-20210701-C00349
  • 1H NMR (500 MHz, DMSO-d6) δ 10.52 (s, 1H), 8.88 (dd. J=4.2.1.6 Hz, 1H), 8.46 (dd, J=8.3, 1.6 Hz, 1H), 8.24 (s, 1H), 8.20 (dd, J=4.0, 2.1 Hz, 2H), 8.06 (dd. J=8.5, 2.2 Hz, 1H), 7.86 (ddd, J=12.6, 8.1, 3.1 Hz, 2H), 7.70 (d, J=8.5 Hz, 1H), 7.53 (s, 2H), 7.51 (d, J=8.1 Hz, 1H), 3.55 (s, 2H), 2.60 (s, 3H), 2.47-2.23 (bs, 10H), 0.97 (1, J=7.1 Hz, 3H); 13C NMR (126 MHz, DMSO) δ 165.32, 158.57, 149.71, 148.19, 143.42, 138.65, 133.12, 132.69, 132.52, 131.67, 131.36, 130.79, 130.34, 128.03, 127.71, 127.07, 123.98, 123.72, 123.42, 117.73, 102.10, 91.74, 90.53, 57.93, 53.27, 52.82, 52.03, 21.19, 12.45.
    • Example 112: 5-((1-aminoisoquinolin-4-yl)ethynyl)-1-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-1H-pyrazole-3-carboxamide (HSN516)
  • Figure US20210198208A1-20210701-C00350
  • 1H NMR (500 MHz, DMSO-d6) δ 10.50 (s, 1H), 8.31-8.27 (m, 2H), 8.23 (s, 1H), 8.06 (dd, J=8.5, 2.2 Hz, 1H), 8.03 (d, J=8.3 Hz, 1H), 7.79 (ddd, J=8.2.6.9, 1.2 Hz, 1H), 7.66 (d, J=8.5 Hz, 11H), 7.58 (ddd, J=8.3, 6.9, 1.2 Hz, 1H), 7.50 (s, 2H), 7.13 (s, 1H), 4.10 (s, 311), 3.55 (s, 21), 2.39 (bs, 8H), 2.19 (s, 311); C NMR (126 MHz, DMSO) δ 160.11, 158.62, 148.44, 145.71, 138.34, 136.18, 132.29, 131.82, 131.59, 128.01, 126.93, 125.04, 124.68, 123.96, 117.70, 116.61, 110.76, 101.63, 95.36, 80.85, 57.85, 55.06, 52.93, 45.94, 38.36.
    • Example 113: 3-((6-amino-4-cyanopyridin-3-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide (HSN517)
  • Figure US20210198208A1-20210701-C00351
  • 1H NMR (500 MHz, DMSO-d6) δ 10.53 (s, 1H), 8.38 (d, J=0.7 Hz, 1H), 8.19 (d, J=2.3 Hz, 1H), 8.09 (d, J=2.0 Hz, 1H), 8.04 (dd. J=8.5, 2.2 Hz, 1H), 7.89 (dd, J=8.0, 2.0 Hz, 1H), 7.69 (d, J=8.5 Hz, 1H), 7.49 (d, J=8.1 Hz, 1H), 7.07 (s, 2H), 6.84 (d, J=0.8 Hz, 1H), 3.55 (s, 2H), 2.54 (s, 3H), 2.38 (s, 8H), 2.18 (s, 3H); 13C NMR (126 MHz, DMSO) δ 165.18, 159.51, 153.13, 143.94, 138.63, 132.70, 132.49, 131.71, 130.83, 130.43, 128.54, 127.74, 123.98, 122.52, 122.29, 117.69, 116.64, 111.01, 106.74, 92.10, 89.37, 57.86, 55.09, 52.99, 46.00, 20.93.
    • Example 114: General Procedure for Preparation of Compounds in Table 4
  • 6-chloroisoquinolin-3-amine (3.2 mmol) was iodinated by N-Iodosuccinimide (675 mg) and purified by flash column (part 1), 4-ethynylbenzaldehyde (1 eq) was dissolved in tert-butyl alcohol and the corresponding diamine (1 eq) was added and stirred for 1 hour at room temperature, 1.1 eq of iodine and 3 eq of potassium carbonate were added and the mixture was reflux overnight. Crude product was subject to column purification (part 2). Pure part 1 (50 mg), 10 mol % Bis(triphenylphosphine)palladium(i) dichloride, 10 mol % triphenylphosphine were added, purged with nitrogen three times before anhydrous DMF (5 mL) was added. The reaction mixture was stirred at 45° C. for another 5 minutes before the corresponding pure part 2 (1.1 eq) was added via syringe in 1 ml anhydrous DMF in 2 minutes. DIPEA (2 mL) was subsequently added and stirred overnight. Crude product was subject to column purification.
    • Example 115: Synthesis Procedure for HSM1859
  • Following the same procedure above, 6-chloroisoquinolin-3-amine (3.2 mmol) was iodinated by N-Iodosuccinimide (675 mg) and purified by flash column. To a solution of iodo compound (1 equiv). Pd(PPh3)4 (20 mol %) and cesium carbonate (1 equiv) in 1,4-dioxane/water (1 mL) were de-oxygenated using steam of Argon gas. A de-oxygenated solution of 4-nonylbenzonitrile (0.49 mmol, 1.5 equiv) in DMF (3 mL) was added slowly over a period of 15 min to the solution and the reaction temperature was increased to 70° C. and allowed to stir 12 h. The reaction was quenched by addition of water (5 mL) at room temperature and subject to flash column purification. After purification, it was dissolved in 2 mL absolute ethanol and 1 mL of hydroxylamine solution was added and reflux for 6 hours. After TLC showed complete consumption of starting material, ethanol was removed in vacuo and pure product was obtained by flash column chromatography.
    • Example 116: 6-chloro-4-((4-(4,5-dihydro-1H-imidazol-2-yl)phenyl)ethynyl)isoquinolin-3-amine (HSM1651)
  • Figure US20210198208A1-20210701-C00352
  • Following the described general procedure IV, yellow solid was obtained. 1H NMR (500 MHz, DMSO-d6) δ 8.92 (s, 1H), 7.96 (d, J=8.6 Hz, 1H), 7.93-7.81 (m, 5H), 7.28 (dd, J=8.6, 1.8 Hz, 1H), 6.85 (s, 2H), 3.68 (s, 4H) 13C NMR (125 MHz, DMSO-d6) δ 163.73, 158.70, 153.30, 138.73, 137.42, 131.64, 131.56, 129.45, 127.78, 125.60, 123.52, 121.33, 120.61, 99.69, 88.45, 85.91, 49.51; HRMS (ESI+) [M+H] calcd for C20H16ClN4 347.1063, found 347.1057.
    • Example 117: 6-chloro-4-((4-(1-(2-(piperidin-1-yl)ethyl)-4,5-dihydro-1H-imidazol-2-yl)phenyl)ethynyl)isoquinolin-3-amine
  • Figure US20210198208A1-20210701-C00353
  • Following the described general procedure IV, yellow solid was obtained. 1H NMR (500 MHz, DMSO-d6) δ 8.93 (s, 1H), 7.99-7.78 (m, 6H), 7.29 (dd. J=8.6, 2.0 Hz, 1H), 6.86 (s, 2H), 3.53-3.46 (m, 2H), 3.42 (dd, J=7.9, 3.1 Hz, 2H), 3.25-3.16 (m, 2H), 2.38 (dd. J=24.1, 22.3 Hz, 6H), 1.55-1.47 (m, 4H), 1.39 (s, 2H); C NMR (126 MHz, DMSO-d6) δ 206.36, 166.05, 158.59, 157.55, 153.58, 138.92, 137.12, 133.90, 131.37, 128.40, 126.15, 123.15, 121.23, 120.71, 99.32, 88.09, 86.12, 72.35, 67.21, 60.93, 54.76, 45.46, 32.08, 26.11, 23.84; HRMS (ESI+) [M+H] calcd for C27H29ClN5 458.2111, found 458.2110.
    • Example 118: 6-chloro-4-((4-(4-cyclopropyl-4,5-dihydro-1H-imidazol-2-yl)phenyl)ethynyl)isoquinolin-3-amine
  • Figure US20210198208A1-20210701-C00354
  • Following the described general procedure IV, yellow solid was obtained. 1H NMR (500 MHz, MeOD) δ 8.83 (s, 1H), 7.88 (ddd, J=62.4, 45.2, 5.0 Hz, 6H), 7.29 (dd, J=8.7, 1.9 Hz, 1H), 4.05-3.90 (m, 1H), 3.67 (dd. J=11.9, 8.0 Hz, 1H), 3.53 (dd, J=18.2, 7.9 Hz, 1H), 1.10-0.98 (m, 1H), 0.66-0.29 (n, 4H). HRMS (ESI+) [M+H] calcd for C23H20ClN4 387.1376, found 387.1.
    • Example 119: 6-chloro-4-((4-(4,4-dimethyl-4,5-dihydro-1H-imidazol-2-yl)phenyl)ethynyl)isoquinolin-3-amine
  • Figure US20210198208A1-20210701-C00355
  • Following the described general procedure IV, yellow solid was obtained. 1H NMR (500 MHz, MeOD) δ 8.75 (s, 1H), 7.88 (d, J=1.2 Hz, 1H), 7.81 (d, J=7.4 Hz, 3H), 7.70 (d, J=8.2 Hz, 2H), 7.22 (dd, J=8.7, 1.9 Hz, 1H), 3.53 (s, 2H), 1.35 (s, 6H); 13C NMR (126 MHz, MeOD) δ 162.62, 157.51, 151.80, 138.75, 138.02, 131.01, 130.32, 129.49, 127.18, 125.73, 123.67, 121.34, 120.78, 99.38, 90.34, 84.27, 62.77, 61.61, 27.34; HRMS (ESI+) [M+H] calcd for C22H20ClN4 350.1376, found 375.1368.
    • Example 120: 4-((4-(4,5-dihydro-1H-imidazol-2-yl)phenyl)ethynyl)-1H-pyrrolo[2,3-c]pyridin-5-amine
  • Figure US20210198208A1-20210701-C00356
  • Following the described general procedure IV, yellow solid was obtained. 1H NMR (500 MHz, MeOD) δ 8.27 (s, 1H), 7.90 (d, J=8.5 Hz, 2H), 7.79 (d, J=8.5 Hz, 2H), 7.53 (d, J=2.9 Hz, 1H), 6.50 (dd J=2.8, 0.7 Hz, 1H), 3.96 (s, 4H); 13C NMR (126 MHz, MeOD) δ 165.52, 153.08, 143.40, 136.88, 133.96, 132.14, 131.63, 131.27, 128.33, 128.20, 127.85, 99.54, 96.35, 87.85, 41.16; HRMS (ESI) [M+H] calcd for C18H16N5 302.1406, found 302.1399.
    • Example 121: 4-((4-(4,5-dihydro-1H-imidazol-2-yl)phenyl)ethynyl)cinnolin-3-amine
  • Figure US20210198208A1-20210701-C00357
  • Following the described general procedure IV, yellow solid was obtained. 1H NMR (500 MHz, DMSO-d6) δ 8.19 (d, J=8.5 Hz, 1H), 8.03 (d, J=2.1 Hz, 1H), 7.91 (d, J=11.9 Hz, 3H), 7.75-7.68 (m, 1H), 7.56-7.48 (m, 1H), 7.11 (d, J=17.1 Hz, 3H), 3.62 (s, 4H); 13C NMR (126 MHz, DMSO-d6) δ 163.46, 157.83, 145.17, 132.88, 132.59, 132.25, 131.49, 130.35, 127.69, 127.32, 126.36, 125.17, 124.06, 123.77, 103.13, 94.50, 83.62, 41.23; HRMS(ESI+) [M+H] calcd for C19H16N5 314.1406. found 314.1396.
    • Example 122: 4-((3-amino-6-chloroisoquinolin-4-yl)ethynyl)benzonitrile
  • Figure US20210198208A1-20210701-C00358
  • Following the described general procedure IV, yellow solid was obtained. 1H NMR (500 MHz, DMSO-d6) δ 8.91 (s, 1H), 7.91 (ddd, J=12.4, 9.9, 5.0 Hz, 6H), 7.26 (d, J=8.6 Hz, 1H), 6.95 (s, 2H); 13C NMR (126 MHz, DMSO-d6) δ 159.04, 153.96, 138.83, 137.63, 132.78, 132.41, 131.61, 128.36, 123.61, 121.33, 120.58, 119.18, 110.60, 98.86, 88.51, 87.73; HRMS (ESI) [M+H] calcd for C18H11ClN3 304.0642, found 304.1411.
    • Example 123: 4-((4-(4,5-dihydro-1H-imidazol-2-yl)phenyl)ethynyl)isoquinoline
  • Figure US20210198208A1-20210701-C00359
  • Following the described general procedure IV, yellow solid was obtained. 1H NMR (500 MHz, DMSO-d6) δ 9.37 (s, 1H), 8.79 (s, 11H), 8.35 (d, J=8.2 Hz, 1H), 8.24 (d, J=8.0 Hz, 1H), 7.96 (dd, J=19.4, 7.8 Hz, 3H), 7.81 (dd, J=13.7, 7.7 Hz, 3H), 3.65 (s, 4H); 13C NMR (126 MHz, DMSO-d6) δ 163.43, 153.15, 146.66, 134.95, 132.48, 131.96, 131.31, 128.96, 128.85, 127.93, 127.85, 124.84, 124.02, 115.01, 96.65, 86.36, 50.06. HRMS (ESI+) [M+] calcd for C20H16N3 298.1344, found 298.1341.
    • Example 124: 3-((3-amino-6-chloroisoquinolin-4-yl)ethynyl)-N-hydroxybenzimidamide
  • Figure US20210198208A1-20210701-C00360
  • Following the described general procedure IV, yellow solid was obtained. 1H NMR (500 MHz, DMSO-d6) δ 9.75 (s, 1H), 8.92 (s, 1H), 8.04 (s, 1H), 7.96 (d, J=8.6 Hz, 1H), 7.88 (s, 1H), 7.78 (d, J=7.5 Hz, 1H), 7.72 (d, J=7.8 Hz, 1H), 7.46 (t, J=7.7 Hz, 1H), 7.28 (d, J=8.5 Hz, 1H), 6.80 (s, 2H), 5.93 (s, 2H); 13C NMR (126 MHz, DMSO-d6) δ 158.57, 153.00, 150.66, 138.73, 137.33, 134.15, 132.13, 131.55, 128.89, 128.65, 125.84, 123.48, 123.22, 121.31, 120.63, 99.88, 88.73, 83.91. HRMS (ESI+) [M+] calcd for C18H14ClN4O, 337.0856. found 337.0873.
    • Example 125:4-((3-amino-6-chloroisoquinolin-4-yl)eth yl)-N-hydroxybenzimidamide
  • Figure US20210198208A1-20210701-C00361
  • Following the described general procedure IV, yellow solid was obtained. 1H NMR (500 MHz, DMSO-d6) δ 9.79 (s, 1H), 8.91 (s, 1H), 7.95 (d, J=8.6 Hz, 1H), 7.88 (d, J=1.4 Hz, 1H), 7.80-7.72 (m, 4H), 7.27 (dd, J=8.6, 1.9 Hz, 1H), 6.80 (s, 2H), 5.90 (s, 2H); 13C NMR (126 MHz, DMSO-d6) δ 158.53, 153.00, 150.71, 138.69, 137.32, 133.41, 131.53, 125.81, 123.66, 123.47, 121.35, 120.62, 99.94, 88.76, 84.85. HRMS (ESI+) [M+H] calcd for C18H14ClN4O, 337.0856. found 337.0865.
    • Example 126: (E)-4-(2-(3-amino-6-chloroisoquinolin-4-yl)vinyl)-N-hydroxybenzimidamide
  • Figure US20210198208A1-20210701-C00362
  • Following the described synthesis procedure V, yellow solid was obtained. 1H NMR 500 MHz, DMSO-d6) δ 9.66 (d, J=6.2 Hz, 1H), 8.88-8.75 (m, 1H), 7.89 (dt, J=17.8, 5.5 Hz, 2H), 7.77-7.63 (m, 4H), 7.33 (t, J=17.4 Hz, 1H), 7.28-7.09 (m, 1H), 7.06-6.94 (m, 1H), 6.24 (s, 2H), 5.83 (s, 2H), 13C NMR (126 MHz, DMSO-d6) δ 154.75, 151.48, 151.00, 138.28, 136.75, 136.24, 134.02, 132.80, 131.32, 126.82, 125.88, 122.80, 122.59, 121.50, 121.20, 104.46, HRMS (ESI+) [M+H] calcd for C18H16ClN4O, 339.1013, found 339.1010.
    • Example 127: Activity Studies Against AML Cell Line, MV4-11
  • Cells were added to 96 well plates at 2000 cells per well for adherent lines and 4000 cells per well for suspension lines and kept in an incubator overnight. The following day the plates were treated with compounds to give rise to the final concentrations of; 100 μM, 10 μM, 5 μM 1 μM, 500 nM, 100 nM, 10 nM, 10 μM. The plates were then stored in the incubator for 72 hours. On the third day the cells were assayed with 20 μL of CellTiter—Blue Cell Viability Assay per well and were incubated for 4 hours. After 4 hours' fluorescence intensity was taken on a plate reader: Excitation: 560/10 Emission: 590/10. IC50 analysis was performed on GraphPad Prism 7.
  • TABLE 1
    Selected IC50 values against AML cell line, MV4-11
    Compound IC50 against MV4-11/uM
    HSM1661 0.016
    HSM1611 0.840
    HSM1617 0.770
    HSM1651 0.008
    HSM1688 0.250
    HSM1669 0.260
    M731 0.036
    HSM1674 0.110
    HSM1673 0.011
    HSM1692 0.450
    HSM1693 0.030
    HSM1702 0.003
    HSM1683 0.003
    HSM1684 0.071
    HSM1690 3.090
    HSM1717 0.050
    HSM1721 0.015
    HSM1725 0.008
    HSN105 0.061
    HSN122 0.009
    HSN129 0.008
    HSN135 0.033
    HSN136 0.095
    HSN137 0.006
    HSD48 0.028
  • TABLE 2
    IC50 against MV4-11 (AML cell line)
    Compound IC50 (nM)
    HSM1683 42.1 ± 1.3 
    HSM1693 14.8 ± 1.4 
    HSM1702 5.5 ± 1.3
    HSM1662 6.2 ± 1.3
    HSM1673 25.0 ± 1.4 
    • Example 128: In Vitro Kinase Assays
  • The Reaction Biology Corporation (www.reactionbiology.com Malverm, Pa.) HotSpot assay platform was used to measure kinase/inhibitor interactions exactly as previously described. Kinase and substrate were mixed in a buffer containing 20 mM HEPES pH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT and 1% DMSO. Single-dose of compounds (500 nM) were then added to each reaction mixture. After 20-minute incubation. ATP (Sigma) and [γ-33P] ATP (Perkin Elmer) were added at a final total concentration of 100 μM for addition 2 hours at room temperature, followed by spotting onto P81 ion exchange cellulose chromatography paper (Whatman, Inc.). Filter paper was washed in 0.75% phosphoric acid to remove unincorporated ATP. Percent remaining kinase activity of a vehicle (DMSO) containing kinase reaction was calculated for each kinase/inhibitor pair using Prism 5 (GraphPad). At a concentration of 500 nM, HSM1856 inhibits 70% of BTK (Bruton's tyrosine kinase) activity and HSN325 blocks 96% of RET activity.
  • IC50 proliferation assay—Cell lines and primary cells we seeded into 96-well plates the afternoon prior to treatment. Approximately 18 hours later, compounds were semi-serially diluted in dimethyl sulfoxide (DMSO) and then growth medium, and added to cells. Plates were incubated for 72 hours prior to addition of Alamar Blue (Life Technologies, Carlsbad. Calif.). Plates were read after 4 additional hours of incubation at 37° C. using a Bio-Tek Synergy HT plate reader (Bio-Tek, Winooski. Vt.). Data was analyzed and graphed using GraphPad Prism Software (Graphpad, La Jolla, Calif.). Experimental results are summarized in Table 3.
  • TABLE 3
    Anti-Tumor Activities of Selected Compound
    Compound Cell line - MV4-11 Cell line - K562
    HSN248 0.225 μM 0.007 μM
    HSN178 0.171 μM 1.443 μM
    HSN247 0.154 μM 0.025 μM
    HSM1702 0.071 μM 5.057 μM
    HSN315  0.54 μM 0.203 μM
    HSN316 0.759 μM 0.759 μM
    HSN317 n/a* 1.483 μM
    HSN285 0.722 μM 1.102 μM
    HSN286 0.0004 μM  n/a
    HSN325 0.135 μM 0.444 μM
    HSN334 0.001 μM 0.006 μM
    HSN353 0.003 μM 0.005 μM
    HSN352 0.003 μM 0.002 μM
    HSN356 0.0004 μM  0.002 μM
    HSM1795  0.1 μM n/a
    HSM1856 0.025 μM n/a
    *n/a: not determined.

    IC50 (proliferation inhibition) against leukemia cell lines MV4-11 and K562. HSM1856 also inhibited MiaPaca-2 and HLY-1 with IC50 of 0.4 and 0.08 μM respectively. MiaPaca-2 (Pancreatic cell line), HLY-1 (Lymphoma cell line), MV4-11 (AML cell line) and K562 (CML cell line).
    • Example 129: Inhibition of FLT3, FLT3 ITD and FLT3 D835Y
  • The compounds of the invention are μFLT3 inhibitors (Table 4 for percentage enzymatic inhibition at 0.5 μM compounds). Detailed characterization of one of HSM1651 revealed that it inhibited FLT3, FLT3 ITD and FLT3 D835Y with IC50 values of 40 nM, 100 nM and 56 nM respectively (FIG. 8A).
  • TABLE 4
    FLT3 inhibition profile and anti-poliferative activities of the compounds of the
    innvention against different leukemia cancer cell lines.
    Anti-proliferative effects
    in leukemia panel (μM)
    MV4-11a
    MOLM14b
    THPc
    % Inhibition of kinases K-562d
    Entry Structure FLT3 at 500 nM HL60 e
     1
    Figure US20210198208A1-20210701-C00363
         		92 0.15 ± 0.01a 0.15 ± 0.01b 1.20 ± 0.20c 3.00 ± 0.96d
     2
    Figure US20210198208A1-20210701-C00364
         		60 0.05 ± 0.01a 0.11 ± 0.02b 1.85 ± 0.92c 1.39 ± 0.01d 3.05 ± 0.07e
     3
    Figure US20210198208A1-20210701-C00365
         		43 0.30 ± 0.20a 0.10 ± 0.02b
     4
    Figure US20210198208A1-20210701-C00366
         		51 0.08 ± 0.02a 0.30 ± 0.08b
     5
    Figure US20210198208A1-20210701-C00367
         		56 0.07 ± 0.02a 0.30 ± 0.01b
     6
    Figure US20210198208A1-20210701-C00368
         		 1 >5a >5b
     7
    Figure US20210198208A1-20210701-C00369
         		34 >5a >5b
     8
    Figure US20210198208A1-20210701-C00370
         		 6 >5a >5b
     9
    Figure US20210198208A1-20210701-C00371
         		21 >5a >5b
    10
    Figure US20210198208A1-20210701-C00372
         		36 >5a >5b
    11*
    Figure US20210198208A1-20210701-C00373
         		61 0.04 ± 0.01a 0.05 ± 0.03b
    12*
    Figure US20210198208A1-20210701-C00374
         		54 0.02 ± 0.01a 0.06 ± 0.01b
    13*
    Figure US20210198208A1-20210701-C00375
         		41 0.35 ± 1.17a
    14
    Figure US20210198208A1-20210701-C00376
         		98 0.001 ± 0.001a 0.001 ± 0.001b
    15
    Figure US20210198208A1-20210701-C00377
         		99 0.005 ± 0.001a 0.004 ± 0.001b
    a-e: these correlate the cell lines tested to respective IC50.
    *hydroxyamidines may be acting as prodrugs of amidines in these cellular assays.
    • Example 130: Inhibition of c-Kit and TrkC Enzymes
  • The compounds of the invention inhibited c-Kit and TrkC enzymes. Table 5 provides % inhibition of TrkC/c-Kit activities by compounds with stable linkers at concentration of 500 nm, in the presence of 100 μM radiolabeled ATP.
  • TABLE 5
    % Inhibition of Trkc/C-Kit Activities
    % inhibition % inhibition
    Compound of TrkC at of c-Kit at
    Entry name 500 nM 500 nM
    1 HSW630-1 99% 68%
    2 HSM1651 64% 83%
    3 HSM1703 49% 60%
    4 HSM1721 52% 80%
    5 HSM1743 44% 78%
    7 HSM1611 16% 63%
    8 HSM1796  7%  5%
    9 HSM1798 11% 15%
    10 HSM1813 17% 39%
    11 HSM1820 74% 86%
    11 HSM1819 80% 82%
    13 HSM1859 42% 62%
  • The compounds of the invention could also potently inhibit AML cell lines (Table 5). Western analysis of MV4-11, treated with HSM1651, revealed that FLT3 phosphorylation as well as the downstream STAT5 phosphorylation were reduced in the presence of HSM1651 (FIGS. 8B and 8C). A few of the alkyne analogs have respectable anti-proliferative properties (HSM1819 has an IC50 value of 20 nM, which is only four times less potent than crenolanib (IC50=5 nM), which proceeded to clinical trials). Regarding structure-activity-relationship studies of the alkyne/alkene analogs, it appears that modifications to the isoquinoline ring greatly affected both kinase inhibition and anti-proliferative activity. For the alkyne series, HSM1813 (11 at 3-position and also lacking Cl at 6-position) was not a potent inhibitor of MV4-11 proliferation (Table 5, entry 10). HSM1651 (amino at 3-position and Cl at 6-position) is a good inhibitor of MV4-11 and MOLM-14 proliferation whereas compounds HSM1781, 1798 and 1796, which differed from HSM1651 at the isoquinoline part, are ineffective anti-proliferative agents in AML cell lines. The amidine group also appears to be important for anti-proliferative activity. The cyano analog HSM1611 is ineffective against MV4-11 and MOLM-14 whereas the hydroxyamidine analog (HSM1819), which is derived from HSM1611, is a very potent anti-proliferative in AML cell lines. The hydroxyamidine HSM1819 inhibits FLT3 and FLT3 ITD with IC50 of 217 and 240 nM, respectively, in vitro. HSM1820, another hydroxyamidine analogue, inhibits FLT3 and FLT3 ITD with IC50 of 359 and 350 nM, respectively, in vitro.
    • Example 131: Antiproliferative Activity Studies
  • Antiproliferative activities against AML cell line. MV4-11 (a FLT3-driven cell line) and three other solid tumors (MCF7, breast; HCT116, colon and HeLa) have been investigated (Tables 6A and 6B and FIG. 10).
  • TABLE 6A
    Percent Inhibition of cancer cell line proliferation in the presence of compounds (1 μM)
    Com- HSN HSN HSM HSN HSN HSN HSN HSN HSN HSN HSN HSN HSN HSN HSN HSN HSN HSN
    pound 210 204 1669 1812 137 1673 1683 105 1610 1674 177 1702 184 1750 145 139 135 1773
    code A3 A4 A5 A6 A7 A9 A10 A11 A12 A13 A14 A15 A16 A17 A20 A22 A23 A24
    MV- 100 77 83 92 99 98 95 88 90 93 91 99 97 93 99 95 100 93
    4-11
    HCT 6 21 46 17 60 28 10 40 39 14 15 33 38 20 35 32 21 24
    116
    HeLa 16 22 20 97 20 38 49 1 20 8 1 17 51 11 11 35 0 24
    MCF- 1 20 98 100 74 56 57 12 29 36 46 100 92 17 6 60 35 43
    7
  • TABLE 6B
    Percent Inhibition of cancer cell line proliferation in the presence of compounds (1 μM)
    Com- HSN HSN HSN HSN HSN HSN HSN HSN HSN HSN HSN HSN HSN HSN HSN HSN HSN HSN
    pound 1692 136 129 N99 1661 1688 161 189 1751 157 174 1717 247 248 178 185 315 286
    code A25 A26 A27 A28 A29 B8 B15 B16 B17 B20 B22 C10 D6 D7 D15 D16 D28 D30
    MV- 81 86 99 97 90 74 97 95 91 96 85 82 58 98 98 97 83 99
    4-11
    HCT 29 38 29 20 0 43 18 7 32 12 28 33 54 76 97 67 66 100
    116
    HeLa 0 0 22 6 1 64 70 18 23 33 10 2 100 100 100 99 100 100
    MCF- 22 33 37 42 96 33 91 49 47 21 40 76 100 100 100 100 100 100
    7
  • From these cell proliferation studies. MV4-11 appeared to be more sensitive to the compounds than the other cell lines (Table 6A). At 1 μM, most of the compounds could inhibit MV4-11 significantly. To identify group of compounds potently inhibiting cancer cell proliferation, a lower concentration of compounds (100 nM) were used to screen against MV4-11 (FIG. 10). From these experiments, potent amide compounds A7. A10, A15, A16, A18. A20. B15 and D30 (as indicated by ***, FIG. 10) were selected. At 100 nM, these selected compounds inhibited MV4-11 at similar levels to midostaurin, a pan kinase inhibitor that recently completely a Phase III clinical trials (FIG. 10). Typically amides that contain basic amines are included in compound libraries to improve aqueous solubility but it appears that the presence of a basic amine in the side chain of the compounds also facilitated the actual inhibition of MV4-11 proliferation. For example, compounds A1, A2. A21 and A25, which did not have a basic amine side chain, were inactive against MV4-11 whereas many of the other compounds containing a basic amine chain were active against MV4-11. Stability of the active compounds, in the presence of mouse liver microsomes revealed that compounds with the D substitution pattern (such as D30) preformed much better in the liver microsomal stability assay compared to the other analogs.
    • Example 132: Proliferation Inhibition (IC50) Against MV4-11 and MOLM-14
  • Compound D30 contains 1-methyl-4-(2-(trifluoromethyl)benzyl)piperazine group, which is found in many kinase inhibitors, including ponatinib. Ponatinib, which is used to treat imatinib-resistant CML, has been shown to inhibit FLT3-driven AML. Unfortunately ponatinib causes adverse cardiovascular effects (Gainor. J. F., et al. Oncologist, 20(8), 847-848 (2015)) and it is now given with a black box warning and as a last resort drug against CML (Talbert, D. R., et al., Toxicol. Sci, 143 (1), 147-155 (2015). In 2014 it was withdrawn from the US market due to blood clotting and cardiovascular adverse effects and therefore it might not be an ideal drug to advance for AML treatment (especially for elderly patients). Therefore further analogs of D30 were investigated if the kinase selectivity of compounds containing the 1-methyl-4-(2-(trifluoromethyl)benzyl)piperazine group could be modulated via a judicious substitution on the isoquinoline core or use of isoquinoline isomers. Compounds HSN352, HSN353. HSN334, HSN356. HSN285 and HSN325 (containing 3-aminoisoquinoline, 1-aminoisoquinoline, 2-aminoquinoline and 2-aminoquinazoline. FIG. 11) were prepared via the Sonogashira coupling. These compounds' proliferation inhibition (IC50) against MV4-11 and MOLM-14 (FLT3-driven AML cell lines) were determined (Table 6B).
  • HSN286 had an IC50 against MV-4-11 and MOLM-14 of 0.5 nM and 0.7 nM respectively (Table 7), 1-Aminoisoquinoline analogs, HSN334 and HSN356, were also potent proliferation inhibitors of MV4-11 and MOLM-14. The degrees of AML proliferation inhibition by the isoquinoline compounds were similar to (or even slightly better than) midostaurin (Table 7). In general, there was a good correlation between the percentage inhibition of FLT3 enzymatic reaction (obtained as percentage inhibition at 500 nM compound. Reaction Biology) and the inhibition of AML cell lines MV4- and MOLM-14 proliferation. Not all of the aminoquinoline compounds were potent inhibitors of the AML cell lines proliferation. For example, HSN248, HSN178, HSN247, MXC 72 and HSN315 that also contained the 2-aminoquinoline core were only moderate inhibitors of AML proliferation or FLT3 enzymatic activity. However, the 1-methyl-4-(2-(trifluoromethyl)benzyl)piperazine moiety (FIG. 11) is not the sole determinant of FLT3 inhibition. The 2-aminoquinolines and quinazoline analogs. HSN285 and HSN325, both contain this moiety but they were neither potent inhibitors of FLT3 nor active against MV4-11 or MOLM-14 cell lines. Therefore it appears that the potencies of these compounds are due to the combined or synergistic effects of the 1-methyl-4-(2-(trifluormethyl)benzyl)piperazine moiety (found in ponatinib) and the aminoisoquinoline moiety.
  • TABLE 7
    IC50 (proliferation) and FMS-like tyrosein
    kinase
    3 inhibition of activity
    % inhibition of
    FLT3 activity IC50 (nM)
    Compound (500 nM) MV4-11 MOLM14
    HSN248 (D7) 73% 181 ± 6.5 180 ± 7.8
    HSN178 (D15) 66% 144 ± 2.6 187 ± 5.5
    HSN247 (D6) 74% 154 ± 7.1 129 ± 8.2
    HSM1702 (A15) 66%  71 ± 1.1 102 ± 11 
    HSN315 (D28) 32% 549 ± 7.4 523 ± 6.4
    HSN285 28% 721 ± 5.8 415 ± 6.9
    HSN286 (D30) 97%  0.49 ± 0.02  0.72 ± 0.02
    HSN325 33%  135 ± 5.87 456 ± 15 
    HSN334 99% 1.38 ± 0.1   1.61 ± 0.02
    HSN353 94%  3.45 ± 0.04 1.97 ± 0.1 
    HSN352 93% 3.09 ± 0.1  3.01 ± 0.1 
    HSN356 98%  0.42 ± 0.02  0.62 ± 0.02
    Midostatin  98%a 18.5 ± 2.5  7.37 ± 0.1 
    a- % FLT3 inhibition at 412 nM.
    • Example 133: Selectivity
  • To test for selectivity. HSN286 was tested against various other cancer lines as well as a normal cell line (MRC5, lung fibroblast cell line) (FIG. 12). When tested against Kasumi-1, a non-FLT3 AML line, the IC50 of HSN286 was determined to be over 10000 nM. The IC50 values for compound HSN286 against HL60, an acute promyelocytic leukemia cell line and THP1 (another non-FLT3-driven AML line) were 2156 nM and 2315 nM respectively (i.e. more than 2000× less active against these cell lines when compared to FLT3-driven cell lines MV4-11 or MOLM-14). In addition, the IC50 of compound HSN286 against MRC5 is 1266 nM (over 1000× less compared to IC50 for MV4-11 or MOLM-14). It therefore appears that HSN286 is selective (at least amongst the cell lines tested) for FLT3-driven leukemia.
    • Example 134: Docking to Inactive Conformater
  • Docking [25] of HSN 286, 334, 356 and 248 to the inactive conformer of FLT3 (a crystal structure of the potent FLT3 inhibitor, quizartinib, was solved in complex with FLT3, PDB #4xuf), revealed that the compounds bind to both the ATP binding site and neighboring site (FIG. 13). The binding of the compounds partly overlap with the quizartinib binding site, but there are some differences in the binding modes (FIGS. 14 and 15).
    • Example 135: Binding with FLT3 Secondary Mutations
  • Although the current drugs on the market or in clinical trials are relatively successful in killing the AML leukemia cells, they currently are unable to deal with secondary mutations that occur after TKI treatment, such as FLT3 (D385V). The binding of HSN286, HSN336, HSN334. HSN248 and HSN247 with several FLT3 secondary mutations (Table 8) was investigated. Interestingly, HSN356 could bind to FLT3 (D835V) with a Kd of 19 nM, whereas a similar compound, HSN334, was a poor binder of FLT3 (D835V) with a Kd of 120 nM (Table 8).
  • TABLE 8
    Kd for isoquinoline analogs binding to FLT3. FLT3-ITD,
    and FLT3 (D835V), determined via DiscoverX Kd Elect service
    HSN286 HSN356 HSN334 HSN178 HSN248
    FLT3  6.5 nM 1.3 nM  5.1 nM  53 nM  47 nM
    FLT3 (IDT) 27.6 nM 6.7 nM   19 nM 450 nM 330 nM
    FLT3  120 nM  19 nM  120 nM ND ND
    (D835V)
    • Example 136: Inhibition of Src-Family Kinases
  • Most kinase inhibitors that have found clinical success have been multikinase inhibitors. For example, sorafenib, used to treat kidney cancer, hepatocellular carcinoma and radioiodine-resistant thyroid cancers, also inhibits several kinases, such as RAF, MEK, ERK, VEGFR, PDGFR, FLT3, c-KIT, FGFR-1, DDR2. Dasatinib, another multikinase inhibitor is a first line treatment for CML and Ph+ ALL inhibits multitudes of kinase. This includes BCR-ABL, YES, EPHA8, c-KIT. SRC, LCK, DDR2, FRK. FYN, ARG, BTK, HCK. Despite the promiscuity of these multikinase inhibitors, safe and tolerable doses have been found for cancer treatment. The successes of these multikinase inhibitors could be derived, in part, from the simultaneous inhibition of different kinases axes.
  • Further, it was investigated if HSN286 and its analogs also inhibited other cancer-related kinases. In addition to FLT3, the Src-family kinases (such as BLK. FGR, FYN, HCK, LYN, SRC and YES) have been shown to play critical roles in leukemia. Lopez et al. recently demonstrated that CDK6 overexpression in FTL3-ITD positive AML is achieved via the Src-family kinase, HCK (Lopez. S., et al., Oncotarget, 7(23), 51163-51173 (2016)). HCK is expressed more in human primary leukemic stem cells than in human normal hematopoietic stem cells. A study showed that when HCK is targeted with small molecules the drug resistance is reduced (Ishikawa, F. et al., Sci. Transl. Med., 5(181), 181 (2013)). Other protein kinases such as SYK, BRAF, p38 (p38MAPK), PDGFRα/β, FGFR1, RET, FLT4, Tie2 have also been linked to leukemia. All this data further strengthen the consensus in the field that leukemia is a heterogeneous disease and hence targeting the aforementioned multiple kinase pathways could lead to a better outcome. Thus, it was tested if HSN286 and analogs were also targeting kinases that play critical roles in AML. The kinase screening services Reaction Biology and DiscoverX were used to characterize the inhibition of kinase activity (enzymatic activity in the presence of 500 nM of compounds). HSN286 and analogs potently inhibit FLT3 and the Src-family kinases but not other kinases such as Aurora A. CDK6 or PIK3Ca. (Table 9). The inhibition of the Src-kinase family could be important clinically because these kinases are downstream of FLT3. In the event of FLT3 mutation, the inhibition of the Src-family kinases could still lead to proliferation inhibition.
  • TABLE 9
    Kd (nM) determined via DiscoverX Kd Elect service
    Kinase HSN286 HSN356
    AURKA >30000 5100
    BLK 3.9 1.2
    CDK6 28000 ND
    CDK9 2300 ND
    FAK 5100 4700
    FGR 7 7.9
    FLT3 7.2 1.3
    FYN 28 38
    HCK 3.6 2.5
    KIT 42 7.9
    LYN 11 5.4
    PIK3CA 26000 >30000
    PIM1 11000 19000
    PLK1 >30000 9600
    SRC 16 15
    • Example 137: Inhibition of FLT3 Kinase Enzymatic Activity by Midostaurin
  • In addition to the binding assays (Table 9), IC50 values for the inhibition of FLT3 kinase enzymatic activity by midostaurin. HSN286, 334 and 356 were determined. All of the four compounds could inhibit FLT3 with low nanomolar values, although midostaurin and HSN356 were better than HSN286 and HSN334 (FIG. 16). Midostaurin and HSN356 inhibited FLT3 and FLT3 ITD with single digit IC50 values. However in the case of Src kinase. HSN286 was the most potent (IC50 of 4.5 nM). HSN356 is also an effective inhibitor of Src kinase with a IC50 of 14.9 nM.
    • Example 138: Phosphorylation of FLT3 and SRC Kinase
  • To determine if the phosphorylation of FLT3, SRC kinase and downstream effectors or kinases (such as STAT3 [44], STAT5 [45] and p-38 [46]) could be affected by the compounds. Western Blot analysis was performed on total protein obtained from MV4-11 treated with HSN286 for FLT3/phosphorylated FLT3, STAT5/phosphorylated STAT5, STAT3/phosphorylated STAT3 as well as SRC kinase/phosphorylated SRC and p-38/phosphorylated p-38 to ascertain that one could indeed target FLT3 and associated signaling axis in cells (target engagement or confirmation, FIG. 17). In line with the in-vitro kinase inhibition data, the phosphorylation of FLT3, STAT5, STAT3 and p-38 could be inhibited by HSN286 (FIG. 17). The level of SRC kinase increased over time (amount at the 48 h time point is greater than at the 6 and 24 h time points). Unfortunately the bands for the phosphorylated SRC kinase are blurred despite repeated attempts to get clearer bands. Despite the technical challenge with the phospho-SRC Western, it is conclusive that at the 48 h time point, the level of unphosphorylated SRC kinase increases as the compound HSN286 is added (compare band corresponding to vehicle to 9 and 45 nM HSN286 in FIG. 17). From the above Western analyses, it is confirmed that the proliferation inhibition of MV4-11 is due to the inhibition of FLT3 signaling axis.
  • The compounds of the invention are novel FLT3 inhibitors which can inhibit the problematic D835 secondary mutants. 4-alkyne substituted aminoisoquinolines (readily obtained via Sonogashira coupling) but not the related quinolines, were potent FLT3 and SRC-kinase inhibitors. Extensive structure-activity relationship (SAR) studies revealed that the FLT3 inhibition profiles and anti-proliferative activities against FLT3-driven cancer cell lines. MV4-11 and MOLM-14 were dictated by the substitution pattern and nature of benzamide. The SAR studies have led to the identification of 3-amino and 1-aminoisoquinoline benzamides, compounds D30 (HSN286). HSN334 and HSN356 as potent FLT3 kinase inhibitors. Some of these novel kinase inhibitors also inhibit the proliferation of FLT3-driven AML cell lines at concentrations as low as 500 μM. In addition to FLT3, the compounds were identified that also inhibit the Src-family kinases and FGFR kinases. It is also shown that one could combine different isoquinolines with 1-methyl-4-(2-(trifluoromethyl)benzyl)piperazine group (a privileged moiety in kinase inhibitors) to develop analogs that have different kinase selectivities (a kind of “plug-and-play” strategy). This has unveiled a new class of aminoisoquinoline benzamide kinase inhibitors, which have a high potential for clinical translation.
    • Example 139: Binding Constant of the Compounds of the Invention
  • Substitution pattern of aminoisoquinolines play important role in kinase binding, in-vitro and in-vivo efficacy of compounds (FIG. 18). Table 10 provides the binding constant, Kd(DiscoverX KdElect) of compounds against FLT3, ABL1 and clinically relevant mutants that lead to drug resistance.
  • TABLE 10
    Binding constant of compounds of the invention (Kd unit = M)
    FLT3 ABL1 ABL1 ABL1 (T315I)
    Com- FLT3 (ITD, phos- non-phos- non-phos-
    pound (ITD) F691L) phorylated phorylated phorylated
    HSN356 6.7 28 1.2 2.5 2.4
    HSN334 19 nd 12 4.4 nd
    HSN286
    26 110 7.9 7.2 29
    HSN461 7.9 91 nd nd nd
    HSN459 5.6 17 nd nd nd
    HSN431 4.8 57 nd nd nd
    HSN248 330 100 2.2 0.29 520
  • From the data in the Kd Table 10, it is clear that it is possible to tune the activity of the claimed compounds towards a specific kinase or drug-resistant mutant. These compounds can therefore be developed against drug-resistant AML (such as AML harboring FLT3 (ITD. F691L) mutation or CML (harboring T315I) mutation.
    • Example 140: Percentage Kinase Inhibition Data
  • To further illustrate the tenability of the claimed compounds, the inhibition of enzymatic activities of several kinases was evaluated by compounds that differ in substitution pattern (FIG. 19 and Tables 11-16) (500 nM of compounds were used. (Reaction Biology, Malvern, Pa.).
  • TABLE 11
    Percentage Kinase Inhibition Data: HSN286,
    HSN 325 and HSM1702
    HSN286 HSN325 HSM1702
    AKT1 0 0 13
    AKT2 3 0 18
    ALK 0 2 7
    Aurora A 0 0 19
    AXL 3 3 0
    BLK 100 30 10
    BRAF 97 38 3
    BRK 92 0 18
    BTK 41 4 5
    c-MER 0 0 6
    c-Mct 20 15 4
    c-Src 99 30 9
    CDK1/cyclin E 0 0 13
    CDK2/cyclin A 0 0 18
    CDK4/cyclin D1 0 0 16
    CDK6/cyclin D3 7 0 50
    CDK9/cyclin K 24 7 53
    CDK9/cyclin T1 0 0 41
    CDK9/cyclin T2 0 0 65
    CSK 93 0 1
    CTK/MATK 0 5 0
    DDR2 77 81 0
    DNA-PK 0 0 ND
    EGFR 44 0 0
    EPHA3 96 6 0
    EPHA5 96 30 4
    EPHB2 96 3 5
    ERBB2/HER2 25 4 0
    ERBB4/HER4 71 7 0
    ERK1 0 0 5
    FAK/PTK2 0 0 6
    FER 0 12 0
    FGFR1 98 58 11
    FGR 100 39 6
    FLT1/VEGFR1 86 42 0
    FLT3 97 34 66
    FLT4/VEGFR3 98 42 10
    FMS 99 93 35
    FRK/PTK5 95 49 0
    FYN 100 10 16
    HCK 95 18 12
    HIPK1 0 0 42
    IGF1R 0 0 3
    IKKa/CHUK 36 6 0
    IR 16 9 9
    IRR/INSRR 0 0 10
    ITK 0 1 0
    JAK2 67 0 0
    JNK1 7 0 0
    KDR/VEGFR2 95 90 9
    KSR1 0 0 0
    LRRK2 6 0 40
    LYN 98 69 6
    LYN B 95 35 0
    MEK1 0 2 0
    MEKK1 6 4 4
    MELK 27 0 12
    MKK7 0 6 0
    MST4 0 0 0
    MUSK 13 0 35
    P38a/MAPK14 81 5 0
    PAK1 0 0 1
    PDGFRa 93 53 48
    PDK1/PDHK1 0 1 0
    PIM1 0 0 34
    PKCa 5 5 3
    PKD2/PRKD2 7 0 6
    RAF1 94 92 5
    RET 100 96 15
    ROCK1 0 3 0
    RON/MST1R 0 0 0
    ROS/ROS1 10 0 15
    RSK2 0 0 7
    SYK 0 0 4
    TAOK1 0 0 12
    TGFBR2 15 0 0
    TIE2/TEK 91 47 8
    TRKB 79 0 40
    TRKC 91 4 81
    TYK2 0 0 2
    YES/YES1 100 41 13
    ZAP70 0 0 0
  • Other Percentage Kinase Inhibition Data: HSN286, HSN325 and HSM1702
  • HSN286 c-kit (61), DAPK11 (9). FGFR2 (96). FGFR3 (88), FGFR4 (82). MEKK2 (52), PDGFRb (96). RIPK2 (25), RIPK3 (96). RIPK4 (32); HSM1702 c-kit (83).
  • TABLE 12
    Percentage Kinase inhibition Data on HSN334,
    HSN356 and HSN285
    HSN334 HSN356 HSN285
    AKT1
    0 0 0
    ALK 0 0 1
    AXL 5 4 0
    BRAF 96 100 64
    BTK 46 65 0
    c-kit 73 87 31
    c-MER 0 0 3
    c-Met 14 15 23
    EGFR 61 59 0
    EPHA5 97 96 0
    EPHB2 98 100 3
    ERBB2/HER2 31 64 0
    FGFR1 96 96 0
    FGR 100 99 0
    FLT1/VEGFR1 79 94 3
    FLT3 100 99 28
    FLT4/VEGFR3 79 94 6
    KDR/VEGFR2 94 97 15
    PDGFRa 86 92 30
    PKCa 0 0 6
    RAF1 96 100 90
    ROS/ROS1 0 0 0
    TIE2/TEK 99 100 0
    TRKB 41 75 0
    TRKC ND 59 0
    YES/YES1 100 100 0
  • Other Percentage Kinase Inhibition Data: HSN334, HSN356 and HSN285
  • HSN334 RET (100);
  • HSN356 RET (100);
  • HSN285 c-Src (0). DAPK (14). FGFR2 (0), FGFR3 (0), FGFR4 (0). MEKK2 (0), PDGFRb (46). RIPK2 (0). RIPK3 (0), RIPK4 (25).
  • TABLE 13
    Percentage Kinase inhibition Data: HSN248
    HSN248
    c-kit 93
    c-Src 23
    FGFR1  9
    FLT3 73
    RET 52
    TRKC 83
  • TABLE 14
    Percentage Kinase Inhibition Data: HSN178
    HSN178
    c-Src 1
    FGFR1 3
    FLT3 67
    RET 0
  • TABLE 15
    Percentage Kinase Inhibition Data: HSN247
    HSN247
    c-kit 86
    c-Src 3
    FGFR1 6
    FLT3 75
    RET 3
    TRKC 77
  • TABLE 16
    Percentage Kinase Inhibition Data:
    HSN353 and HSN352
    HSN353 HSN352
    c-kit 82 78
    c-Src 98 100
    FGFR1 93 100
    FLT3 94 93
    • Example 141: In Vivo Efficacy Study
  • The in-vitro efficacies of HSN356, HSN334, HSN286. HSN461 and HSN431 against AML cell line MV4-11 are similar (all have IC50<1 nM against MV4-11) yet the compounds have differing potencies in-vivo. For example HSN286 and HSN286 are both 3-aminoisoquinolines but HSN286 is not efficacious in-vivo whereas HSN431 is efficacious (FIG. 20). Also HSN334 only differs from HSN356 and HSN461 via a carbon to nitrogen but the percent survival of mice injected with MV4-11 cell lines of HSN334 is different from both HSN356 and HSN461.
  • Method: Six week old female NSG mice were injected intravenously with 1×106 logarithmically growing MV4-11 cells expressing luciferase (MV4-11). Luciferase expressing leukemia cells were imaged using the IVIS Xenogen system (Perkin Elmer, Waltham Mass.). On day of imaging, mice are injected IP with 150 mg/kg luciferin (Perkin Elmer. Waltham, Mass.), anaesthetized and then placed in imaging chamber. Maximal luminescence is recorded and then averaged among each treatment group. Ten days post cell injection, mice were imaged and then sorted into groups so that leukemic burden was similar and dosing started. Mice were dosed either with vehicle (10% DMSO/10% Tween 20/80% saline) or 25 mg/kg of compounds three times per week for the duration of the experiment. Mice were weighed and observed five days per week and imaged once per week.
    • Example 142: Activity Against Lung Cancer
  • In addition to AML, the compounds of the invention are also active against several other cancers. For example the claimed compounds are active against lung cancer (Table 17). This is to be expected since the compounds can be tuned to inhibit different kinases, which drive specific tumors (Tables 11-16).
  • TABLE 17
    IC50 against NCI H1703 (NSCLC)/ nM
    IC50 against NCI
    Compound H1703 (NSCLC)/ nM
    HSN356
    88
    HSN379 13
    HSN334 98
    HSN286 50
    HSN459 38
    HSN461 157
    HSN431 247
    • Example 143: Inhibition of Proliferation of K562 Cell Lines (CML)
  • The compounds of the invention potently inhibit proliferation of K562 cell lines (CML) (Table 18).
  • TABLE 18
    Inhibition of Proliferation of K562
    Cell Lines (CML)
    HSL41 30.1 ± 0.19 nM
    HSL45 25.3 ± 0.1 nM
    HSL58 94.5 ± 0.1 nM
    HSN178 1443 ± 0.21 nM
    HSN285 1102 ± 0.08 nM
    HSN316 913 ± 0.1 nM
    HSN334 6.1 ± 0.1 nM
    HSN356 1.8 ± 0.03 nM
    HSL43 10.1 ± 0.1 nM
    HSL47 161.1 ± 0.11 nM
    HSL64 1932 ± 0.41 nM
    HSN247 25.7 ± 0.31 nM
    HSN286 3.5 ± 0.02 nM
    HSN317 1483 ± 0.1 nM
    HSN352 2.4 ± 0.06 nM
    HSN375 8.8 ± 0.4 nM
    HSL44 43.5 ± 0.14 nM
    HSL56 95.4 ± 0.23 nM
    HSM1702 5057 ± 0.45 nM
    HSN248 7.0 ± 0.1 nM
    HSN315 203 ± 0.1 nM
    HSN325 44 ± 0.1 nM
    HSN353 5.2 ± 0.02 nM
    HSN393 7.3 ± 0.04 nM
  • While the inventions have been illustrated and described in detail in the drawings and foregoing description, the same is to be considered as illustrative and not restrictive in character, it being understood that only certain embodiments have been shown and described and that all changes and modifications that come within the spirit of the invention are desired to be.

Claims (22)

1. A compound represented by a compound of formula (IV)
Figure US20210198208A1-20210701-C00378
wherein
W is NR′, alkene, alkyne, C1-8 alkyl, heteroalkyl containing 1-8 carbon and hetero atoms, cycloalkyl, hetereocycloalkyl, aryl, or heteroaryl, wherein cycloalkyl, hetereocycloalkyl, aryl, and heteroaryl optionally form a fused aryl or heteroaryl group with Ring A;
U, Y, and Z are each N or CR6, wherein R6 is H or NRaRb;
R7 and R8 are each independently H, alkyl, alkenyl, alkynyl, halo, nitro, ORc, SRc, CN, haloalkyl, O-haloalkyl, (CO)Rd, NRaRb, NH(CO)Rd, NH(CO)ORc, NH(CO)NRaRb, (CO)ORc, (CO)NRaRb, SO2NRaRb, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
or R7 and R8, together with the carbon atoms to which they are attached, form a cycloalkyl, heterocycloalkyl, aryl, or heteroaryl group, each optionally substituted with substituents independently selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, halo, nitro, ORc, SRc, CN, haloalkyl, O-haloalkyl, NRaRb, (CO)Rd, (CO)ORc, (CO)NRaRb, SO2NRaRb, and —C(CH3)(═N—NHC(NH)NH2;
Ring A is a 5- or 6-membered aryl or heteroaryl group, wherein Ring A is optionally substituted with substituents selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, halo, nitro, ORc, SRc, CN, haloalkyl, O-haloalkyl, NRmRn, (CO)Rd, (CO)ORc, SO2NRmRn, (CO)NRmRn, C(NH)NRmRn, NH(CO)Rd, NH(CO)ORc, NH(CO)NRmRn, aryl, and heteroaryl;
Rm and Rn are each independently
H, OH,
alkyl, —(CH2)p-T, -aryl-(CH2)p-T, —(CH2)p-aryl-T, -heteroaryl-(CH2)p-T, —(CH2)p-heteroaryl-T, each optionally substituted with alkyl, halo, nitro, CN, haloalkyl, O-haloalkyl, ORc, SRc, NRaRb, (CO)Rd, NH(CO)Rd, NH(CO)ORc, NH(CO)NRaRb, NHC(NH)NH2, (CO)ORc, (CO)NRaRb, SO2NRaRb, arylamino, or heteroarylamino,
or Rm and Rn, together with the nitrogen atom they are attached, form a heterocycloalkyl group, optionally substituted with alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, halo, nitro, CN, ORc, SRc, CORd, NRaRb, NH(CO)Rd, NH(CO)ORc, NH(CO)NRaRb, a guanidine group, (CO)ORc, or (CO)NRaRb;
T is NRaRb, ORc, SRc, O—(CH2)q—NRaRb, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, a guanidine group, or an isonicotinimidamide group;
R′ is H, alkyl, or cycloalkyl;
Ra, Rb, Rc, and Rd are each independently H, alkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, —(CH2)q-cycloalkyl, —(CH)q-heterocycloalkyl, —(CH2)q-aryl, —(CH)q-heteroaryl, —(CO)-alkyl, —(CO)-cycloalkyl, —(CO)-heterocycloalkyl, —(SO2)-alkyl, —(SO2)-cycloalkyl, or —(SO2)-heterocycloalkyl, or Ra and Rb, together with the nitrogen atom to which they are attached, form a heterocycloalkyl group, wherein cycloalkyl, heterocycloalkyl, aryl and heteroaryl are each optioncally substituted with a group consisting of alkyl, halo, nitro, CN, haloalkyl, O-haloalkyl, OH, O-alkyl, SH, S-alkyl, NH2, NH(alkyl), and N(alkyl)2; and
p and q are each independently 0-8;
or a pharmaceutically acceptable salt, N-oxide, hydrate, solvate, tautomer, or optical isomer thereof.
2. The compound of claim 1, wherein said compound of formula (IV) is represented by a compound of formula (V)
Figure US20210198208A1-20210701-C00379
wherein
W is NR′, —C≡C—, or a heterocycloalkyl group containing a 5- or 6-membered ring, wherein R′ is H or alkyl;
U, Y, and Z are each N or CR6, wherein R6 is H or NRaRb;
V, U1, Y1, and Z1 are each N or CR6′;
R1, R2, and R6′ are each independently H, alkyl, cycloalkyl, halo, nitro, ORc, SRc, CN, haloalkyl, O-haloalkyl, or NRaRb;
R3, R4, and R5 are each independently H, alkyl, cycloalkyl, heterocycloalkyl, halo, nitro, ORc, SRc, CN, haloalkyl, O-haloalkyl, NRmRn, (CO)Rd, (CO)ORc, SO2NRmRn, (CO)NRmRn, C(NH)NRmRn, NH(CO)Rd, NH(CO)ORc, NH(CO)NRmRn, aryl, or heteroaryl;
Rm and Rn are each independently
H, OH,
alkyl, —(CH2)p-T, -aryl-(CH2)p-T, —(CH2)p-aryl-T, -heteroaryl-(CH2)p-T, —(CH2)p-heteroaryl-T, each optionally substituted with alkyl, cycloalkyl, halo, nitro, CN, haloalkyl, O-haloalkyl, ORc, SRc, (CO)Rd, NRaRb, NH(CO)Rd, NH(CO)ORc, NH(CO)NRaRb, NHC(NH)NH2, (CO)ORc, (CO)NRaRb, and SO2NRaRb,
or Rm and Rn, together with the nitrogen atom they are attached, form a heterocycloalkyl group, optionally substituted with alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, halo, nitro, CN, ORc, SRc, CORd, NRaRb, NH(CO)Rd, NH(CO)ORc, NH(CO)NRaRb, a guanidine group, (CO)ORc, and (CO)NRaRb;
T is NRaRb, ORc, SRc, O—(CH2)q—NRaRb, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, a guanidine group, or an isonicotinimidamide group;
Ra, Rb, Rc, and Rd are each independently H, alkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, —(CH2)q-cycloalkyl, —(CH)q-heterocycloalkyl, —(CH2)q-aryl, —(CH)q-heteroaryl, —(CO)-alkyl, —(CO)-cycloalkyl, or —(CO)-heterocycloalkyl, or Ra and Rb, together with the nitrogen atom to which they are attached, form a heterocycloalkyl group, wherein cycloalkyl, heterocycloalkyl, aryl and heteroaryl are each optioncally substituted with a group consisting of alkyl, halo, nitro, CN, haloalkyl, O-haloalkyl, OH, O-alkyl, SH, S-alkyl, NH2, NH(alkyl), and N(alkyl)2; and
p and q are each independently 0-5;
or a pharmaceutically acceptable salt, N-oxide, hydrate, solvate, tautomer, or optical isomer thereof.
3. The compound of claim 2, wherein R6 is NRaRb.
4. The compound of claim 2, wherein one of R3, R4, and R5 is heterocycloalkyl, CN, NRmRn, (CO)Rd, (CO)ORc, SO2NRmRn, (CO)NRmRn, C(NH)NRmRn, or NH(CO)Rd.
5. The compound of claim 2, wherein one of R3, R4, and R5 is (CO)NRmRn.
6. The compound of claim 5, wherein Rm is H and Rn is —(CH2)p-T, -aryl-(CH2)p-T, —(CH2)p-aryl-T, or -heteroaryl-(CH2)p-T, each optionally substituted with alkyl, halo, and ORc.
7. The compound of claim 6, wherein T is NRaRb, O—(CH2)q—NRaRb, heterocycloalkyl, aryl, or heteroaryl.
8. The compound of claim 5, wherein Rm and Rn, together with the nitrogen atom they are attached, form a heterocycloalkyl group, optionally substituted with alkyl, cycloalkyl, heterocycloalkyl, NRaRb, NH(CO)Rd, NH(CO)ORc, and NH(CO)NRaRb.
9. The compound of claim 2, wherein R1 and R2 are each independently H, alkyl, halo, CN, ORc, SRc, or NRaRb.
10. The compound of claim 1, wherein said compound is a compound of the following formula:
Figure US20210198208A1-20210701-C00380
Figure US20210198208A1-20210701-C00381
Figure US20210198208A1-20210701-C00382
Figure US20210198208A1-20210701-C00383
Figure US20210198208A1-20210701-C00384
Figure US20210198208A1-20210701-C00385
wherein
R1, R2, R10, R11, R12, and R13 are each independently H, alkyl, cycloalkyl, halo, nitro, ORc, SRc, CN, haloalkyl, O-haloalkyl, or NRaRb;
R3, R4, and R5 are each independently H, alkyl, cycloalkyl, heterocycloalkyl, halo, nitro, ORc, SRc, CN, haloalkyl, O-haloalkyl, NRmRn, (CO)Rd, (CO)ORc, SO2NRmRn, (CO)NRmRn, C(NH)NRmRn, NH(CO)Rd, NH(CO)ORc, NH(CO)NRmRn, aryl, or heteroaryl;
R6 is H or NRaRb;
Rm and Rn are each independently
H, OH,
alkyl, —(CH2)p-T, -aryl-(CH2)p-T, —(CH2)p-aryl-T, -heteroaryl-(CH2)p-T, —(CH2)p-heteroaryl-T, each optionally substituted with alkyl, cycloalkyl, halo, nitro, CN, haloalkyl, O-haloalkyl, ORc, SRc, (CO)Rd, NRaRb, NH(CO)Rd, NH(CO)ORc, NH(CO)NRaRb, NHC(NH)NH2, (CO)ORc, (CO)NRaRb, and SO2NRaRb,
or Rm and Rn, together with the nitrogen atom they are attached, form a heterocycloalkyl group, optionally substituted with alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, halo, nitro, CN, ORc, SRc, CORd, NRaRb, NH(CO)Rd, NH(CO)ORc, NH(CO)NRaRb, a guanidine group, (CO)ORc, and (CO)NRaRb;
T is NRaRb, ORc, SRc, O—(CH2)q—NRaRb, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, a guanidine group, or an isonicotinimidamide group;
Ra, Rb, Rc, and Rd are each independently H, alkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, —(CH2)q-cycloalkyl, —(CH)q-heterocycloalkyl, —(CH2)q-aryl, —(CH)q-heteroaryl, —(CO)-alkyl, —(CO)-cycloalkyl, or —(CO)-heterocycloalkyl, or Ra and Rb, together with the nitrogen atom to which they are attached, form a heterocycloalkyl group, wherein cycloalkyl, heterocycloalkyl, aryl and heteroaryl are each optioncally substituted with a group consisting of alkyl, halo, nitro, CN, haloalkyl, O-haloalkyl, OH, O-alkyl, SH, S-alkyl, NH2, NH(alkyl), and N(alkyl)2; and
p and q are each independently 0-5;
or a pharmaceutically acceptable salt, N-oxide, hydrate, solvate, tautomer, or optical isomer thereof.
11. The compound of claim 1, wherein said compound is a compound of the following formula:
Figure US20210198208A1-20210701-C00386
wherein
V, U1, Y1, and Z1 are each N or CR6′,
Wherein one of V, U1, Y1, and Z1 is N,
Wherein V, U1, Y1, and Z1 together with the carbon atom they are attached, form a pyridyl group;
R1, and R6′ are each independently H, alkyl, cycloalkyl, halo, nitro, ORc, SRc, CN, haloalkyl, O-haloalkyl, or NRaRb;
R3, R4, and R5 are each independently H, alkyl, cycloalkyl, heterocycloalkyl, halo, nitro, ORc, SRc, CN, haloalkyl, O-haloalkyl, NRmRn, (CO)Rd, (CO)ORc, SO2NRmRn, (CO)NRmRn, C(NH)NRmRn, NH(CO)Rd, NH(CO)ORc, NH(CO)NRmRn, aryl, or heteroaryl;
R6 is H;
Rm and Rn are each independently
H, OH,
alkyl, —(CH2)p-T, -aryl-(CH2)p-T, —(CH2)p-aryl-T, -heteroaryl-(CH2)p-T, —(CH2)p-heteroaryl-T, each optionally substituted with alkyl, cycloalkyl, halo, nitro, CN, haloalkyl, O-haloalkyl, ORc, SRc, (CO)Rd, NRaRb, NH(CO)Rd, NH(CO)ORc, NH(CO)NRaRb, NHC(NH)NH2, (CO)ORc, (CO)NRaRb, and SO2NRaRb,
or Rm and Rn, together with the nitrogen atom they are attached, form a heterocycloalkyl group, optionally substituted with alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, halo, nitro, CN, ORc, SRc, CORd, NRaRb, NH(CO)Rd, NH(CO)ORc, NH(CO)NRaRb, a guanidine group, (CO)ORc, and (CO)NRaRb;
T is NRaRb, ORc, SRc, O—(CH2)q—NRaRb, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, a guanidine group, or an isonicotinimidamide group;
Ra, Rb, Rc, and Rd are each independently H, alkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, —(CH2)q-cycloalkyl, —(CH)q-heterocycloalkyl, —(CH2)q-aryl, —(CH)q-heteroaryl, —(CO)-alkyl, —(CO)-cycloalkyl, or —(CO)-heterocycloalkyl, or Ra and Rb, together with the nitrogen atom to which they are attached, form a heterocycloalkyl group, wherein cycloalkyl, heterocycloalkyl, aryl and heteroaryl are each optioncally substituted with a group consisting of alkyl, halo, nitro, CN, haloalkyl, O-haloalkyl, OH, O-alkyl, SH, S-alkyl, NH2, NH(alkyl), and N(alkyl)2; and
p and q are each independently 0-5;
or a pharmaceutically acceptable salt, N-oxide, hydrate, solvate, tautomer, or optical isomer thereof.
12. The compound of claim 1, wherein said compound is a compound of the following formula:
Figure US20210198208A1-20210701-C00387
Figure US20210198208A1-20210701-C00388
Figure US20210198208A1-20210701-C00389
Figure US20210198208A1-20210701-C00390
wherein
V, U1, Y1, and Z1 are each N or CR6′;
R1, R2, and R6′ are each independently H, alkyl, cycloalkyl, halo, nitro, ORc, SRc, CN, haloalkyl, O-haloalkyl, or NRaRb;
R3, R4, and R5 are each independently H, alkyl, cycloalkyl, heterocycloalkyl, halo, nitro, ORc, SRc, CN, haloalkyl, O-haloalkyl, NRmRn, (CO)Rd, (CO)ORc, SO2NRmRn, (CO)NRmRn, C(NH)NRmRn, NH(CO)Rd, NH(CO)ORc, NH(CO)NRmRn, aryl, or heteroaryl;
R6 is H or NRaRb;
R7 and R8 are each independently H, alkyl, alkenyl, alkynyl, halo, nitro, ORc, SRc, CN, haloalkyl, O-haloalkyl, (CO)Rd, NRaRb, NH(CO)Rd, NH(CO)ORc, NH(CO)NRaRb, (CO)ORc, (CO)NRaRb, SO2NRaRb, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
Rm and Rn are each independently
H, OH,
alkyl, —(CH2)p-T, -aryl-(CH2)p-T, —(CH2)p-aryl-T, -heteroaryl-(CH2)p-T, —(CH2)p-heteroaryl-T, each optionally substituted with alkyl, cycloalkyl, halo, nitro, CN, haloalkyl, O-haloalkyl, ORc, SRc, (CO)Rd, NRaRb, NH(CO)Rd, NH(CO)ORc, NH(CO)NRaRb, NHC(NH)NH2, (CO)ORc (CO)NRaRb, and SO2NRaRb,
or Rm and Rn, together with the nitrogen atom they are attached, form a heterocycloalkyl group, optionally substituted with alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, halo, nitro, CN, ORc, SRc, CORd, NRaRb, NH(CO)Rd, NH(CO)ORc, NH(CO)NRaRb, a guanidine group, (CO)ORc, and (CO)NRaRb;
T is NRaRb, ORc, SRc, O—(CH2)q—NRaRb, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, a guanidine group, or an isonicotinimidamide group;
Ra, Rb, Rc, and Rd are each independently H, alkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, —(CH2)q-cycloalkyl, —(CH)q-heterocycloalkyl, —(CH2)q-aryl, —(CH)q-heteroaryl, —(CO)-alkyl, —(CO)-cycloalkyl, or —(CO)-heterocycloalkyl, or Ra and Rb, together with the nitrogen atom to which they are attached, form a heterocycloalkyl group, wherein cycloalkyl, heterocycloalkyl, aryl and heteroaryl are each optioncally substituted with a group consisting of alkyl, halo, nitro, CN, haloalkyl, O-haloalkyl, OH, O-alkyl, SH, S-alkyl, NH2, NH(alkyl), and N(alkyl)2; and
p and q are each independently 0-5;
or a pharmaceutically acceptable salt, N-oxide, hydrate, solvate, tautomer, or optical isomer thereof.
13. The compound of claim 1, wherein said compound is a compound of formula (XV)
Figure US20210198208A1-20210701-C00391
wherein
R′ is H or alkyl;
R1, R2, R10, R11, R12, and R13 are each independently H, alkyl, cycloalkyl, halo, nitro, ORc, SRc, CN, haloalkyl, O-haloalkyl, or NRaRb;
R3, R4, and R5 are each independently H, alkyl, cycloalkyl, heterocycloalkyl, halo, nitro, ORc, SRc, CN, haloalkyl, O-haloalkyl, NRmRn, (CO)Rd, (CO)ORc, SO2NRmRn, (CO)NRmRn, C(NH)NRmRn, NH(CO)Rd, NH(CO)ORc, NH(CO)NRmRn, aryl, or heteroaryl;
Rm and Rn are each independently
H, OH,
alkyl, —(CH2)p-T, -aryl-(CH2)p-T, —(CH2)p-aryl-T, -heteroaryl-(CH2)p-T, —(CH2)p-heteroaryl-T, each optionally substituted with alkyl, cycloalkyl, halo, nitro, CN, haloalkyl, O-haloalkyl, ORc, SRc, (CO)Rd, NRaRb, NH(CO)Rd, NH(CO)ORc, NH(CO)NRaRb, NHC(NH)NH2, (CO)ORc, (CO)NRaRb, and SO2NRaRb,
or Rm and Rn, together with the nitrogen atom they are attached, form a heterocycloalkyl group, optionally substituted with alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, halo, nitro, CN, ORc, SRc, CORd, NRaRb, NH(CO)Rd, NH(CO)ORc, NH(CO)NRaRb, a guanidine group, (CO)ORc, and (CO)NRaRb;
T is NRaRb, ORc, SRc, O—(CH2)q—NRaRb, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, a guanidine group, or an isonicotinimidamide group;
Ra, Rb, Rc, and Rd are each independently H, alkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, —(CH2)q-cycloalkyl, —(CH)q-heterocycloalkyl, —(CH2)q-aryl, —(CH)q-heteroaryl, —(CO)-alkyl, —(CO)-cycloalkyl, or —(CO)-heterocycloalkyl, or Ra and Rb, together with the nitrogen atom to which they are attached, form a heterocycloalkyl group, wherein cycloalkyl, heterocycloalkyl, aryl and heteroaryl are each optioncally substituted with a group consisting of alkyl, halo, nitro, CN, haloalkyl, O-haloalkyl, OH, O-alkyl, SH, S-alkyl, NH2, NH(alkyl), and N(alkyl)2; and
p and q are each independently 0-5,
or a pharmaceutically acceptable salt, N-oxide, hydrate, solvate, tautomer, or optical isomer thereof.
14. The compound of claim 1, wherein said compound is:
Figure US20210198208A1-20210701-C00392
Figure US20210198208A1-20210701-C00393
Figure US20210198208A1-20210701-C00394
Figure US20210198208A1-20210701-C00395
Figure US20210198208A1-20210701-C00396
Figure US20210198208A1-20210701-C00397
Figure US20210198208A1-20210701-C00398
Figure US20210198208A1-20210701-C00399
Figure US20210198208A1-20210701-C00400
Figure US20210198208A1-20210701-C00401
Figure US20210198208A1-20210701-C00402
Figure US20210198208A1-20210701-C00403
Figure US20210198208A1-20210701-C00404
Figure US20210198208A1-20210701-C00405
Figure US20210198208A1-20210701-C00406
Figure US20210198208A1-20210701-C00407
Figure US20210198208A1-20210701-C00408
15. A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt, N-oxide, hydrate, solvent, tautomer, or optical isomer thereof, and a pharmaceutically acceptable carrier or diluent.
16. A method of treating, inhibiting, suppressing, or reducing the severity of cancer in a subject in need thereof, wherein the method comprises administering to the subject a therapeutically effective amount of a compound of claim 1.
17. The method of claim 16, wherein said cancer is selected from the group consisting of acute myeloid leukemia, chronic myeloid leukemia, ovarian cancer, cervical cancer, pancreatic cancer, breast cancer, brain cancer, skin cancer, lung cancer, prostate cancer, Lymphoma, Leukemia, colon cancer, head cancer, neck cancer, thyroid cancer, kidney cancer, liver cancer, and stomach cancer.
18. A method of treating, inhibiting, suppressing, or reducing the severity of a disease or a disorder associated with protein kinase in a subject in need thereof, wherein the method comprises administering to the subject a therapeutically effective amount of a compound of claim 1.
19. The method of claim 18, wherein said protein kinase is Abl, Abl2, AFK, ALK, AMPK_group, ATM, ATR, Aurora A, Aurora B, Axl, BCKDK, BLK, BMPR1B, BMX, Brk, BRSK1, BTK, CaM-KIalpha, CaM-KIIalpha, CaMKK_group, CaM-KIV, CaM-KKalpha, CaM-KKbeta, CCDPK, CCRK, CDK1, CDK11, CDK2, CDK4, CDK5, CDK6, CDK7, CDK9, CDK_group, CDPK, Chak1, CHK1, CHK2, CK1 alpha, CK1 delta, CK1 epsilon, CK1_group, CK2 alpha, CK2_beta, CK2_group, CLK1, CSF1R, Csk, DAPK1, DAPK2, DAPK3, DAPK_group, DCAMKL1, DMPK_group, DNA-PK, DYRK1A, DYRK1B, DYRK2, DYRK3, eEF2K, Eg3 kinase, EGFR, EIF2AK2, EphA2, EphA3, EphA4, EphA8, EphB1, EphB2, EphB3, EphB5, ErbB2, FAK, Fer, Fes, FGFR1, FGFR3, FGFR4, FGFR_group, Fgr, FLT1, FLT3, FLT4, Fyn, GRK-1, GRK-2, GRK-3, GRK-4, GRK-5, GRK-6, GRK_group, GSK-3alpha, GSK-3beta, GSK-3_group, HCK, HIPK2, HIPK3, HRI, ICK, IGF1R, IKK-alpha, IKK-beta, IKK-epsilon ILK, InsR, IPL1, IRAK1, IRAK4, ITK, JAK1, JAK2, JAK3, JAK_group, JNK_group, KDR, KIS, Kit, KSR1, Lck, LIMK1, LIMK2, LKB1, LOK, Lyn, MAP2K1, MAP2K2, MAP2K3, MAP2K4, MAP2K6, MAP2K7, MAPK2_group, MAP3K1, MAP3K11, MAP3K14, MAP3K5, MAP3K7, MAP3K8, MAPK3_group, MAP4K1, MAP4K2, MAP4K4, MAPK1, MAPK10, MAPK11, MAPK12, MAPK13, MAPK14, MAPK3, MAPK4, MAPK6, MAPK7, MAPK8, MAPK9, MAPK_group, MAPKAPK2, MARK_group, Mer, Met, MHCK, MLCK_group, Mnk1, Mnk2, MOS, MRCKa, MST1, MST3, mTOR, NDR1, NDR2, NEK1, NEK2, NEK6, NEK9, NEK_group, NLK, NuaK1, p37 kinase, p38_group, p7056K, p70S6Kb, P70S6K_group, PAK1, PAK2, PAK3, PAK5, PAK6, PAK_group, PASK, P-CIP2, PCTAIRE1, PDGFR alpha, PDGFR beta, PDGFR_group, PDHK1, PDHK2, PDHK3, PDHK4, PDK-1, PDK-2, PDK_group, PHK_group, PIK3CA, PIK3CB, PIK3CD, PIK3CG, Pim-1, PKA alpha, Pka_group, PKB beta, PKB_group, PKC alpha, PKC beta, PKC delta, PKC epsilon, PKC eta, PKC gamma, PKC iota, PKC theta, PKC zeta, PKC_group, PKD1, PKD2, PKD3, PKG1/cGK-1, PKG2/cGK-1, PKG2/cGK_group, PKN1, PLK1, PLK2, PLK3, PRP4, PYK2, RAF1, Ret, ROCK1, ROCK2, Ron, RPL10, RSK-1, RSK-2, RSK-3, RSK-5, SDK1, SGK_group, SIK, Sky, Src, Src_group, STLK3, Syk, TBK1, Tec, TESK1, TESK2, TGFbR1, TGFbR2, Tie1, Tie2, Titin kinase, TNK2, TRKA, TRKB, tropomyosin kinase, TSSK3, TXK, Tyk2, TYK2, VRK1, Wee1, Wnk1, WNK1, Yes, or ZAP70.
20. The method of claim 18, wherein said disease or disorder is cancer, diabetes, malaria, viral infections, cardiovascular and hypertension, CNS and neurodegeneration, osteoporosis, pulmonary fibrosis, retinitis pigmentosis, Wet macular degeneration, Duchenne muscular dystrophy, diabetic eye disease, inflammation and autoimmune, or allergy.
21. A method of treating, inhibiting, suppressing, or reducing the severity of cancer in a subject in need thereof, wherein the method comprises administering to the subject a therapeutically effective amount of a compound of claim 15.
22. A method of treating, inhibiting, suppressing, or reducing the severity of a disease or a disorder associated with protein kinase in a subject in need thereof, wherein the method comprises administering to the subject a therapeutically effective amount of a compound of claim 15.
US17/187,931 2016-08-15 2021-03-01 4-substituted aminoisoquinoline derivatives Pending US20210198208A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US17/187,931 US20210198208A1 (en) 2016-08-15 2021-03-01 4-substituted aminoisoquinoline derivatives

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662375154P 2016-08-15 2016-08-15
US201762461295P 2017-02-21 2017-02-21
PCT/US2017/046843 WO2018035072A1 (en) 2016-08-15 2017-08-15 4-substituted aminoisoquinoline derivatives
US201916325022A 2019-02-12 2019-02-12
US17/187,931 US20210198208A1 (en) 2016-08-15 2021-03-01 4-substituted aminoisoquinoline derivatives

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US16/325,022 Division US11001559B2 (en) 2016-08-15 2017-08-15 4-substituted aminoisoquinoline derivatives
PCT/US2017/046843 Division WO2018035072A1 (en) 2016-08-15 2017-08-15 4-substituted aminoisoquinoline derivatives

Publications (1)

Publication Number Publication Date
US20210198208A1 true US20210198208A1 (en) 2021-07-01

Family

ID=61196993

Family Applications (2)

Application Number Title Priority Date Filing Date
US16/325,022 Active US11001559B2 (en) 2016-08-15 2017-08-15 4-substituted aminoisoquinoline derivatives
US17/187,931 Pending US20210198208A1 (en) 2016-08-15 2021-03-01 4-substituted aminoisoquinoline derivatives

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US16/325,022 Active US11001559B2 (en) 2016-08-15 2017-08-15 4-substituted aminoisoquinoline derivatives

Country Status (6)

Country Link
US (2) US11001559B2 (en)
EP (2) EP4011882A1 (en)
JP (1) JP2019527725A (en)
CN (1) CN109843294A (en)
CA (2) CA3158951A1 (en)
WO (1) WO2018035072A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11613548B2 (en) 2021-02-19 2023-03-28 Sudo Biosciences Limited Substituted pyridines, pyridazines, pyrimidines, and 1,2,4-triazines as TYK2 inhibitors

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108456163A (en) * 2017-02-20 2018-08-28 中国科学院上海药物研究所 Compound and its preparation method and application containing adjacent amino heteroaryl cycloalkynyl radical
CN111971286B (en) 2018-01-18 2023-04-14 阿雷生物药品公司 Substituted pyrrolo [2,3-d ] pyrimidine compounds as RET kinase inhibitors
US11472802B2 (en) 2018-01-18 2022-10-18 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors
JP7394831B2 (en) * 2018-07-27 2023-12-08 アーカス バイオサイエンシズ インコーポレイティド Pyridone A2R antagonist
CA3108065A1 (en) 2018-07-31 2020-02-06 Loxo Oncology, Inc. Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide
CN113227094A (en) * 2018-09-12 2021-08-06 普渡研究基金会 Alkynyl nicotinamide compounds as kinase inhibitors
WO2020069402A1 (en) * 2018-09-30 2020-04-02 Genentech, Inc. Cinnoline compounds and for the treatment of hpk1-dependent disorders such as cancer
CR20210284A (en) 2018-11-29 2021-07-09 Pfizer Pyrazoles as modulators of hemoglobin
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CN111285874A (en) 2018-12-07 2020-06-16 广东东阳光药业有限公司 RET inhibitors, pharmaceutical compositions thereof and uses thereof
AU2019392232A1 (en) 2018-12-07 2021-05-20 Sunshine Lake Pharma Co., Ltd. RET inhibitors, pharmaceutical compositions and uses thereof
JP2022537833A (en) * 2019-06-24 2022-08-30 ベネボレントエーアイ バイオ リミティド Novel compounds and methods
WO2021252123A2 (en) * 2020-05-19 2021-12-16 Purdue Research Foundation Continuous flow sonogashira coupling synthesis method
CA3188108A1 (en) * 2020-06-24 2021-12-30 Purdue Research Foundation 2,3-disubstituted pyrido[3,4-b]pyrazine-containing compounds as kinase inhibitors
KR20220009349A (en) * 2020-07-14 2022-01-24 보로노이바이오 주식회사 aryl or heteroaryl derivatives, and pharmaceutical composition thereof for use in preventing or treating kinase-related disease
BR112023001145A2 (en) * 2020-07-23 2023-04-04 Cytosinlab Therapeutics Co Ltd COMPOUND HAVING KINASE INHIBITORY ACTIVITY
WO2022149855A1 (en) * 2021-01-05 2022-07-14 주식회사 비투에스바이오 Heteroaryl-ethynyl derivative compound and use thereof
WO2023169453A1 (en) * 2022-03-11 2023-09-14 中国科学院上海药物研究所 Heteroaromatic ring-containing alkynyl compound, and preparation method therefor and use thereof
CN115851946B (en) * 2022-11-24 2023-09-01 中山大学孙逸仙纪念医院 Application of CaMKI serving as therapeutic target in preparation of pancreatic cancer therapeutic drug

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU645504B2 (en) * 1989-10-11 1994-01-20 Teijin Limited Bicyclic pyrimidine derivative, method of producing the same, and pharmaceutical preparation containing the same as active ingredient
WO2003024931A1 (en) * 2001-09-14 2003-03-27 Merck & Co., Inc. Tyrosine kinase inhibitors
AU2004253967B2 (en) * 2003-07-03 2010-02-18 Cytovia, Inc. 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis
US7776869B2 (en) * 2004-10-18 2010-08-17 Amgen Inc. Heteroaryl-substituted alkyne compounds and method of use
US7737279B2 (en) * 2005-05-10 2010-06-15 Bristol-Myers Squibb Company 1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same
WO2007133560A2 (en) 2006-05-08 2007-11-22 Ariad Pharmaceuticals, Inc. Acetylenic heteroaryl compounds
WO2008009078A2 (en) * 2006-07-20 2008-01-24 Gilead Sciences, Inc. 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
CA2709806A1 (en) * 2008-01-22 2009-07-30 Merck Patent Gmbh Protein kinase inhibitors and use thereof
EA201100126A1 (en) * 2008-07-03 2011-08-30 Мерк Патент Гмбх NAFTHYRIDINOES AS PROTEINKINAZ INHIBITORS
US8383094B2 (en) * 2008-10-01 2013-02-26 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AR076332A1 (en) 2009-04-21 2011-06-01 Boehringer Ingelheim Int HETEROCICLIC DERIVATIVES OF 5-ALQUINIL-PIRIDINAS, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM AND USE OF THE SAME FOR THE TREATMENT AND / OR PREVENTION OF CANCER, INFLAMMATORY PROCESSES, AUTOIMMUNES, AND / OR INFECTIONS.
JP2013506691A (en) * 2009-10-02 2013-02-28 バーテックス ファーマシューティカルズ インコーポレイテッド Pyrazole inhibitors of phosphatidylinositol 3-kinase
CA2790613C (en) * 2010-02-22 2018-01-02 Merck Patent Gmbh Hetarylaminonaphthyridines
CN101885722B (en) * 2010-07-01 2013-07-24 中国科学院广州生物医药与健康研究院 Heterocycle alkyne and benzene compound, medicinal composition and application thereof
WO2012097479A1 (en) * 2011-01-21 2012-07-26 Abbott Laboratories Bicyclic inhibitors of anaphastic lymphoma kinase
CN103030637A (en) * 2011-10-10 2013-04-10 上海恒瑞医药有限公司 Imidazole quinoline derivative, and pharmaceutically acceptable salts thereof, preparation method thereof and application thereof on medicines
US9932317B2 (en) 2012-03-19 2018-04-03 Imperial Innovations Limited Quinazoline compounds and their use in therapy
CN104211639A (en) 2013-06-05 2014-12-17 中国科学院上海药物研究所 Alkynyl heterocyclic compounds and application thereof
GB2522226A (en) * 2014-01-17 2015-07-22 Agency Science Tech & Res Heteroaryl alkyne derivatives and uses thereof
WO2016014674A1 (en) 2014-07-22 2016-01-28 University Of Maryland, College Park Linked diaryl compounds with anticancer properties and methods of using the same

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11613548B2 (en) 2021-02-19 2023-03-28 Sudo Biosciences Limited Substituted pyridines, pyridazines, pyrimidines, and 1,2,4-triazines as TYK2 inhibitors

Also Published As

Publication number Publication date
CA3033752A1 (en) 2018-02-22
CA3158951A1 (en) 2018-02-22
CA3033752C (en) 2022-05-31
CN109843294A (en) 2019-06-04
EP3496717A4 (en) 2020-01-15
EP3496717A1 (en) 2019-06-19
WO2018035072A1 (en) 2018-02-22
US11001559B2 (en) 2021-05-11
US20190177278A1 (en) 2019-06-13
JP2019527725A (en) 2019-10-03
EP4011882A1 (en) 2022-06-15

Similar Documents

Publication Publication Date Title
US20210198208A1 (en) 4-substituted aminoisoquinoline derivatives
US10421761B2 (en) Compounds for kinase modulation, and indications therefor
EP2499117B1 (en) A compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent
KR101931435B1 (en) Novel imidazopyridine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating cancer containing the same as an active ingredient
US8604217B2 (en) Compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent
US20110263541A1 (en) Kinase inhibitors and their use as pharmaceutical agents
JP7262599B2 (en) Novel pyrido[3,4-D]pyrimidin-8-one derivative having protein kinase inhibitory activity and pharmaceutical composition for prevention, improvement or treatment of cancer containing the same
US10544149B2 (en) Bicyclic alkyne derivatives and uses thereof
US20210139505A1 (en) PIKfyve Inhibitors
JP7427098B2 (en) 7-amino-3,4-dihydropyrimidopyrimidin-2-one derivatives having protein kinase inhibitory activity and therapeutic pharmaceutical compositions containing the same
EA021421B1 (en) Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors, process for preparation thereof, pharmaceutical composition comprising same and method for treating diseases using such compounds
US9695182B2 (en) Chemical compounds (derivatives) and their application for the treatment of oncological diseases
US10059717B2 (en) Urea compounds containing 3,4-dihydropyrimido[4,5-D]pyrimidin-2(1H)-one skeleton as protein kinase inhibitors
US11530221B2 (en) Pyrimido[4,5-d]pyrimidin-2-one derivatives as protein kinase inhibitors
US20230219934A1 (en) 2,3-disubstituted pyrido[3,4-b]pyrazine-containing compounds as kinase inhibitors
KR102329723B1 (en) NOVEL PYRIMIDO[4,5-d]PYRIMIDIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS
KR102328423B1 (en) Novel triazolo-pyrimidine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating protein kinase related disease containg the same as an active ingredient
KR101721128B1 (en) Ureidobenzothiazole derivatives and pharmaceutical compositions for preventing or treating cancer containing the same
KR20220041462A (en) Novel quinazoline derivatives having FLT3-inhibitory activity and use thereof
KR20180106597A (en) Novel [1,2,4]triazolo[4,3-a]quinoxaline amino phenyl derivatives or pharmaceutically acceptable salts thereof, preparation method therof and pharmaceutical composition for use in preventing or treating bromodomain extra-terminal(BET) protein activity related diseases containing the same as an active ingredient

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED